US20190255091A1 - RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION - Google Patents

RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION Download PDF

Info

Publication number
US20190255091A1
US20190255091A1 US16/267,194 US201916267194A US2019255091A1 US 20190255091 A1 US20190255091 A1 US 20190255091A1 US 201916267194 A US201916267194 A US 201916267194A US 2019255091 A1 US2019255091 A1 US 2019255091A1
Authority
US
United States
Prior art keywords
seq
sequence
antisense strand
rnai agent
sense strand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/267,194
Inventor
Zhen Li
Rui Zhu
Christine I. Wooddell
Bruce D. Given
Tao Pei
David L. Lewis
Lauren J. Almeida
David B. Rozema
Darren H. Wakefield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arrowhead Pharmaceuticals Inc
Original Assignee
Arrowhead Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arrowhead Pharmaceuticals Inc filed Critical Arrowhead Pharmaceuticals Inc
Priority to US16/267,194 priority Critical patent/US20190255091A1/en
Publication of US20190255091A1 publication Critical patent/US20190255091A1/en
Assigned to Arrowhead Pharmaceuticals, Inc. reassignment Arrowhead Pharmaceuticals, Inc. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LEWIS, DAVID L., ROZEMA, DAVID B., WAKEFIELD, DARREN H., PEI, TAO, WOODDELL, CHRISTINE I., LI, ZHEN, ZHU, Rui, ALMEIDA, LAUREN J., GIVEN, BRUCE D.
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • RNA interference (RNAi) agents for inhibition of Hepatitis B Virus gene expression, compositions that include HBV RNAi agents, and methods of use thereof.
  • the Hepatitis B Virus is a strict hepatotrophic, double-stranded DNA containing virus. Although DNA is the genetic material, the replication cycle involves a reverse transcription step to copy a pregenomic RNA into DNA. Hepatitis B Virus is classified as one member of the Hepadnaviruses and belongs to the family of Hepadnaviridae. The primary infection of adult humans with Hepatitis B Virus causes an acute hepatitis with symptoms of organ inflammation, fever, jaundice and increased liver transaminases in blood. Those patients that are not able to overcome the virus infection suffer a chronic disease progression over many years with increased risk of developing cirrhotic liver or liver cancer. Perinatal transmission from Hepatitis B Virus-infected mothers to newborns also leads to chronic hepatitis.
  • ccc covalently closed circular
  • the cccDNA serves as a template for transcription of five major viral mRNAs, which are 3.5, 3.5, 2.4, 2.1 and 0.7 kb long. All mRNAs are 5′-capped and polyadenylated at the 3′-end. There is sequence overlap at the 3′-end between all five mRNAs.
  • One 3.5 kb mRNA serves as template for core protein and polymerase production.
  • the same transcript serves as a pre-genomic replication intermediate and allows the viral polymerase to initiate the reverse transcription into DNA.
  • Core protein is needed for nucleocapsid formation.
  • the other 3.5 kb mRNA encodes pre-core, the secretable e-antigen (HBeAg).
  • HBeAg secretable e-antigen
  • the 2.4 and 2.1 kb mRNAs carry the open reading frames (“ORF”) pre-S1, pre-S2 and S for expression of viral large, medium and small surface antigen.
  • the s-antigen is associated with infectious, complete particles.
  • blood of infected patients also contain non-infectious particles derived from s-antigen alone, free of genomic DNA or polymerase. The function of these particles is not fully understood.
  • the complete and lasting depletion of detectable s-antigen in blood is considered as a reliable indicator for Hepatitis B Virus clearance.
  • the 0.7 kb mRNA encodes the X protein. This gene product is important for efficient transcription of viral genes and also acts as a transactivator on host gene expression. The latter activity seems to be important for hepatocyte transformation during development of liver cancer.
  • a second treatment option is the administration of interferon-alpha.
  • patients receive high doses of interferon-alpha over a period of 6 months.
  • the Asian genotype B gives very poor response rates.
  • Co-infection with Hepatitis D Virus (HDV) or Human Immunodeficiency Virus has been shown to render interferon-alpha therapy completely ineffective. Patients with strong liver damage and heavy fibrotic conditions are not qualified for interferon-alpha therapy.
  • RNAi Hepatitis B Virus-specific RNA interference
  • dsRNA double-stranded ribonucleic acid
  • RNAi agents also herein termed RNAi agent, RNAi trigger, or trigger
  • HBV Hepatitis B Virus
  • HBV gene-specific RNAi agents able to selectively and efficiently decrease expression of an HBV gene.
  • the described HBV RNAi agents can be used in methods for therapeutic treatment and/or prevention of symptoms and diseases associated with HBV infection, including but not limited to chronic liver diseases/disorders, inflammations, fibrotic conditions, proliferative disorders (including cancers, such as hepatocellular carcinoma), Hepatitis D Virus (HDV) infection, and acute HBV infection.
  • the HBV RNAi agents can be used in methods for therapeutic treatment and/or prevention of symptoms and diseases associated with chronic HBV infection and/or HDV infection.
  • Such methods comprise administration of one or more HBV RNAi agents as described herein to a subject, e.g., a human or animal subject.
  • compositions comprising one or more of the disclosed HBV RNAi agents that are able to selectively and efficiently decrease expression of an HBV gene.
  • the compositions comprising one or more HBV RNAi agents can be administered to a subject, such as a human or animal subject, for the treatment and/or prevention of symptoms and diseases associated with HBV infection.
  • Each HBV RNAi agent disclosed herein includes at least a sense strand and an antisense strand.
  • the sense strand and the antisense strand can be partially, substantially, or fully complementary to each other.
  • the length of the RNAi agent sense and antisense strands described herein each can be 16 to 30 nucleotides in length.
  • the sense and antisense strands are independently 17 to 26 nucleotides in length.
  • the sense and antisense strands are independently 19 to 26 nucleotides in length.
  • the sense and antisense strands are independently 21 to 26 nucleotides in length.
  • the sense and antisense strands are independently 21 to 24 nucleotides in length.
  • the sense and antisense strands can be either the same length or different lengths.
  • the HBV RNAi agents disclosed herein have been designed to include antisense strand sequences that are at least partially complementary to a sequence in the HBV genome that is conserved across the majority of known serotypes of HBV.
  • the RNAi agents described herein upon delivery to a cell expressing HBV, inhibit the expression of one or more HBV genes in vivo or in vitro.
  • An HBV RNAi agent includes a sense strand (also referred to as a passenger strand) that includes a first sequence, and an antisense strand (also referred to as a guide strand) that includes a second sequence.
  • a sense strand of the HBV RNAi agents described herein includes a core stretch having at least about 85% identity to a nucleotide sequence of at least 16 consecutive nucleotides in an HBV mRNA.
  • the sense strand core nucleotide stretch having at least about 85% identity to a sequence in an HBV mRNA is 16, 17, 18, 19, 20, 21, 22, or 23 nucleotides in length.
  • An antisense strand of an HBV RNAi agent comprises a nucleotide sequence having at least about 85% complementary over a core stretch of at least 16 consecutive nucleotides to a sequence in an HBV mRNA and the corresponding sense strand.
  • the antisense strand core nucleotide sequence having at least about 85% complementarity to a sequence in an HBV mRNA or the corresponding sense strand is 16, 17, 18, 19, 20, 21, 22, or 23 nucleotides in length.
  • HBV RNAi agent sense strands and antisense strands that can be used in HBV RNAi agents are provided in Tables 3 and 4.
  • Examples of HBV RNAi agent duplexes are provided in Table 5.
  • Examples of 19-nucleotide core stretch sequences that consist of or are included in the sense strands and antisense strands of HBV RNAi agents disclosed herein, are provided in Table 2.
  • one or more HBV RNAi agents are delivered to target cells or tissues using any oligonucleotide delivery technology known in the art.
  • Nucleic acid delivery methods include, but are not limited to, by encapsulation in liposomes, by iontophoresis, or by incorporation into other vehicles, such as hydrogels, cyclodextrins, biodegradable nanocapsules, and bioadhesive microspheres, proteinaceous vectors or Dynamic Polyconjugates (DPCs) (see, for example WO 2000/053722, WO 2008/0022309, WO 2011/104169, and WO 2012/083185, each of which is incorporated herein by reference).
  • DPCs Dynamic Polyconjugates
  • an HBV RNAi agent is delivered to target cells or tissues by covalently linking the RNAi agent to a targeting group.
  • the targeting group can include a cell receptor ligand, such as an asialoglycoprotein receptor (ASGPr) ligand.
  • ASGPr asialoglycoprotein receptor
  • an ASGPr ligand includes or consists of a galactose derivative cluster.
  • a galactose derivative cluster includes an N-acetyl-galactosamine trimer or an N-acetyl-galactosamine tetramer.
  • a galactose derivative cluster is an N-acetyl-galactosamine trimer or an N-acetyl-galactosamine tetramer.
  • a targeting group can be linked to the 3′ or 5′ end of a sense strand or an antisense strand of an HBV RNAi agent. In some embodiments, a targeting group is linked to the 3′ or 5′ end of the sense strand. In some embodiments, a targeting group is linked to the 5′ end of the sense strand. In some embodiments, a targeting group is linked to the RNAi agent via a linker.
  • a targeting group, with or without a linker can be linked to the 5′ or 3′ end of any of the sense and/or antisense strands disclosed in Tables 2, 3, and 4.
  • a linker, with or without a targeting group can be attached to the 5′ or 3′ end of any of the sense and/or antisense strands disclosed in Tables 2, 3, and 4.
  • compositions that include one or more HBV RNAi agents having the duplex sequences disclosed in Table 5.
  • compositions that include a combination or cocktail of at least two HBV RNAi agents having different nucleotide sequences.
  • the two or more different HBV RNAi agents are each separately and independently linked to targeting groups.
  • the two or more different HBV RNAi agents are each linked to targeting groups comprised of N-acetyl-galactosamines.
  • each of the RNAi agents is linked to the same targeting group.
  • each of the RNAi agents is linked to different targeting groups, such as targeting groups having different chemical structures.
  • targeting groups are linked to the HBV RNAi agents without the use of an additional linker.
  • the targeting group is designed having a linker readily present to facilitate the linkage to an HBV RNAi agent.
  • the two or more RNAi agents may be linked to the targeting groups using the same linkers.
  • the two or more RNAi agents are linked to the targeting groups using different linkers.
  • compositions that include a combination of at least two HBV RNAi agents having different sequences, wherein each HBV RNAi agent targets a different location or different region of an HBV gene.
  • compositions that include a combination of at least two HBV RNAi agents, wherein each HBV RNAi agent is designed to target a different HBV transcript for example, a composition that includes two HBV RNAi agents, wherein the first HBV RNAi agent includes an antisense strand that is at least partially complementary to a nucleotide sequence located in the S ORF of an HBV gene, while the second HBV RNAi agent includes an antisense strand that is at least partially complementary to a nucleotide sequence located in the X ORF of an HBV gene).
  • an RNAi agent that includes an antisense strand at least partially complementary to a nucleotide sequence located in the S ORF targets a portion of the HBV genome of SEQ ID NO: 1 between positions 1-1307 and 3185-3221.
  • an RNAi agent that includes an antisense strand at least partially complementary to a nucleotide sequence located in the X ORF targets a portion of the HBV genome of SEQ ID NO: 1 between positions 1308-1930.
  • HBV mRNA is known to be polycistronic, resulting in the translation of multiple polypeptides, and separate mRNAs overlap in RNA sequence, therefore a single RNAi agent targeting an HBV gene may result in inhibition of most or all HBV transcripts.
  • compositions that includes two or more HBV RNAi agents targeting different locations or regions of an HBV gene may provide for additional advantages over a composition that includes only a single HBV RNAi agent, such as (a) ensuring that all HBV viral transcripts are targeted (i.e., 3.5 kb pre-genomic RNA; 3.5 kb pre-core mRNA; 2.4 kb pre-S1 mRNA; 2.1 kb pre-S2/S mRNA; 0.7 kb ⁇ mRNA; as well as any S-antigen expressing mRNAs produced from integrated HBV DNA); (b) serving to expand the genotype coverage to potentially address a larger patient population; and/or (c) potentially decreasing the viral resistance due to mutations in the siRNA binding site
  • compositions that include a combination of one HBV RNAi agent that targets the S ORF of an HBV RNA (i.e., having an antisense strand that targets the S transcripts (S, pre-S1, and pre-S2), the pregenomic RNA (core and polymerase), and the pre-core transcripts (HBeAg) of an HBV genome), and one HBV RNAi agent that targets the X ORF of an HBV RNA (i.e., having an antisense strand that targets the X transcript of an HBV genome, the S transcripts (S, pre-S1, and pre-S2), the pregenomic RNA (core and polymerase), and the pre-core transcripts (HBeAg) of an HBV genome).
  • compositions described herein include at least one HBV RNAi agent that contains a sequence that targets the S ORF of an HBV gene, and a second HBV RNAi agent that contains a sequence that targets the X ORF of an HBV gene.
  • HBV RNAi agents having an antisense strand comprising the sequence of any of the sequences in Table 3.
  • HBV RNAi agents having a sense strand comprising the sequence of any of the sequences in Table 4.
  • HBV RNAi agents having an antisense strand comprising the sequence of any of the sequences in Table 3, and a sense strand comprising the sequence of any of the sequences in Table 4 that is at least partially complementary to the antisense strand.
  • HBV RNAi agents having an antisense strand that consists of the sequence of any of the sequences in Table 3, and a sense strand that consists of the sequence of any of the sequences in Table 4 that is at least partially complementary to the antisense strand.
  • HBV RNAi agents having the duplex structure of Table 5.
  • HBV RNAi agents having an antisense strand comprising the sequence of any of the sequences in Table 3.
  • HBV RNAi agents having a sense strand comprising the sequence of any of the sequences in Table 4.
  • HBV RNAi agents having an antisense strand comprising the sequence of any of the sequences in Table 3, and a sense strand comprising the sequence of any of the sequences in Table 4 that is at least partially complementary to the antisense strand.
  • HBV RNAi agents having an antisense strand that consists of the sequence of any of the sequences in Table 3, and a sense strand that consists of the sequence of any of the sequences in Table 4 that is at least partially complementary to the antisense strand.
  • HBV RNAi agents having the duplex structure of Table 5.
  • HBV RNAi agent having an antisense strand comprising or consisting of the sequence of any of the sequences in Table 2 or Table 3
  • a second HBV RNAi agent having an antisense strand comprising or consisting of the sequence of any of the sequences in Table 2 or Table 3.
  • a first HBV RNAi agent having an antisense strand comprising or consisting of the sequence of any of the sequences in Table 2 or Table 3 and a sense strand comprising or consisting of the sequence of any of the sequences in Table 2 or Table 4 that is at least partially complementary to the antisense strand of the first HBV RNAi agent
  • a second HBV RNAi agent having an antisense strand comprising or consisting of the sequence of any of the sequences in Table 2 or Table 3 and a sense strand comprising or consisting of the sequence of any of the sequences in Table 2 or Table 4 that is at least partially complementary to the antisense strand of the second HBV RNAi agent.
  • a first HBV RNAi agent having an antisense strand comprising or consisting of the sequence of any of the sequences in Table 2 or Table 3 and a sense strand comprising or consisting of the sequence of any of the sequences in Table 2 or Table 4 that is at least partially complementary to the antisense strand of the first HBV RNAi agent
  • a second HBV RNAi agent having an antisense strand comprising or consisting of the sequence of any of the sequences in Table 2 or Table 3 and a sense strand comprising or consisting of the sequence of any of the sequences in Table 2 or Table 4 that is at least partially complementary to the antisense strand of the second HBV RNAi agent.
  • an HBV RNAi agent disclosed herein comprises:
  • compositions for inhibiting expression of an HBV gene in a cell comprising an HBV RNAi agent.
  • compositions for inhibiting expression of an HBV gene in a cell comprising two or more HBV RNAi agents, wherein a first HBV RNAi agent comprises:
  • compositions for inhibiting expression of an HBV gene in a cell comprising two or more HBV RNAi agents, wherein a first HBV RNAi agent comprises:
  • compositions for inhibiting expression of an HBV gene in a cell comprising two or more HBV RNAi agents, wherein a first HBV RNAi agent comprises:
  • compositions for inhibiting expression of an HBV gene in a cell comprising two or more HBV RNAi agents, wherein a first HBV RNAi agent comprises:
  • compositions for inhibiting expression of an HBV gene in a cell comprising two or more HBV RNAi agents, wherein a first HBV RNAi agent comprises an antisense strand having a sequence that is at least partially complementary to a portion of the S ORF of an HBV mRNA, and wherein a second HBV RNAi agent comprises:
  • an HBV RNAi agent disclosed herein comprises:
  • an HBV RNAi agent disclosed herein comprises:
  • an HBV RNAi agent disclosed herein comprises:
  • an HBV RNAi agent disclosed herein comprises:
  • an HBV RNAi agent disclosed herein comprises:
  • an HBV RNAi agent disclosed herein comprises:
  • compositions for inhibiting expression of an HBV gene in a cell comprising two HBV RNAi agents, wherein a first HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′ ⁇ 3′) UAUUGAGAGAAGUCCACCACUU (SEQ ID NO: 175), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′ ⁇ 3′) GUGGUGGACUUCUCUCAAUAUU (SEQ ID NO: 307); and wherein a second HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′ ⁇ 3′) UACCAAUUUAUGCCUACAGUU (SEQ ID NO: 154), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or
  • compositions for inhibiting expression of an HBV gene in a cell comprising two HBV RNAi agents, wherein a first HBV RNAi agent comprises an antisense strand that consists of the nucleobase sequence (5′ ⁇ 3′) UAUUGAGAGAAGUCCACCACUU (SEQ ID NO: 175), and a sense strand that consists of the nucleobase sequence (5′ ⁇ 3′) GUGGUGGACUUCUCUCAAUAUU (SEQ ID NO: 307); and wherein a second HBV RNAi agent comprises an antisense strand that consists of the nucleobase sequence (5′ ⁇ 3′) UACCAAUUUAUGCCUACAGUU (SEQ ID NO: 154), and a sense strand that consists of the nucleobase sequence (5′ ⁇ 3′) CUGUAGGCAUAAAUUGGUA (SEQ ID NO: 292).
  • a first HBV RNAi agent comprises an antisense strand that consists of the nucleobase sequence (5′ ⁇ 3′
  • compositions for inhibiting expression of an HBV gene in a cell comprising two HBV RNAi agents, wherein a first HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′ ⁇ 3′) AGAAAAUUGAGAGAAGUCCAC (SEQ ID NO: 171), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′ ⁇ 3′) GUGGACUUCUCUCAAUUUUCU (SEQ ID NO: 302); and wherein a second HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′ ⁇ 3′) UACCAAUUUAUGCCUACAGCG (SEQ ID NO: 188), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3
  • compositions for inhibiting expression of an HBV gene in a cell comprising two HBV RNAi agents, wherein a first HBV RNAi agent comprises an antisense strand that consists of the nucleobase sequence (5′ ⁇ 3′) AGAAAAUUGAGAGAAGUCCAC (SEQ ID NO: 171), and a sense strand that consists of the nucleobase sequence (5′ ⁇ 3′) GUGGACUUCUCUCAAUUUUCU (SEQ ID NO: 302); and wherein a second HBV RNAi agent comprises an antisense strand that consists of the nucleobase sequence (5′ ⁇ 3′) UACCAAUUUAUGCCUACAGCG (SEQ ID NO: 188), and a sense strand that consists of the nucleobase sequence (5′ ⁇ 3′) CGCUGUAGGCAUAAAUUGGUA (SEQ ID NO: 328).
  • a first HBV RNAi agent comprises an antisense strand that consists of the nucleobase sequence (5′ ⁇ 3
  • compositions for inhibiting expression of an HBV gene in a cell comprising two HBV RNAi agents, wherein a first HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′ ⁇ 3′) AGAAAAUUGAGAGAAGUCCAC (SEQ ID NO: 171), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′ ⁇ 3′) GUGGACUUCUCUCAAUUUUCU (SEQ ID NO: 302); and wherein a second HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′ ⁇ 3′) UACCAAUUUAUGCCUACAGCC (SEQ ID NO: 162), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3
  • compositions for inhibiting expression of an HBV gene in a cell comprising two HBV RNAi agents, wherein a first HBV RNAi agent comprises an antisense strand that consists of the nucleobase sequence (5′ ⁇ 3′) AGAAAAUUGAGAGAAGUCCAC (SEQ ID NO: 171), and a sense strand that consists of the nucleobase sequence (5′ ⁇ 3′) GUGGACUUCUCUCAAUUUUCU (SEQ ID NO: 302); and wherein a second HBV RNAi agent comprises an antisense strand that consists of the nucleobase sequence (5′ ⁇ 3′) UACCAAUUUAUGCCUACAGCC (SEQ ID NO: 162), and a sense strand that consists of the nucleobase sequence (5′ ⁇ 3′) GGCUGUAGGCAUAAAUUGGUA (SEQ ID NO: 294).
  • a first HBV RNAi agent comprises an antisense strand that consists of the nucleobase sequence (5′ ⁇ 3
  • compositions for inhibiting expression of an HBV gene in a cell comprising two HBV RNAi agents, wherein a first HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′ ⁇ 3′) AGAAAAUUGAGAGAAGUCCAC (SEQ ID NO: 171), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′ ⁇ 3′) GUGGACUUCUCUCAAUUUUCU (SEQ ID NO: 302); and wherein a second HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′ ⁇ 3′) UACCAAUUUAUGCCUACAGCC (SEQ ID NO: 162), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3
  • compositions for inhibiting expression of an HBV gene in a cell comprising two HBV RNAi agents, wherein a first HBV RNAi agent comprises an antisense strand that consists of the nucleobase sequence (5′ ⁇ 3′) AGAAAAUUGAGAGAAGUCCAC (SEQ ID NO: 171), and a sense strand that consists of the nucleobase sequence (5′ ⁇ 3′) GUGGACUUCUCUCAAUUUUCU (SEQ ID NO: 302); and wherein a second HBV RNAi agent comprises an antisense strand that consists of the nucleobase sequence (5′ ⁇ 3′) UACCAAUUUAUGCCUACAGCC (SEQ ID NO: 162), and a sense strand that consists of the nucleobase sequence (5′ ⁇ 3′) GUGGUGGACUUCUCUCAAUAUU (SEQ ID NO: 307).
  • a first HBV RNAi agent comprises an antisense strand that consists of the nucleobase sequence (5′ ⁇
  • compositions for inhibiting expression of an HBV gene in a cell comprising two HBV RNAi agents, wherein all or substantially all of the nucleotides in the sense strand are modified and/or all or substantially all of the nucleotides in the antisense strand in the first and/or second HBV RNAi agent are modified nucleotides
  • the first HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′ ⁇ 3′) UAUUGAGAGAAGUCCACCACUU (SEQ ID NO: 175), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′ ⁇ 3′) GUGGUGGACUUCUCUCAAUAUU (SEQ ID NO: 307); and wherein the second HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by
  • compositions for inhibiting expression of an HBV gene in a cell comprising two HBV RNAi agents, wherein all or substantially all of the nucleotides in the sense strand are modified and/or all or substantially all of the nucleotides in the antisense strand in the first and/or second HBV RNAi agent are modified nucleotides
  • the first HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′ ⁇ 3′) AGAAAAUUGAGAGAAGUCCAC (SEQ ID NO: 171)
  • a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′ ⁇ 3′) GUGGACUUCUCUCAAUUUUCU (SEQ ID NO: 302)
  • the second HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0,
  • compositions for inhibiting expression of an HBV gene in a cell comprising two HBV RNAi agents, wherein all or substantially all of the nucleotides in the sense strand are modified and/or all or substantially all of the nucleotides in the antisense strand in the first and/or second HBV RNAi agent are modified nucleotides
  • the first HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′ ⁇ 3′) AGAAAAUUGAGAGAAGUCCAC (SEQ ID NO: 171)
  • a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′ ⁇ 3′) GUGGACUUCUCUCAAUUUUCU (SEQ ID NO: 302)
  • the second HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0,
  • compositions for inhibiting expression of an HBV gene in a cell comprising two HBV RNAi agents, wherein all or substantially all of the nucleotides in the sense strand are modified and/or all or substantially all of the nucleotides in the antisense strand in the first and/or second HBV RNAi agent are modified nucleotides
  • the first HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′ ⁇ 3′) AGAAAAUUGAGAGAAGUCCAC (SEQ ID NO: 171)
  • a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′ ⁇ 3′) GUGGACUUCUCUCAAUUUUCU (SEQ ID NO: 302)
  • the second HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0,
  • compositions for inhibiting expression of an HBV gene in a cell comprising two HBV RNAi agents, wherein all or substantially all of the nucleotides in the sense strand are modified and/or all or substantially all of the nucleotides in the antisense strand in the first and/or second HBV RNAi agent are modified nucleotides
  • the first HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′ ⁇ 3′) UAUUGAGAGAAGUCCACCACUU (SEQ ID NO: 175), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′ ⁇ 3′) GUGGUGGACUUCUCUCAAUAUU (SEQ ID NO: 307); and wherein the second HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by
  • compositions for inhibiting expression of an HBV gene in a cell comprising two HBV RNAi agents, wherein all or substantially all of the nucleotides in the sense strand are modified and/or all or substantially all of the nucleotides in the antisense strand in the first and/or second HBV RNAi agent are modified nucleotides
  • the first HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′ ⁇ 3′) AGAAAAUUGAGAGAAGUCCAC (SEQ ID NO: 171)
  • a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′ ⁇ 3′) GUGGACUUCUCUCAAUUUUCU (SEQ ID NO: 302)
  • the second HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0,
  • compositions for inhibiting expression of an HBV gene in a cell comprising two HBV RNAi agents, wherein all or substantially all of the nucleotides in the sense strand are modified and/or all or substantially all of the nucleotides in the antisense strand in the first and/or second HBV RNAi agent are modified nucleotides
  • the first HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′ ⁇ 3′) AGAAAAUUGAGAGAAGUCCAC (SEQ ID NO: 171)
  • a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′ ⁇ 3′) GUGGACUUCUCUCAAUUUUCU (SEQ ID NO: 302)
  • the second HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0,
  • compositions for inhibiting expression of an HBV gene in a cell comprising two HBV RNAi agents, wherein all or substantially all of the nucleotides in the sense strand are modified and/or all or substantially all of the nucleotides in the antisense strand in the first and/or second HBV RNAi agent are modified nucleotides
  • the first HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′ ⁇ 3′) AGAAAAUUGAGAGAAGUCCAC (SEQ ID NO: 171)
  • a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′ ⁇ 3′) GUGGACUUCUCUCAAUUUUCU (SEQ ID NO: 302)
  • the second HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0,
  • disclosed herein are methods of treatment of an HBV infection or prevention of disease or symptoms caused by an HBV infection comprising administering to a subject in need thereof an effective amount of AD04872 and an effective amount of AD05070.
  • the ratio of AD04872 to AD05070 administered to a subject in need thereof is about 2:1.
  • the ratio of AD04872 to AD05070 administered to a subject in need thereof is about 3:1.
  • the ratio of AD04872 to AD05070 administered to a subject in need thereof is about 1:1.
  • the ratio of AD04872 to AD05070 administered to a subject in need thereof is about 4:1.
  • the ratio of AD04872 to AD05070 administered to a subject in need thereof is about 5:1.
  • the ratio of AD04872 to AD05070 administered to a subject in need thereof is about 1:2.
  • about 1 mg/kg (mpk) of AD04872 and about 1 mg/kg of AD05070 are administered to a subject in need thereof. In some embodiments, about 1.5 mg/kg of AD04872 and about 1.5 mg/kg of AD05070 are administered to a subject in need thereof. In some embodiments, about 2.0 mg/kg of AD04872 and about 1.0 mg/kg of AD05070 are administered to a subject in need thereof. In some embodiments, about 3.0 mg/kg of AD04872 and about 1.0 mg/kg of AD05070 are administered to a subject in need thereof. In some embodiments, about 3.2 mg/kg of AD04872 and about 0.8 mg/kg of AD05070 are administered to a subject in need thereof.
  • about 2.7 mg/kg of AD04872 and about 1.3 mg/kg of AD05070 are administered to a subject in need thereof.
  • about 4.0 mg/kg of AD04872 and about 1.0 mg/kg of AD05070 are administered to a subject in need thereof.
  • about 3.3 mg/kg of AD04872 and about 1.7 mg/kg of AD05070 are administered to a subject in need thereof.
  • between about 0.05 and about 5 mg/kg of AD04872 and between about 0.05 and about 5 mg/kg of AD05070 are administered to a subject in need thereof.
  • about AD04872 and about AD05070 are administered separately (e.g., in separate injections).
  • the respective dose of AD04872 and the respective dose of AD05070 are administered together (e.g., in the same injection). In some embodiments, the respective dose of AD04872 and the respective dose of AD05070 are prepared in a single pharmaceutical composition.
  • disclosed herein are methods of treatment of an HBV infection or prevention of diseases or symptoms caused by an HBV infection comprising administering to a subject in need thereof an effective amount of AD04872 and an effective amount of AD04776.
  • the ratio of AD04872 to AD04776 administered to a subject in need thereof is about 2:1.
  • the ratio of AD04872 to AD04776 administered to a subject in need thereof is about 3:1.
  • the ratio of AD04872 to AD04776 administered to a subject in need thereof is about 4:1.
  • the ratio of AD04872 to AD04776 administered to a subject in need thereof is about 1:1.
  • the ratio of AD04872 to AD04776 administered to a subject in need thereof is 5:1.
  • the ratio of AD04872 to AD04776 administered to a subject in need thereof is 1:2.
  • about 1 mg/kg (mpk) of AD04872 and about 1 mg/kg of AD04776 are administered to a subject in need thereof. In some embodiments, about 1.5 mg/kg of AD04872 and about 1.5 mg/kg of AD04776 are administered to a subject in need thereof. In some embodiments, about 2.0 mg/kg of AD04872 and about 1.0 mg/kg of AD04776 are administered to a subject in need thereof. In some embodiments, about 3.0 mg/kg of AD04872 and about 1.0 mg/kg of AD04776 are administered to a subject in need thereof. In some embodiments, about 3.2 mg/kg of AD04872 and about 0.8 mg/kg of AD04776 are administered to a subject in need thereof.
  • about 2.7 mg/kg of AD04872 and about 1.3 mg/kg of AD04776 are administered to a subject in need thereof.
  • about 4.0 mg/kg of AD04872 and about 1.0 mg/kg of AD04776 are administered to a subject in need thereof.
  • about 3.3 mg/kg of AD04872 and about 1.7 mg/kg of AD04776 are administered to a subject in need thereof.
  • between about 0.05 and about 5 mg/kg of AD04872 and between about 0.05 and about 5 mg/kg of AD04776 are administered to a subject in need thereof.
  • the respective doses of AD04872 and AD04776 are administered separately (e.g., in separate injections). In some embodiments, the respective doses of AD04872 and AD04776 are administered together (e.g., in the same injection). In some embodiments, the respective doses of AD04872 and AD04776 are prepared in a single pharmaceutical composition.
  • the ratio of AD04872 to AD04982 administered to a subject in need thereof is about 2:1. In some embodiments, the ratio of AD04872 to AD04982 administered to a subject in need thereof is about 3:1. In some embodiments, the ratio of AD04872 to AD04982 administered to a subject in need thereof is about 4:1. In some embodiments, the ratio of AD04872 to AD04982 administered to a subject in need thereof is about 1:1. In some embodiments, the ratio of AD04872 to AD04982 administered to a subject in need thereof is about 5:1. In some embodiments, the ratio of AD04872 to AD04982 administered to a subject in need thereof is 1:2.
  • about 1 mg/kg (mpk) of AD04872 and about 1 mg/kg of AD04982 are administered to a subject in need thereof. In some embodiments, about 1.5 mg/kg of AD04872 and about 1.5 mg/kg of AD04982 are administered to a subject in need thereof. In some embodiments, about 2.0 mg/kg of AD04872 and about 1.0 mg/kg of AD04982 are administered to a subject in need thereof. In some embodiments, about 3.0 mg/kg of AD04872 and about 1.0 mg/kg of AD04982 are administered to a subject in need thereof. In some embodiments, about 3.2 mg/kg of AD04872 and about 0.8 mg/kg of AD04982 are administered to a subject in need thereof.
  • about 2.7 mg/kg of AD04872 and about 1.3 mg/kg of AD04982 are administered to a subject in need thereof.
  • about 4.0 mg/kg of AD04872 and about 1.0 mg/kg of AD04982 are administered to a subject in need thereof.
  • about 3.3 mg/kg of AD04872 and about 1.7 mg/kg of AD04982 are administered to a subject in need thereof.
  • between about 0.05 and about 5 mg/lg of AD04872 and between about 0.05 and about 5 mg/kg of AD04982 are administered to a subject in need thereof.
  • the respective doses of AD04872 and AD04982 are administered separately (e.g., in separate injections). In some embodiments, the respective doses of AD04872 and AD04982 are administered together (e.g., in the same injection). In some embodiments, the respective doses of AD04872 and AD04982 are prepared in a single pharmaceutical composition.
  • disclosed herein are methods of treatment of an HBV infection or prevention of disease or symptoms caused by an HBV infection comprising administering to a subject in need thereof an effective amount of AD04580 and an effective amount of AD04585.
  • the ratio of AD04580 to AD04585 administered to a subject in need thereof is about 2:1.
  • the ratio of AD04580 to AD04585 administered to a subject in need thereof is about 3:1.
  • the ratio of AD04580 to AD04585 administered to a subject in need thereof is about 4:1.
  • the ratio of AD04580 to AD04585 administered to a subject in need thereof is about 5:1.
  • the ratio of AD04580 to AD04585 administered to a subject in need thereof is about 1:1. In some embodiments, the ratio of AD04580 to AD04585 administered to a subject in need thereof is about 1:2. In some embodiments, about 1 mg/kg (mpk) of AD04580 and about 1 mg/kg of AD04585 are administered to a subject in need thereof. In some embodiments, about 1.5 mg/kg of AD04580 and about 1.5 mg/kg of AD04585 are administered to a subject in need thereof. In some embodiments, between about 0.05 and about 5 mg/kg of AD04580 and between about 0.05 and about 5 mg/kg of AD04585 are administered to a subject in need thereof.
  • an HBV RNAi agent disclosed herein consists of or comprises AD05070 linked to (NAG37)s shown as a sodium salt having the structure represented by the following:
  • an HBV RNAi agent disclosed herein consists of or comprises AD05070 linked to (NAG25)s shown as a sodium salt having the structure represented by the following:
  • an HBV RNAi agent disclosed herein consists of or comprises AD05070 linked to (NAG37)s shown as a free acid having the structure represented by the following:
  • an HBV RNAi agent disclosed herein consists of or comprises AD04580 linked to (NAG31)s shown as a sodium salt having the structure represented by the following:
  • an HBV RNAi agent disclosed herein consists of or comprises AD04585 linked to (NAG25)s shown as a sodium salt having the structure represented by the following:
  • an HBV RNAi agent disclosed herein consists of or comprises AD04872 linked to (NAG37)s shown as a sodium salt having the structure represented by the following:
  • an HBV RNAi agent disclosed herein consists of or comprises AD04872 linked to (NAG25)s shown as a sodium salt having the structure represented by the following:
  • an HBV RNAi agent disclosed herein consists of or comprises AD04872 linked to (NAG37)s shown as a free acid having the structure represented by the following:
  • the described HBV RNAi agent(s) are optionally combined with one or more additional (i.e., second, third, etc.) therapeutics.
  • a second therapeutic can be another HBV RNAi agent (e.g., a HBV RNAi agent which targets a different sequence within an HBV genome).
  • An additional therapeutic can also be a small molecule drug, antibody, antibody fragment, and/or vaccine.
  • the HBV RNAi agents, with or without the one or more additional therapeutics, can be combined with one or more excipients to form pharmaceutical compositions.
  • the described HBV RNAi agent(s) are optionally combined with one or more additional therapeutics, wherein the additional therapeutic is a nucleoside inhibitor or nucleotide inhibitor. In some embodiments, the described HBV RNAi agent(s) are optionally combined with one or more additional therapeutics, wherein the additional therapeutic entecavir, tenofovir, tenofovir alafenamide, tenofovir disoproxil, lamivudine, or another antiviral therapeutic. In some embodiments, the described HBV RNAi agent(s) are optionally combined with one or more additional therapeutics, wherein the additional therapeutic is an interferon.
  • the described HBV RNAi agent(s) are optionally combined with one or more additional therapeutics, wherein the additional therapeutic is interferon-alpha. In some embodiments, the described HBV RNAi agent(s) are optionally combined with one or more HBV additional therapeutics, wherein the additional therapeutic is an HBV vaccine.
  • the described HBV RNAi agent(s) are optionally combined with one or more additional therapeutics in a single dosage form (i.e., a cocktail included in a single injection).
  • the described HBV RNAi agent(s) may be administered separately from one or more optional additional therapeutics.
  • the described HBV RNAi agent(s) are administered to a subject in need thereof via subcutaneous injection, and the one or more optional additional therapeutics are administered orally, which together provide for a treatment regimen for diseases and conditions associated with HBV infection.
  • the described HBV RNAi agent(s) are administered to a subject in need thereof via subcutaneous injection, and the one or more optional additional therapeutics are administered via a separate subcutaneous injection.
  • compositions for delivering an HBV RNAi agent to a liver cell in vivo including an HBV RNAi agent conjugated or linked to a targeting group.
  • the targeting group is an asialoglycoprotein receptor ligand.
  • compositions for delivering an HBV RNAi agent to a liver cell in vivo are described, the composition including an HBV RNAi agent linked to an N-acetyl-galactosamine targeting ligand.
  • one or more of the described HBV RNAi agents are administered to a mammal in a pharmaceutically acceptable carrier or diluent.
  • the mammal is a human.
  • Hepatitis B Virus RNAi agent(s) provides methods for therapeutic and/or prophylactic treatment of diseases/disorders which are associated with HBV infection.
  • the described HBV RNAi agents mediate RNA interference to inhibit the expression of one or more genes necessary for replication and/or pathogenesis of Hepatitis B Virus.
  • HBV RNAi agents may inhibit viral polymerase, core protein, surface antigen, e-antigen and/or the X protein, in a cell, tissue or mammal.
  • HBV RNAi agents can be used to treat HBV infection.
  • HBV RNAi agents can also be used to treat or prevent chronic liver diseases/disorders, inflammations, fibrotic conditions and proliferative disorders, like cancers, associated with HBV infection.
  • the methods further comprise treatment of Hepatitis D Virus (HDV) in the subject.
  • HDV Hepatitis D Virus
  • Such methods comprise administration of HBV RNAi agent to a human being or animal infected with HBV. Further, compositions for delivery of HBV RNAi agents to liver cells in vivo are described.
  • compositions comprising one or more HBV RNAi agents can be administered in a number of ways depending upon whether local or systemic treatment is desired. Administration can be, but is not limited to, intravenous, intraarterial, subcutaneous, intraperitoneal, subdermal (e.g., via an implanted device), and intraparenchymal administration. In some embodiments, the pharmaceutical compositions described herein are administered by subcutaneous injection.
  • HBV RNAi agents and/or compositions can be used in methods for therapeutic treatment of HBV infection or disease or conditions caused by HBV infection. Such methods include administration of an HBV RNAi agent as described herein to a subject, e.g., a human or animal subject.
  • oligonucleotide and “polynucleotide” mean a polymer of linked nucleosides each of which can be independently modified or unmodified.
  • RNAi agent or “RNAi trigger” means a composition that contains an RNA or RNA-like (e.g., chemically modified RNA) oligonucleotide molecule that is capable of degrading or inhibiting translation of messenger RNA (mRNA) transcripts of a target mRNA in a sequence specific manner.
  • RNAi agents may operate through the RNA interference mechanism (i.e., inducing RNA interference through interaction with the RNA interference pathway machinery (RNA-induced silencing complex or RISC) of mammalian cells), or by any alternative mechanism(s) or pathway(s).
  • RNAi agents While it is believed that RNAi agents, as that term is used herein, operate primarily through the RNA interference mechanism, the disclosed RNAi agents are not bound by or limited to any particular pathway or mechanism of action.
  • RNAi agents disclosed herein are comprised of a sense strand and an antisense strand, and include, but are not limited to: short interfering RNAs (siRNAs), double-stranded RNAs (dsRNA), micro RNAs (miRNAs), short hairpin RNAs (shRNA), and dicer substrates.
  • the antisense strand of the RNAi agents described herein is at least partially complementary to the mRNA being targeted.
  • RNAi agents may be comprised of modified nucleotides and/or one or more non-phosphodiester linkages.
  • the terms “silence,” “reduce,” “inhibit,” “down-regulate,” or “knockdown” when referring to expression of a given gene mean that the expression of the gene, as measured by the level of RNA transcribed from the gene or the level of polypeptide, protein or protein subunit translated from the mRNA in a cell, group of cells, tissue, organ, or subject in which the gene is transcribed, is reduced when the cell, group of cells, tissue, organ, or subject is treated with oligomeric compounds, such as RNAi agents, described herein as compared to a second cell, group of cells, tissue, organ, or subject that has not or have not been so treated.
  • sequence or “nucleotide sequence” mean a succession or order of nucleobases or nucleotides, described with a succession of letters using standard nomenclature.
  • nucleotide base is a heterocyclic pyrimidine or purine compound, which is a standard constituent of all nucleic acids, and includes the bases that form the nucleotides adenine (A), guanine (G), cytosine (C), thymine (T), and uracil (U).
  • a nucleobase may further be modified to include, without limitation, universal bases, hydrophobic bases, promiscuous bases, size-expanded bases, and fluorinated bases.
  • the term “complementary,” when used to describe a first nucleotide sequence (e.g., RNAi agent sense strand or targeted mRNA) in relation to a second nucleotide sequence (e.g., RNAi agent antisense strand or a single-stranded antisense oligonucleotide), means the ability of an oligonucleotide or polynucleotide including the first nucleotide sequence to hybridize (form base pair hydrogen bonds under mammalian physiological conditions (or similar conditions in vitro)) and form a duplex or double helical structure under certain conditions with an oligonucleotide or polynucleotide including the second nucleotide sequence.
  • Complementary sequences include Watson-Crick base pairs or non-Watson-Crick base pairs and include natural or modified nucleotides or nucleotide mimics, at least to the extent that the above hybridization requirements are fulfilled. Sequence identity or complementarity is independent of modification. For example, a and Af are complementary to U (or T) and identical to A for the purposes of determining identity or complementarity.
  • perfect complementary or “fully complementary” means that all (100%) of the bases in a contiguous sequence of a first polynucleotide will hybridize with the same number of bases in a contiguous sequence of a second polynucleotide.
  • the contiguous sequence may comprise all or a part of a first or second nucleotide sequence.
  • partially complementary means that in a hybridized pair of nucleobase sequences, at least 70%, but not all, of the bases in a contiguous sequence of a first polynucleotide will hybridize with the same number of bases in a contiguous sequence of a second polynucleotide.
  • substantially complementary means that in a hybridized pair of nucleobase sequences, at least about 85%, but not all, of the bases in a contiguous sequence of a first polynucleotide will hybridize with the same number of bases in a contiguous sequence of a second polynucleotide.
  • complementary may be used with respect to the base matching between the sense strand and the antisense strand of a double-stranded RNAi agent, between the antisense strand of an RNAi agent and a sequence of a target mRNA, or between a single-stranded antisense oligonucleotide and a sequence of a target mRNA.
  • nucleic acid sequence comprises a sequence that has at least about 85% sequence identity or more, preferably at least 90%, at least 95%, or at least 99%, compared to a reference sequence. Percentage of sequence identity is determined by comparing two optimally aligned sequences over a comparison window. The percentage is calculated by determining the number of positions at which the identical nucleic acid base occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity.
  • the inventions disclosed herein encompasses nucleotide sequences substantially identical to those disclosed herein. e.g., in Tables 2, 3, and 4. In some embodiments, the sequences disclosed herein are exactly identical, or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% percent identical to those disclosed herein, e.g., in Tables 1, 2, 3 and 4.
  • the terms “treat,” “treatment,” and the like mean the methods or steps taken to provide relief from or alleviation of the number, severity, and/or frequency of one or more symptoms of a disease or condition in a subject.
  • the phrase “introducing into a cell,” when referring to an oligomeric compound, means functionally delivering the oligomeric compound into a cell.
  • the phrase “functional delivery,” means that delivering the oligomeric compound to the cell in a manner that enables the oligomeric compound to have the expected biological activity, e.g., sequence-specific inhibition of gene expression.
  • isomers refers to compounds that have identical molecular formulae, but that differ in the nature or the sequence of bonding of their atoms or in the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers.” Stereoisomers that are not mirror images of one another are termed “diastereoisomers,” and stereoisomers that are non-superimposable mirror images are termed “enantiomers,” or sometimes optical isomers. A carbon atom bonded to four non-identical substituents is termed a “chiral center.”
  • each structure disclosed herein is intended to represent all such possible isomers, including their optically pure and racemic forms.
  • the structures disclosed herein are intended to cover mixtures of diastereomers as well as single stereoisomers.
  • the phrase “consisting of” excludes any element, step, or ingredient not specified in the claim.
  • the phrase “consisting essentially of” limits the scope of a claim to the specified materials or steps and those that do not materially affect the basic and novel characteristic(s) of the claimed invention.
  • the compounds and compositions disclosed herein may have certain atoms (e.g., N, O, or S atoms) in a protonated or deprotonated state, depending upon the environment in which the compound or composition is placed.
  • the structures disclosed herein envisage that certain functional groups, such as, for example, OH, SH, or NH, may be protonated or deprotonated.
  • the disclosure herein is intended to cover the disclosed compounds and compositions regardless of their state of protonation based on the environment (such as pH), as would be readily understood by the person of ordinary skill in the art.
  • RNAi agents for inhibiting expression of Hepatitis B Virus (referred to herein as HBV RNAi agents or HBV RNAi triggers).
  • HBV RNAi agents for inhibiting expression of Hepatitis B Virus (HBV) (referred to herein as HBV RNAi agents or HBV RNAi triggers).
  • HBV RNAi agents comprises a sense strand and an antisense strand.
  • the sense strand and the antisense strand each can be 16 to 30 nucleotides in length.
  • the sense and antisense strands each can be 17 to 26 nucleotides in length.
  • the sense and antisense strands can be either the same length or they can be different lengths.
  • the sense and antisense strands are each independently 17 to 26 nucleotides in length.
  • the sense and antisense strands are each independently 17-21 nucleotides in length. In some embodiments, both the sense and antisense strands are each 21-26 nucleotides in length. In some embodiments, the sense strand is about 19 nucleotides in length while the antisense strand is about 21 nucleotides in length. In some embodiments, the sense strand is about 21 nucleotides in length while the antisense strand is about 23 nucleotides in length. In some embodiments, both the sense and antisense strands are each 26 nucleotides in length.
  • the RNAi agent sense and antisense strands are each independently 17, 18, 19, 20, 21, 22, 23, 24, 25, or 26 nucleotides in length.
  • a double-stranded RNAi agent has a duplex length of about 16, 17, 18, 19, 20, 21, 22, 23 or 24 nucleotides.
  • This region of perfect or substantial complementarity between the sense strand and the antisense strand is typically 15-25 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25) nucleotides in length and occurs at or near the 5′ end of the antisense strand (e.g., this region may be separated from the 5′ end of the antisense strand by 0, 1, 2, 3, or 4 nucleotides that are not perfectly or substantially complementary).
  • the sense strand and antisense strand each contain a core stretch sequence that is 16 to 23 nucleobases in length.
  • An antisense strand core stretch sequence is 100% (perfectly) complementary or at least about 85% (substantially) complementary to a nucleotide sequence (sometimes referred to, e.g., as a target sequence) present in the HBV mRNA target.
  • a sense strand core stretch sequence is 100% (perfectly) complementary or at least about 85% (substantially) complementary to a core stretch sequence in the antisense strand, and thus the sense strand core stretch sequence is perfectly identical or at least about 85% identical to a nucleotide sequence (target sequence) present in the HBV mRNA target.
  • a sense strand core stretch sequence can be the same length as a corresponding antisense core sequence or it can be a different length.
  • the antisense strand core stretch sequence is 16, 17, 18, 19, 20, 21, 22, or 23 nucleotides in length.
  • the sense strand core stretch sequence is 16, 17, 18, 19, 20, 21, 22, or 23 nucleotides in length.
  • RNAi agent duplexes examples include the nucleotide sequences in Tables 3 and 4, are provided in Table 5.
  • the HBV RNAi agent sense and antisense strands anneal to form a duplex.
  • a sense strand and an antisense strand of an HBV RNAi agent may be partially, substantially, or fully complementary to each other.
  • the sense strand core stretch sequence is at least about 85% complementary or 100% complementary to the antisense core stretch sequence.
  • the sense strand core stretch sequence contains a sequence of at least 16, at least 17, at least 18, at least 19, at least 20, or at least 21 nucleotides that is at least about 85% or 100% complementary to a corresponding 16, 17, 18, 19, 20, or 21 nucleotide sequence of the antisense strand core stretch sequence (i.e., the sense strand and antisense core stretch sequences of an HBV RNAi agent have a region of at least 16, at least 17, at least 18, at least 19, at least 20, or at least 21 nucleotides that is at least 85% base paired or 100% base paired.).
  • the antisense strand of an HBV RNAi agent disclosed herein differs by 0, 1, 2, or 3 nucleotides from any of the antisense strand sequences in Table 2 or Table 3. In some embodiments, the sense strand of an HBV RNAi agent disclosed herein differs by 0, 1, 2, or 3 nucleotides from any of the sense strand sequences in Table 2 or Table 4.
  • the length of the HBV RNAi agent sense and antisense strands described herein are independently 16 to 30 nucleotides in length. In some embodiments, the sense and antisense strands are independently 17 to 26 nucleotides in length. In some embodiments, the sense and antisense strands are 19-26 nucleotides in length. In some embodiments, the described RNAi agent sense and antisense strands are independently 17, 18, 19, 20, 21, 22, 23, 24, 25, or 26 nucleotides in length. The sense and antisense strands can be either the same length or they can be different lengths. In some embodiments, a sense strand and an antisense strand are each 26 nucleotides in length.
  • a sense strand is 23 nucleotides in length and an antisense strand is 21 nucleotides in length. In some embodiments, a sense strand is 22 nucleotides in length and an antisense strand is 21 nucleotides in length. In some embodiments, a sense strand is 21 nucleotides in length and an antisense strand is 21 nucleotides in length. In some embodiments, a sense strand is 19 nucleotides in length and an antisense strand is 21 nucleotides in length.
  • the sense strand and/or the antisense strand may optionally and independently contain an additional 1, 2, 3, 4, 5, or 6 nucleotides (extension) at the 3′ end, the 5′ end, or both the 3′ and 5′ ends of the core sequences.
  • the antisense strand additional nucleotides, if present, may or may not be complementary to the corresponding sequence in an HBV mRNA.
  • the sense strand additional nucleotides, if present, may or may not be identical to the corresponding sequence in an HBV mRNA.
  • the antisense strand additional nucleotides, if present may or may not be complementary to the corresponding sense strand's additional nucleotides, if present.
  • an extension comprises 1, 2, 3, 4, 5, or 6 nucleotides at the 5′ and/or 3′ end of the sense strand core stretch sequence and/or antisense strand core stretch sequence.
  • the extension nucleotides on a sense strand may or may not be complementary to nucleotides, either core stretch sequence nucleotides or extension nucleotides, in the corresponding antisense strand.
  • the extension nucleotides on an antisense strand may or may not be complementary to nucleotides, either core stretch sequence nucleotides or extension nucleotides, in the corresponding sense strand.
  • both the sense strand and the antisense strand of an RNAi agent contain 3′ and 5′ extensions.
  • an HBV RNAi agent has an antisense strand having a 3′ extension and a sense strand having a 5′ extension.
  • an HBV RNAi agent comprises an antisense strand having a 3′ extension of 1, 2, 3, 4, 5, or 6 nucleotides in length. In other embodiments, an HBV RNAi agent comprises an antisense strand having a 3′ extension of 1, 2, or 3 nucleotides in length. In some embodiments, one or more of the antisense strand extension nucleotides comprise uracil or thymidine nucleotides or nucleotides which are complementary to a corresponding HBV mRNA sequence.
  • a 3′ antisense strand extension includes or consists of, but is not limited to: AUA, UGCUU, CUG, UG, UGCC, CUGCC, CGU, CUU. UGCCUA, CUGCCU, UGCCU, UGAUU, GCCUAU, T, TT, U, UU (each listed 5′ to 3′).
  • the 3′ end of the antisense strand may include additional abasic nucleosides (Ab). In some embodiments, Ab or AbAb may be added to the 3′ end of the antisense strand.
  • an HBV RNAi agent comprises an antisense strand having a 5′ extension of 1, 2, 3, 4, or 5 nucleotides in length. In other embodiments, an HBV RNAi agent comprises an antisense strand having a 5′ extension of 1 or 2 nucleotides in length. In some embodiments, one or more of the antisense strand extension nucleotides comprises uracil or thymidine nucleotides or nucleotides which are complementary to a corresponding HBV mRNA sequence. In some embodiments, the 5′ antisense strand extension includes or consists of, but is no limited to, UA, TU, U. T, UU, TT, CUC (each listed 5′ to 3′). An antisense strand may have any of the 3′ extensions described above in combination with any of the 5′ antisense strand extensions described, if present.
  • an HBV RNAi agent comprises a sense strand having a 3′ extension of 1, 2, 3, 4, or 5 nucleotides in length.
  • one or more of the sense strand extension nucleotides comprises adenosine, uracil, or thymidine nucleotides, AT dinucleotide, or nucleotides which correspond to nucleotides in the HBV mRNA sequence.
  • the 3′ sense strand extension includes or consists of, but is not limited to: T, UT, TT, UU, UUT, TTT, or TTIT (each listed 5′ to 3′).
  • the 3′ end of the sense strand may include additional abasic nucleosides.
  • UUAb, UAb, or Ab may be added to the 3′ end of the sense strand.
  • the one or more abasic nucleosides added to the 3′ end of the sense strand may be inverted (invAb).
  • one or more inverted abasic nucleosides may be inserted between the targeting ligand and the nucleobase sequence of the sense strand of the RNAi agent.
  • the inclusion of one or more inverted abasic nucleosides at or near the terminal end or terminal ends of the sense strand of an RNAi agent may allow for enhanced activity or other desired properties of an RNAi agent.
  • an HBV RNAi agent comprises a sense strand having a 5′ extension of 1, 2, 3, 4, 5, or 6 nucleotides in length.
  • one or more of the sense strand extension nucleotides comprise uracil or adenosine nucleotides or nucleotides which correspond to nucleotides in the HBV mRNA sequence.
  • the sense strand 5′ extension can be, but is not limited to: CA, AUAGGC, AUAGG, AUAG. AUA. A, AA, AC, GCA, GGCA, GGC, UAUCA, UAUC, UCA. UAU, U, UU (each listed 5′ to 3′).
  • a sense strand may have a 3′ extension and/or a 5′ extension.
  • the 5′ end of the sense strand may include an additional abasic nucleoside (Ab) or nucleosides (AbAb).
  • the one or more abasic nucleosides added to the 5′ end of the sense strand may be inverted (invAb).
  • one or more inverted abasic nucleosides may be inserted between the targeting ligand and the nucleobase sequence of the sense strand of the RNAi agent.
  • the inclusion of one or more inverted abasic nucleosides at or near the terminal end or terminal ends of the sense strand of an RNAi agent may allow for enhanced activity or other desired properties of an RNAi agent.
  • an HBV RNAi agent antisense strand includes a nucleotide sequence of any of the sequences in Table 3.
  • an HBV RNAi agent antisense strand includes the sequence of nucleotides 1-17, 2-15, 2-17, 1-18, 2-18, 1-19, 2-19, 1-20, 2-20, 1-21, 2-21, 1-22, 2-22, 1-23, 2-23, 1-24, 2-24, 1-25, 2-25, 1-26, or 2-26 of any of the sequences in Table 3.
  • an HBV RNAi agent sense strand includes the nucleotide sequence of any of the sequences in Table 4.
  • an HBV RNAi agent sense strand includes the sequence of nucleotides 1-18, 1-19, 1-20, 1-21, 1-22, 1-23, 1-24, 1-25, 1-26, 2-19, 2-20, 2-21, 2-22, 2-23, 2-24, 2-25, 2-26, 3-20, 3-21, 3-22, 3-23, 3-24, 3-25, 3-26, 4-21, 4-22, 4-23, 4-24, 4-25, 4-26, 5-22, 5-23, 5-24, 5-25, 5-26, 6-23, 6-24, 6-25, 6-26, 7-24, 7-25, 7-25, 8-25, 8-26 of any of the sequences in Table 4.
  • the sense and antisense strands of the RNAi agents described herein contain the same number of nucleotides. In some embodiments, the sense and antisense strands of the RNAi agents described herein contain different numbers of nucleotides. In some embodiments, the sense strand 5′ end and the antisense strand 3′ end of an RNAi agent form a blunt end. In some embodiments, the sense strand 3′ end and the antisense strand 5′ end of an RNAi agent form a blunt end. In some embodiments, both ends of an RNAi agent form blunt ends. In some embodiments, neither end of an RNAi agent is blunt-ended.
  • blunt end refers to an end of a double stranded RNAi agent in which the terminal nucleotides of the two annealed strands are complementary (form a complementary base-pair).
  • the sense strand 5′ end and the antisense strand 3′ end of an RNAi agent form a frayed end.
  • the sense strand 3′ end and the antisense strand 5′ end of an RNAi agent form a frayed end.
  • both ends of an RNAi agent form a frayed end.
  • neither end of an RNAi agent is a frayed end.
  • a frayed end refers to an end of a double stranded RNAi agent in which the terminal nucleotides of the two annealed strands from a pair (i.e. do not form an overhang) but are not complementary (i.e. form a non-complementary pair).
  • an overhang is a stretch of one or more unpaired nucleotides at the end of one strand of a double stranded RNAi agent.
  • the unpaired nucleotides may be on the sense strand or the antisense strand, creating either 3′ or 5′ overhangs.
  • the RNAi agent contains: a blunt end and a frayed end, a blunt end and 5′ overhang end, a blunt end and a 3′ overhang end, a frayed end and a 5′ overhang end, a frayed end and a 3′ overhang end, two 5′ overhang ends, two 3′ overhang ends, a 5′ overhang end and a 3′ overhang end, two frayed ends, or two blunt ends.
  • a nucleotide base is a heterocyclic pyrimidine or purine compound which is a constituent of all nucleic acids and includes adenine (A), guanine (G), cytosine (C), thymine (T), and uracil (U).
  • nucleotide can include a modified nucleotide (such as, for example, a nucleotide mimic, abasic site (Ab), or a surrogate replacement moiety).
  • Modified nucleotides when used in various polynucleotide or oligonucleotide constructs, may preserve activity of the compound in cells while at the same time increasing the serum stability of these compounds, and can also minimize the possibility of activating interferon activity in humans upon administering of the polynucleotide or oligonucleotide construct.
  • an HBV RNAi agent is prepared or provided as a salt, mixed salt, or a free-acid. In some embodiments, an HBV RNAi agent is prepared as a sodium salt. Such forms are within the scope of the inventions disclosed herein.
  • an HBV RNAi agent contains one or more modified nucleotides.
  • a “modified nucleotide” is a nucleotide other than a ribonucleotide (2′-hydroxyl nucleotide).
  • at least 50% (e.g., at least 600/%, at least 70%, at least 80%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100%) of the nucleotides are modified nucleotides.
  • modified nucleotides include, but are not limited to, deoxyribonucleotides, nucleotide mimics, abasic nucleotides (represented herein as Ab), 2′-modified nucleotides, 3′ to 3′ linkages (inverted) nucleotides (represented herein as invdN, invN, invn, invAb), non-natural base-comprising nucleotides, bridged nucleotides, peptide nucleic acids (PNAs), 2′,3′-seco nucleotide mimics (unlocked nucleobase analogues, represented herein as N UNA or NUNA), locked nucleotides (represented herein as N LNA or NLNA), 3′-O-methoxy (2′ internucleoside linked) nucleotides (represented herein as 3′-OMen), 2′-F-Arabino nucleotides (represented herein as NfANA or Nf ANA
  • 2′-modified nucleotides include, but are not limited to, 2′-O-methyl nucleotides (represented herein as a lower case letter ‘n’ in a nucleotide sequence), 2′-deoxy-2′-fluoro nucleotides (represented herein as Nf, also represented herein as 2′-fluoro nucleotide), 2′-deoxy nucleotides (represented herein as dN), 2′-methoxyethyl (2′-O-2-methoxylethyl) nucleotides (represented herein as NM or 2′-MOE), 2′-amino nucleotides, and 2′-alkyl nucleotides.
  • 2′-O-methyl nucleotides represented herein as a lower case letter ‘n’ in a nucleotide sequence
  • 2′-deoxy-2′-fluoro nucleotides represented herein as Nf, also represented herein as 2′-fluoro nucleot
  • HBV RNAi agent sense strands and antisense strands may be synthesized and/or modified by methods known in the art. Modification at one nucleotide is independent of modification at another nucleotide.
  • Modified nucleobases include synthetic and natural nucleobases, such as 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and 0-6 substituted purines, (e.g., 2-aminopropyladenine, 5-propynyluracil, or 5-propynylcytosine), 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-alkyl (e.g., 6-methyl, 6-ethyl, 6-isopropyl, or 6-n-butyl) derivatives of adenine and guanine, 2-alkyl (e.g., 2-methyl, 2-ethyl, 2-isopropyl, or 2-n-butyl) and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine, 2-thiocytosine, 5-halouracil, cyto
  • all or substantially all of the nucleotides of an RNAi agent are modified nucleotides.
  • an RNAi agent wherein substantially all of the nucleotides present are modified nucleotides is an RNAi agent having four or fewer (i.e., 0, 1, 2, 3, or 4) nucleotides in both the sense strand and the antisense strand being ribonucleotides.
  • a sense strand wherein substantially all of the nucleotides present are modified nucleotides is a sense strand having two or fewer (i.e., 0, 1, or 2) nucleotides in the sense strand being ribonucleotides.
  • an antisense sense strand wherein substantially all of the nucleotides present are modified nucleotides is an antisense strand having two or fewer (i.e., 0, 1, or 2) nucleotides in the sense strand being ribonucleotides.
  • one or more nucleotides of an RNAi agent is a ribonucleotide.
  • one or more nucleotides of an HBV RNAi agent are linked by non-standard linkages or backbones (i.e., modified internucleoside linkages or modified backbones).
  • a modified internucleoside linkage is a non-phosphate-containing covalent internucleoside linkage.
  • Modified internucleoside linkages or backbones include, but are not limited to, 5′-phosphorothioate groups (represented herein as a lower case “s”), chiral phosphorothioates, thiophosphates, phosphorodithioates, phosphotriesters, aminoalkyl-phosphotriesters, alkyl phosphonates (e.g., methyl phosphonates or 3′-alkylene phosphonates), chiral phosphonates, phosphinates, phosphoramidates (e.g., 3′-amino phosphoramidate, aminoalkylphosphoramidates, or thionophosphoramidates), thionoalkyl-phosphonates, thionoalkylphosphotriesters, morpholino linkages, boranophosphates having normal 3′-5′ linkages, 2′-5′ linked analogs of boranophosphates, or boranophosphates having inverted polarity wherein the adjacent pairs of nu
  • a modified internucleoside linkage or backbone lacks a phosphorus atom.
  • Modified internucleoside linkages lacking a phosphorus atom include, but are not limited to, short chain alkyl or cycloalkyl inter-sugar linkages, mixed heteroatom and alkyl or cycloalkyl inter-sugar linkages, or one or more short chain heteroatomic or heterocyclic inter-sugar linkages.
  • modified internucleoside backbones include, but are not limited to, siloxane backbones, sulfide backbones, sulfoxide backbones, sulfone backbones, formacetl and thioformacetyl backbones, methylene formacetyl and thioformacetyl backbones, alkene-containing backbones, sulfamate backbones, methyleneimino and methylenehydrazino backbones, sulfonate and sulfonamide backbones, amide backbones, and other backbones having mixed N, O, S, and CH 2 components.
  • a sense strand of an HBV RNAi agent can contain 1, 2, 3, 4, 5, or 6 phosphorothioate linkages
  • an antisense strand of an HBV RNAi agent can contain 1, 2, 3, 4, 5, or 6 phosphorothioate linkages
  • both the sense strand and the antisense strand independently can contain 1, 2, 3, 4, 5, or 6 phosphorothioate linkages.
  • a sense strand of an HBV RNAi agent can contain 1, 2, 3, or 4 phosphorothioate linkages
  • an antisense strand of an HBV RNAi agent can contain 1, 2, 3, or 4 phosphorothioate linkages
  • both the sense strand and the antisense strand independently can contain 1, 2, 3, or 4 phosphorothioate linkages.
  • an HBV RNAi agent sense strand contains at least two phosphorothioate internucleoside linkages. In some embodiments, the at least two phosphorothioate internucleoside linkages are between the nucleotides at positions 1-3 from the 3′ end of the sense strand. In some embodiments, the at least two phosphorothioate internucleoside linkages are between the nucleotides at positions 1-3, 2-4, 3-5, 4-6, 4-5, or 6-8 from the 5′ end of the sense strand. In some embodiments, an HBV RNAi agent antisense strand contains four phosphorothioate internucleoside linkages.
  • the four phosphorothioate internucleoside linkages are between the nucleotides at positions 1-3 from the 5′ end of the sense strand and between the nucleotides at positions 19-21, 20-22, 21-23, 22-24, 23-25, or 24-26 from the 5′ end.
  • an HBV RNAi agent contains at least two phosphorothioate internucleoside linkages in the sense strand and three or four phosphorothioate internucleoside linkages in the antisense strand.
  • an HBV RNAi agent contains one or more modified nucleotides and one or more modified internucleoside linkages. In some embodiments, a 2′-modified nucleoside is combined with modified internucleoside linkage.
  • the HBV RNAi agents disclosed herein target an HBV gene at or near the positions of the HBV genome shown in the following Table 1.
  • the antisense strand of an HBV RNAi agent disclosed herein includes a core stretch sequence that is fully, substantially, or at least partially complementary to a target HBV 19-mer sequence disclosed in Table 1.
  • HBV 19-mer HBV cDNA target sequences for HBV RNAi agents taken from Hepatitis B virus (subtype ADW2), genotype A, complete genome GenBank AM282986.1 (SEQ ID NO: 1)).
  • HBV 19-mer Genome Region of SEQ Target Sequence Position of HBV Gene ID No. (5′ ⁇ 3′) SEQ ID NO: 1 Targeted 2 GTGGTGGACTTCTCTCAAT 256-274 S ORF 3 TGGTGGACTTCTCTCAATT 257-275 S ORF 4 GGACTTCTCTCAATTTTCT 261-279 S ORF 5 GCTGTAGGCATAAATTGGT 1780-1798 X ORF 6 CTGTAGGCATAAATTGGTC 1781-1799 X ORF
  • an HBV RNAi agent includes an antisense strand wherein position 19 of the antisense strand (5′ ⁇ 3′) is capable of forming a base pair with position 1 of a 19-mer target sequence disclosed in Table 1. In some embodiments, an HBV RNAi agent includes an antisense strand wherein position 1 of the antisense strand (5′ ⁇ 3′) is capable of forming a base pair with position 19 of the 19-mer target sequence disclosed in Table 1.
  • an HBV RNAi agent includes an antisense strand wherein position 2 of the antisense strand (5′ ⁇ 3′) is capable of forming a base pair with position 18 of the 19-mer target sequence disclosed in Table 1. In some embodiments, an HBV RNAi agent includes an antisense strand wherein positions 2 through 18 of the antisense strand (5′ ⁇ 3′) are capable of forming base pairs with each of the respective complementary bases located at positions 18 through 2 of the 19-mer target sequence disclosed in Table 1.
  • the HBV RNAi agents include core 19-mer nucleotide sequences shown in the following Table 2.
  • the HBV RNAi agent sense strands and antisense strands that comprise or consist of the nucleotide sequences in Table 2 can be modified nucleotides or unmodified nucleotides.
  • the HBV RNAi agents having the sense and antisense strand sequences that comprise or consist of the nucleotide sequences in Table 2 are all or substantially all modified nucleotides.
  • the antisense strand of an HBV RNAi agent disclosed herein differs by 0, 1, 2, or 3 nucleotides from any of the antisense strand sequences in Table 2. In some embodiments, the sense strand of an HBV RNAi agent disclosed herein differs by 0, 1, 2, or 3 nucleotides from any of the sense strand sequences in Table 2.
  • Modified HBV RNAi agent antisense strand sequences are provided in Table 3.
  • Modified HBV RNAi agent sense strands are provided in Table 4.
  • each of the nucleotides in each of the unmodified sequences listed in Tables 3 and 4 may be a modified nucleotide.
  • the terminal nucleotide at the 3′ end of a given oligonucleotide sequence would typically have a hydroxyl (—OH) group at the respective 3′ position of the given monomer instead of a phosphate moiety ex vivo.
  • the “g” modified nucleotide on the terminal 3′ end of the antisense strand of AM06606-AS has a hydroxyl group positioned at its 3′ position.
  • Targeting groups and linking groups include the following, for which their chemical structures are provided below in Table 6: (PAZ), (NAG13), (NAG13)s, (NAG18), (NAG18)s, (NAG24), (NAG24)s, (NAG25), (NAG25)s, (NAG26), (NAG26)s, (NAG27), (NAG27)s, (NAG28), (NAG28)s, (NAG29), (NAG29)s, (NAG30), (NAG30)s, (NAG31), (NAG31)s, (NAG32), (NAG32)s, (NAG33), (NAG33)s, (NAG34), (NAG34)s, (NAG35), (NAG35)s, (NAG36), (NAG36)s, (NAG37), (NAG37)s, (NAG38), (NAG38)s, (NAG39), (NAG39)s.
  • the HBV RNAi agents described herein are formed by annealing an antisense strand with a sense strand.
  • a sense strand containing a sequence listed in Table 4 can be hybridized to any antisense strand containing a sequence listed in Table 3, provided the two sequences have a region of at least about 85% complementarity over a contiguous 16, 17, 18, 19, 20, or 21 nucleotide sequence.
  • the antisense strand of an HBV RNAi agent disclosed herein differs by 0, 1, 2, or 3 nucleotides from any of the antisense strand sequences in Table 3. In some embodiments, the sense strand of an HBV RNAi agent disclosed herein differs by 0, 1, 2, or 3 nucleotides from any of the sense strand sequences in Table 4.
  • an HBV RNAi agent antisense strand comprises a nucleotide sequence of any of the sequences in Table 3. In some embodiments, an HBV RNAi agent antisense strand comprises the sequence of nucleotides (from 5′ end ⁇ 3′ end) 1-17, 2-17, 1-18, 2-18, 1-19, 2-19, 1-20, 2-20, 1-21, 2-21, 1-22, 2-22, 1-23, 2-23, 1-24, 2-24, 1-25, 2-25, 1-26, or 2-26 of any of the sequences in Table 3.
  • an HBV RNAi agent sense strand comprises the nucleotide sequence of any of the sequences in Table 4. In some embodiments, an HBV RNAi agent sense strand comprises the sequence of nucleotides (from 5′ end ⁇ 3′ end) 1-17, 2-17, 3-17, 4-17, 1-18, 2-18, 3-18, 4-18, 1-19, 2-19, 3-19, 4-19, 1-20, 2-20, 3-20, 4-20, 1-21, 2-21, 3-21, 4-21, 1-22, 2-22, 3-22, 4-22, 1-23, 2-23, 3-23, 4-23, 1-24, 2-24, 3-24, 4-24, 1-25, 2-25, 3-25, 4-25, 1-26, 2-26, 3-26, or 4-26 of any of the sequences in Table 4.
  • the nucleotide at position 1 of the antisense strand can be perfectly complementary to an HBV gene, or can be non-complementary to an HBV gene.
  • the nucleotide at position 1 of the antisense strand is a U, A, or dT.
  • the nucleotide at position 1 of the antisense strand forms an A:U or U:A base pair with the sense strand.
  • an HBV RNAi agent antisense strand comprises the sequence of nucleotides (from 5′ end ⁇ 3′ end) 2-18 or 2-19 of any of the antisense strand sequences in Table 3.
  • an HBV RNAi sense strand comprises the sequence of nucleotides (from 5′ end ⁇ 3′ end) 1-17 or 1-18 of any of the sense strand sequences in Table 4.
  • an HBV RNAi agent includes (i) an antisense strand comprising the sequence of nucleotides (from 5′ end ⁇ 3′ end) 2-18 or 2-19 of any of the antisense strand sequences in Table 3, and (ii) a sense strand comprising the sequence of nucleotides (from 5′ end ⁇ 3′ end) 1-17 or 1-18 of any of the sense strand sequences in Table 4.
  • a sense strand containing a sequence listed in Table 4 can be hybridized to any antisense strand containing a sequence listed in Table 3 provided the two sequences have a region of at least about 85% complementarity over a contiguous 16, 17, 18, 19, 20, or 21 nucleotide sequence.
  • Representative sequence pairings are exemplified by the Duplex ID Nos. shown in Table 5.
  • an HBV RNAi agent comprises of any of the Duplex ID Nos. presented herein. In some embodiments, an HBV RNAi agent consists of any of the Duplex ID Nos. presented herein. In some embodiments, an HBV RNAi agent comprises the sense strand and/or the antisense strand nucleotide sequences of any of the Duplex ID Nos. presented herein. In some embodiments, an HBV RNAi agent comprises the sense strand and antisense strand nucleotide sequences of any of the Duplex ID Nos. presented herein and a targeting group and/or linking group wherein the targeting group and/or linking group is covalently linked (i.e. conjugated) to the sense strand or the antisense strand.
  • an HBV RNAi agent comprises the sense strand and antisense strand modified nucleotide sequences of any of the Duplex ID Nos. presented herein. In some embodiments, an HBV RNAi agent comprises the sense strand and antisense strand modified nucleotide sequences of any of the Duplex ID Nos. presented herein and a targeting group and/or linking group wherein the targeting group and/or linking group is covalently linked to the sense strand or the antisense strand.
  • an HBV RNAi agent comprises an antisense strand and a sense strand having the nucleotide sequences of any of the antisense strand/sense strand duplexes of Table 5, and further comprises an asialoglycoprotein receptor ligand targeting group.
  • an HBV RNAi agent comprises an antisense strand and a sense strand having the nucleotide sequences of any of the antisense strand and/or sense strand nucleotide sequences of any of the duplexes of Table 5, and further comprises a targeting group selected from the group consisting of (PAZ), (NAG13), (NAG13)s, (NAG18), (NAG18)s, (NAG24), (NAG24)s, (NAG25), (NAG25)s, (NAG26), (NAG26)s, (NAG27), (NAG27)s, (NAG28), (NAG28)s, (NAG29), (NAG29)s, (NAG30), (NAG30)s, (NAG31), (NAG31)s, (NAG32), (NAG32)s, (NAG33), (NAG33)s, (NAG34), (NAG34)s, (NAG35), (NAG35)s, (NAG35)s
  • an HBV RNAi agent comprises an antisense strand and a sense strand having the modified nucleotide sequences of any of the antisense strand and/or sense strand nucleotide sequences of any of the duplexes of Table 5.
  • an HBV RNAi agent comprises an antisense strand and a sense strand having the modified nucleotide sequences of any of the antisense strand and/or sense strand nucleotide sequences of any of the duplexes of Table 5, and further comprises an asialoglycoprotein receptor ligand targeting group.
  • an HBV RNAi agent comprises any of the duplexes of Table 5.
  • an HBV RNAi agent consists of any of the duplexes of Table 5.
  • an HBV RNAi agent is prepared or provided as a salt, mixed salt, or a free-acid.
  • the RNAi agents described herein upon delivery to a cell expressing an HBV gene, inhibit or knockdown expression of one or more HBV genes in vivo.
  • an HBV RNAi agent is conjugated to one or more non-nucleotide groups including, but not limited to a targeting group, linking group, delivery polymer, or a delivery vehicle.
  • the non-nucleotide group can enhance targeting, delivery or attachment of the RNAi agent. Examples of targeting groups and linking groups are provided in Table 6.
  • the non-nucleotide group can be covalently linked to the 3′ and/or 5′ end of either the sense strand and/or the antisense strand.
  • an HBV RNAi agent contains a non-nucleotide group linked to the 3′ and/or 5′ end of the sense strand.
  • a non-nucleotide group is linked to the 5′ end of an HBV RNAi agent sense strand.
  • a non-nucleotide group may be linked directly or indirectly to the RNAi agent via a linker/linking group.
  • a non-nucleotide group is linked to the RNAi agent via a labile, cleavable, or reversible bond or linker.
  • a non-nucleotide group enhances the pharmacokinetic or biodistribution properties of an RNAi agent or conjugate to which it is attached to improve cell- or tissue-specific distribution and cell-specific uptake of the conjugate. In some embodiments, a non-nucleotide group enhances endocytosis of the RNAi agent.
  • Targeting groups or targeting moieties enhance the pharmacokinetic or biodistribution properties of a conjugate to which they are attached to improve cell-specific distribution and cell-specific uptake of the conjugate.
  • a targeting group can be monovalent, divalent, trivalent, tetravalent, or have higher valency.
  • Representative targeting groups include, without limitation, compounds with affinity to cell surface molecule, cell receptor ligands, hapten, antibodies, monoclonal antibodies, antibody fragments, and antibody mimics with affinity to cell surface molecules.
  • a targeting group is linked to an RNAi agent using a linker, such as a PEG linker or one, two, or three abasic and/or ribitol (abasic ribose) groups.
  • a targeting group comprises a galactose derivative cluster.
  • the HBV RNAi agents described herein may be synthesized having a reactive group, such as an amine group, at the 5′-terminus.
  • the reactive group may be used to subsequently attach a targeting moiety using methods typical in the art.
  • a targeting group comprises an asialoglycoprotein receptor ligand.
  • an asialoglycoprotein receptor ligand includes or consists of one or more galactose derivatives.
  • galactose derivative includes both galactose and derivatives of galactose having affinity for the asialoglycoprotein receptor that is equal to or greater than that of galactose.
  • Galactose derivatives include, but are not limited to: galactose, galactosamine, N-formylgalactosamine, N-acetyl-galactosamine, N-propionyl-galactosamine, N-n-butanoyl-galactosamine, and N-iso-butanoylgalactos-amine (see for example: Iobst. S. T. and Drickamer, K. J.B.C. 1996, 271, 6686).
  • Galactose derivatives, and clusters of galactose derivatives, that are useful for in vivo targeting of oligonucleotides and other molecules to the liver are known in the art (see, for example, Baenziger and Fiete, 1980. Cell, 22, 611-620; Connolly et al., 1982, J. Biol. Chem., 257, 939-945).
  • Galactose derivatives have been used to target molecules to hepatocytes in vivo through their binding to the asialoglycoprotein receptor (ASGPr) expressed on the surface of hepatocytes.
  • ASGPr asialoglycoprotein receptor
  • ASGPr ligands Binding of ASGPr ligands to the ASGPr(s) facilitates cell-specific targeting to hepatocytes and endocytosis of the molecule into hepatocytes.
  • ASGPr ligands can be monomeric (e.g., having a single galactose derivative) or multimeric (e.g., having multiple galactose derivatives).
  • the galactose derivative or galactose derivative cluster may be attached to the 3′ or 5′ end of the RNAi polynucleotide using methods known in the art.
  • the preparation of targeting groups, such as galactose derivative clusters is described in, for example, U.S. patent application Ser. Nos. 15/452,324 and 15/452,423, the contents of both of which are incorporated herein in their entirety.
  • a galactose derivative cluster comprises a molecule having two to four terminal galactose derivatives. A terminal galactose derivative is attached to a molecule through its C-1 carbon.
  • the galactose derivative cluster is a galactose derivative trimer (also referred to as tri-antennary galactose derivative or tri-valent galactose derivative).
  • the galactose derivative cluster comprises N-acetyl-galactosamines.
  • the galactose derivative cluster comprises three N-acetyl-galactosamines.
  • the galactose derivative cluster is a galactose derivative tetramer (also referred to as tetra-antennary galactose derivative or tetra-valent galactose derivative). In some embodiments, the galactose derivative cluster comprises four N-acetyl-galactosamines.
  • a galactose derivative trimer contains three galactose derivatives, each linked to a central branch point.
  • a galactose derivative tetramer contains four galactose derivatives, each linked to a central branch point.
  • the galactose derivatives can be attached to the central branch point through the C-1 carbons of the saccharides.
  • the galactose derivatives are linked to the branch point via linkers or spacers.
  • the linker or spacer is a flexible hydrophilic spacer, such as a PEG group (see, for example, U.S. Pat. No. 5,885,968; Biessen et al. J. Med. Chem. 1995 Vol.
  • the PEG spacer is a PEG 3 spacer.
  • the branch point can be any small molecule which permits attachment of three galactose derivatives and further permits attachment of the branch point to the RNAi agent.
  • An example of branch point group is a di-lysine or di-glutamate. Attachment of the branch point to the RNAi agent can occur through a linker or spacer.
  • the linker or spacer comprises a flexible hydrophilic spacer, such as, but not limited to, a PEG spacer.
  • the linker comprises a rigid linker, such as a cyclic group.
  • a galactose derivative comprises or consists of N-acetyl-galactosamine.
  • the galactose derivative cluster is comprised of a galactose derivative tetramer, which can be, for example, an N-acetyl-galactosamine tetramer.
  • compositions for delivering an HBV RNAi agent to a liver cell in vivo are described.
  • Such pharmaceutical compositions can include, for example, an HBV RNAi agent conjugated to a galactose derivative cluster.
  • the galactose derivative cluster is comprised of a galactose derivative trimer, which can be, for example, an N-acetyl-galactosamine trimer, or galactose derivative tetramer, which can be, for example, an N-acetyl-galactosamine tetramer.
  • Targeting groups include, but are not limited to, (PAZ), (NAG13), (NAG13)s, (NAG18), (NAG18)s, (NAG24), (NAG24)s, (NAG25), (NAG25)s, (NAG26), (NAG26)s, (NAG27), (NAG27)s, (NAG28), (NAG28)s, (NAG29), (NAG29)s, (NAG30), (NAG30)s, (NAG31), (NAG31)s, (NAG32), (NAG32)s, (NAG33), (NAG33)s, (NAG34), (NAG34)s, (NAG35), (NAG35)s, (NAG36), (NAG36)s, (NAG37), (NAG37)s, (NAG38), (NAG38)s, (NAG39), and (NAG39)s.
  • Other targeting groups including galactose cluster targeting ligands, are known in the
  • a linking group is conjugated to the RNAi agent.
  • the linking group facilitates covalent linkage of the agent to a targeting group or delivery polymer or delivery vehicle.
  • the linking group can be linked to the 3′ or the 5′ end of the RNAi agent sense strand or antisense strand.
  • the linking group is linked to the RNAi agent sense strand.
  • the linking group is conjugated to the 5′ or 3′ end of an RNAi agent sense strand.
  • a linking group is conjugated to the 5′ end of an RNAi agent sense strand.
  • linking groups include, but are not limited to: reactive groups such a primary amines and alkynes, alkyl groups, abasic nucleosides, ribitol (abasic ribose), and/or PEG groups.
  • a linker or linking group is a connection between two atoms that links one chemical group (such as an RNAi agent) or segment of interest to another chemical group (such as a targeting group or delivery polymer) or segment of interest via one or more covalent bonds.
  • a labile linkage contains a labile bond.
  • a linkage may optionally include a spacer that increases the distance between the two joined atoms. A spacer may further add flexibility and/or length to the linkage.
  • Spacers may include, but are not be limited to, alkyl groups, alkenyl groups, alkynyl groups, aryl groups, aralkyl groups, aralkenyl groups, and aralkynyl groups; each of which can contain one or more heteroatoms, heterocycles, amino acids, nucleotides, and saccharides. Spacer groups are well known in the art and the preceding list is not meant to limit the scope of the description.
  • HBV RNAi agent nucleotide sequences listed in Tables 3 and 4 may contain 3′ or 5′ targeting group and/or linking group.
  • Any of the HBV RNAi agent sequences listed in Table 3 and 4 which contain a 3′ or 5′ targeting group and/or linking group may alternatively contain no 3′ or 5′ targeting group and/or linking group, or may contain a different 3′ or 5′ targeting group and/or linking group including, but not limited to, those depicted in Table 3.
  • HBV RNAi agent duplexes listed in Table 5, whether modified or unmodified may further comprise a targeting group and/or linking group, including, but not limited to, those depicted in Table 3, and the targeting group or linking group may be attached to the 3′ or 5′ terminus of either the sense strand or the antisense strand of the HBV RNAi agent duplex.
  • Table 4 provides several embodiments of HBV RNAi agent sense strands having a targeting group or linking group linked to the 5′ or 3′ end.
  • NAG comprises an N-acetyl-galactosamine or another ASGPr ligand, as would be understood by a person of ordinary skill in the art to be attached in view of the structures above and description provided herein.
  • NAG in the structures provided in Table 6 is represented by the following structure:
  • Each (NAGx) may be attached to an HBV RNAi agent via a phosphate group (as in (NAG25), (NAG30), and (NAG31)), or a phosphorothioate group, (as is (NAG25)s, (NAG29)s, (NAG30)s, (NAG31)s, or (NAG37)s), or another linking group.
  • a delivery vehicle may be used to deliver an RNAi agent to a cell or tissue.
  • a delivery vehicle is a compound that improves delivery of the RNAi agent to a cell or tissue.
  • a delivery vehicle can include, or consist of, but is not limited to: a polymer, such as an amphipathic polymer, a membrane active polymer, a peptide, a melittin peptide, a melittin-like peptide (MLP), a lipid, a reversibly modified polymer or peptide, or a reversibly modified membrane active polyamine.
  • the RNAi agents can be combined with lipids, nanoparticles, polymers, liposomes, micelles, DPCs or other delivery systems available in the art.
  • the RNAi agents can also be chemically conjugated to targeting groups, lipids (including, but not limited to cholesterol and cholesteryl derivatives), nanoparticles, polymers, liposomes, micelles, DPCs (see, for example WO 2000/053722, WO 2008/0022309, WO 2011/104169, and WO 2012/083185, WO 2013/032829, WO 2013/158141, each of which is incorporated herein by reference), or other delivery systems available in the art.
  • the HBV RNAi agents disclosed herein may be prepared as pharmaceutical compositions or formulations.
  • pharmaceutical compositions include at least one HBV RNAi agent. These pharmaceutical compositions are particularly useful in the inhibition of the expression of the target mRNA in a target cell, a group of cells, a tissue, or an organism.
  • the pharmaceutical compositions can be used to treat a subject having a disease or disorder that would benefit from reduction in the level of the target mRNA, or inhibition in expression of the target gene.
  • the pharmaceutical compositions can be used to treat a subject at risk of developing a disease or disorder that would benefit from reduction of the level of the target mRNA or an inhibition in expression the target gene.
  • the method includes administering an HBV RNAi agent linked to a targeting ligand as described herein, to a subject to be treated.
  • one or more pharmaceutically acceptable excipients are added to the pharmaceutical compositions including an HBV RNAi agent, thereby forming a pharmaceutical formulation suitable for in vivo delivery to a human.
  • compositions that include an HBV RNAi agent and methods disclosed herein may decrease the level of the target mRNA in a cell, group of cells, group of cells, tissue, or subject, including: administering to the subject a therapeutically effective amount of a herein described HBV RNAi agent, thereby inhibiting the expression of a target mRNA in the subject.
  • the described pharmaceutical compositions including an HBV RNAi agent are used for treating or managing clinical presentations associated with HBV infection.
  • a therapeutically or prophylactically effective amount of one or more of pharmaceutical compositions is administered to a subject in need of such treatment, prevention or management.
  • administration of any of the disclosed HBV RNAi agents can be used to decrease the number, severity, and/or frequency of symptoms of a disease in a subject.
  • the described pharmaceutical compositions including an HBV RNAi agent can be used to treat at least one symptom in a subject having a disease or disorder that would benefit from reduction or inhibition in expression of HBV mRNA.
  • the subject is administered a therapeutically effective amount of one or more pharmaceutical compositions including an HBV RNAi agent thereby treating the symptom.
  • the subject is administered a prophylactically effective amount of one or more HBV RNAi agents, thereby preventing the at least one symptom.
  • the route of administration is the path by which an HBV RNAi agent is brought into contact with the body.
  • methods of administering drugs and nucleic acids for treatment of a mammal are well known in the art and can be applied to administration of the compositions described herein.
  • the HBV RNAi agents disclosed herein can be administered via any suitable route in a preparation appropriately tailored to the particular route.
  • herein described pharmaceutical compositions can be administered by injection, for example, intravenously, intramuscularly, intracutaneously, subcutaneously, intraarticularly, or intraperitoneally. In some embodiments, there herein described pharmaceutical compositions via subcutaneous injection.
  • compositions including an HBV RNAi agent described herein can be delivered to a cell, group of cells, tumor, tissue, or subject using oligonucleotide delivery technologies known in the art.
  • any suitable method recognized in the art for delivering a nucleic acid molecule in vitro or in vivo can be adapted for use with a herein described compositions.
  • delivery can be by local administration, (e.g., direct injection, implantation, or topical administering), systemic administration, or subcutaneous, intravenous, intraperitoneal, or parenteral routes, including intracranial (e.g., intraventricular, intraparenchymal and intrathecal), intramuscular, transdermal, airway (aerosol), nasal, oral, rectal, or topical (including buccal and sublingual) administration.
  • the compositions are administered by subcutaneous or intravenous infusion or injection.
  • the herein described pharmaceutical compositions may comprise one or more pharmaceutically acceptable excipients.
  • the pharmaceutical compositions described herein can be formulated for administration to a subject.
  • a pharmaceutical composition or medicament includes a pharmacologically effective amount of at least one of the described therapeutic compounds and one or more pharmaceutically acceptable excipients.
  • Pharmaceutically acceptable excipients are substances other than the Active Pharmaceutical ingredient (API, therapeutic product, e.g., HBV RNAi agent) that are intentionally included in the drug delivery system.
  • Excipients do not exert or are not intended to exert a therapeutic effect at the intended dosage. Excipients may act to a) aid in processing of the drug delivery system during manufacture, b) protect, support or enhance stability, bioavailability or patient acceptability of the API, c) assist in product identification, and/or d) enhance any other attribute of the overall safety, effectiveness, of delivery of the API during storage or use.
  • a pharmaceutically acceptable excipient may or may not be an inert substance.
  • Excipients include, but are not limited to: absorption enhancers, anti-adherents, anti-foaming agents, anti-oxidants, binders, buffering agents, carriers, coating agents, colors, delivery enhancers, delivery polymers, dextran, dextrose, diluents, disintegrants, emulsifiers, extenders, fillers, flavors, glidants, humectants, lubricants, oils, polymers, preservatives, saline, salts, solvents, sugars, suspending agents, sustained release matrices, sweeteners, thickening agents, tonicity agents, vehicles, water-repelling agents, and wetting agents.
  • compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
  • suitable carriers include physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, N.J.) or phosphate buffered saline. It should be stable under the conditions of manufacture and storage and should be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol), and suitable mixtures thereof.
  • the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • isotonic agents for example, sugars, polyalcohols such as mannitol, sorbitol, and sodium chloride in the composition.
  • Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
  • Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filter sterilization.
  • dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above.
  • methods of preparation include vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • Formulations suitable for intra-articular administration can be in the form of a sterile aqueous preparation of the drug that can be in microcrystalline form, for example, in the form of an aqueous microcrystalline suspension.
  • Liposomal formulations or biodegradable polymer systems can also be used to present the drug for both intra-articular and ophthalmic administration.
  • the active compounds can be prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
  • a controlled release formulation including implants and microencapsulated delivery systems.
  • Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art.
  • Liposomal suspensions can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.
  • the HBV RNAi agents can be formulated in compositions in dosage unit form for ease of administration and uniformity of dosage.
  • Dosage unit form refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • the specification for the dosage unit forms of the disclosure are dictated by and directly dependent on the unique characteristics of the active compound and the therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.
  • a pharmaceutical composition can contain other additional components commonly found in pharmaceutical compositions.
  • additional components include, but are not limited to: anti-pruritics, astringents, local anesthetics, or anti-inflammatory agents (e.g., antihistamine, diphenhydramine, etc.).
  • anti-pruritics e.g., antihistamine, diphenhydramine, etc.
  • anti-inflammatory agents e.g., antihistamine, diphenhydramine, etc.
  • cells, tissues or isolated organs that express or comprise the herein defined RNAi agents may be used as “pharmaceutical compositions.”
  • “pharmacologically effective amount,” “therapeutically effective amount,” or simply “effective amount” refers to that amount of an RNAi agent to produce a pharmacological, therapeutic or preventive result.
  • an effective amount of an active compound will be in the range of from about 0.1 to about 100 mg/kg of body weight/day, e.g., from about 1.0 to about 50 mg/kg of body weight/day. In some embodiments, an effective amount of an active compound will be in the range of from about 0.25 to about 5 mg/kg of body weight per dose. In some embodiments, an effective amount of an active ingredient will be in the range of from about 0.5 to about 3 mg/kg of body weight per dose.
  • the amount administered will also likely depend on such variables as the overall health status of the patient, the relative biological efficacy of the compound delivered, the formulation of the drug, the presence and types of excipients in the formulation, and the route of administration. Also, it is to be understood that the initial dosage administered can be increased beyond the above upper level in order to rapidly achieve the desired blood-level or tissue level, or the initial dosage can be smaller than the optimum.
  • compositions described herein including an HBV RNAi agent can be combined with an excipient or with a second therapeutic agent or treatment including, but not limited to: a second or other RNAi agent, a small molecule drug, an antibody, an antibody fragment, and/or a vaccine.
  • HBV RNAi agents when added to pharmaceutically acceptable excipients or adjuvants, can be packaged into kits, containers, packs, or dispensers.
  • the pharmaceutical compositions described herein may be packaged in pre-filled syringes or vials.
  • the HBV RNAi agents disclosed herein can be used to treat a subject (e.g., a human or mammal) having a disease or disorder that would benefit from administration of the compound.
  • the RNAi agents disclosed herein can be used to treat a subject (e.g., a human) having a disease or disorder that would benefit from reduction or inhibition in expression of HBV mRNA.
  • the subject is administered a therapeutically effective amount of any one or more RNAi agents.
  • the subject can be a human, patient, or human patient.
  • the subject may be an adult, adolescent, child, or infant.
  • the described pharmaceutical compositions including an HBV RNAi agent can be used to provide methods for the therapeutic treatment of diseases. Such methods include administration of a pharmaceutical composition described herein to a human being or animal.
  • the HBV RNAi agents described herein are used to treat a subject infected with HBV.
  • the described HBV RNAi agents are used to treat at least one symptom in a subject having a HBV infection.
  • the subject is administered a therapeutically effective amount of any one or more of the described RNAi agents.
  • the subject has both a HBV infection and a HDV infection.
  • the HBV RNAi agents described herein are used to treat a subject infected with both HBV and HDV.
  • the described HBV RNAi agents are used to treat at least one symptom in a subject having a HBV or a HDV infection.
  • the subject is administered a therapeutically effective amount of any one or more of the described RNAi agents.
  • the HBV RNAi agents are used to treat or manage a clinical presentation wherein a subject infected with HBV.
  • the subject is administered a therapeutically or effective amount of one or more of the HBV RNAi agents or HBV RNAi agent-containing compositions described herein.
  • the method comp rises administering a composition comprising an HBV RNAi agent described herein to a subject to be treated.
  • the gene expression level and/or mRNA level of an HBV gene in a subject to whom a described HBV RNAi agent is administered is reduced by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or greater than 99% relative to the subject prior to being administered the HBV RNAi agent or to a subject not receiving the HBV RNAi agent.
  • the gene expression level and/or mRNA level in the subject may be reduced in a cell, group of cells, and/or tissue of the subject.
  • the expressed protein level of an HBV gene in a subject to whom a described HBV RNAi agent has been administered is reduced by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or greater than 99% relative to the subject prior to being administered the HBV RNAi agent or to a subject not receiving the HBV RNAi agent.
  • the protein level in the subject may be reduced in a cell, group of cells, tissue, blood, and/or other fluid of the subject.
  • the amount or level of Hepatitis B surface antigen (HBsAg) in a subject to whom a described HBV RNAi agent has been administered is reduced by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or greater than 99% relative to the subject prior to being administered the HBV RNAi agent or to a subject not receiving the HBV RNAi agent.
  • the amount or level of Hepatitis B e-antigen (HBeAg) in a subject to whom a described HBV RNAi agent has been administered is reduced by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or greater than 99% relative to the subject prior to being administered the HBV RNAi agent or to a subject not receiving the HBV RNAi agent.
  • the amount or level of serum HBV DNA in a subject to whom a described HBV RNAi agent has been administered is reduced by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%/0, 90%, 95%, 96%, 97%, 98%, 99%, or greater than 99% relative to the subject prior to being administered the HBV RNAi agent or to a subject not receiving the HBV RNAi agent.
  • a reduction in the presence of serum HBV DNA, HBV gene expression, HBV mRNA, or HBV protein amounts or levels may be assessed by methods known in the art. Reduction or decrease in HBV mRNA amount or level, expressed protein amount or level, and/or serum HBV DNA amount or level, are collectively referred to herein as a reduction or decrease in HBV or inhibiting or reducing the expression of HBV.
  • Cells, tissues, and non-human organisms that include at least one of the HBV RNAi agents described herein is contemplated.
  • the cell, tissue, or non-human organism is made by delivering the RNAi agent to the cell, tissue, or non-human organism.
  • HBV RNAi agent duplexes shown in Table 5 were synthesized in accordance with the following:
  • the sense and antisense strands of the HBV RNAi agents were synthesized according to phosphoramidite technology on solid phase used in oligonucleotide synthesis. Depending on the scale, either a MerMade96E® (Bioautomation), a MerMade12® (Bioautomation), or an OP Pilot 100 (GE Healthcare) was used. Syntheses were performed on a solid support made of controlled pore glass (CPG, 500 ⁇ or 600 ⁇ , obtained from Prime Synthesis, Aston, Pa., USA). All RNA and 2′-modified phosphoramidites were purchased from Thermo Fisher Scientific (Milwaukee, Wis., USA).
  • 2′-O-methyl phosphoramidites were used: (5′-O-dimethoxytrityl-N 6 -(benzoyl)-2′-O-methyl-adenosine-3′-O-(2-cyanoethyl-N,N-diisopropylamino) phosphoramidite, 5′-O-dimethoxy-tritvl-N 4 -(acetyl)-2′-O-methyl-cytidine-3′-O-(2-cyanoethyl-N,N-diisopropyl-amino) phosphoramidite, (5′-O-dimethoxytrityl-N 2 -(isobutyryl)-2′-O-methyl-guanosine-3′-O-(2-cyanoethyl-N,N-diisopropylamino) phosphoramidite, and 5′-O-dimethoxytrityl-2′-O-methyl-uridine
  • the 2′-deoxy-2′-fluoro-phosphoramidites carried the same protecting groups as the 2′-O-methyl amidites.
  • the abasic (3′-O-dimethoxytrityl-2′-deoxyribose-5′-O-(2-cyanoethyl-N,N-diisopropylanino) phosphoramidites were purchased from ChemGenes (Wilmington, Mass., USA).
  • Targeting ligand containing phosphoramidites were dissolved in anhydrous dichloromethane or anhydrous acetonitrile (50 mM), while all other amidites were dissolved in anhydrous acetonitrile (50 mM) and molecular sieves (3 ⁇ ) were added.
  • 5-Benzylthio-1H-tetrazole (BTT, 250 mM in acetonitrile) or 5-Ethylthio-1H-tetrazole (ETT, 250 mM in acetonitrile) was used as activator solution. Coupling times were 12 min (RNA), 15 min (targeting ligand), 90 sec (2′OMe), and 60 sec (2′F).
  • the dried solid support was treated with a 1:1 volume solution of 40 wt. % methylamine in water and 28% ammonium hydroxide solution (Aldrich) for 1.5 hours at 30° C. The solution was evaporated and the solid residue was reconstituted in water (see below).
  • Crude oligomers were purified by anionic exchange HPLC using a TSKgel SuperQ-5PW 13 ⁇ m column and Shimadzu LC-8 system.
  • Buffer A was 20 mM Tris, 5 mM EDTA, pH 9.0 and contained 20%0/Acetonitrile and buffer B was the same as buffer A with the addition of 1.5 M sodium chloride. UV traces at 260 nm were recorded. Appropriate fractions were pooled then run on size exclusion HPLC using a GE Healthcare XK 26/40 column packed with Sephadex G-25 fine with a running buffer of filtered DI water or 100 mM ammonium bicarbonate, pH 6.7 and 20% Acetonitrile.
  • RNAi agents were lyophilized and stored at ⁇ 15 to ⁇ 25° C.
  • Duplex concentration was determined by measuring the solution absorbance on a UV-Vis spectrometer in 1 ⁇ Phosphate-Buffered Saline. The solution absorbance at 260 nm was then multiplied by a conversion factor and the dilution factor to determine the duplex concentration. Unless otherwise stated, all conversion factor was 0.037 mg/(mL-cm). For some experiments, a conversion factor was calculated from an experimentally determined extinction coefficient.
  • NOD-SCID mice Six to eight-week-old female NOD.CB17-Prkdscid/NcrCrl (NOD-SCID) mice were transiently transfected in vivo with MC-HBV1.3 by hydrodynamic tail vein injection (Yang P L et al. “Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection,” PNAS USA 2002 Vol. 99: p. 13825-13830), administered 30 to 45 days prior to administration of an HBV RNAi agent or control.
  • MC-HBV1.3 is a plasmid-derived minicircle that contains the same terminally redundant human hepatitis B virus sequence HBV1.3 as in plasmid pHBV1.3 and in the HBV1.3.32 transgenic mice (GenBank accession #V01460) (Guidotti L G et al., “High-level hepatitis B virus replication in transgenic mice,” J Virol 1995 Vol. 69, p 6158-6169.). 5 or 10 ⁇ g MC-HBV1.3 in Ringer's Solution in a total volume of 10% of the animal's body weight was injected into mice via tail vein to create pHBV model of chronic HBV infection.
  • HBsAg Hepatitis B surface antigen
  • HBV expression levels were normalized to pre-administration expression levels and to control mice injected with phosphate buffered saline (“PBS”).
  • PBS phosphate buffered saline
  • mice were anesthetized with 2-3% isoflurane and blood samples were collected from the submandibular area into serum separation tubes (Sarstedt AG & Co., Nümbrecht, Germany). Blood was allowed to coagulate at ambient temperature for 20 min. The tubes were centrifuged at 8,000 ⁇ g for 3 min to separate the serum and stored at 4° C.
  • HBsAg levels were determined with a GS HBsAg EIA 3.0 kit (Bio-Rad Laboratories, Inc., Redmond, Wash.) as described by the manufacturer. Recombinant HBsAg protein, ayw subtype, also diluted in nonfat milk in PBS, was used as a primary standard (Aldevron).
  • HBsAg expression for each animal was normalized to the control group of mice injected with PBS in order to account for the non-treatment related decline in expression of MC-HBV1.3.
  • the HBsAg level for each animal at a time point was divided by the pre-treatment level of expression in that animal in order to determine the ratio of expression “normalized to pre-treatment”.
  • Expression at a specific time point was then normalized to the control group by dividing the “normalized to pre-treatment” ratio for an individual animal by the average “normalized to pre-treatment” ratio of all mice in the normal PBS control group.
  • HBeAg analysis was performed with the HBeAg enzyme linked immunosorbent assay (ELISA) as described by the manufacturer (DiaSorin) using serum diluted 4- to 20-fold in 5% nonfat dry milk. The amount of antigen was determined in the linear range of the assay and quantitated against HBeAg protein standards (Fitzgerald Industries International, catalog #30-AH18, Acton, Mass.).
  • ELISA enzyme linked immunosorbent assay
  • HBeAg expression for each animal was normalized to the control group of mice injected with PBS in order to account for the non-treatment related decline in expression of MC-HBV1.3.
  • HBeAg is analyzed from pooled group or subgroup serum samples. First, the HBeAg level for each pooled group or subgroup was divided by the pre-treatment level of expression in the same group or subgroup in order to determine the ratio of expression “normalized to pre-treatment”. Expression at a specific time point was then normalized to the control group by dividing the “normalized to pre-treatment” ratio for a group or subgroup by the average “normalized to pre-treatment” ratio of all samples from the normal PBS control group.
  • Equal volumes of serum from mice in a group or subgroup were pooled to a final volume of 100 ⁇ L.
  • DNA was isolated from serum samples using the QIAamp MinElute Virus Spin Kit (Qiagen, Valencia, Calif.) following the manufacturer's instructions. Sterile 0.9% saline was added to each sample to a final volume of 200 ⁇ L. Serum samples were added to tubes containing buffer and protease. Carrier RNA was added to aid in the isolation of small amounts of DNA. 1 ng of pHCR/UbC-SEAP plasmid DNA (Wooddell C I, et al.
  • the number of copies of HBV genomes in DNA isolated from the pHBV mouse model serum was determined by qPCR. Plasmid pSEAP-HBV353-777, encoding a short segment of the HBV genome within the S gene (bases 353-777 of GenBank accession #V01460), was used to create a six log standard curve. Samples with recovery of DNA below 2 standard deviations from the average, based on detection of pHCR/UbC-SEAP were omitted. TaqMan chemistry-based primers and probes with fluor/ZEN/IBFQ are utilized.
  • qPCR assays were performed on a 7500 Fast or StepOne Plus Real-Time PCR system (Life Technologies).
  • DNA was isolated from singlet or duplicate purification steps from pooled group serum samples. Quantitations of HBV DNA and recovery control plasmid were determined by qPCR reactions performed in triplicate. The probes to quantitate HBV and pHCR/UbC-SEAP were included in each reaction.
  • PBS phosphate buffered saline
  • HBV RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5′-terminal end of the sense strand, as shown in Tables 4 and 5.
  • the HBV RNAi agents tested included those having the duplex numbers shown in Table 7, below.
  • RNAi agents AD04178, AD04579, AD04580, AD04570, AD04572, AD04573, AD04574, AD04575, AD04419, and AD04578 were each designed to have antisense strand sequences at least partially complementary to the X open reading frame at positions 1781-1789 of the HBV genome shown in Tables 1 and 2, above.
  • Each of the HBV RNAi agents showed substantial reduction in HBsAg as compared to the PBS control across all measured time points.
  • AD04580 showed greater than 95% reduction in s-antigen levels at day 8 (0.048 ⁇ 0.007 HBsAg level) when normalized to pre-treatment and PBS control.
  • Each of the HBV RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5′-terminal end of the sense strand, as shown in Tables 4 and 5.
  • the HBV RNAi agents administered included those listed in Table 9, below.
  • RNAi agents AD04010, AD04581, AD04591, AD04434, AD04583, AD04584, AD04585, AD04586, AD04588, and AD04438 were designed to have antisense strand sequences that are at least partially complementary to the S open reading frame at positions 257-275 of the HBV genome, as shown in Tables 1 and 2.
  • AD04585 exhibited approximately a 900/o reduction of HBsAg at day 8, a 95% reduction at day 15, a 97% reduction at day 22, and a 95% reduction at day 29.
  • HBV RNAi agent AD04585 provided a reduction in HBV DNA levels compared to the PBS group.
  • mice were divided into various groups including those set forth in Table 11, below, and the mice were given 200 ⁇ l subcutaneous injections pursuant to the dosing regimen set forth in Table 11:
  • RNAi Agent and Dose Dosing Regimen A PBS (no RNAi agent) Single injection on day 1 B 3.0 mg/kg AD04585 Single injection on day 1 C 3.0 mg/kg AD04585 Injection on day 1, day 8, and day 15 (i.e., three weekly injections) D 3.0 mg/kg AD04580 Single injection on day 1 E 3.0 mg/kg AD04580 Injection on day 1, day 8, and day 15 (i.e., three weekly injections) F 1.0 mg/kg AD4585 + Injection on day 1, and another injection 1.0 mg/kg AD04580 on day 22 G 1.0 mg/kg AD4585 + Injection on day 1, day 8, day 15, 1.0 mg/kg AD04580 and day 43 H 1.5 mg/kg AD4585 + Injection on day 1, day 22, and day 43 1.5 mg/kg AD04580 I 1.5 mg/kg AD4585 + Injection on day 1, day 8, day 15, 1.5 mg/kg AD04580 and day 43
  • Each mouse was given a subcutaneous administration of 200 ⁇ l containing the amount of HBV RNAi agent(s) formulated in phosphate buffered saline, or 200 ⁇ l of phosphate buffered saline without an HBV RNAi agent, as set forth in Table 11.
  • HBV RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5′-terminal end of the sense strand, as shown in Tables 4 and 5.
  • HBV RNAi agents AD04580 and AD04585 each individually showed a reduction in HBsAg as compared to the PBS control across all measured time points. Furthermore, combination treatment of AD04585 and AD04580, which as noted in the Examples above target different regions of the HBV genome, also showed reduction in HBsAg as compared to the PBS control across all measured time points.
  • RNAi agents examined both individually and in combination, provided a reduction in HBV DNA levels compared to the PBS group. Re-dosing or increasing the dose amount yielded additional HBV DNA reductions.
  • mice were divided into various groups as set forth in Table 14, below, and each mouse was administered a single 200 ⁇ l subcutaneous injection pursuant to the dosing regimen set forth in Table 14:
  • RNAi Agent and Dose Dosing Regimen A PBS (no RNAi agent) Single injection on day 1 B 4.0 mg/kg AD04981 Single injection on day 1 C 1.0 mg/kg AD04981 Single injection on day 1 D 2.0 mg/kg AD04981 Single injection on day 1 E 1.0 mg/kg AD04963 Single injection on day 1 F 2.0 mg/kg AD04963 Single injection on day 1 G 3.0 mg/kg AD04872 Single injection on day 1 H 3.0 mg/kg AD04872 + Single injection on day 1 1.0 mg/kg AD04981 I 3.0 mg/kg AD04872 + Single injection on day 1 1.0 mg/kg AD04963 J 3.0 mg/kg AD04872 + Single injection on day 1 2.0 mg/kg AD04981
  • Each mouse was given a subcutaneous administration of 200 ⁇ l containing the amount of HBV RNAi agent(s) formulated in phosphate buffered saline, or 200 ⁇ l of phosphate buffered saline without an HBV RNAi agent, as set forth in Table 14.
  • HBV RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5′-terminal end of the sense strand, as shown in Tables 4 and 5.
  • the HBV RNAi agents tested showed a reduction in HBsAg as compared to the PBS control across all measured time points.
  • combination treatment of AD04872 which includes an antisense strand sequence that is at least partially complementary to the S ORF at positions 261-279 of the HBV genome, as shown in Tables 1 and 2) and either AD04981 or AD04963 (both of which include antisense strand sequences that are at least partially complementary to the X ORF at positions 1781-1799 of the HBV genome, as shown in Tables 1 and 2), which are shown in Groups H, I, and J of Example 6, illustrate that combination treatment of two RNAi agents targeting, one which targets in the S ORF, and the other which targets in the X ORF of the HBV genome, similarly showed reduction in HBsAg compared to the PBS control across all measured time points.
  • Serum Hepatitis B e-antigen (HBeAg) levels were also assessed. Samples from the mice in each respective group were first pooled, and the resulting serum samples were assayed in singlet. Data from the experiment is shown in the following Table:
  • AD04872 which targets the S ORF of the HBV genome
  • AD04981 or AD04963 both of which target the X ORF of the HBV genome
  • mice were divided into various groups as set forth in Table 17, below, and each mouse was administered a single 200 ⁇ l subcutaneous injection pursuant to the dosing regimen set forth in Table 17:
  • RNAi Agent and Dose Dosing Regimen A PBS (no RNAi agent) Single injection on day 1 B 4.0 mg/kg AD04776 Single injection on day 1 C 1.0 mg/kg AD04982 Single injection on day 1 D 2.0 mg/kg AD04982 Single injection on day 1 E 1.0 mg/kg AD04776 Single injection on day 1 F 2.0 mg/kg AD04776 Single injection on day 1 G 3.0 mg/kg AD04872 Single injection on day 1 H 3.0 ma/kg AD04872 + Single injection on day 1 1.0 mg/kg AD04982 I 3.0 mg/kg AD04872 + Single injection on day 1 2.0 mg/kg AD04982
  • Each mouse was given a subcutaneous administration of 200 ⁇ l containing the amount of HBV RNAi agent(s) formulated in phosphate buffered saline, or 200 ⁇ l of phosphate buffered saline without an HBV RNAi agent, as set forth in Table 17.
  • HBV RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5′-terminal end of the sense strand, as shown in Tables 4 and 5.
  • the injections were performed between the skin and muscle (i.e. subcutaneous injections) into the loose skin over the neck and shoulder area.
  • HBV RNAi agents tested showed a reduction in HBsAg as compared to the PBS control across all measured time points.
  • Serum Hepatitis B e-antigen (HBeAg) levels were also assessed. Samples from the mice in each respective group were first pooled, and the resulting serum samples were assayed in singlet. Data from the experiment is shown in the following Table:
  • Table 19-1 reflects the fold knockdown ratio of HBeAg compared to control, which is calculated as normalized HBeAg level of the control (PBS) group/normalized HBeAg level of the respected RNAi agent(s) group (i.e., 1.000/HBeAg level).
  • the data in Table 19-1 indicate that the combination of AD04872 (which, as noted above, includes an antisense strand sequence that is at least partially complementary to the S ORF at positions 261-279 of the HBV genome) with AD04982 (which includes an antisense strand sequence that is at least partially complementary to the X ORF at positions 1781-1799 of the HBV genome), showed a further reduction in HBeAg levels relative to administering the individual RNAi agents alone (See.
  • serum HBV DNA levels were determined for each of the groups in Table 17 from serum samples collected on days ⁇ 1, 8, 15, 22, 29, and 36, pursuant to the procedure set forth in Example 2, above. Serum HBV DNA was isolated from each animal at each time point. Data are presented in the following Table:
  • RNAi agents examined both individually and in combination, provided a reduction in HBV DNA levels compared to the PBS group, and further show that the combination of AD04872 (which targets the S ORF) and AD04982 (which targets the X ORF) reduces serum HBV DNA to a similar degree as an equal amount of AD04872 alone.
  • mice were divided into various groups as set forth in Table 21, below, and each mouse was administered a single 200 ⁇ l subcutaneous injection pursuant to the dosing regimen set forth in Table 21:
  • RNAi Agent Single injection on day 1 4 2A 4.0 mg/kg AD04872 + Single injection on day 1 4 1.0 mg/kg AD05070 2B 4.0 mg/kg AD04872 + Single injection on day 1 4 1.0 mg/kg AD05070 3A 3.3 mg/kg AD04872 + Single injection on day 1 4 1.7 mg/kg AD05070 3B 3.3 mg/kg AD04872 + Single injection on day 1 4 1.7 mg/kg AD05070 4A 3.2 mg/kg AD04872 + Single injection on day 1 4 0.8 mg/kg AD05070 4B 3.2 mg/kg AD04872 + Single injection on day 1 4 0.8 mg/kg AD05070 5A 2.7 mg/kg AD04872 + Single injection on day 1 4 1.3 mg/kg AD05070 5B 2.7 mg/kg AD04872 + Single injection on day 1 4 1.3 mg/kg AD05070 5B 2.7 mg/kg AD04872 + Single injection on day 1 4 1.3 mg/kg AD05070 5
  • mice are scheduled to be euthanized pursuant to the following schedule:
  • Each mouse was given a subcutaneous administration of 200 ⁇ l containing the amount of HBV RNAi agent(s) formulated in phosphate buffered saline, or 200 ⁇ l of phosphate buffered saline without an HBV RNAi agent, as set forth in Table 21.
  • HBV RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5′-terminal end of the sense strand, as shown in Tables 4 and 5.
  • the injections were performed between the skin and muscle (i.e. subcutaneous injections) into the loose skin over the neck and shoulder area.
  • HBV RNAi agents tested both alone and in combination, showed a substantial reduction in HBsAg as compared to the PBS control across all measured time points.
  • the HBV RNAi agents tested included those having the duplex numbers shown in Table 23, below, which each included N-acetyl-galactosamine targeting ligands conjugated to the 5′-terminal end of the sense strand, as shown in Tables 4 and 5.
  • Each of the RNAi agents showed a significant knockdown compared to PBS control.
  • mice were divided into various groups as set forth in Table 24, below, and each mouse was administered a single 200 ⁇ l subcutaneous injection pursuant to the dosing regimen set forth in Table 24:
  • RNAi Agent and Dose Dosing Regimen A PBS Group I (no RNAi Single injection on day 1 and day 22 agent) B PBS Group II (no RNAi Single injection on day 1 and day 22 agent) C 3.0 mg/kg AD04585 Single injection on day 1, day 22, day 50, and day 64 D 3.0 mg/kg AD04771 Single injection on day 1 and day 22 E 3.0 mg/kg AD04580 Single injection on day 1, day 22, day 50, and day 64 F 3.0 mg/kg AD04776 Single injection on day 1 and day 22 G 1.5 mg/kg AD04585 + Single injection on day 1, day 22, 1.5 mg/kg AD04580 day 50, and day 64 H 1.5 mg/kg AD04771 + Single injection on day 1 and day 22 1.5 mg/kg AD04776 I 2.0 mg/kg AD04771 + Single injection on day 1 and day 22 1.0 mg/kg AD04776 J 2.25 mg/kg AD04771 + Single injection on day 1 and day 22
  • Each mouse was given a subcutaneous administration of 200 ⁇ l containing the amount of HBV RNAi agent(s) formulated in phosphate buffered saline, or 200 ⁇ l of phosphate buffered saline without an HBV RNAi agent, as set forth in Table 24.
  • HBV RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5′-terminal end of the sense strand, as shown in Tables 4 and 5.
  • Serum Hepatitis B surface antigen (HBsAg) levels were determined pursuant to the procedure set forth in Example 2, above. Data from the experiment is shown in the following:
  • HBV RNAi agents AD04585 and AD04771 were designed to have antisense strand sequences that are at least partially complementary to the S open reading frame at positions 257-275 of the HBV genome, as shown in Tables 1 and 2.
  • HBV RNAi agents AD04580 and AD04776 were designed to have antisense strand sequences that are at least partially complementary to the X open reading frame at positions 1781-1799 of the HBV genome, as shown in Tables 1 and 2
  • the HBV RNAi agents tested, both alone and in combination, showed a reduction in HBsAg as compared to the PBS control across all measured time points. Each subsequent dose further reduced the nadir of HBsAg reduction.
  • serum HBV DNA levels were determined for Group C (3.0 mg/kg AD04585), Group E (3.0 mg/kg AD04580), and Group G (1.5 mg/kg AD04585+1.5 mg/kg AD04580) in Table 24, from serum samples collected on days ⁇ 1, 8, 15, 22, 29, and 36, 43 and 50 pursuant to the procedure set forth in Example 2, above. Serum HBV DNA was isolated for each animal at each of these time points. Data are presented in the following Table:
  • the data in Table 26 indicate that the HBV RNAi agents examined, both individually and in combination, provided a reduction in HBV DNA levels compared to the PBS group.
  • mice were divided into various groups as set forth in Table 27, below, and each mouse was administered a single 200 ⁇ l subcutaneous injection pursuant to the dosing regimen set forth in Table 27:
  • RNAi Agent and Dose Dosing Regimen A PBS (no RNAi agent) Single injection on day 1 B 3.0 mg/kg AD04962 Single injection on day 1 C 3.0 mg/kg AD04963 Single injection on day 1 D 1.5 mg/kg AD04962 + Single injection on day 1 1.5 mg/kg AD04963 E 2.0 mg/kg AD04962 + Single injection on day 1 1.0 mg/kg AD04963 F 2.25 mg/kg AD04962 + Single injection on day 1 0.75 mg/kg AD04963 G 1.5 mg/kg AD04962 + Single injection on day 1 1.5 mg/kg AD04963 H 3.0 mg/kg AD04962 + Single injection on day 1 3.0 mg/kg AD04963 I 1.5 mg/kg AD04962 + Single injection on day 1 1.5 mg/kg AD04963 J 4.5 mg/kg AD04962 + Single injection on day 1 4.5 mg/kg AD04963 K 3.0 mg/kg AD04872 Single injection on
  • Each mouse was given a subcutaneous administration of 200 ⁇ l containing the amount of HBV RNAi agent(s) formulated in phosphate buffered saline, or 200 ⁇ l of phosphate buffered saline without an HBV RNAi agent, as set forth in Table 24.
  • HBV RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5′-terminal end of the sense strand, as shown in Tables 4 and 5.
  • RNAi agent AD04962 was designed to have an antisense strand sequence that is at least partially complementary to the S open reading frame at positions 257-275 of the HBV genome, as shown in Tables 1 and 2.
  • RNAi agent AD04872 was designed to have an antisense strand sequence that is at least partially complementary to the S open reading frame at positions 261-279 of the HBV genome, as shown in Tables 1 and 2.
  • RNAi agent AD04963 was designed to have an antisense strand sequence that is at least partially complementary to the X open reading frame at positions 1781-1799 of the HBV genome, as shown in Tables 1 and 2.
  • RNAi agents AD04882 and AD04885 were designed to have antisense strand sequences that are at least partially complementary to the X open reading frame at positions 1780-1798 of the HBV genome, as shown in Tables 1 and 2.
  • Serum Hepatitis B e-antigen (HBeAg) levels were also assessed for all groups except Groups L and M. Samples from the mice in each respective group were first pooled, and the resulting serum samples were assayed in singlet. Data from the experiment is shown in the following Table:
  • serum HBV DNA levels were determined for each of the groups in Table 27 from serum samples collected on days 8, 15, 22, and 29, pursuant to the procedure set forth in Example 2, above. Serum HBV DNA was isolated from each animal at each time point. Data are presented in the following Table:
  • mice were divided into various groups as set forth in Table 31, below, and each mouse was administered a single 200 ⁇ l subcutaneous injection pursuant to the dosing regimen set forth in Table 31:
  • RNAi Agent and Dose Dosing Regimen A PBS (no RNAi agent) Single injection on day 1 B 2.0 mg/kg AD04871 Single injection on day 1 C 2.0 mg/kg AD04872 Single injection on day 1 D 2.0 mg/kg AD04874 Single injection on day 1 E 2.0 mg/kg AD04875 Single injection on day 1 F 2.0 mg/kg AD04876 Single injection on day 1 G 2.0 mg/kg AD04881 Single injection on day 1 H 2.0 mg/kg AD04883 Single injection on day 1 I 2.0 mg/kg AD04884 Single injection on day 1
  • Each mouse was given a subcutaneous administration of 200 ⁇ l containing the amount of HBV RNAi agent formulated in phosphate buffered saline, or 200 ⁇ l of phosphate buffered saline without an HBV RNAi agent, as set forth in Table 24.
  • HBV RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5′-terminal end of the sense strand, as shown in Tables 4 and 5.
  • Group A PBS
  • Group B 2.0 mg/kg AD04871
  • Group C 2.0 mg/kg AD04872
  • Group D 2.0 mg/kg AD04874
  • Group E 2.0 mg/kg AD04875
  • Group F 2.0 mg/kg AD04876
  • Serum Hepatitis B surface antigen (HBsAg) levels were determined pursuant to the procedure set forth in Example 2, above. Data from the experiment is shown in the following Table:
  • HBV RNAi agents AD04871, AD04872, AD04874, AD04875, and AD04876 were each designed to have antisense strand sequences that are at least partially complementary to the S open reading frame at positions 261-279 of the HBV genome, as shown in Tables 1 and 2.
  • Each of these HBV RNAi agents should a substantial reduction in HBsAg compared to PBS control.
  • a single 2 mg/kg dose of each of AD04871 (Group B), AD04872 (Group C) and AD04874 (Group D), and AD04876 (Group F) exhibited a greater than 90% reduction in HBsAg for each of the timepoints measured from day 15 through day 43 compared to control.
  • HBV RNAi agents AD04881, AD04883, AD04884 were each designed to have antisense strand sequences that are at least partially complementary to the X open reading frame at positions 1780-1798 of the HBV genome, as shown in Tables 1 and 2.
  • RNAi agent that includes an antisense strand sequence that is at least partially complementary to a region located in the S ORF of an HBV mRNA
  • a second RNAi agent that includes an antisense strand sequence that is at least partially complementary to a region located in the X ORF of an HBV mRNA
  • a plasmid was generated that included the HBV genome with a knockout of the binding site for HBV RNAi agents that target positions 1780 and 1781, as shown in Tables 1 and 2 (hereinafter referred to as X Region Knockout mice). This model was generated by mutating ten (10) bases in the pHBV1.3 plasmid within the binding site of these RNAi agents.
  • HBV RNAi agent having an antisense strand that targets positions 1780 and 1781 of the HBV genome disclosed herein is expected to be ineffective in silencing expression.
  • mice were divided into various groups including those set forth in Table 33, below, and the mice were given 200 ⁇ l subcutaneous injections pursuant to the dosing regimen set forth in the following Table:
  • RNAi Agents Single injection 4 on day 1 2 2.0 mg/kg AD04585 + Single injection 4 1.0 mg/kg AD04963 on day 1 3 2.0 mg/kg AD04872 + Single injection 4 1.0 mg/kg AD04963 on day 1 4 2.5 mg/kg AD04585 + Single injection 4 0.5 mg/kg AD04963 on day 1 5 2.5 mg/kg AD04872 + Single injection 4 0.5 mg/kg AD04963 on day 1 6 3.0 mg/kg AD04963 Single injection 1 on day 15
  • Each mouse was given a subcutaneous administration of 200 ⁇ l containing the amount of HBV RNAi agent(s) formulated in phosphate buffered saline, or 200 ⁇ l of phosphate buffered saline without an HBV RNAi agent, as set forth in Table 33.
  • HBV RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5′-terminal end of the sense strand, as shown in Tables 4 and 5.
  • Group 6 which was a single dose of 3.0 mg/kg of HBV RNAi agent AD04963 and includes an antisense strand that is at least partially complementary to the X open reading frame at positions 1781-1799 of the HBV genome, was unable to provide knockdown of HBsAg. Additionally, each of Groups 2 through 5 provided substantial knockdown of HBsAg compared to PBS control, with both Group 3 and Group 5 exhibiting a greater than 2 log reduction in HBsAg at nadir (day 22).
  • mice were divided into various groups including those set forth in Table 31, below, and each mouse was administered a single 200 ⁇ l subcutaneous injection pursuant to the dosing regimen set forth in Table 35:
  • Each mouse was given a subcutaneous administration of 200 ⁇ l containing the amount of HBV RNAi agent(s) formulated in phosphate buffered saline, or 200 ⁇ l of phosphate buffered saline without an HBV RNAi agent, as set forth in Table 35.
  • HBV RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5′-terminal end of the sense strand, as shown in Tables 4 and 5.
  • the injections were performed between the skin and muscle (i.e. subcutaneous injections) into the loose skin over the neck and shoulder area.
  • HBsAg serum Hepatitis B surface antigen
  • Table 36 shows that HBV RNAi agent AD04872 administered alone, and the combination of AD04872 (which includes an antisense strand that is at least partially complementary to the S open reading from at positions 261-279 of the HBV genome) and AD05070 (which includes an antisense strand that is at least partially complementary to the X open reading frame at positions 1781-1799 of the HBV genome), provided significant knockdown of HBsAg compared to PBS control across each of the time points measured.
  • Addition of 0.7 mg/kg to 2 mg/kg HBV RNAi agent AD05070 for which there was a mutated target site in this X Region Knockout model did not diminish the activity of the 2 mg/kg HBV RNAi agent AD04872.
  • serum HBV DNA levels were determined from serum samples collected on days 8, 15, and 22 pursuant to the procedure set forth in Example 2, above. Serum from each group was pooled and then DNA was isolated from the serum in singlet. Data are presented in the following Table:
  • mice were divided into various groups including those set forth in Table 38, below, and each mouse was administered a single 200 d subcutaneous injection pursuant to the dosing regimen set forth in Table 38:
  • RNAi Agent and Dose Dosing Regimen 1 PBS (no RNAi agent) Single injection on day 1 2 2.0 mg/kg AD04776 Single injection on day 1 3 2.0 mg/kg AD05069 Single injection on day 1 4 2.0 mg/kg AD05070 Single injection on day 1 5 2.0 mg/kg AD05071 Single injection on day 1 6 2.0 mg/kg AD05073 Single injection on day 1 7 2.0 mg/kg AD05074 Single injection on day 1 8 2.0 mg/kg AD05075 Single injection on day 1 9 2.0 mg/kg AD05076 Single injection on day 1 10 2.0 mg/kg AD05077 Single injection on day 1 11 2.0 mg/kg AD05078 Single injection on day 1 12 3.0 mg/kg AD04872 + Single injection on day 1 1.0 mg/kg AD04776 13 3.0 mg/kg AD04872 + Single injection on day 1 1.0 mg/kg AD05069 14 3.0 mg/kg AD04872 + Single injection on day 1 1.0 mg/kg AD05069 14 3.0 mg/kg AD04872
  • Each mouse was given a subcutaneous administration of 200 ⁇ l containing the amount of HBV RNAi agent(s) formulated in phosphate buffered saline, or 200 ⁇ l of phosphate buffered saline without an HBV RNAi agent, as set forth in Table 38.
  • HBV RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5′-terminal end of the sense strand, as shown in Tables 4 and 5.
  • Serum Hepatitis B surface antigen (HBsAg) levels were determined pursuant to the procedure set forth in Example 2, above. Data from the experiment is shown in the following Table 39, with Average HBsAg reflecting the normalized average value of HBsAg:
  • RNAi agents AD04776, AD05069, AD05070, AD05071, AD05073, and AD05074 were each designed to have an antisense strand sequence that is at least partially complementary to the X open reading frame at positions 1781-1799 of the HBV genome, as shown in Tables 1 and 2.
  • RNAi agents AD05075, AD05076. AD05077, and AD05078 were each designed to have antisense strand sequences that are at least partially complementary to the X open reading frame at positions 1780-1798 of the HBV genome, as shown in Tables 1 and 2.
  • Table 39 shows that HBV RNAi agents AD04776, AD05069, AD05070, AD05071, AD05073, and AD05074 administered alone or their combination with AD04872 (which includes an antisense strand that is at least partially complementary to the S open reading from at positions 261-279 of the HBV genome) provided significant knockdown of HBsAg compared to PBS control across each of the time points measured.
  • mice were divided into various groups as set forth in Table 40, below, and each mouse was administered a single 200 ⁇ l subcutaneous injection pursuant to the dosing regimen set forth in Table 40:
  • Each mouse was given a subcutaneous administration of 200 ⁇ l containing the amount of HBV RNAi agent(s) formulated in phosphate buffered saline, or 200 ⁇ l of phosphate buffered saline without an HBV RNAi agent, as set forth in Table 40.
  • HBV RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5′-terminal end of the sense strand, as shown in Tables 4 and 5.
  • Serum Hepatitis B e-antigen (HBeAg) levels were also assessed.
  • HBeAg Serum Hepatitis B e-antigen
  • HBeAg HBeAg expression was further reduced in all groups that were re-dosed on day 22.
  • HBV RNAi agents tested both individually and in combination, showed a reduction in serum HBV DNA as compared to the saline control across all measured time points except in groups 11 and 12 that had no reduction in serum HBV DNA at Day 8.
  • mice were divided into various groups as set forth in Table 44, below, and each mouse was administered a single 200 td subcutaneous injection pursuant to the dosing regimen set forth in Table 44:
  • Each mouse was given a subcutaneous administration of 200 ⁇ l containing the amount of HBV RNAi agent(s) formulated in phosphate buffered saline, or 200 ⁇ l of phosphate buffered saline without an HBV RNAi agent, as set forth in Table 44.
  • HBV RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5′-terminal end of the sense strand, as shown in Tables 4 and 5.
  • HBV RNAi agent combinations tested showed a reduction in HBsAg as compared to the saline control across all measured time points.
  • Combinations containing AD04872 showed greater reductions than the equivalent combinations with AD04585 in place of AD04872.
  • HBV RNAi agent combinations tested showed a reduction in serum HBV DNA as compared to the saline control across all measured time points.
  • Combinations containing AD04872 showed greater reductions than the equivalent combinations with AD04585 in place of AD04872. These greater reductions were observed at Day 22 and Day 29.
  • mice Male FRG® (genotype Fah ⁇ / ⁇ /Rag2 ⁇ / ⁇ /Il2rg ⁇ / ⁇ triple knockout mice on a C57BL/6 background (Yecuris) were transplanted with human hepatocytes when they were 1-2 months old.
  • the human hepatocytes were allowed to repopulate the liver for approximately 6 months with periodic NTBC treatment to discourage growth of mouse hepatocytes.
  • the mice were given an intravenous inoculation of 4 ⁇ 10 8 genomes/kg HBV genotype C, which infected the human hepatocytes.
  • Pre-treatment serum samples were taken on day ⁇ 10 and day ⁇ 3. Beginning on day 1, each mouse was administered an oral daily gavage with 0.01 mg/kg Entecavir dissolved in water to inhibit HBV replication. Daily dosing of Entecavir continued until the day mice were euthanized. Entecavir administration was expected to reduce serum HBV DNA in chronically infected human patients, but not reduce HBsAg.
  • mice were divided into various groups including those set forth in Table 47, below:
  • RNAi Agent and Terminal Group Dose Dosing Regimen Day A- mouse PBS (no RNAi Single injection Euthanized 1 agent) on day 1 day 21 (unhealthy animal) A- mouse PBS (no RNAi Single injection Euthanized 2 agent) on day 1 and day day 36 29 B- mouse 4.0 mg/kg AD04872 + Single injection Euthanized 1 2.0 mg/kg AD05070 on day 1 and day day 36 29 B- mouse 4.0 mg/kg AD04872 + Single injection Euthanized 2 2.0 mg/kg AD05070 on day 1 and day day 40 29 C- mouse 4.5 mg/kg AD04872 + Single injection Euthanized 1 1.5 mg/kg AD05070 on day 1 day 15 C- mouse 4.5 mg/kg AD04872 + Single injection Euthanized 2 1.5 mg/kg AD05070 on day 1 and day day 36 29 C- mouse 4.5 mg/kg AD04872 + Single injection Euthanized 3 1.5 mg//
  • Each mouse was also given a subcutaneous administration of 100 ⁇ l per 20 grams body weight containing the amount of HBV RNAi agent(s) formulated in phosphate buffered saline, or an equal volume of phosphate buffered saline without an HBV RNAi agent, on day 1 and on day 29 (if still alive on day 29), pursuant to the schedule as set forth in Table 47, directly above.
  • HBV RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5′-terminal end of the sense strand, as shown in Tables 4 and 5. The injections were performed between the skin and muscle (i.e. subcutaneous injections) into the loose skin over the neck and shoulder area.
  • Entecavir reduced viral replication in both the absence and presence of HBV RNAi agents.

Abstract

Described are compositions and methods for inhibition of Hepatitis B virus gene expression. RNA interference (RNAi) agents for inhibiting the expression of Hepatitis B virus gene are described. The HBV RNAi agents disclosed herein may be targeted to cells, such as hepatocytes, for example, by using conjugated targeting ligands. Pharmaceutical compositions comprising one or more HBV RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described HBV RNAi agents to infected liver in vivo provides for inhibition of HBV gene expression and treatment of diseases and conditions associated with HBV infection.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This application claims priority from U.S. Provisional Patent Application Ser. No. 62/540,639, filed on Aug. 3, 2017, U.S. Provisional Patent Application Ser. No. 62/534,733, filed on Jul. 20, 2017, and U.S. Provisional Patent Application Ser. No. 62/370,754, filed on Aug. 4, 2016, the contents of each of which are incorporated herein by reference in their entirety.
    • FIELD OF THE INVENTION
  • Disclosed herein are RNA interference (RNAi) agents for inhibition of Hepatitis B Virus gene expression, compositions that include HBV RNAi agents, and methods of use thereof.
    • BACKGROUND
  • The Hepatitis B Virus (HBV) is a strict hepatotrophic, double-stranded DNA containing virus. Although DNA is the genetic material, the replication cycle involves a reverse transcription step to copy a pregenomic RNA into DNA. Hepatitis B Virus is classified as one member of the Hepadnaviruses and belongs to the family of Hepadnaviridae. The primary infection of adult humans with Hepatitis B Virus causes an acute hepatitis with symptoms of organ inflammation, fever, jaundice and increased liver transaminases in blood. Those patients that are not able to overcome the virus infection suffer a chronic disease progression over many years with increased risk of developing cirrhotic liver or liver cancer. Perinatal transmission from Hepatitis B Virus-infected mothers to newborns also leads to chronic hepatitis.
  • Upon uptake by hepatocvtes, the nucleocapsid is transferred to the nucleus and DNA is released. There, the DNA strand synthesis is completed and gaps repaired to give the covalently closed circular (ccc) supercoiled DNA of 3.2 kb. The cccDNA serves as a template for transcription of five major viral mRNAs, which are 3.5, 3.5, 2.4, 2.1 and 0.7 kb long. All mRNAs are 5′-capped and polyadenylated at the 3′-end. There is sequence overlap at the 3′-end between all five mRNAs.
  • One 3.5 kb mRNA serves as template for core protein and polymerase production. In addition, the same transcript serves as a pre-genomic replication intermediate and allows the viral polymerase to initiate the reverse transcription into DNA. Core protein is needed for nucleocapsid formation. The other 3.5 kb mRNA encodes pre-core, the secretable e-antigen (HBeAg). In the absence of replication inhibitors, the abundance of e-antigen in blood correlates with Hepatitis B Virus replication in liver and serves as an important diagnostic marker for monitoring the disease progression.
  • The 2.4 and 2.1 kb mRNAs carry the open reading frames (“ORF”) pre-S1, pre-S2 and S for expression of viral large, medium and small surface antigen. The s-antigen is associated with infectious, complete particles. In addition, blood of infected patients also contain non-infectious particles derived from s-antigen alone, free of genomic DNA or polymerase. The function of these particles is not fully understood. The complete and lasting depletion of detectable s-antigen in blood is considered as a reliable indicator for Hepatitis B Virus clearance.
  • The 0.7 kb mRNA encodes the X protein. This gene product is important for efficient transcription of viral genes and also acts as a transactivator on host gene expression. The latter activity seems to be important for hepatocyte transformation during development of liver cancer.
  • Patients with detectable s-antigen, e-antigen, and/or viral DNA in the blood for more than 6 months are considered chronically infected. Nucleoside analogs as inhibitors of reverse transcriptase activity are typically the first treatment option for many patients. Administration of lamivudine, tenofovir, and/or entecavir has been shown to suppress Hepatitis B Virus replication, sometimes to undetectable levels, with improvement of liver function and reduction of liver inflammation typically seen as the most important benefits. However, only few patients achieve complete and lasting remission after the end of treatment. Furthermore, the Hepatitis B Virus develops drug resistance with increasing duration of treatment. This is especially difficult for patients co-infected with Hepatitis B and Human Immunodeficiency Virus (HIV). Both viruses are susceptible to nucleoside analogue drugs and may co-develop resistance.
  • A second treatment option is the administration of interferon-alpha. Here, patients receive high doses of interferon-alpha over a period of 6 months. The Asian genotype B gives very poor response rates. Co-infection with Hepatitis D Virus (HDV) or Human Immunodeficiency Virus has been shown to render interferon-alpha therapy completely ineffective. Patients with strong liver damage and heavy fibrotic conditions are not qualified for interferon-alpha therapy.
  • Certain Hepatitis B Virus-specific RNA interference (RNAi) agents have been previously shown to inhibit expression of HBV gene expression. For example, U.S. Patent Application Publication No. 2013/0005793, to Chin et al., which is incorporated herein by reference in its entirety, discloses certain double-stranded ribonucleic acid (dsRNA) molecules for inhibiting the expression of Hepatitis B Virus gene.
    • SUMMARY
  • There exists a need for novel Hepatitis B Virus (HBV)-specific RNA interference (RNAi) agents (also herein termed RNAi agent, RNAi trigger, or trigger) that are able to selectively and efficiently inhibit the expression of an Hepatitis B Virus (HBV) gene. Further, there exists a need for combinations of novel HBV-specific RNAi agents for the treatment of HBV infection and prevention of diseases associated with HBV.
  • Described herein are HBV gene-specific RNAi agents able to selectively and efficiently decrease expression of an HBV gene. The described HBV RNAi agents can be used in methods for therapeutic treatment and/or prevention of symptoms and diseases associated with HBV infection, including but not limited to chronic liver diseases/disorders, inflammations, fibrotic conditions, proliferative disorders (including cancers, such as hepatocellular carcinoma), Hepatitis D Virus (HDV) infection, and acute HBV infection. In some embodiments, the HBV RNAi agents can be used in methods for therapeutic treatment and/or prevention of symptoms and diseases associated with chronic HBV infection and/or HDV infection. Such methods comprise administration of one or more HBV RNAi agents as described herein to a subject, e.g., a human or animal subject.
  • Additionally, described herein are compositions comprising one or more of the disclosed HBV RNAi agents that are able to selectively and efficiently decrease expression of an HBV gene. The compositions comprising one or more HBV RNAi agents can be administered to a subject, such as a human or animal subject, for the treatment and/or prevention of symptoms and diseases associated with HBV infection.
  • Each HBV RNAi agent disclosed herein includes at least a sense strand and an antisense strand. The sense strand and the antisense strand can be partially, substantially, or fully complementary to each other. The length of the RNAi agent sense and antisense strands described herein each can be 16 to 30 nucleotides in length. In some embodiments, the sense and antisense strands are independently 17 to 26 nucleotides in length. In some embodiments, the sense and antisense strands are independently 19 to 26 nucleotides in length. In some embodiments, the sense and antisense strands are independently 21 to 26 nucleotides in length. In some embodiments, the sense and antisense strands are independently 21 to 24 nucleotides in length. The sense and antisense strands can be either the same length or different lengths. The HBV RNAi agents disclosed herein have been designed to include antisense strand sequences that are at least partially complementary to a sequence in the HBV genome that is conserved across the majority of known serotypes of HBV. The RNAi agents described herein, upon delivery to a cell expressing HBV, inhibit the expression of one or more HBV genes in vivo or in vitro.
  • An HBV RNAi agent includes a sense strand (also referred to as a passenger strand) that includes a first sequence, and an antisense strand (also referred to as a guide strand) that includes a second sequence. A sense strand of the HBV RNAi agents described herein includes a core stretch having at least about 85% identity to a nucleotide sequence of at least 16 consecutive nucleotides in an HBV mRNA. In some embodiments, the sense strand core nucleotide stretch having at least about 85% identity to a sequence in an HBV mRNA is 16, 17, 18, 19, 20, 21, 22, or 23 nucleotides in length. An antisense strand of an HBV RNAi agent comprises a nucleotide sequence having at least about 85% complementary over a core stretch of at least 16 consecutive nucleotides to a sequence in an HBV mRNA and the corresponding sense strand. In some embodiments, the antisense strand core nucleotide sequence having at least about 85% complementarity to a sequence in an HBV mRNA or the corresponding sense strand is 16, 17, 18, 19, 20, 21, 22, or 23 nucleotides in length.
  • Examples of HBV RNAi agent sense strands and antisense strands that can be used in HBV RNAi agents are provided in Tables 3 and 4. Examples of HBV RNAi agent duplexes are provided in Table 5. Examples of 19-nucleotide core stretch sequences that consist of or are included in the sense strands and antisense strands of HBV RNAi agents disclosed herein, are provided in Table 2.
  • In some embodiments, one or more HBV RNAi agents are delivered to target cells or tissues using any oligonucleotide delivery technology known in the art. Nucleic acid delivery methods include, but are not limited to, by encapsulation in liposomes, by iontophoresis, or by incorporation into other vehicles, such as hydrogels, cyclodextrins, biodegradable nanocapsules, and bioadhesive microspheres, proteinaceous vectors or Dynamic Polyconjugates (DPCs) (see, for example WO 2000/053722, WO 2008/0022309, WO 2011/104169, and WO 2012/083185, each of which is incorporated herein by reference). In some embodiments, an HBV RNAi agent is delivered to target cells or tissues by covalently linking the RNAi agent to a targeting group. In some embodiments, the targeting group can include a cell receptor ligand, such as an asialoglycoprotein receptor (ASGPr) ligand. In some embodiments, an ASGPr ligand includes or consists of a galactose derivative cluster. In some embodiments, a galactose derivative cluster includes an N-acetyl-galactosamine trimer or an N-acetyl-galactosamine tetramer. In some embodiments, a galactose derivative cluster is an N-acetyl-galactosamine trimer or an N-acetyl-galactosamine tetramer.
  • A targeting group can be linked to the 3′ or 5′ end of a sense strand or an antisense strand of an HBV RNAi agent. In some embodiments, a targeting group is linked to the 3′ or 5′ end of the sense strand. In some embodiments, a targeting group is linked to the 5′ end of the sense strand. In some embodiments, a targeting group is linked to the RNAi agent via a linker.
  • A targeting group, with or without a linker, can be linked to the 5′ or 3′ end of any of the sense and/or antisense strands disclosed in Tables 2, 3, and 4. A linker, with or without a targeting group, can be attached to the 5′ or 3′ end of any of the sense and/or antisense strands disclosed in Tables 2, 3, and 4.
  • In some embodiments, described herein are compositions that include one or more HBV RNAi agents having the duplex sequences disclosed in Table 5.
  • In some embodiments, described herein are compositions that include a combination or cocktail of at least two HBV RNAi agents having different nucleotide sequences. In some embodiments, the two or more different HBV RNAi agents are each separately and independently linked to targeting groups. In some embodiments, the two or more different HBV RNAi agents are each linked to targeting groups comprised of N-acetyl-galactosamines. In some embodiments, when two or more RNAi agents are included in a composition, each of the RNAi agents is linked to the same targeting group. In some embodiments, when two or more RNAi agents are included in a composition, each of the RNAi agents is linked to different targeting groups, such as targeting groups having different chemical structures.
  • In some embodiments, targeting groups are linked to the HBV RNAi agents without the use of an additional linker. In some embodiments, the targeting group is designed having a linker readily present to facilitate the linkage to an HBV RNAi agent. In some embodiments, when two or more RNAi agents are included in a composition, the two or more RNAi agents may be linked to the targeting groups using the same linkers. In some embodiments, when two or more RNAi agents are included in a composition, the two or more RNAi agents are linked to the targeting groups using different linkers.
  • In some embodiments, described herein are compositions that include a combination of at least two HBV RNAi agents having different sequences, wherein each HBV RNAi agent targets a different location or different region of an HBV gene. In some embodiments, described herein are compositions that include a combination of at least two HBV RNAi agents, wherein each HBV RNAi agent is designed to target a different HBV transcript (for example, a composition that includes two HBV RNAi agents, wherein the first HBV RNAi agent includes an antisense strand that is at least partially complementary to a nucleotide sequence located in the S ORF of an HBV gene, while the second HBV RNAi agent includes an antisense strand that is at least partially complementary to a nucleotide sequence located in the X ORF of an HBV gene). As used herein, an RNAi agent that includes an antisense strand at least partially complementary to a nucleotide sequence located in the S ORF targets a portion of the HBV genome of SEQ ID NO: 1 between positions 1-1307 and 3185-3221. As used herein, an RNAi agent that includes an antisense strand at least partially complementary to a nucleotide sequence located in the X ORF targets a portion of the HBV genome of SEQ ID NO: 1 between positions 1308-1930.
  • HBV mRNA is known to be polycistronic, resulting in the translation of multiple polypeptides, and separate mRNAs overlap in RNA sequence, therefore a single RNAi agent targeting an HBV gene may result in inhibition of most or all HBV transcripts. However, while not wishing to be bound to any theory, it is hypothesized that a composition that includes two or more HBV RNAi agents targeting different locations or regions of an HBV gene (and, in particular, two or more HBV RNAi agents wherein one HBV RNAi agent targets the S ORF and a second HBV RNAi agent targets the X ORF) may provide for additional advantages over a composition that includes only a single HBV RNAi agent, such as (a) ensuring that all HBV viral transcripts are targeted (i.e., 3.5 kb pre-genomic RNA; 3.5 kb pre-core mRNA; 2.4 kb pre-S1 mRNA; 2.1 kb pre-S2/S mRNA; 0.7 kb×mRNA; as well as any S-antigen expressing mRNAs produced from integrated HBV DNA); (b) serving to expand the genotype coverage to potentially address a larger patient population; and/or (c) potentially decreasing the viral resistance due to mutations in the siRNA binding site.
  • In some embodiments, described herein are compositions that include a combination of one HBV RNAi agent that targets the S ORF of an HBV RNA (i.e., having an antisense strand that targets the S transcripts (S, pre-S1, and pre-S2), the pregenomic RNA (core and polymerase), and the pre-core transcripts (HBeAg) of an HBV genome), and one HBV RNAi agent that targets the X ORF of an HBV RNA (i.e., having an antisense strand that targets the X transcript of an HBV genome, the S transcripts (S, pre-S1, and pre-S2), the pregenomic RNA (core and polymerase), and the pre-core transcripts (HBeAg) of an HBV genome). In some embodiments, the compositions described herein include at least one HBV RNAi agent that contains a sequence that targets the S ORF of an HBV gene, and a second HBV RNAi agent that contains a sequence that targets the X ORF of an HBV gene.
  • Disclosed herein are methods for inhibiting expression of an HBV gene, the method comprising administering one or more HBV RNAi agents having an antisense strand comprising the sequence of any of the sequences in Table 3.
  • Disclosed herein are methods for inhibiting expression of an HBV gene, the method comprising administering one or more HBV RNAi agents having a sense strand comprising the sequence of any of the sequences in Table 4.
  • Disclosed herein are methods for inhibiting expression of an HBV gene, the method comprising administering one or more HBV RNAi agents having an antisense strand comprising the sequence of any of the sequences in Table 3, and a sense strand comprising the sequence of any of the sequences in Table 4 that is at least partially complementary to the antisense strand.
  • Disclosed herein are methods for inhibiting expression of an HBV gene, the method comprising administering one or more HBV RNAi agents having an antisense strand that consists of the sequence of any of the sequences in Table 3, and a sense strand that consists of the sequence of any of the sequences in Table 4 that is at least partially complementary to the antisense strand.
  • Disclosed herein are methods for inhibiting expression of an HBV gene in a cell, the method comprising administering one or more HBV RNAi agents having the duplex structure of Table 5.
  • Disclosed herein are methods of treatment of an HBV infection or prevention of disease or symptoms caused by an HBV infection, the method comprising administering one or more HBV RNAi agents having an antisense strand comprising the sequence of any of the sequences in Table 3.
  • Disclosed herein are methods of treatment of an HBV infection or prevention of disease or symptoms caused by an HBV infection, the method comprising administering one or more HBV RNAi agents having a sense strand comprising the sequence of any of the sequences in Table 4.
  • Disclosed herein are methods of treatment of an HBV infection or prevention of disease or symptoms caused by an HBV infection, the method comprising administering one or more HBV RNAi agents having an antisense strand comprising the sequence of any of the sequences in Table 3, and a sense strand comprising the sequence of any of the sequences in Table 4 that is at least partially complementary to the antisense strand.
  • Disclosed herein are methods of treatment of an HBV infection or prevention of disease or symptoms caused by an HBV infection, the method comprising administering one or more HBV RNAi agents having an antisense strand that consists of the sequence of any of the sequences in Table 3, and a sense strand that consists of the sequence of any of the sequences in Table 4 that is at least partially complementary to the antisense strand.
  • Disclosed herein are methods of treatment of an HBV infection or prevention of disease or symptoms caused by an HBV infection, the method comprising administering one or more HBV RNAi agents having the duplex structure of Table 5.
  • Disclosed herein are methods for inhibiting expression of an HBV gene, the method comprising administering (i) an HBV RNAi agent having an antisense strand comprising or consisting of the sequence of any of the sequences in Table 2 or Table 3, and (ii) a second HBV RNAi agent having an antisense strand comprising or consisting of the sequence of any of the sequences in Table 2 or Table 3.
  • Disclosed herein are methods of treatment of an HBV infection or prevention of disease or symptoms caused by an HBV infection, the method comprising administering (i) an HBV RNAi agent having an antisense strand comprising or consisting of the sequence of any of the sequences in Table 2 or Table 3, and (ii) a second HBV RNAi agent having an antisense strand comprising or consisting of the sequence of any of the sequences in Table 2 or Table 3.
  • Disclosed herein are methods for inhibiting expression of an HBV gene, the method comprising administering (i) a first HBV RNAi agent having an antisense strand comprising or consisting of the sequence of any of the sequences in Table 2 or Table 3 and a sense strand comprising or consisting of the sequence of any of the sequences in Table 2 or Table 4 that is at least partially complementary to the antisense strand of the first HBV RNAi agent, and (ii) a second HBV RNAi agent having an antisense strand comprising or consisting of the sequence of any of the sequences in Table 2 or Table 3 and a sense strand comprising or consisting of the sequence of any of the sequences in Table 2 or Table 4 that is at least partially complementary to the antisense strand of the second HBV RNAi agent.
  • Disclosed herein are methods of treatment of an HBV infection or prevention of disease or symptoms caused by an HBV infection, the method comprising administering (i) a first HBV RNAi agent having an antisense strand comprising or consisting of the sequence of any of the sequences in Table 2 or Table 3 and a sense strand comprising or consisting of the sequence of any of the sequences in Table 2 or Table 4 that is at least partially complementary to the antisense strand of the first HBV RNAi agent, and (ii) a second HBV RNAi agent having an antisense strand comprising or consisting of the sequence of any of the sequences in Table 2 or Table 3 and a sense strand comprising or consisting of the sequence of any of the sequences in Table 2 or Table 4 that is at least partially complementary to the antisense strand of the second HBV RNAi agent.
  • In some embodiments, an HBV RNAi agent disclosed herein comprises:
      • a. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) AUUGAGAGAAGUCCACCAC (SEQ ID NO: 7), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) GUGGUGGACUUCUCUCAAU (SEQ ID NO: 34); or
      • b. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UUUGAGAGAAGUCCACCAC (SEQ ID NO: 8), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) GUGGUGGACUUCUCUCAAA (SEQ ID NO: 35); or
      • c. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) AAUUGAGAGAAGUCCACCA (SEQ ID NO: 12), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UGGUGGACUUCUCUCAAUU (SEQ ID NO: 39); or
      • d. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UAUUGAGAGAAGUCCACCA (SEQ ID NO: 13), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UGGUGGACUUCUCUCAAUA (SEQ ID NO: 40); or
      • e. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) AGAAAAUUGAGAGAAGUCC (SEQ ID NO: 17), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) GGACUUCUCUCAAUUUUCU (SEQ ID NO: 44); or
      • f. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UGAAAAUUGAGAGAAGUCC (SEQ ID NO: 18), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) GGACUUCUCUCAAUUUUCA (SEQ ID NO: 45); or
      • g. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) ACCAAUUUAUGCCUACAGC (SEQ ID NO: 22), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) GCUGUAGGCAUAAAUUGGU (SEQ ID NO: 49); or
      • h. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UCCAAUUUAUGCCUACAGC (SEQ ID NO: 23), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) GCUGUAGGCAUAAAUUGGA (SEQ ID NO: 50); or
      • i. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) GACCAAUUUAUGCCUACAG (SEQ ID NO: 27), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) CUGUAGGCAUAAAUUGGUC (SEQ ID NO: 54); or
      • j. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) AACCAAUUUAUGCCUACAG (SEQ ID NO: 28), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) CUGUAGGCAUAAAUUGGUU (SEQ ID NO: 55); or
      • k. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UACCAAUUUAUGCCUACAG (SEQ ID NO: 29), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) CUGUAGGCAUAAAUUGGUA (SEQ ID NO: 56).
  • In some embodiments, disclosed herein are compositions for inhibiting expression of an HBV gene in a cell, the composition comprising an HBV RNAi agent.
  • In some embodiments, disclosed herein are compositions for inhibiting expression of an HBV gene in a cell, the composition comprising two or more HBV RNAi agents, wherein a first HBV RNAi agent comprises:
      • i) an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) AAUUGAGAGAAGUCCACCA (SEQ ID NO: 12), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UGGUGGACUUCUCUCAAUU (SEQ ID NO: 39); or
      • ii) an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UAUUGAGAGAAGUCCACCA (SEQ ID NO: 13), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UGGUGGACUUCUCUCAAUA (SEQ ID NO: 40);
        and wherein a second HBV RNAi agent comprises:
      • i) an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) GACCAAUUUAUGCCUACAG (SEQ ID NO: 27), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) CUGUAGGCAUAAAUUGGUC (SEQ ID NO: 54); or
      • ii) an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) AACCAAUUUAUGCCUACAG (SEQ ID NO: 28), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) CUGUAGGCAUAAAUUGGUU (SEQ ID NO: 55); or
      • iii) an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UACCAAUUUAUGCCUACAG (SEQ ID NO: 29), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) CUGUAGGCAUAAAUUGGUA (SEQ ID NO: 56).
  • In some embodiments, disclosed herein are compositions for inhibiting expression of an HBV gene in a cell, the composition comprising two or more HBV RNAi agents, wherein a first HBV RNAi agent comprises:
      • i) an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) AGAAAAUUGAGAGAAGUCC (SEQ ID NO: 17), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) GGACUUCUCUCAAUUUUCU (SEQ ID NO: 44); or
      • ii) an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UGAAAAUUGAGAGAAGUCC (SEQ ID NO: 18), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) GGACUUCUCUCAAUUUUCA (SEQ ID NO: 45);
        and wherein a second HBV RNAi agent comprises:
      • i) an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) GACCAAUUUAUGCCUACAG (SEQ ID NO: 27), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) CUGUAGGCAUAAAUUGGUC (SEQ ID NO: 54); or
      • ii) an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) AACCAAUUUAUGCCUACAG (SEQ ID NO: 28), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) CUGUAGGCAUAAAUUGGUU (SEQ ID NO: 55); or
      • iii) an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UACCAAUUUAUGCCUACAG (SEQ ID NO: 29), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) CUGUAGGCAUAAAUUGGUA (SEQ ID NO: 56).
  • In some embodiments, disclosed herein are compositions for inhibiting expression of an HBV gene in a cell, the composition comprising two or more HBV RNAi agents, wherein a first HBV RNAi agent comprises:
      • i) an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) AAUUGAGAGAAGUCCACCA (SEQ ID NO: 12), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UGGUGGACUUCUCUCAAUU (SEQ ID NO: 39); or
      • ii) an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UAUUGAGAGAAGUCCACCA (SEQ ID NO: 13), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UGGUGGACUUCUCUCAAUA (SEQ ID NO: 40);
        and wherein a second HBV RNAi agent comprises an antisense strand having a sequence that is at least partially complementary to a portion of the X ORF of an HBV mRNA.
  • In some embodiments, disclosed herein are compositions for inhibiting expression of an HBV gene in a cell, the composition comprising two or more HBV RNAi agents, wherein a first HBV RNAi agent comprises:
      • i) an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) AGAAAAUUGAGAGAAGUCC (SEQ ID NO: 17), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) GGACUUCUCUCAAUUUUCU (SEQ ID NO: 44); or
      • ii) an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UGAAAAUUGAGAGAAGUCC (SEQ ID NO: 18), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) GGACUUCUCUCAAUUUUCA (SEQ ID NO: 45);
        and wherein a second HBV RNAi agent comprises an antisense strand having a sequence that is at least partially complementary to a portion of the X ORF of an HBV mRNA:
  • In some embodiments, disclosed herein are compositions for inhibiting expression of an HBV gene in a cell, the composition comprising two or more HBV RNAi agents, wherein a first HBV RNAi agent comprises an antisense strand having a sequence that is at least partially complementary to a portion of the S ORF of an HBV mRNA, and wherein a second HBV RNAi agent comprises:
      • i) an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) GACCAAUUUAUGCCUACAG (SEQ ID NO: 27), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→93′) CUGUAGGCAUAAAUUGGUC (SEQ ID NO: 54); or
      • ii) an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) AACCAAUUUAUGCCUACAG (SEQ ID NO: 28), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) CUGUAGGCAUAAAUUGGUU (SEQ ID NO: 55); or
      • iii) an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UACCAAUUUAUGCCUACAG (SEQ ID NO: 29), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) CUGUAGGCAUAAAUUGGUA (SEQ ID NO: 56).
  • In some embodiments, an HBV RNAi agent disclosed herein comprises:
      • a. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UACCAAUUUAUGCCUACAGGCCUUAU (SEQ ID NO: 149); or
      • b. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UACCAAUUUAUGCCUACAGGCCU (SEQ ID NO: 150); or
      • c. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UACCAAUUUAUGCCUACAGGC (SEQ ID NO: 151); or
      • d. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′3′) UGAAAAUUGAGAGAAGUCCUU (SEQ ID NO: 152); or
      • e. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UACCAAUUUAUGCCUACAGUU (SEQ ID NO: 154); or
      • f. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UAUUGAGAGAAGUCCACCACG (SEQ ID NO: 160); or
      • g. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UACCAAUUUAUGCCUACAGCC (SEQ ID NO: 162); or
      • h. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UACCAAUUUAUGCCUACAGCCUU (SEQ ID NO: 163); or
      • i. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UAUUGAGAGAAGUCCACCACGA (SEQ ID NO: 170); or
      • j. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) AGAAAAUUGAGAGAAGUCCAC (SEQ ID NO: 171); or
      • k. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UACCAAUUUAUGCCUACAGCUU (SEQ ID NO: 172); or
      • l. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UACCAAUUUAUGCCUACAGCCU (SEQ ID NO: 173); or
      • m. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UAUUGAGAGAAGUCCACCAUU (SEQ ID NO: 174); or
      • n. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UAUUGAGAGAAGUCCACCACUU (SEQ ID NO: 175); or
      • o. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) AGAAAAUUGAGAGAAGUCCUU (SEQ ID NO: 178); or
      • p. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) AGAAAAUUGAGAGAAGUCCACUU (SEQ ID NO: 179); or
      • q. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) AGAAAAUUGAGAGAAGUCCACC (SEQ ID NO: 180); or
      • r. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UGAAAAUUGAGAGAAGUCCAC (SEQ ID NO: 181); or
      • s. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) ACCAAUUUAUGCCUACAGCUU (SEQ ID NO: 182); or
      • t. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) ACCAAUUUAUGCCUACAGCCUU (SEQ ID NO: 183); or
      • u. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) ACCAAUUUAUGCCUACAGCCUC (SEQ ID NO: 184); or
      • v. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UCCAAUUUAUGCCUACAGCUU (SEQ ID NO: 185); or
      • w. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UCCAAUUUAUGCCUACAGCCUU (SEQ ID NO: 186); or
      • x. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UACCAAUUUAUGCCUACAGCU (SEQ ID NO: 187); or
      • y. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UACCAAUUUAUGCCUACAGCG (SEQ ID NO: 188); or
      • z. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) AACCAAUUUAUGCCUACAGCC (SEQ ID NO: 189); or
      • aa. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) ACCAAUUUAUGCCUACAGCCU (SEQ ID NO: 190); or
      • bb. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UCCAAUUUAUGCCUACAGCCU (SEQ ID NO: 191); or
      • cc. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) ACCAAUUUAUGCCUACAGCCG (SEQ ID NO: 192); or
      • dd. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UCCAAUUUAUGCCUACAGCCG (SEQ ID NO: 193); or
      • ee. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UACCAAUUUAUGCCUACAGGG (SEQ ID NO: 194):
        and wherein the HBV RNAi agent further comprises a sense strand at least partially complementary to the respective antisense strand.
  • In some embodiments, an HBV RNAi agent disclosed herein comprises:
      • a. an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UACCAAUUUAUGCCUACAGGCCUUAU (SEQ ID NO: 149); or
      • b. an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UACCAAUUUAUGCCUACAGGCCU (SEQ ID NO: 150); or
      • c. an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UACCAAUUUAUGCCUACAGGC (SEQ ID NO: 151); or
      • d. an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UGAAAAUUGAGAGAAGUCCUU (SEQ ID NO: 152); or
      • e. an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UACCAAUUUAUGCCUACAGUU (SEQ ID NO: 154); or
      • f. an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UAUUGAGAGAAGUCCACCACG (SEQ ID NO: 160); or
      • g. an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UACCAAUUUAUGCCUACAGCC (SEQ ID NO: 162); or
      • h. an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UACCAAUUUAUGCCUACAGCCUU (SEQ ID NO: 163); or
      • i. an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UAUUGAGAGAAGUCCACCACGA (SEQ ID NO: 170); or
      • j. an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) AGAAAAUUGAGAGAAGUCCAC (SEQ ID NO: 171); or
      • k. an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UACCAAUUUAUGCCUACAGCUU (SEQ ID NO: 172); or
      • l. an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UACCAAUUUAUGCCUACAGCCU (SEQ ID NO: 173); or
      • m. an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UAUUGAGAGAAGUCCACCAUU (SEQ ID NO: 174); or
      • n. an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UAUUGAGAGAAGUCCACCACUU (SEQ ID NO: 175); or
      • o. an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) AGAAAAUUGAGAGAAGUCCUU (SEQ ID NO: 178); or
      • p. an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) AGAAAAUUGAGAGAAGUCCACUU (SEQ ID NO: 179); or
      • q. an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) AGAAAAUUGAGAGAAGUCCACC (SEQ ID NO: 180); or
      • r. an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UGAAAAUUGAGAGAAGUCCAC (SEQ ID NO: 181); or
      • s. an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) ACCAAUUUAUGCCUACAGCUU (SEQ ID NO: 182); or
      • t. an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) ACCAAUUUAUGCCUACAGCCUU (SEQ ID NO: 183); or
      • u. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) ACCAAUUUAUGCCUACAGCCUC (SEQ ID NO: 184); or
      • v. an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UCCAAUUUAUGCCUACAGCUU (SEQ ID NO: 185); or
      • w. an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UCCAAUUUAUGCCUACAGCCUU (SEQ ID NO: 186); or
      • x. an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UACCAAUUUAUGCCUACAGCU (SEQ ID NO: 187); or
      • y. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UACCAAUUUAUGCCUACAGCG (SEQ ID NO: 188); or
      • z. an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) AACCAAUUUAUGCCUACAGCC (SEQ ID NO: 189); or
      • aa. an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) ACCAAUUUAUGCCUACAGCCU (SEQ ID NO: 190); or
      • bb. an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UCCAAUUUAUGCCUACAGCCU (SEQ ID NO: 191); or
      • cc. an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) ACCAAUUUAUGCCUACAGCCG (SEQ ID NO: 192); or
      • dd. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UCCAAUUUAUGCCUACAGCCG (SEQ ID NO: 193); or.
      • ee. an antisense strand that consists of the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UACCAAUUUAUGCCUACAGGG (SEQ ID NO: 194);
        and wherein the HBV RNAi agent further comprises a sense strand at least partially complementary to the respective antisense strand.
  • In some embodiments, an HBV RNAi agent disclosed herein comprises:
      • i. an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5′→3′) usAfscCfaAfuUfuAfuGfcCfuAfcAfgGfccsusuAu (SEQ ID NO: 61); or
      • ii. an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5′→3′) usAfscCfaAfuUfuAfuGfcCfuAfcAfgGfcscsu (SEQ ID NO: 62); or
      • iii. an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5′→3′) usAfscsCfaAfuUfuAfuGfcCfuAfcAfgGfccsu (SEQ ID NO: 63); or
      • iv. an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5′→3′) usAfscsCfaAfuUfuAfuGfcCfuAfcAfgGfsc (SEQ ID NO: 64); or
      • v. an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5′→3′) usAfscsCfaAfuUfuAfuGfcCfuAfcAfgusu (SEQ ID NO: 68); or
      • vi. an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5′→3′) usAfscscaauUfuAfuGfcCfuacagcsc (SEQ ID NO: 85); or
      • vii. an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5′→3′) usAfsusugagAfgAfaGfuCfcaccacsg (SEQ ID NO: 94); or
      • viii. an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5′ 3′) usAfsusUfgAfgAfgAfaGfuCfcAfcCfaCfgsa (SEQ ID NO: 98); or
      • ix. an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5′→3′) usAfscsCfaAfuuuauGfcCfuAfcAfgcsc (SEQ ID NO: 102); or
      • x. an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5′→3′) usAfscsCfaAfuuuauGfcCfuAfcAfgcusu (SEQ ID NO: 103); or
      • xi. an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5′→3′) usAfscsCfaAfuuuauGfcCfuAfcAfgccsu (SEQ ID NO: 104); or
      • xii. an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5′→3′) usAfscsCfaAfuuuauGfcCfuAfcAfgccusu (SEQ ID NO: 105); or
      • xiii. an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5′43′) cPrpusAfscsCfaAfuUfuAfuGfcCfuAfcAfgusu (SEQ ID NO: 107); or
      • xiv. an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5′→3′) cPrpusAfsusUfgAfgAfgAfaGfuCfcAfcCfaCfsg (SEQ ID NO: 108); or
      • xv. an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5′→3′) usAfsusUfgAfgagaaGfuCfcAfcCfausu (SEQ ID NO: 109); or
      • xvi. an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5′→3′) usAfsusUfgAfgagaaGfuCfcAfcCfacsg (SEQ ID NO: 110); or
      • xvii. an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5′→3′) usAfsusUfgAfgagaaGfuCfcAfcCfacsusu (SEQ ID NO: 111); or
      • xviii. an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5′→3′) usAfsusUfgAfgagaaGfuCfcAfcCfacsgsa (SEQ ID NO: 112); or
      • xix. an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5′→3′) usAfsusUfgAfgagaaGfuCfcAfcCfacusu (SEQ ID NO: 120); or
      • xx. an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5′→3′) asGfsasAfaAfuUfgAfgAfgAfaGfuCfcusu (SEQ ID NO: 125);
      • xxi. an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5′→3′) asGfsasAfaAfuUfgAfgAfgAfaGfuCfcasc (SEQ ID NO: 126); or
      • xxii. an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5′→3′) asGfsasAfaAfuUfgAfgAfgAfaGfuCfcacusu (SEQ ID NO: 127); or
      • xxiii. an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5′→3′) asGfsasAfaAfuUfgAfgAfgAfaGfuCfcacsc (SEQ ID NO: 128); or
      • xxiv. an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5′→3′) usGfsasAfaAfuUfgAfgAfgAfaGfuCfcusu (SEQ ID NO: 129); or
      • xxv. an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5′→3′) usGfsasAfaAfuUfgAfgAfgAfaGfuCfcasc (SEQ ID NO: 130); or
      • xxvi. an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5′→3′) asCfscsAfaUfuUfaUfgCfcUfaCfaGfcusu (SEQ ID NO: 131); or
      • xxvii. an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5′→3′) asCfscsAfaUfuUfaUfgCfcUfaCfaGfccusu (SEQ ID NO: 132); or
      • xxviii. an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5′→3′) asCfscsAfaUfuUfaUfgCfcUfaCfaGfccusc (SEQ ID NO: 133); or
      • xxix. an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5′→3′) usCfscsAfaUfuUfaUfgCfcUfaCfaGfcusu (SEQ ID NO: 134); or
      • xxx. an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5′→3′) usCfscsAfaUfuUfaUfgCfcUfaCfaGfccusu (SEQ ID NO: 135); or
      • xxxi. an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5′→3′) cPrpusAfscsCfaAfuUfuAfuGfcCfuAfcAfgcsc (SEQ ID NO: 136); or
      • xxxii. an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5′→3′) usAfscsCfaAfuUfuAfuGfcCfuAfcAfgscsc (SEQ ID NO: 137); or
      • xxxiii. an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5′→3′) cPrpusAfscsCfaAfuUfuAfuGfcCfuAfcAfgscsc (SEQ ID NO: 138); or
      • xxxiv. an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5′→3′) usAfscsCfaAfuUfuAfuGfcCfuAfcAfgcsu (SEQ ID NO: 139); or
      • xxxv. an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5′→3′) usAfscsCfaAfuUfuAfuGfcCfuAfcAfgcsg (SEQ ID NO: 140); or
      • xxxvi. an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5′→3′) asAfscsCfaAfuUfuAfuGfcCfuAfcAfgcsc (SEQ ID NO: 141); or
      • xxxvii. an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5′→3′) usAfscsCfaAfuUfUfAfuGfcCfuAfcAfgusu (SEQ ID NO: 142); or
      • xxxviii. an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5′→3′) usAfscsCfaAfuUfuAfuGfcCfuAfcAfgCfsc (SEQ ID NO: 143); or
      • xxxix. an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5′→3′) asCfscAfaUfuUfaUfgCfcUfaCfaGfcCfsu (SEQ ID NO: 144); or
      • xl. an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5′→3′) usCfscAfaUfuUfaUfgCfcUfaCfaGfcCfsu (SEQ ID NO: 145); or
      • xli. an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5′→3′) asCfscAfaUfuUfaUfgCfcUfaCfaGfccsg (SEQ ID NO: 146); or
      • xlii. an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5′→3′) usCfscAfaUfuUfaUfgCfcUfaCfaGfccsg (SEQ ID NO: 147); or
      • xliii. an antisense strand that comprises the sequence differing by 0, 1, 2 or 3 nucleotides from the sequence (5′→3′) usAfscsCfaAfuUfuAfuGfcCfuAfcAfggsg (SEQ ID NO: 148);
        wherein a, g, c and u are 2′-O-methyl (2′-OMe) modified nucleotides; Af, Cf, Gf, and Uf are 2′-fluoro modified nucleotides; s is a phosphorothioate internucleoside linkage and the remaining nucleotide monomers are linked by phosphodiester bonds; and cPrpu is 5′-cyclopropyl phosphonate-2′-O-methyl modified nucleotide; and wherein the HBV RNAi agent further comprises a sense strand at least partially complementary to the respective antisense strand.
  • In some embodiments, an HBV RNAi agent disclosed herein comprises:
      • i. an antisense strand that consists of the sequence (5′→3′) usAfscCfaAfuUfuAfuGfcCfuAfcAfgGfccsusuAu (SEQ ID NO: 61); or
      • ii. an antisense strand that consists of the sequence (5′→3′) usAfscCfaAfuUfuAfuGfcCfuAfcAfgGfcscsu (SEQ ID NO: 62); or
      • iii. an antisense strand that consists of the sequence (5′→3′) usAfscsCfaAfuUfuAfuGfcCfuAfcAfgGfccsu (SEQ ID NO: 63); or
      • iv. an antisense strand that consists of the sequence (5′→3′) usAfscsCfaAfuUfuAfuGfcCfuAfcAfgGfsc (SEQ ID NO: 64); or
      • v. an antisense strand that consists of the sequence (5′→3′) usAfscsCfaAfuUfuAfuGfcCfuAfcAfgusu (SEQ ID NO: 68); or
      • vi. an antisense strand that consists of the sequence (5′→3′) usAfscscaauUfuAfuGfcCfuacagcsc (SEQ ID NO: 85); or
      • vii. an antisense strand that consists of the sequence (5′→3′) usAfsusugagAfgAfaGfuCfcaccacsg (SEQ ID NO: 94); or
      • viii. an antisense strand that consists of the sequence (5′→3′) usAfsusUfgAfgAfgAfaGfuCfcAfcCfaCfgsa (SEQ ID NO: 98); or
      • ix. an antisense strand that consists of the sequence (5′→3′) usAfscsCfaAfuuuauGfcCfuAfcAfgcsc (SEQ ID NO: 102); or
      • x. an antisense strand that consists of the sequence (5′→3′) usAfscsCfaAfuuuauGfcCfuAfcAfgcusu (SEQ ID NO: 103); or
      • xi. an antisense strand that consists of the sequence (5′→3′) usAfscsCfaAfuuuauGfcCfuAfcAfgccsu (SEQ ID NO: 104); or
      • xii. an antisense strand that consists of the sequence (5′→93′) usAfscsCfaAfuuuauGfcCfuAfcAfgccusu (SEQ ID NO: 105); or
      • xiii. an antisense strand that consists of the sequence (5′→3′) cPrpusAfscsCfaAfuUfuAfuGfcCfuAfcAfgusu (SEQ ID NO: 107); or
      • xiv. an antisense strand that consists of the sequence (5′→3′) cPrpusAfsusUfgAfgAfgAfaGfuCfcAfcCfaCfsg (SEQ ID NO: 108); or
      • xv. an antisense strand that consists of the sequence (5′→3′) usAfsusUfgAfgagaaGfuCfcAfcCfausu (SEQ ID NO: 109); or
      • xvi. an antisense strand that consists of the sequence (5′→3′) usAfsusUfgAfgagaaGfuCfcAfcCfacsg (SEQ ID NO: 110); or
      • xvii. an antisense strand that consists of the sequence (5′→3′) usAfsusUfgAfgagaaGfuCfcAfcCfacsusu (SEQ ID NO: 111); or
      • xviii. an antisense strand that consists of the sequence (5′→3′) usAfsusUfgAfgagaaGfuCfcAfcCfacsgsa (SEQ ID NO: 112); or
      • xix. an antisense strand that consists of the sequence (5′→3′) usAfsusUfgAfgagaaGfuCfcAfcCfacusu (SEQ ID NO: 120); or
      • xx. an antisense strand that consists of the sequence (5′→3′) asGfsasAfaAfuUfgAfgAfgAfaGfuCfcusu (SEQ ID NO: 125);
      • xxi. an antisense strand that consists of the sequence (5′→3′) asGfsasAfaAfuUfgAfgAfgAfaGfuCfcasc (SEQ ID NO: 126); or
      • xxii. an antisense strand that consists of the sequence (5′→3′) asGfsasAfaAfuUfgAfgAfgAfaGfuCfcacusu (SEQ ID NO: 127); or
      • xxiii. an antisense strand that consists of the sequence (5′→3′) asGfsasAfaAfuUfgAfgAfgAfaGfuCfcacsc (SEQ ID NO: 128); or
      • xxiv. an antisense strand that consists of the sequence (5′→3′) usGfsasAfaAfuUfgAfgAfgAfaGfuCfcusu (SEQ ID NO: 129); or
      • xxv. an antisense strand that consists of the sequence (5′→3′) usGfsasAfaAfuUfgAfgAfgAfaGfuCfcasc (SEQ ID NO: 130); or
      • xxvi. an antisense strand that consists of the sequence (5′→3′) asCfscsAfaUfuUfaUfgCfcUfaCfaGfcusu (SEQ ID NO: 131); or
      • xxvii. an antisense strand that consists of the sequence (5′→3′) asCfscsAfaUfuUfaUfgCfcUfaCfaGfccusu (SEQ ID NO: 132); or
      • xxviii. an antisense strand that consists of the sequence (5′→3′) asCfscsAfaUfuUfaUfgCfcUfaCfaGfccusc (SEQ ID NO: 133); or
      • xxix. an antisense strand that consists of the sequence (5′→3′) usCfscsAfaUfuUfaUfgCfcUfaCfaGfcusu (SEQ ID NO: 134); or
      • xxx. an antisense strand that consists of the sequence (5′→3′) usCfscsAfaUfuUfaUfgCfcUfaCfaGfccusu (SEQ ID NO: 135); or
      • xxxi. an antisense strand that consists of the sequence (5′→3′) cPrpusAfscsCfaAfuUfuAfuGfcCfuAfcAfgcsc (SEQ ID NO: 136); or
      • xxxii. an antisense strand that consists of the sequence (5′→3′) usAfscsCfaAfuUfuAfuGfcCfuAfcAfgscsc (SEQ ID NO: 137); or
      • xxxiii. an antisense strand that consists of the sequence (5′→3′) cPrpusAfscsCfaAfuUfuAfuGfcCfuAfcAfgscsc (SEQ ID NO: 138); or
      • xxxiv. an antisense strand that consists of the sequence (5′→3′) usAfscsCfaAfuUfuAfuGfcCfuAfcAfgcsu (SEQ ID NO: 139); or
      • xxxv. an antisense strand that consists of the sequence (5′→3′) usAfscsCfaAfuUfuAfuGfcCfuAfcAfgcsg (SEQ ID NO: 140); or
      • xxxvi. an antisense strand that consists of the sequence (5′→3′) asAfscsCfaAfuUfuAfuGfcCfuAfcAfgcsc (SEQ ID NO: 141); or
      • xxxvii. an antisense strand that consists of the sequence (5′→3′) usAfscsCfaAfuUfUfAfuGfcCfuAfcAfgusu (SEQ ID NO: 142); or
      • xxxviii. an antisense strand that consists of the sequence (5′→3′) usAfscsCfaAfuUfuAfuGfcCfuAfcAfgCfsc (SEQ ID NO: 143); or
      • xxxix. an antisense strand that consists of the sequence (5′→3′) asCfscAfaUfuUfaUfgCfcUfaCfaGfcCfsu (SEQ ID NO: 144); or
      • xl. an antisense strand that consists of the sequence (5′→3′) usCfscAfaUfuUfaUfgCfcUfaCfaGfcCfsu (SEQ ID NO: 145); or
      • xli. an antisense strand that consists of the sequence (5′→3′) asCfscAfaUfuUfaUfgCfcUfaCfaGfccsg (SEQ ID NO: 146); or
      • xlii. an antisense strand that consists of the sequence (5′→3′) usCfscAfaUfuUfaUfgCfcUfaCfaGfccsg (SEQ ID NO: 147); or
      • xliii. an antisense strand that consists of the sequence (5′→3′) usAfscsCfaAfuUfuAfuGfcCfuAfcAfggsg (SEQ ID NO: 148);
        wherein a, g, c and u are 2′-O-methyl (2′-OMe) modified nucleotides; Af, Cf, Of, and Uf are 2′-fluoro modified nucleotides; s is a phosphorothioate internucleoside linkage and the remaining nucleotide monomers are linked by phosphodiester bonds; and cPrpu is 5′-cyclopropyl phosphonate-2′-O-methyl modified nucleotide; and wherein the HBV RNAi agent further comprises a sense strand at least partially complementary to the respective antisense strand.
  • In some embodiments, an HBV RNAi agent disclosed herein comprises:
      • a. a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UUGCCUGUAGGCAUAAAUUGGUAUT (SEQ ID NO: 275); or
      • b. a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UAUAUGCCUGUAGGCAUAAAUUGGUA (SEQ ID NO: 276); or
      • c. a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) CUGUAGGCAUAAAUUGGUAUU (SEQ ID NO: 278); or
      • d. a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) CGUGGUGGACUUCUCUCAAUU (SEQ ID NO: 285); or
      • e. a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) CGUGGUGGACUUCUCUCAAUA (SEQ ID NO: 289); or
      • f. a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) CUGUAGGCAUAAAUUGGUA (SEQ ID NO: 292); or
      • g. a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) GGCUGUAGGCAUAAAUUGGUA (SEQ ID NO: 294); or
      • h. a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UCGUGGUGGACUUCUCUCAAUU (SEQ ID NO: 300); or
      • i. a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) GUGGACUUCUCUCAAUUUUCU (SEQ ID NO: 302); or
      • j. a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) GCUGUAGGCAUAAAUUGGUAUU (SEQ ID NO: 303); or
      • k. a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) GGCUGUAGGCAUAAAUUGGUAUU (SEQ ID NO: 304); or
      • l. a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UGGUGGACUUCUCUCAAUAUU (SEQ ID NO: 306); or
      • m. a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) GUGGUGGACUUCUCUCAAUAUU (SEQ ID NO: 307); or
      • n. a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) AAUGGUGGACUUCUCUCAAUAUU (SEQ ID NO: 308); or
      • o. a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) GGACUUCUCUCAAUUUUCU (SEQ ID NO: 318); or
      • p. a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) GGUGGACUUCUCUCAAUUUUCU (SEQ ID NO: 319); or
      • q. a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) GGACUUCUCUCAAUUUUCA (SEQ ID NO: 320); or
      • r. a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) GUGGACUUCUCUCAAUUUUCA (SEQ ID NO: 321); or
      • s. a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) GCUGUAGGCAUAAAUUGGU (SEQ ID NO: 322); or
      • t. a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) GGCUGUAGGCAUAAAUUGGU (SEQ ID NO: 323); or
      • u. a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) GAGGCUGUAGGCAUAAAUUGGU (SEQ ID NO: 324); or
      • v. a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) GCUGUAGGCAUAAAUUGGA (SEQ ID NO: 325); or
      • w. a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) GGCUGUAGGCAUAAAUUGGA (SEQ ID NO: 326); or
      • x. a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) AGCUGUAGGCAUAAAUUGGUA (SEQ ID NO: 327); or
      • y. a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) CGCUGUAGGCAUAAAUUGGUA (SEQ ID NO: 328); or
      • z. a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) GGCUGUAGGCAUAAAUUGGUU (SEQ ID NO: 329); or
      • aa. an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) AGGCUGUAGGCAUAAAUUGGU (SEQ ID NO: 330); or
      • bb. a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) AGGCUGUAGGCAUAAAUUGGA (SEQ ID NO: 331); or
      • cc. a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) CGGCUGUAGGCAUAAAUUGGU (SEQ ID NO: 332); or
      • dd. a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) CGGCUGUAGGCAUAAAUUGGA (SEQ ID NO: 333); or
      • ee. a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) CCCUGUAGGCAUAAAUUGGUA (SEQ ID NO: 334);
        and wherein the HBV RNAi agent further comprises an antisense strand at least partially complementary to the respective antisense strand.
  • In some embodiments, an HBV RNAi agent disclosed herein comprises:
      • a. a sense strand that consists of the nucleobase sequence (5′→3′) UUGCCUGUAGGCAUAAAUUGGUAUT (SEQ ID NO: 275); or
      • b. a sense strand that consists of the nucleobase sequence (5′→3′) UAUAUGCCUGUAGGCAUAAAUUGGUA (SEQ ID NO: 276); or
      • c. a sense strand that consists of the nucleobase sequence (5′→3′) CUGUAGGCAUAAAUUGGUAUU (SEQ ID NO: 278); or
      • d. a sense strand that consists of the nucleobase sequence (5′→3′) CGUGGUGGACUUCUCUCAAUU (SEQ ID NO: 285); or
      • e. a sense strand that consists of the nucleobase sequence (5′→3′) CGUGGUGGACUUCUCUCAAUA (SEQ ID NO: 289); or
      • f. a sense strand that consists of the nucleobase sequence (5′→3′) CUGUAGGCAUAAAUUGGUA (SEQ ID NO: 292); or
      • g. a sense strand that consists of the nucleobase sequence (5′→3′) GGCUGUAGGCAUAAAUUGGUA (SEQ ID NO: 294); or
      • h. a sense strand that consists of the nucleobase sequence (5′→3′) UCGUGGUGGACUUCUCUCAAUU (SEQ ID NO: 300); or
      • i. a sense strand that consists of the nucleobase sequence (5′→3′) GUGGACUUCUCUCAAUUUUCU (SEQ ID NO: 302); or
      • j. a sense strand that consists of the nucleobase sequence (5′→3′) GCUGUAGGCAUAAAUUGGUAUU (SEQ ID NO: 303); or
      • k. a sense strand that consists of the nucleobase sequence (5′→3′) GGCUGUAGGCAUAAAUUGGUAUU (SEQ ID NO: 304); or
      • l. a sense strand that consists of the nucleobase sequence (5′→3′) UGGUGGACUUCUCUCAAUAUU (SEQ ID NO: 306); or
      • m. a sense strand that consists of the nucleobase sequence (5′→3′) GUGGUGGACUUCUCUCAAUAUU (SEQ ID NO: 307); or
      • n. a sense strand that consists of the nucleobase sequence (5′→3′) AAUGGUGGACUUCUCUCAAUAUU (SEQ ID NO: 308); or
      • o. a sense strand that comprises the nucleobase sequence (5′→3′) GGACUUCUCUCAAUUUUCU (SEQ ID NO: 318); or
      • p. a sense strand that consists of the nucleobase sequence (5′→3′) GGUGGACUUCUCUCAAUUUUCU (SEQ ID NO: 319); or
      • q. a sense strand that consists of the nucleobase sequence (5′→3′) GGACUUCUCUCAAUUUUCA (SEQ ID NO: 320); or
      • r. a sense strand that consists of the nucleobase sequence (5′→3′) GUGGACUUCUCUCAAUUUUCA (SEQ ID NO: 321); or
      • s. a sense strand that consists of the nucleobase sequence (5′→3′) GCUGUAGGCAUAAAUUGGU (SEQ ID NO: 322); or
      • t. a sense strand that consists of the nucleobase sequence (5′→3′) GGCUGUAGGCAUAAAUUGGU (SEQ ID NO: 323); or
      • u. a sense strand that consists of the nucleobase sequence (5′→3′) GAGGCUGUAGGCAUAAAUUGGU (SEQ ID NO: 324); or
      • v. a sense strand that consists of the nucleobase sequence (5′→3′) GCUGUAGGCAUAAAUUGGA (SEQ ID NO: 325); or
      • w. a sense strand that consists of the nucleobase sequence (5′→3′) GGCUGUAGGCAUAAAUUGGA (SEQ ID NO: 326); or
      • x. a sense strand that consists of the nucleobase sequence (5′→3′) AGCUGUAGGCAUAAAUUGGUA (SEQ ID NO: 327); or
      • y. a sense strand that consists of the nucleobase sequence (5′→3′) CGCUGUAGGCAUAAAUUGGUA (SEQ ID NO: 328); or
      • z. a sense strand that consists of the nucleobase sequence (5′→3′) GGCUGUAGGCAUAAAUUGGUU (SEQ ID NO: 329); or
      • aa. an antisense strand that comprises the nucleobase sequence (5′→3′) AGGCUGUAGGCAUAAAUUGGU (SEQ ID NO: 330); or
      • bb. a sense strand that consists of the nucleobase sequence (5′→3′) AGGCUGUAGGCAUAAAUUGGA (SEQ ID NO: 331); or
      • cc. a sense strand that consists of the nucleobase sequence (5′→3′) CGGCUGUAGGCAUAAAUUGGU (SEQ ID NO: 332); or
      • dd. a sense strand that consists of the nucleobase sequence (5′→3′) CGGCUGUAGGCAUAAAUUGGA (SEQ ID NO: 333); or
      • ee. a sense strand that consists of the nucleobase sequence (5′→3′) CCCUGUAGGCAUAAAUUGGUA (SEQ ID NO: 334);
        and wherein the HBV RNAi agent further comprises an antisense strand at least partially complementary to the respective antisense strand.
  • In some embodiments, disclosed herein are compositions for inhibiting expression of an HBV gene in a cell, the composition comprising two HBV RNAi agents, wherein a first HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UAUUGAGAGAAGUCCACCACUU (SEQ ID NO: 175), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) GUGGUGGACUUCUCUCAAUAUU (SEQ ID NO: 307); and wherein a second HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UACCAAUUUAUGCCUACAGUU (SEQ ID NO: 154), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) CUGUAGGCAUAAAUUGGUA (SEQ ID NO: 292).
  • In some embodiments, disclosed herein are compositions for inhibiting expression of an HBV gene in a cell, the composition comprising two HBV RNAi agents, wherein a first HBV RNAi agent comprises an antisense strand that consists of the nucleobase sequence (5′→3′) UAUUGAGAGAAGUCCACCACUU (SEQ ID NO: 175), and a sense strand that consists of the nucleobase sequence (5′→3′) GUGGUGGACUUCUCUCAAUAUU (SEQ ID NO: 307); and wherein a second HBV RNAi agent comprises an antisense strand that consists of the nucleobase sequence (5′→3′) UACCAAUUUAUGCCUACAGUU (SEQ ID NO: 154), and a sense strand that consists of the nucleobase sequence (5′→3′) CUGUAGGCAUAAAUUGGUA (SEQ ID NO: 292).
  • In some embodiments, disclosed herein are compositions for inhibiting expression of an HBV gene in a cell, the composition comprising two HBV RNAi agents, wherein a first HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) AGAAAAUUGAGAGAAGUCCAC (SEQ ID NO: 171), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) GUGGACUUCUCUCAAUUUUCU (SEQ ID NO: 302); and wherein a second HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UACCAAUUUAUGCCUACAGCG (SEQ ID NO: 188), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′43′) CGCUGUAGGCAUAAAUUGGUA (SEQ ID NO: 328).
  • In some embodiments, disclosed herein are compositions for inhibiting expression of an HBV gene in a cell, the composition comprising two HBV RNAi agents, wherein a first HBV RNAi agent comprises an antisense strand that consists of the nucleobase sequence (5′→3′) AGAAAAUUGAGAGAAGUCCAC (SEQ ID NO: 171), and a sense strand that consists of the nucleobase sequence (5′→3′) GUGGACUUCUCUCAAUUUUCU (SEQ ID NO: 302); and wherein a second HBV RNAi agent comprises an antisense strand that consists of the nucleobase sequence (5′→3′) UACCAAUUUAUGCCUACAGCG (SEQ ID NO: 188), and a sense strand that consists of the nucleobase sequence (5′→3′) CGCUGUAGGCAUAAAUUGGUA (SEQ ID NO: 328).
  • In some embodiments, disclosed herein are compositions for inhibiting expression of an HBV gene in a cell, the composition comprising two HBV RNAi agents, wherein a first HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) AGAAAAUUGAGAGAAGUCCAC (SEQ ID NO: 171), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) GUGGACUUCUCUCAAUUUUCU (SEQ ID NO: 302); and wherein a second HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UACCAAUUUAUGCCUACAGCC (SEQ ID NO: 162), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) GGCUGUAGGCAUAAAUUGGUA (SEQ ID NO: 294).
  • In some embodiments, disclosed herein are compositions for inhibiting expression of an HBV gene in a cell, the composition comprising two HBV RNAi agents, wherein a first HBV RNAi agent comprises an antisense strand that consists of the nucleobase sequence (5′→3′) AGAAAAUUGAGAGAAGUCCAC (SEQ ID NO: 171), and a sense strand that consists of the nucleobase sequence (5′→3′) GUGGACUUCUCUCAAUUUUCU (SEQ ID NO: 302); and wherein a second HBV RNAi agent comprises an antisense strand that consists of the nucleobase sequence (5′→3′) UACCAAUUUAUGCCUACAGCC (SEQ ID NO: 162), and a sense strand that consists of the nucleobase sequence (5′→3′) GGCUGUAGGCAUAAAUUGGUA (SEQ ID NO: 294).
  • In some embodiments, disclosed herein are compositions for inhibiting expression of an HBV gene in a cell, the composition comprising two HBV RNAi agents, wherein a first HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) AGAAAAUUGAGAGAAGUCCAC (SEQ ID NO: 171), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) GUGGACUUCUCUCAAUUUUCU (SEQ ID NO: 302); and wherein a second HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UACCAAUUUAUGCCUACAGCC (SEQ ID NO: 162), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) GUGGUGGACUUCUCUCAAUAUU (SEQ ID NO: 307).
  • In some embodiments, disclosed herein are compositions for inhibiting expression of an HBV gene in a cell, the composition comprising two HBV RNAi agents, wherein a first HBV RNAi agent comprises an antisense strand that consists of the nucleobase sequence (5′→3′) AGAAAAUUGAGAGAAGUCCAC (SEQ ID NO: 171), and a sense strand that consists of the nucleobase sequence (5′→3′) GUGGACUUCUCUCAAUUUUCU (SEQ ID NO: 302); and wherein a second HBV RNAi agent comprises an antisense strand that consists of the nucleobase sequence (5′→3′) UACCAAUUUAUGCCUACAGCC (SEQ ID NO: 162), and a sense strand that consists of the nucleobase sequence (5′→3′) GUGGUGGACUUCUCUCAAUAUU (SEQ ID NO: 307).
  • In some embodiments, disclosed herein are compositions for inhibiting expression of an HBV gene in a cell, the composition comprising two HBV RNAi agents, wherein all or substantially all of the nucleotides in the sense strand are modified and/or all or substantially all of the nucleotides in the antisense strand in the first and/or second HBV RNAi agent are modified nucleotides, and wherein the first HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UAUUGAGAGAAGUCCACCACUU (SEQ ID NO: 175), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) GUGGUGGACUUCUCUCAAUAUU (SEQ ID NO: 307); and wherein the second HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UACCAAUUUAUGCCUACAGUU (SEQ ID NO: 154), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) CUGUAGGCAUAAAUUGGUA (SEQ ID NO: 292).
  • In some embodiments, disclosed herein are compositions for inhibiting expression of an HBV gene in a cell, the composition comprising two HBV RNAi agents, wherein all or substantially all of the nucleotides in the sense strand are modified and/or all or substantially all of the nucleotides in the antisense strand in the first and/or second HBV RNAi agent are modified nucleotides, and wherein the first HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) AGAAAAUUGAGAGAAGUCCAC (SEQ ID NO: 171), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) GUGGACUUCUCUCAAUUUUCU (SEQ ID NO: 302); and wherein the second HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UACCAAUUUAUGCCUACAGCG (SEQ ID NO: 188), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) CGCUGUAGGCAUAAAUUGGUA (SEQ ID NO: 328).
  • In some embodiments, disclosed herein are compositions for inhibiting expression of an HBV gene in a cell, the composition comprising two HBV RNAi agents, wherein all or substantially all of the nucleotides in the sense strand are modified and/or all or substantially all of the nucleotides in the antisense strand in the first and/or second HBV RNAi agent are modified nucleotides, and wherein the first HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) AGAAAAUUGAGAGAAGUCCAC (SEQ ID NO: 171), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) GUGGACUUCUCUCAAUUUUCU (SEQ ID NO: 302); and wherein the second HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UACCAAUUUAUGCCUACAGCC (SEQ ID NO: 162), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) GGCUGUAGGCAUAAAUUGGUA (SEQ ID NO: 294).
  • In some embodiments, disclosed herein are compositions for inhibiting expression of an HBV gene in a cell, the composition comprising two HBV RNAi agents, wherein all or substantially all of the nucleotides in the sense strand are modified and/or all or substantially all of the nucleotides in the antisense strand in the first and/or second HBV RNAi agent are modified nucleotides, and wherein the first HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) AGAAAAUUGAGAGAAGUCCAC (SEQ ID NO: 171), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) GUGGACUUCUCUCAAUUUUCU (SEQ ID NO: 302); and wherein the second HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UACCAAUUUAUGCCUACAGCC (SEQ ID NO: 162), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) GUGGUGGACUUCUCUCAAUAUU (SEQ ID NO: 307).
  • In some embodiments, disclosed herein are compositions for inhibiting expression of an HBV gene in a cell, the composition comprising two HBV RNAi agents, wherein all or substantially all of the nucleotides in the sense strand are modified and/or all or substantially all of the nucleotides in the antisense strand in the first and/or second HBV RNAi agent are modified nucleotides, and wherein the first HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UAUUGAGAGAAGUCCACCACUU (SEQ ID NO: 175), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) GUGGUGGACUUCUCUCAAUAUU (SEQ ID NO: 307); and wherein the second HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UACCAAUUUAUGCCUACAGUU (SEQ ID NO: 154), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) CUGUAGGCAUAAAUUGGUA (SEQ ID NO: 292), and wherein the sense strand of the first HBV RNAi agent and the second HBV RNAi agent are conjugated to a targeting ligand comprising N-acetyl-galactosamine.
  • In some embodiments, disclosed herein are compositions for inhibiting expression of an HBV gene in a cell, the composition comprising two HBV RNAi agents, wherein all or substantially all of the nucleotides in the sense strand are modified and/or all or substantially all of the nucleotides in the antisense strand in the first and/or second HBV RNAi agent are modified nucleotides, and wherein the first HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) AGAAAAUUGAGAGAAGUCCAC (SEQ ID NO: 171), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) GUGGACUUCUCUCAAUUUUCU (SEQ ID NO: 302); and wherein the second HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UACCAAUUUAUGCCUACAGCG (SEQ ID NO: 188), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) CGCUGUAGGCAUAAAUUGGUA (SEQ ID NO: 328), and wherein the sense strand of the first HBV RNAi agent and the second HBV RNAi agent are conjugated to a targeting ligand comprising N-acetyl-galactosamine.
  • In some embodiments, disclosed herein are compositions for inhibiting expression of an HBV gene in a cell, the composition comprising two HBV RNAi agents, wherein all or substantially all of the nucleotides in the sense strand are modified and/or all or substantially all of the nucleotides in the antisense strand in the first and/or second HBV RNAi agent are modified nucleotides, and wherein the first HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) AGAAAAUUGAGAGAAGUCCAC (SEQ ID NO: 171), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) GUGGACUUCUCUCAAUUUUCU (SEQ ID NO: 302); and wherein the second HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UACCAAUUUAUGCCUACAGCC (SEQ ID NO: 162), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) GGCUGUAGGCAUAAAUUGGUA (SEQ ID NO: 294), and wherein the sense strand of the first HBV RNAi agent and the second HBV RNAi agent are conjugated to a targeting ligand comprising N-acetyl-galactosamine.
  • In some embodiments, disclosed herein are compositions for inhibiting expression of an HBV gene in a cell, the composition comprising two HBV RNAi agents, wherein all or substantially all of the nucleotides in the sense strand are modified and/or all or substantially all of the nucleotides in the antisense strand in the first and/or second HBV RNAi agent are modified nucleotides, and wherein the first HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) AGAAAAUUGAGAGAAGUCCAC (SEQ ID NO: 171), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) GUGGACUUCUCUCAAUUUUCU (SEQ ID NO: 302); and wherein the second HBV RNAi agent comprises an antisense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) UACCAAUUUAUGCCUACAGCC (SEQ ID NO: 162), and a sense strand that comprises the nucleobase sequence differing by 0, 1, 2 or 3 nucleobases from the sequence (5′→3′) GUGGUGGACUUCUCUCAAUAUU (SEQ ID NO: 307), and wherein the sense strand of the first HBV RNAi agent and the second HBV RNAi agent are conjugated to a targeting ligand comprising N-acetyl-galactosamine.
  • In some embodiments, disclosed herein are methods of treatment of an HBV infection or prevention of disease or symptoms caused by an HBV infection comprising administering to a subject in need thereof an effective amount of AD04872 and an effective amount of AD05070. In some embodiments, the ratio of AD04872 to AD05070 administered to a subject in need thereof is about 2:1. In some embodiments, the ratio of AD04872 to AD05070 administered to a subject in need thereof is about 3:1. In some embodiments, the ratio of AD04872 to AD05070 administered to a subject in need thereof is about 1:1. In some embodiments, the ratio of AD04872 to AD05070 administered to a subject in need thereof is about 4:1. In some embodiments, the ratio of AD04872 to AD05070 administered to a subject in need thereof is about 5:1. In some embodiments, the ratio of AD04872 to AD05070 administered to a subject in need thereof is about 1:2.
  • In some embodiments, about 1 mg/kg (mpk) of AD04872 and about 1 mg/kg of AD05070 are administered to a subject in need thereof. In some embodiments, about 1.5 mg/kg of AD04872 and about 1.5 mg/kg of AD05070 are administered to a subject in need thereof. In some embodiments, about 2.0 mg/kg of AD04872 and about 1.0 mg/kg of AD05070 are administered to a subject in need thereof. In some embodiments, about 3.0 mg/kg of AD04872 and about 1.0 mg/kg of AD05070 are administered to a subject in need thereof. In some embodiments, about 3.2 mg/kg of AD04872 and about 0.8 mg/kg of AD05070 are administered to a subject in need thereof. In some embodiments, about 2.7 mg/kg of AD04872 and about 1.3 mg/kg of AD05070 are administered to a subject in need thereof. In some embodiments, about 4.0 mg/kg of AD04872 and about 1.0 mg/kg of AD05070 are administered to a subject in need thereof. In some embodiments, about 3.3 mg/kg of AD04872 and about 1.7 mg/kg of AD05070 are administered to a subject in need thereof. In some embodiments, between about 0.05 and about 5 mg/kg of AD04872 and between about 0.05 and about 5 mg/kg of AD05070 are administered to a subject in need thereof. In some embodiments, about AD04872 and about AD05070 are administered separately (e.g., in separate injections). In some embodiments, the respective dose of AD04872 and the respective dose of AD05070 are administered together (e.g., in the same injection). In some embodiments, the respective dose of AD04872 and the respective dose of AD05070 are prepared in a single pharmaceutical composition.
  • In some embodiments, disclosed herein are methods of treatment of an HBV infection or prevention of diseases or symptoms caused by an HBV infection comprising administering to a subject in need thereof an effective amount of AD04872 and an effective amount of AD04776. In some embodiments, the ratio of AD04872 to AD04776 administered to a subject in need thereof is about 2:1. In some embodiments, the ratio of AD04872 to AD04776 administered to a subject in need thereof is about 3:1. In some embodiments, the ratio of AD04872 to AD04776 administered to a subject in need thereof is about 4:1. In some embodiments, the ratio of AD04872 to AD04776 administered to a subject in need thereof is about 1:1. In some embodiments, the ratio of AD04872 to AD04776 administered to a subject in need thereof is 5:1. In some embodiments, the ratio of AD04872 to AD04776 administered to a subject in need thereof is 1:2.
  • In some embodiments, about 1 mg/kg (mpk) of AD04872 and about 1 mg/kg of AD04776 are administered to a subject in need thereof. In some embodiments, about 1.5 mg/kg of AD04872 and about 1.5 mg/kg of AD04776 are administered to a subject in need thereof. In some embodiments, about 2.0 mg/kg of AD04872 and about 1.0 mg/kg of AD04776 are administered to a subject in need thereof. In some embodiments, about 3.0 mg/kg of AD04872 and about 1.0 mg/kg of AD04776 are administered to a subject in need thereof. In some embodiments, about 3.2 mg/kg of AD04872 and about 0.8 mg/kg of AD04776 are administered to a subject in need thereof. In some embodiments, about 2.7 mg/kg of AD04872 and about 1.3 mg/kg of AD04776 are administered to a subject in need thereof. In some embodiments, about 4.0 mg/kg of AD04872 and about 1.0 mg/kg of AD04776 are administered to a subject in need thereof. In some embodiments, about 3.3 mg/kg of AD04872 and about 1.7 mg/kg of AD04776 are administered to a subject in need thereof. In some embodiments, between about 0.05 and about 5 mg/kg of AD04872 and between about 0.05 and about 5 mg/kg of AD04776 are administered to a subject in need thereof. In some embodiments, the respective doses of AD04872 and AD04776 are administered separately (e.g., in separate injections). In some embodiments, the respective doses of AD04872 and AD04776 are administered together (e.g., in the same injection). In some embodiments, the respective doses of AD04872 and AD04776 are prepared in a single pharmaceutical composition.
  • In some embodiments, disclosed herein are methods of treatment of an HBV infection or prevention of disease or symptoms caused by an HBV infection comprising administering to a subject in need thereof an effective amount of AD04872 and an effective amount of AD04982. In some embodiments, the ratio of AD04872 to AD04982 administered to a subject in need thereof is about 2:1. In some embodiments, the ratio of AD04872 to AD04982 administered to a subject in need thereof is about 3:1. In some embodiments, the ratio of AD04872 to AD04982 administered to a subject in need thereof is about 4:1. In some embodiments, the ratio of AD04872 to AD04982 administered to a subject in need thereof is about 1:1. In some embodiments, the ratio of AD04872 to AD04982 administered to a subject in need thereof is about 5:1. In some embodiments, the ratio of AD04872 to AD04982 administered to a subject in need thereof is 1:2.
  • In some embodiments, about 1 mg/kg (mpk) of AD04872 and about 1 mg/kg of AD04982 are administered to a subject in need thereof. In some embodiments, about 1.5 mg/kg of AD04872 and about 1.5 mg/kg of AD04982 are administered to a subject in need thereof. In some embodiments, about 2.0 mg/kg of AD04872 and about 1.0 mg/kg of AD04982 are administered to a subject in need thereof. In some embodiments, about 3.0 mg/kg of AD04872 and about 1.0 mg/kg of AD04982 are administered to a subject in need thereof. In some embodiments, about 3.2 mg/kg of AD04872 and about 0.8 mg/kg of AD04982 are administered to a subject in need thereof. In some embodiments, about 2.7 mg/kg of AD04872 and about 1.3 mg/kg of AD04982 are administered to a subject in need thereof. In some embodiments, about 4.0 mg/kg of AD04872 and about 1.0 mg/kg of AD04982 are administered to a subject in need thereof. In some embodiments, about 3.3 mg/kg of AD04872 and about 1.7 mg/kg of AD04982 are administered to a subject in need thereof. In some embodiments, between about 0.05 and about 5 mg/lg of AD04872 and between about 0.05 and about 5 mg/kg of AD04982 are administered to a subject in need thereof. In some embodiments, the respective doses of AD04872 and AD04982 are administered separately (e.g., in separate injections). In some embodiments, the respective doses of AD04872 and AD04982 are administered together (e.g., in the same injection). In some embodiments, the respective doses of AD04872 and AD04982 are prepared in a single pharmaceutical composition.
  • In some embodiments, disclosed herein are methods of treatment of an HBV infection or prevention of disease or symptoms caused by an HBV infection comprising administering to a subject in need thereof an effective amount of AD04580 and an effective amount of AD04585. In some embodiments, the ratio of AD04580 to AD04585 administered to a subject in need thereof is about 2:1. In some embodiments, the ratio of AD04580 to AD04585 administered to a subject in need thereof is about 3:1. In some embodiments, the ratio of AD04580 to AD04585 administered to a subject in need thereof is about 4:1. In some embodiments, the ratio of AD04580 to AD04585 administered to a subject in need thereof is about 5:1. In some embodiments, the ratio of AD04580 to AD04585 administered to a subject in need thereof is about 1:1. In some embodiments, the ratio of AD04580 to AD04585 administered to a subject in need thereof is about 1:2. In some embodiments, about 1 mg/kg (mpk) of AD04580 and about 1 mg/kg of AD04585 are administered to a subject in need thereof. In some embodiments, about 1.5 mg/kg of AD04580 and about 1.5 mg/kg of AD04585 are administered to a subject in need thereof. In some embodiments, between about 0.05 and about 5 mg/kg of AD04580 and between about 0.05 and about 5 mg/kg of AD04585 are administered to a subject in need thereof.
  • In some embodiments, an HBV RNAi agent disclosed herein consists of or comprises AD05070 linked to (NAG37)s shown as a sodium salt having the structure represented by the following:
  • In some embodiments, an HBV RNAi agent disclosed herein consists of or comprises AD05070 linked to (NAG25)s shown as a sodium salt having the structure represented by the following:
  • In some embodiments, an HBV RNAi agent disclosed herein consists of or comprises AD05070 linked to (NAG37)s shown as a free acid having the structure represented by the following:
  • In some embodiments, an HBV RNAi agent disclosed herein consists of or comprises AD04580 linked to (NAG31)s shown as a sodium salt having the structure represented by the following:
  • In some embodiments, an HBV RNAi agent disclosed herein consists of or comprises AD04585 linked to (NAG25)s shown as a sodium salt having the structure represented by the following:
  • In some embodiments, an HBV RNAi agent disclosed herein consists of or comprises AD04872 linked to (NAG37)s shown as a sodium salt having the structure represented by the following:
  • In some embodiments, an HBV RNAi agent disclosed herein consists of or comprises AD04872 linked to (NAG25)s shown as a sodium salt having the structure represented by the following:
  • In some embodiments, an HBV RNAi agent disclosed herein consists of or comprises AD04872 linked to (NAG37)s shown as a free acid having the structure represented by the following:
  • In some embodiments, the described HBV RNAi agent(s) are optionally combined with one or more additional (i.e., second, third, etc.) therapeutics. A second therapeutic can be another HBV RNAi agent (e.g., a HBV RNAi agent which targets a different sequence within an HBV genome). An additional therapeutic can also be a small molecule drug, antibody, antibody fragment, and/or vaccine. The HBV RNAi agents, with or without the one or more additional therapeutics, can be combined with one or more excipients to form pharmaceutical compositions.
  • In some embodiments, the described HBV RNAi agent(s) are optionally combined with one or more additional therapeutics, wherein the additional therapeutic is a nucleoside inhibitor or nucleotide inhibitor. In some embodiments, the described HBV RNAi agent(s) are optionally combined with one or more additional therapeutics, wherein the additional therapeutic entecavir, tenofovir, tenofovir alafenamide, tenofovir disoproxil, lamivudine, or another antiviral therapeutic. In some embodiments, the described HBV RNAi agent(s) are optionally combined with one or more additional therapeutics, wherein the additional therapeutic is an interferon. In some embodiments, the described HBV RNAi agent(s) are optionally combined with one or more additional therapeutics, wherein the additional therapeutic is interferon-alpha. In some embodiments, the described HBV RNAi agent(s) are optionally combined with one or more HBV additional therapeutics, wherein the additional therapeutic is an HBV vaccine.
  • In some embodiments, the described HBV RNAi agent(s) are optionally combined with one or more additional therapeutics in a single dosage form (i.e., a cocktail included in a single injection). In some embodiments, the described HBV RNAi agent(s) may be administered separately from one or more optional additional therapeutics. In some embodiments, the described HBV RNAi agent(s) are administered to a subject in need thereof via subcutaneous injection, and the one or more optional additional therapeutics are administered orally, which together provide for a treatment regimen for diseases and conditions associated with HBV infection. In some embodiments, the described HBV RNAi agent(s) are administered to a subject in need thereof via subcutaneous injection, and the one or more optional additional therapeutics are administered via a separate subcutaneous injection.
  • In some embodiments, disclosed herein are compositions for delivering an HBV RNAi agent to a liver cell in vivo, the composition including an HBV RNAi agent conjugated or linked to a targeting group. In some embodiments, the targeting group is an asialoglycoprotein receptor ligand. In some embodiments, compositions for delivering an HBV RNAi agent to a liver cell in vivo are described, the composition including an HBV RNAi agent linked to an N-acetyl-galactosamine targeting ligand.
  • In some embodiments, one or more of the described HBV RNAi agents are administered to a mammal in a pharmaceutically acceptable carrier or diluent. In some embodiments, the mammal is a human.
  • The use of Hepatitis B Virus RNAi agent(s) provides methods for therapeutic and/or prophylactic treatment of diseases/disorders which are associated with HBV infection. The described HBV RNAi agents mediate RNA interference to inhibit the expression of one or more genes necessary for replication and/or pathogenesis of Hepatitis B Virus. In particular, for example, HBV RNAi agents may inhibit viral polymerase, core protein, surface antigen, e-antigen and/or the X protein, in a cell, tissue or mammal. HBV RNAi agents can be used to treat HBV infection. HBV RNAi agents can also be used to treat or prevent chronic liver diseases/disorders, inflammations, fibrotic conditions and proliferative disorders, like cancers, associated with HBV infection. In some embodiments, the methods further comprise treatment of Hepatitis D Virus (HDV) in the subject. Such methods comprise administration of HBV RNAi agent to a human being or animal infected with HBV. Further, compositions for delivery of HBV RNAi agents to liver cells in vivo are described.
  • The pharmaceutical compositions comprising one or more HBV RNAi agents can be administered in a number of ways depending upon whether local or systemic treatment is desired. Administration can be, but is not limited to, intravenous, intraarterial, subcutaneous, intraperitoneal, subdermal (e.g., via an implanted device), and intraparenchymal administration. In some embodiments, the pharmaceutical compositions described herein are administered by subcutaneous injection.
  • The described HBV RNAi agents and/or compositions can be used in methods for therapeutic treatment of HBV infection or disease or conditions caused by HBV infection. Such methods include administration of an HBV RNAi agent as described herein to a subject, e.g., a human or animal subject.
  • As used herein, the terms “oligonucleotide” and “polynucleotide” mean a polymer of linked nucleosides each of which can be independently modified or unmodified.
  • As used herein, an “RNAi agent” or “RNAi trigger” means a composition that contains an RNA or RNA-like (e.g., chemically modified RNA) oligonucleotide molecule that is capable of degrading or inhibiting translation of messenger RNA (mRNA) transcripts of a target mRNA in a sequence specific manner. As used herein. RNAi agents may operate through the RNA interference mechanism (i.e., inducing RNA interference through interaction with the RNA interference pathway machinery (RNA-induced silencing complex or RISC) of mammalian cells), or by any alternative mechanism(s) or pathway(s). While it is believed that RNAi agents, as that term is used herein, operate primarily through the RNA interference mechanism, the disclosed RNAi agents are not bound by or limited to any particular pathway or mechanism of action. RNAi agents disclosed herein are comprised of a sense strand and an antisense strand, and include, but are not limited to: short interfering RNAs (siRNAs), double-stranded RNAs (dsRNA), micro RNAs (miRNAs), short hairpin RNAs (shRNA), and dicer substrates. The antisense strand of the RNAi agents described herein is at least partially complementary to the mRNA being targeted. RNAi agents may be comprised of modified nucleotides and/or one or more non-phosphodiester linkages.
  • As used herein, the terms “silence,” “reduce,” “inhibit,” “down-regulate,” or “knockdown” when referring to expression of a given gene, mean that the expression of the gene, as measured by the level of RNA transcribed from the gene or the level of polypeptide, protein or protein subunit translated from the mRNA in a cell, group of cells, tissue, organ, or subject in which the gene is transcribed, is reduced when the cell, group of cells, tissue, organ, or subject is treated with oligomeric compounds, such as RNAi agents, described herein as compared to a second cell, group of cells, tissue, organ, or subject that has not or have not been so treated.
  • As used herein, the term “sequence” or “nucleotide sequence” mean a succession or order of nucleobases or nucleotides, described with a succession of letters using standard nomenclature.
  • As used herein, a “nucleotide base,” or “‘nucleobase’” is a heterocyclic pyrimidine or purine compound, which is a standard constituent of all nucleic acids, and includes the bases that form the nucleotides adenine (A), guanine (G), cytosine (C), thymine (T), and uracil (U). A nucleobase may further be modified to include, without limitation, universal bases, hydrophobic bases, promiscuous bases, size-expanded bases, and fluorinated bases.
  • As used herein, and unless otherwise indicated, the term “complementary,” when used to describe a first nucleotide sequence (e.g., RNAi agent sense strand or targeted mRNA) in relation to a second nucleotide sequence (e.g., RNAi agent antisense strand or a single-stranded antisense oligonucleotide), means the ability of an oligonucleotide or polynucleotide including the first nucleotide sequence to hybridize (form base pair hydrogen bonds under mammalian physiological conditions (or similar conditions in vitro)) and form a duplex or double helical structure under certain conditions with an oligonucleotide or polynucleotide including the second nucleotide sequence. Complementary sequences include Watson-Crick base pairs or non-Watson-Crick base pairs and include natural or modified nucleotides or nucleotide mimics, at least to the extent that the above hybridization requirements are fulfilled. Sequence identity or complementarity is independent of modification. For example, a and Af are complementary to U (or T) and identical to A for the purposes of determining identity or complementarity.
  • As used herein, “perfectly complementary” or “fully complementary” means that all (100%) of the bases in a contiguous sequence of a first polynucleotide will hybridize with the same number of bases in a contiguous sequence of a second polynucleotide. The contiguous sequence may comprise all or a part of a first or second nucleotide sequence.
  • As used herein, “partially complementary” means that in a hybridized pair of nucleobase sequences, at least 70%, but not all, of the bases in a contiguous sequence of a first polynucleotide will hybridize with the same number of bases in a contiguous sequence of a second polynucleotide.
  • As used herein, “substantially complementary” means that in a hybridized pair of nucleobase sequences, at least about 85%, but not all, of the bases in a contiguous sequence of a first polynucleotide will hybridize with the same number of bases in a contiguous sequence of a second polynucleotide. The terms “complementary,” “fully complementary,” and “substantially complementary” herein may be used with respect to the base matching between the sense strand and the antisense strand of a double-stranded RNAi agent, between the antisense strand of an RNAi agent and a sequence of a target mRNA, or between a single-stranded antisense oligonucleotide and a sequence of a target mRNA.
  • As used herein, the term “substantially identical” or“substantially identity” as applied to nucleic acid sequence means that a nucleic acid sequence comprises a sequence that has at least about 85% sequence identity or more, preferably at least 90%, at least 95%, or at least 99%, compared to a reference sequence. Percentage of sequence identity is determined by comparing two optimally aligned sequences over a comparison window. The percentage is calculated by determining the number of positions at which the identical nucleic acid base occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity. The inventions disclosed herein encompasses nucleotide sequences substantially identical to those disclosed herein. e.g., in Tables 2, 3, and 4. In some embodiments, the sequences disclosed herein are exactly identical, or at least about 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% percent identical to those disclosed herein, e.g., in Tables 1, 2, 3 and 4.
  • As used herein, the terms “treat,” “treatment,” and the like, mean the methods or steps taken to provide relief from or alleviation of the number, severity, and/or frequency of one or more symptoms of a disease or condition in a subject.
  • As used herein, the phrase “introducing into a cell,” when referring to an oligomeric compound, means functionally delivering the oligomeric compound into a cell. The phrase “functional delivery,” means that delivering the oligomeric compound to the cell in a manner that enables the oligomeric compound to have the expected biological activity, e.g., sequence-specific inhibition of gene expression.
  • Unless stated otherwise, use of the symbol
    Figure US20190255091A1-20190822-P00009
    as used herein means that any group or groups may be linked thereto that is in accordance with the scope of the inventions described herein.
  • As used herein, the term “isomers” refers to compounds that have identical molecular formulae, but that differ in the nature or the sequence of bonding of their atoms or in the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers.” Stereoisomers that are not mirror images of one another are termed “diastereoisomers,” and stereoisomers that are non-superimposable mirror images are termed “enantiomers,” or sometimes optical isomers. A carbon atom bonded to four non-identical substituents is termed a “chiral center.”
  • As used herein, unless specifically identified in a structure as having a particular conformation, for each structure in which asymmetric centers are present and thus give rise to enantiomers, diastereomers, or other stereoisomeric configurations, each structure disclosed herein is intended to represent all such possible isomers, including their optically pure and racemic forms. For example, the structures disclosed herein are intended to cover mixtures of diastereomers as well as single stereoisomers.
  • As used in a claim herein, the phrase “consisting of” excludes any element, step, or ingredient not specified in the claim. When used in a claim herein, the phrase “consisting essentially of” limits the scope of a claim to the specified materials or steps and those that do not materially affect the basic and novel characteristic(s) of the claimed invention.
  • The person of ordinary skill in the art would readily understand and appreciate that the compounds and compositions disclosed herein may have certain atoms (e.g., N, O, or S atoms) in a protonated or deprotonated state, depending upon the environment in which the compound or composition is placed. Accordingly, as used herein, the structures disclosed herein envisage that certain functional groups, such as, for example, OH, SH, or NH, may be protonated or deprotonated. The disclosure herein is intended to cover the disclosed compounds and compositions regardless of their state of protonation based on the environment (such as pH), as would be readily understood by the person of ordinary skill in the art.
  • Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.
  • Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.
    • DETAILED DESCRIPTION
  • Described herein are RNAi agents for inhibiting expression of Hepatitis B Virus (HBV) (referred to herein as HBV RNAi agents or HBV RNAi triggers). Each HBV RNAi agent comprises a sense strand and an antisense strand. The sense strand and the antisense strand each can be 16 to 30 nucleotides in length. In some embodiments, the sense and antisense strands each can be 17 to 26 nucleotides in length. The sense and antisense strands can be either the same length or they can be different lengths. In some embodiments, the sense and antisense strands are each independently 17 to 26 nucleotides in length. In some embodiments, the sense and antisense strands are each independently 17-21 nucleotides in length. In some embodiments, both the sense and antisense strands are each 21-26 nucleotides in length. In some embodiments, the sense strand is about 19 nucleotides in length while the antisense strand is about 21 nucleotides in length. In some embodiments, the sense strand is about 21 nucleotides in length while the antisense strand is about 23 nucleotides in length. In some embodiments, both the sense and antisense strands are each 26 nucleotides in length. In some embodiments, the RNAi agent sense and antisense strands are each independently 17, 18, 19, 20, 21, 22, 23, 24, 25, or 26 nucleotides in length. In some embodiments, a double-stranded RNAi agent has a duplex length of about 16, 17, 18, 19, 20, 21, 22, 23 or 24 nucleotides. This region of perfect or substantial complementarity between the sense strand and the antisense strand is typically 15-25 (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25) nucleotides in length and occurs at or near the 5′ end of the antisense strand (e.g., this region may be separated from the 5′ end of the antisense strand by 0, 1, 2, 3, or 4 nucleotides that are not perfectly or substantially complementary).
  • The sense strand and antisense strand each contain a core stretch sequence that is 16 to 23 nucleobases in length. An antisense strand core stretch sequence is 100% (perfectly) complementary or at least about 85% (substantially) complementary to a nucleotide sequence (sometimes referred to, e.g., as a target sequence) present in the HBV mRNA target. A sense strand core stretch sequence is 100% (perfectly) complementary or at least about 85% (substantially) complementary to a core stretch sequence in the antisense strand, and thus the sense strand core stretch sequence is perfectly identical or at least about 85% identical to a nucleotide sequence (target sequence) present in the HBV mRNA target. A sense strand core stretch sequence can be the same length as a corresponding antisense core sequence or it can be a different length. In some embodiments, the antisense strand core stretch sequence is 16, 17, 18, 19, 20, 21, 22, or 23 nucleotides in length. In some embodiments, the sense strand core stretch sequence is 16, 17, 18, 19, 20, 21, 22, or 23 nucleotides in length.
  • Examples of sense and antisense strand nucleotide sequences used in forming HBV RNAi agents are provided in Tables 3 and 4. Examples of RNAi agent duplexes, that include the nucleotide sequences in Tables 3 and 4, are provided in Table 5.
  • The HBV RNAi agent sense and antisense strands anneal to form a duplex. A sense strand and an antisense strand of an HBV RNAi agent may be partially, substantially, or fully complementary to each other. Within the complementary duplex region, the sense strand core stretch sequence is at least about 85% complementary or 100% complementary to the antisense core stretch sequence. In some embodiments, the sense strand core stretch sequence contains a sequence of at least 16, at least 17, at least 18, at least 19, at least 20, or at least 21 nucleotides that is at least about 85% or 100% complementary to a corresponding 16, 17, 18, 19, 20, or 21 nucleotide sequence of the antisense strand core stretch sequence (i.e., the sense strand and antisense core stretch sequences of an HBV RNAi agent have a region of at least 16, at least 17, at least 18, at least 19, at least 20, or at least 21 nucleotides that is at least 85% base paired or 100% base paired.).
  • In some embodiments, the antisense strand of an HBV RNAi agent disclosed herein differs by 0, 1, 2, or 3 nucleotides from any of the antisense strand sequences in Table 2 or Table 3. In some embodiments, the sense strand of an HBV RNAi agent disclosed herein differs by 0, 1, 2, or 3 nucleotides from any of the sense strand sequences in Table 2 or Table 4.
  • The length of the HBV RNAi agent sense and antisense strands described herein are independently 16 to 30 nucleotides in length. In some embodiments, the sense and antisense strands are independently 17 to 26 nucleotides in length. In some embodiments, the sense and antisense strands are 19-26 nucleotides in length. In some embodiments, the described RNAi agent sense and antisense strands are independently 17, 18, 19, 20, 21, 22, 23, 24, 25, or 26 nucleotides in length. The sense and antisense strands can be either the same length or they can be different lengths. In some embodiments, a sense strand and an antisense strand are each 26 nucleotides in length. In some embodiments, a sense strand is 23 nucleotides in length and an antisense strand is 21 nucleotides in length. In some embodiments, a sense strand is 22 nucleotides in length and an antisense strand is 21 nucleotides in length. In some embodiments, a sense strand is 21 nucleotides in length and an antisense strand is 21 nucleotides in length. In some embodiments, a sense strand is 19 nucleotides in length and an antisense strand is 21 nucleotides in length.
  • The sense strand and/or the antisense strand may optionally and independently contain an additional 1, 2, 3, 4, 5, or 6 nucleotides (extension) at the 3′ end, the 5′ end, or both the 3′ and 5′ ends of the core sequences. The antisense strand additional nucleotides, if present, may or may not be complementary to the corresponding sequence in an HBV mRNA. The sense strand additional nucleotides, if present, may or may not be identical to the corresponding sequence in an HBV mRNA. The antisense strand additional nucleotides, if present, may or may not be complementary to the corresponding sense strand's additional nucleotides, if present.
  • As used herein, an extension comprises 1, 2, 3, 4, 5, or 6 nucleotides at the 5′ and/or 3′ end of the sense strand core stretch sequence and/or antisense strand core stretch sequence. The extension nucleotides on a sense strand may or may not be complementary to nucleotides, either core stretch sequence nucleotides or extension nucleotides, in the corresponding antisense strand. Conversely, the extension nucleotides on an antisense strand may or may not be complementary to nucleotides, either core stretch sequence nucleotides or extension nucleotides, in the corresponding sense strand. In some embodiments, both the sense strand and the antisense strand of an RNAi agent contain 3′ and 5′ extensions. In some embodiments, one or more of the 3′ extension nucleotides of one strand base pairs with one or more 5′ extension nucleotides of the other strand. In other embodiments, one or more of 3′ extension nucleotides of one strand do not base pair with one or more 5′ extension nucleotides of the other strand. In some embodiments, an HBV RNAi agent has an antisense strand having a 3′ extension and a sense strand having a 5′ extension.
  • In some embodiments, an HBV RNAi agent comprises an antisense strand having a 3′ extension of 1, 2, 3, 4, 5, or 6 nucleotides in length. In other embodiments, an HBV RNAi agent comprises an antisense strand having a 3′ extension of 1, 2, or 3 nucleotides in length. In some embodiments, one or more of the antisense strand extension nucleotides comprise uracil or thymidine nucleotides or nucleotides which are complementary to a corresponding HBV mRNA sequence. In some embodiments, a 3′ antisense strand extension includes or consists of, but is not limited to: AUA, UGCUU, CUG, UG, UGCC, CUGCC, CGU, CUU. UGCCUA, CUGCCU, UGCCU, UGAUU, GCCUAU, T, TT, U, UU (each listed 5′ to 3′).
  • In some embodiments, the 3′ end of the antisense strand may include additional abasic nucleosides (Ab). In some embodiments, Ab or AbAb may be added to the 3′ end of the antisense strand.
  • In some embodiments, an HBV RNAi agent comprises an antisense strand having a 5′ extension of 1, 2, 3, 4, or 5 nucleotides in length. In other embodiments, an HBV RNAi agent comprises an antisense strand having a 5′ extension of 1 or 2 nucleotides in length. In some embodiments, one or more of the antisense strand extension nucleotides comprises uracil or thymidine nucleotides or nucleotides which are complementary to a corresponding HBV mRNA sequence. In some embodiments, the 5′ antisense strand extension includes or consists of, but is no limited to, UA, TU, U. T, UU, TT, CUC (each listed 5′ to 3′). An antisense strand may have any of the 3′ extensions described above in combination with any of the 5′ antisense strand extensions described, if present.
  • In some embodiments, an HBV RNAi agent comprises a sense strand having a 3′ extension of 1, 2, 3, 4, or 5 nucleotides in length. In some embodiments, one or more of the sense strand extension nucleotides comprises adenosine, uracil, or thymidine nucleotides, AT dinucleotide, or nucleotides which correspond to nucleotides in the HBV mRNA sequence. In some embodiments, the 3′ sense strand extension includes or consists of, but is not limited to: T, UT, TT, UU, UUT, TTT, or TTIT (each listed 5′ to 3′).
  • In some embodiments, the 3′ end of the sense strand may include additional abasic nucleosides. In some embodiments, UUAb, UAb, or Ab may be added to the 3′ end of the sense strand. In some embodiments, the one or more abasic nucleosides added to the 3′ end of the sense strand may be inverted (invAb). In some embodiments, one or more inverted abasic nucleosides may be inserted between the targeting ligand and the nucleobase sequence of the sense strand of the RNAi agent. In some embodiments, the inclusion of one or more inverted abasic nucleosides at or near the terminal end or terminal ends of the sense strand of an RNAi agent may allow for enhanced activity or other desired properties of an RNAi agent.
  • In some embodiments, an HBV RNAi agent comprises a sense strand having a 5′ extension of 1, 2, 3, 4, 5, or 6 nucleotides in length. In some embodiments, one or more of the sense strand extension nucleotides comprise uracil or adenosine nucleotides or nucleotides which correspond to nucleotides in the HBV mRNA sequence. In some embodiments, the sense strand 5′ extension can be, but is not limited to: CA, AUAGGC, AUAGG, AUAG. AUA. A, AA, AC, GCA, GGCA, GGC, UAUCA, UAUC, UCA. UAU, U, UU (each listed 5′ to 3′). A sense strand may have a 3′ extension and/or a 5′ extension.
  • In some embodiments, the 5′ end of the sense strand may include an additional abasic nucleoside (Ab) or nucleosides (AbAb). In some embodiments, the one or more abasic nucleosides added to the 5′ end of the sense strand may be inverted (invAb). In some embodiments, one or more inverted abasic nucleosides may be inserted between the targeting ligand and the nucleobase sequence of the sense strand of the RNAi agent. In some embodiments, the inclusion of one or more inverted abasic nucleosides at or near the terminal end or terminal ends of the sense strand of an RNAi agent may allow for enhanced activity or other desired properties of an RNAi agent.
  • Examples of nucleotide sequences used in forming HBV RNAi agents are provided in Tables 3 and 4. In some embodiments, an HBV RNAi agent antisense strand includes a nucleotide sequence of any of the sequences in Table 3. In some embodiments, an HBV RNAi agent antisense strand includes the sequence of nucleotides 1-17, 2-15, 2-17, 1-18, 2-18, 1-19, 2-19, 1-20, 2-20, 1-21, 2-21, 1-22, 2-22, 1-23, 2-23, 1-24, 2-24, 1-25, 2-25, 1-26, or 2-26 of any of the sequences in Table 3. In some embodiments, an HBV RNAi agent sense strand includes the nucleotide sequence of any of the sequences in Table 4. In some embodiments, an HBV RNAi agent sense strand includes the sequence of nucleotides 1-18, 1-19, 1-20, 1-21, 1-22, 1-23, 1-24, 1-25, 1-26, 2-19, 2-20, 2-21, 2-22, 2-23, 2-24, 2-25, 2-26, 3-20, 3-21, 3-22, 3-23, 3-24, 3-25, 3-26, 4-21, 4-22, 4-23, 4-24, 4-25, 4-26, 5-22, 5-23, 5-24, 5-25, 5-26, 6-23, 6-24, 6-25, 6-26, 7-24, 7-25, 7-25, 8-25, 8-26 of any of the sequences in Table 4.
  • In some embodiments, the sense and antisense strands of the RNAi agents described herein contain the same number of nucleotides. In some embodiments, the sense and antisense strands of the RNAi agents described herein contain different numbers of nucleotides. In some embodiments, the sense strand 5′ end and the antisense strand 3′ end of an RNAi agent form a blunt end. In some embodiments, the sense strand 3′ end and the antisense strand 5′ end of an RNAi agent form a blunt end. In some embodiments, both ends of an RNAi agent form blunt ends. In some embodiments, neither end of an RNAi agent is blunt-ended. As used herein a blunt end refers to an end of a double stranded RNAi agent in which the terminal nucleotides of the two annealed strands are complementary (form a complementary base-pair). In some embodiments, the sense strand 5′ end and the antisense strand 3′ end of an RNAi agent form a frayed end. In some embodiments, the sense strand 3′ end and the antisense strand 5′ end of an RNAi agent form a frayed end. In some embodiments, both ends of an RNAi agent form a frayed end. In some embodiments, neither end of an RNAi agent is a frayed end. As used herein a frayed end refers to an end of a double stranded RNAi agent in which the terminal nucleotides of the two annealed strands from a pair (i.e. do not form an overhang) but are not complementary (i.e. form a non-complementary pair). As used herein, an overhang is a stretch of one or more unpaired nucleotides at the end of one strand of a double stranded RNAi agent. The unpaired nucleotides may be on the sense strand or the antisense strand, creating either 3′ or 5′ overhangs. In some embodiments, the RNAi agent contains: a blunt end and a frayed end, a blunt end and 5′ overhang end, a blunt end and a 3′ overhang end, a frayed end and a 5′ overhang end, a frayed end and a 3′ overhang end, two 5′ overhang ends, two 3′ overhang ends, a 5′ overhang end and a 3′ overhang end, two frayed ends, or two blunt ends.
  • A nucleotide base (or nucleobase) is a heterocyclic pyrimidine or purine compound which is a constituent of all nucleic acids and includes adenine (A), guanine (G), cytosine (C), thymine (T), and uracil (U). As used herein, the term “nucleotide” can include a modified nucleotide (such as, for example, a nucleotide mimic, abasic site (Ab), or a surrogate replacement moiety). Modified nucleotides, when used in various polynucleotide or oligonucleotide constructs, may preserve activity of the compound in cells while at the same time increasing the serum stability of these compounds, and can also minimize the possibility of activating interferon activity in humans upon administering of the polynucleotide or oligonucleotide construct.
  • In some embodiments, an HBV RNAi agent is prepared or provided as a salt, mixed salt, or a free-acid. In some embodiments, an HBV RNAi agent is prepared as a sodium salt. Such forms are within the scope of the inventions disclosed herein.
    • Modified Nucleotides
  • In some embodiments, an HBV RNAi agent contains one or more modified nucleotides. As used herein, a “modified nucleotide” is a nucleotide other than a ribonucleotide (2′-hydroxyl nucleotide). In some embodiments, at least 50% (e.g., at least 600/%, at least 70%, at least 80%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100%) of the nucleotides are modified nucleotides. As used herein, modified nucleotides include, but are not limited to, deoxyribonucleotides, nucleotide mimics, abasic nucleotides (represented herein as Ab), 2′-modified nucleotides, 3′ to 3′ linkages (inverted) nucleotides (represented herein as invdN, invN, invn, invAb), non-natural base-comprising nucleotides, bridged nucleotides, peptide nucleic acids (PNAs), 2′,3′-seco nucleotide mimics (unlocked nucleobase analogues, represented herein as NUNA or NUNA), locked nucleotides (represented herein as NLNA or NLNA), 3′-O-methoxy (2′ internucleoside linked) nucleotides (represented herein as 3′-OMen), 2′-F-Arabino nucleotides (represented herein as NfANA or NfANA), 5′-Me, 2′-fluoro nucleotide (represented herein as 5Me-Nf), morpholino nucleotides, vinyl phosphonate deoxyribonucleotides (represented herein as vpdN), vinyl phosphonate containing nucleotides, and cyclopropyl phosphonate containing nucleotides (cPrpN). 2′-modified nucleotides (i.e. a nucleotide with a group other than a hydroxyl group at the 2′ position of the five-membered sugar ring) include, but are not limited to, 2′-O-methyl nucleotides (represented herein as a lower case letter ‘n’ in a nucleotide sequence), 2′-deoxy-2′-fluoro nucleotides (represented herein as Nf, also represented herein as 2′-fluoro nucleotide), 2′-deoxy nucleotides (represented herein as dN), 2′-methoxyethyl (2′-O-2-methoxylethyl) nucleotides (represented herein as NM or 2′-MOE), 2′-amino nucleotides, and 2′-alkyl nucleotides. It is not necessary for all positions in a given compound to be uniformly modified. Conversely, more than one modification may be incorporated in a single HBV RNAi agent or even in a single nucleotide thereof. The HBV RNAi agent sense strands and antisense strands may be synthesized and/or modified by methods known in the art. Modification at one nucleotide is independent of modification at another nucleotide. Modified nucleobases include synthetic and natural nucleobases, such as 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and 0-6 substituted purines, (e.g., 2-aminopropyladenine, 5-propynyluracil, or 5-propynylcytosine), 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-alkyl (e.g., 6-methyl, 6-ethyl, 6-isopropyl, or 6-n-butyl) derivatives of adenine and guanine, 2-alkyl (e.g., 2-methyl, 2-ethyl, 2-isopropyl, or 2-n-butyl) and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine, 2-thiocytosine, 5-halouracil, cytosine, 5-propynyl uracil, 5-propynyl cytosine, 6-azo uracil, 6-azo cytosine, 6-azo thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-sulfhydryl, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo (e.g., 5-bromo), 5-trifluoromethyl, and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine, 7-deazaadenine, 3-deazaguanine, and 3-deazaadenine.
  • In some embodiments, all or substantially all of the nucleotides of an RNAi agent are modified nucleotides. As used herein, an RNAi agent wherein substantially all of the nucleotides present are modified nucleotides is an RNAi agent having four or fewer (i.e., 0, 1, 2, 3, or 4) nucleotides in both the sense strand and the antisense strand being ribonucleotides. As used herein, a sense strand wherein substantially all of the nucleotides present are modified nucleotides is a sense strand having two or fewer (i.e., 0, 1, or 2) nucleotides in the sense strand being ribonucleotides. As used herein, an antisense sense strand wherein substantially all of the nucleotides present are modified nucleotides is an antisense strand having two or fewer (i.e., 0, 1, or 2) nucleotides in the sense strand being ribonucleotides. In some embodiments, one or more nucleotides of an RNAi agent is a ribonucleotide.
    • Modified Internucleoside Linkages
  • In some embodiments, one or more nucleotides of an HBV RNAi agent are linked by non-standard linkages or backbones (i.e., modified internucleoside linkages or modified backbones). In some embodiments, a modified internucleoside linkage is a non-phosphate-containing covalent internucleoside linkage. Modified internucleoside linkages or backbones include, but are not limited to, 5′-phosphorothioate groups (represented herein as a lower case “s”), chiral phosphorothioates, thiophosphates, phosphorodithioates, phosphotriesters, aminoalkyl-phosphotriesters, alkyl phosphonates (e.g., methyl phosphonates or 3′-alkylene phosphonates), chiral phosphonates, phosphinates, phosphoramidates (e.g., 3′-amino phosphoramidate, aminoalkylphosphoramidates, or thionophosphoramidates), thionoalkyl-phosphonates, thionoalkylphosphotriesters, morpholino linkages, boranophosphates having normal 3′-5′ linkages, 2′-5′ linked analogs of boranophosphates, or boranophosphates having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3′-5′ to 5′-3′ or 2′-5′ to 5′-2′. In some embodiments, a modified internucleoside linkage or backbone lacks a phosphorus atom. Modified internucleoside linkages lacking a phosphorus atom include, but are not limited to, short chain alkyl or cycloalkyl inter-sugar linkages, mixed heteroatom and alkyl or cycloalkyl inter-sugar linkages, or one or more short chain heteroatomic or heterocyclic inter-sugar linkages. In some embodiments, modified internucleoside backbones include, but are not limited to, siloxane backbones, sulfide backbones, sulfoxide backbones, sulfone backbones, formacetl and thioformacetyl backbones, methylene formacetyl and thioformacetyl backbones, alkene-containing backbones, sulfamate backbones, methyleneimino and methylenehydrazino backbones, sulfonate and sulfonamide backbones, amide backbones, and other backbones having mixed N, O, S, and CH2 components.
  • In some embodiments, a sense strand of an HBV RNAi agent can contain 1, 2, 3, 4, 5, or 6 phosphorothioate linkages, an antisense strand of an HBV RNAi agent can contain 1, 2, 3, 4, 5, or 6 phosphorothioate linkages, or both the sense strand and the antisense strand independently can contain 1, 2, 3, 4, 5, or 6 phosphorothioate linkages. In some embodiments, a sense strand of an HBV RNAi agent can contain 1, 2, 3, or 4 phosphorothioate linkages, an antisense strand of an HBV RNAi agent can contain 1, 2, 3, or 4 phosphorothioate linkages, or both the sense strand and the antisense strand independently can contain 1, 2, 3, or 4 phosphorothioate linkages.
  • In some embodiments, an HBV RNAi agent sense strand contains at least two phosphorothioate internucleoside linkages. In some embodiments, the at least two phosphorothioate internucleoside linkages are between the nucleotides at positions 1-3 from the 3′ end of the sense strand. In some embodiments, the at least two phosphorothioate internucleoside linkages are between the nucleotides at positions 1-3, 2-4, 3-5, 4-6, 4-5, or 6-8 from the 5′ end of the sense strand. In some embodiments, an HBV RNAi agent antisense strand contains four phosphorothioate internucleoside linkages. In some embodiments, the four phosphorothioate internucleoside linkages are between the nucleotides at positions 1-3 from the 5′ end of the sense strand and between the nucleotides at positions 19-21, 20-22, 21-23, 22-24, 23-25, or 24-26 from the 5′ end. In some embodiments, an HBV RNAi agent contains at least two phosphorothioate internucleoside linkages in the sense strand and three or four phosphorothioate internucleoside linkages in the antisense strand.
  • In some embodiments, an HBV RNAi agent contains one or more modified nucleotides and one or more modified internucleoside linkages. In some embodiments, a 2′-modified nucleoside is combined with modified internucleoside linkage.
    • HBV RNAi Agents
  • In some embodiments, the HBV RNAi agents disclosed herein target an HBV gene at or near the positions of the HBV genome shown in the following Table 1. In some embodiments, the antisense strand of an HBV RNAi agent disclosed herein includes a core stretch sequence that is fully, substantially, or at least partially complementary to a target HBV 19-mer sequence disclosed in Table 1.
  • TABLE 1
    Example 19-mer HBV cDNA target sequences for HBV
    RNAi agents (taken from Hepatitis B virus
    (subtype ADW2), genotype A, complete genome
    GenBank AM282986.1 (SEQ ID NO: 1)).
    HBV 19-mer Genome Region of
    SEQ Target Sequence Position of HBV Gene
    ID No. (5′→3′) SEQ ID NO: 1 Targeted
    2 GTGGTGGACTTCTCTCAAT 256-274 S ORF
    3 TGGTGGACTTCTCTCAATT 257-275 S ORF
    4 GGACTTCTCTCAATTTTCT 261-279 S ORF
    5 GCTGTAGGCATAAATTGGT 1780-1798 X ORF
    6 CTGTAGGCATAAATTGGTC 1781-1799 X ORF
  • In some embodiments, an HBV RNAi agent includes an antisense strand wherein position 19 of the antisense strand (5′→3′) is capable of forming a base pair with position 1 of a 19-mer target sequence disclosed in Table 1. In some embodiments, an HBV RNAi agent includes an antisense strand wherein position 1 of the antisense strand (5′→3′) is capable of forming a base pair with position 19 of the 19-mer target sequence disclosed in Table 1.
  • In some embodiments, an HBV RNAi agent includes an antisense strand wherein position 2 of the antisense strand (5′→3′) is capable of forming a base pair with position 18 of the 19-mer target sequence disclosed in Table 1. In some embodiments, an HBV RNAi agent includes an antisense strand wherein positions 2 through 18 of the antisense strand (5′→3′) are capable of forming base pairs with each of the respective complementary bases located at positions 18 through 2 of the 19-mer target sequence disclosed in Table 1.
  • In some embodiments, the HBV RNAi agents include core 19-mer nucleotide sequences shown in the following Table 2.
  • TABLE 2
    HBV RNAi agent antisense strand and sense strand core stretch sequences
    (N = any nucleotide).
    Genome
    SEQ Antisense Sequence SEQ Sense Sequence Position of
    ID NO: (5′→3′) (19-mer) ID NO: (5′→3′) (19-mer) SEQ ID NO: 1
     7 AUUGAGAGAAGUCCACCAC 34 GUGGUGGACUUCUCUCAAU 256-274
     8 UUUGAGAGAAGUCCACCAC 35 GUGGUGGACUUCUCUCAAA 256-274
     9 AUUGAGAGAAGUCCACCAN 36 NUGGUGGACUUCUCUCAAU 256-274
    10 UUUGAGAGAAGUCCACCAN 37 NUGGUGGACUUCUCUCAAA 256-274
    11 NUUGAGAGAAGUCCACCAN 38 NUGGUGGACUUCUCUCAAN 256-274
    12 AAUUGAGAGAAGUCCACCA 39 UGGUGGACUUCUCUCAAUU 257-275
    13 UAUUGAGAGAAGUCCACCA 40 UGGUGGACUUCUCUCAAUA 257-275
    14 AAUUGAGAGAAGUCCACCN 41 NGGUGGACUUCUCUCAAUU 257-275
    15 UAUUGAGAGAAGUCCACCN 42 NGGUGGACUUCUCUCAAUA 257-275
    16 NAUUGAGAGAAGUCCACCN 43 NGGUGGACUUCUCUCAAUN 257-275
    17 AGAAAAUUGAGAGAAGUCC 44 GGACUUCUCUCAAUUUUCU 261-279
    18 UGAAAAUUGAGAGAAGUCC 45 GGACUUCUCUCAAUUUUCA 261-279
    19 AGAAAAUUGAGAGAAGUCN 46 NGACUUCUCUCAAUUUUCU 261-279
    20 UGAAAAUUGAGAGAAGUCN 47 NGACUUCUCUCAAUUUUCA 261-279
    21 NGAAAAUUGAGAGAAGUCN 48 NGACUUCUCUCAAUUUUCN 261-279
    22 ACCAAUUUAUGCCUACAGC 49 GCUGUAGGCAUAAAUUGGU 1780-1798
    23 UCCAAUUUAUGCCUACAGC 50 GCUGUAGGCAUAAAUUGGA 1780-1798
    24 ACCAAUUUAUGCCUACAGN 51 NCUGUAGGCAUAAAUUGGU 1780-1798
    25 UCCAAUUUAUGCCUACAGN 52 NCUGUAGGCAUAAAUUGGA 1780-1798
    26 NCCAAUUUAUGCCUACAGN 53 NCUGUAGGCAUAAAUUGGN 1780-1798
    27 GACCAAUUUAUGCCUACAG 54 CUGUAGGCAUAAAUUGGUC 1781-1799
    28 AACCAAUUUAUGCCUACAG 55 CUGUAGGCAUAAAUUGGUU 1781-1799
    29 UACCAAUUUAUGCCUACAG 56 CUGUAGGCAUAAAUUGGUA 1781-1799
    30 GACCAAUUUAUGCCUACAN 57 NUGUAGGCAUAAAUUGGUC 1781-1799
    31 AACCAAUUUAUGCCUACAN 58 NUGUAGGCAUAAAUUGGUU 1781-1799
    32 UACCAAUUUAUGCCUACAN 59 NUGUAGGCAUAAAUUGGUA 1781-1799
    33 NACCAAUUUAUGCCUACAN 60 NUGUAGGCAUAAAUUGGUN 1781-1799
  • The HBV RNAi agent sense strands and antisense strands that comprise or consist of the nucleotide sequences in Table 2 can be modified nucleotides or unmodified nucleotides. In some embodiments, the HBV RNAi agents having the sense and antisense strand sequences that comprise or consist of the nucleotide sequences in Table 2 are all or substantially all modified nucleotides.
  • In some embodiments, the antisense strand of an HBV RNAi agent disclosed herein differs by 0, 1, 2, or 3 nucleotides from any of the antisense strand sequences in Table 2. In some embodiments, the sense strand of an HBV RNAi agent disclosed herein differs by 0, 1, 2, or 3 nucleotides from any of the sense strand sequences in Table 2.
  • Modified HBV RNAi agent antisense strand sequences, as well as their underlying unmodified sequences, are provided in Table 3. Modified HBV RNAi agent sense strands, as well as their underlying unmodified sequences, are provided in Table 4. In forming HBV RNAi agents, each of the nucleotides in each of the unmodified sequences listed in Tables 3 and 4 may be a modified nucleotide.
  • As used herein (including in Tables 3 and 4), the following notations are used to indicate modified nucleotides, targeting groups, and linking groups. As the person of ordinary skill in the art would readily understand, unless otherwise indicated by the sequence, that when present in an oligonucleotide, the monomers are mutually linked by 5′-3′-phosphodiester bonds:
      • A=adenosine-3′-phosphate;
      • C=cytidine-3′-phosphate;
      • G=guanosine-3′-phosphate;
      • U=uridine-3′-phosphate
      • n=any 2′-OMe modified nucleotide
      • a=2′-O-methyladenosine-3′-phosphate
      • as =2′-O-methyladenosine-3′-phosphorothioate
      • c=2′-O-methylcytidine-3′-phosphate
      • cs=2′-O-methylcytidine-3′-phosphorothioate
      • g=2′-O-methylguanosine-3′-phosphate
      • gs=2′-O-methylguanosine-3′-phosphorothioate
      • t=2′-O-methyl-5-methyluridine-3′-phosphate
      • ts=2′-O-methyl-5-methyluridine-3′-phosphorothioate
      • u=2′-O-methyluridine-3′-phosphate
      • us=2′-O-methyluridine-3′-phosphorothioate
      • Nf=any 2′-fluoro modified nucleotide
      • Af=2′-fluoroadenosine-3′-phosphate
      • Afs=2′-fluoroadenosine-3′-phosporothioate
      • Cf=2′-fluorocytidine-3′-phosphate
      • Cfs=2′-fluorocytidine-3′-phosphorothioate
      • Gf=2′-fluoroguanosine-3′-phosphate
      • Gfs=2′-fluoroguanosine-3′-phosphorothioate
      • Tf=2′-fluoro-5′-methyluridine-3′-phosphate
      • Tfs=2′-fluoro-5′-methyluridine-3′-phosphorothioate
      • Uf=2′-fluorouridine-3′-phosphate
      • Ufs=2′-fluorouridine-3′-phosphorothioate
      • dN=any 2′-deoxyribonucleotide
      • dT=2′-deoxythymidine-3′-phosphate
      • NUNA=2′,3′-seco nucleotide mimics (unlocked nucleobase analogs)
      • NLNA=locked nucleotide
      • NfANA=2′-F-Arabino nucleotide
      • NM=2′-methoxyethyl nucleotide
      • AM=2′-methoxyethyladenosine-3′-phosphate
      • AMs=2′-methoxyethyladenosine-3′-phosphorothioate
      • TM=2′-methoxyethylthymidine-3′-phosphate
      • TMs=2′-methoxyethylthymidine-3′-phosphorothioate
      • R=ribitol
      • (invdN)=any inverted deoxyribonucleotide (3′-3′ linked nucleotide)
      • (invAb)=inverted (3′-3′ linked) abasic deoxyribonucleotide, see Table 6
      • (invAb)s=inverted (3′-3′ linked) abasic deoxyribonucleotide-5′-phosphorothioate, see Table 6
      • (invn)=any inverted 2′-OMe nucleotide (3′-3′ linked nucleotide)
      • s=phosphorothioate linkage
      • vpdN=vinyl phosphonate deoxyribonucleotide
      • (5Me-Nf)=5′-Me, 2′-fluoro nucleotide
      • cPrp=cyclopropyl phosphonate, see Table 6
      • epTcPr=see Table 6
      • epTM=see Table 6
  • The person or ordinary skill in the art would readily understand that the terminal nucleotide at the 3′ end of a given oligonucleotide sequence would typically have a hydroxyl (—OH) group at the respective 3′ position of the given monomer instead of a phosphate moiety ex vivo. Thus, for example, as shown above in the structure representation of AD05070, above, the “g” modified nucleotide on the terminal 3′ end of the antisense strand of AM06606-AS has a hydroxyl group positioned at its 3′ position. Unless expressly indicated otherwise herein, such understandings of the person of ordinary skill in the art are used when describing the HBV RNAi agents and compositions of HBV RNAi agents disclosed herein.
  • Targeting groups and linking groups include the following, for which their chemical structures are provided below in Table 6: (PAZ), (NAG13), (NAG13)s, (NAG18), (NAG18)s, (NAG24), (NAG24)s, (NAG25), (NAG25)s, (NAG26), (NAG26)s, (NAG27), (NAG27)s, (NAG28), (NAG28)s, (NAG29), (NAG29)s, (NAG30), (NAG30)s, (NAG31), (NAG31)s, (NAG32), (NAG32)s, (NAG33), (NAG33)s, (NAG34), (NAG34)s, (NAG35), (NAG35)s, (NAG36), (NAG36)s, (NAG37), (NAG37)s, (NAG38), (NAG38)s, (NAG39), (NAG39)s. Each sense strand and/or antisense strand can have any targeting groups or linking groups listed above, as well as other targeting or linking groups, conjugated to the 5′ and/or 3′ end of the sequence.
  • TABLE 3
    HBV RNAi Agent antisense strand sequences.
    SEQ SEQ
    AS Strand ID Modified sequence (5′→3′) ID NO. Unmodified sequence (5′→3′) ID NO.
    AM03508-AS usAfscCfaAfuUfuAfuGfcCfuAfcAfgGgccsusuAu  61 UACCAAUUUAUGCCUACAGGCCUUAU 149
    AM04441-AS usAfscCgaAfuUfuAfuGfcCfuAfcAfgGfcscsu  62 UACCAAUUUAUGCCUACAGGCCU 150
    AM04442-AS usAfscsCfaAfuUfuAfuGfcCfuAfcAfgGfccsu  63 UACCAAUUUAUGCCUACAGGCCU 150
    AM04443-AS usAfscsCfaAfuUfuAfuGfcCfuAfcAfgGfsc  64 UACCAAUUUAUGCCUACAGGC 151
    AM04661-AS usGfsugaAfgCfGfaaguGfcAfcacsusu  65 UGUGAAGCGAAGUGCACACUU 152
    AM04768-AS usAfscCfaAfuUfuAfuGfcCfuAfcAfgCfcsusccgc  66 UACCAAUUUAUGCCUACAGCCUCCGC 153
    AM04769-AS vpusAfscCfaAfuUfuAfuGfcCfuAfcAfgCfcsusccgc  67 UACCAAUUUAUGCCUACAGCCUCCGC 153
    AM05011-AS usAfscsCfaAfuUfuAfuGfcCfuAfcAfgusu  68 UACCAAUUUAUGCCUACAGUU 154
    AM05012-AS usAfscsCfaAfuUfuAfuGfcCfuAfcAfggsc  69 UACCAAUUUAUGCCUACAGGU 151
    AM05013-AS vpusAfscsCfaAfuUfuAfuGfcCfuAfcAfgGfsc  70 UACCAAUUUAUGCCUACAGGC 151
    AM05014-AS vpusAfscsCfaAfuUfuAfuGfcCfuAfcAfgusu  71 UACCAAUUUAUGCCUACAGUU 154
    AM05052-AS asUfsusGfaGfaGfaAfgUfcCfaCfcAfcGfsa  72 AUUGAGAGAAGUCCACCACGA 155
    AM05053-AS asUfsusGfaGfaGfaAfgUfcCfaCfcAfcgsa  73 AUUGAGAGAAGUCCACCACGA 155
    AM05054-AS asUfsusGfaGfaGfaAfgUfcCfaCfcAfcusu  74 AUUGAGAGAAGUCCACCACUU 156
    AM05055-AS vpusUfsusGfaGfaGfaAfgUfcCfaCfcAfcGfsa  75 UUUGAGAGAAGUCCACCACGA 157
    AM05056-AS asAfsusUfgAfgAfgAfaGfuCfcAfcCfaCfsg  76 AAUUGAGAGAAGUCCACCACG 158
    AM05057-AS asAfsusUfgAfgAfgAfaGfuCfcAfcCfacsg  77 AAUUGAGAGAAGUCCACCACG 158
    AM05058-AS asAfsusUfgAfgAfgAfaGfuCfcAfcCfausu  78 AAUUGAGAGAAGUCCACCAUU 159
    AM05060-AS vpusAfsusUfgAfgAfgAfaGfuCfcAfcCfaCfsg  79 UAUUGAGAGAAGUCCACCACG 160
    AM05351-AS usAfscsCfaAfuUfuAfuGfcCfuAfcAfgGfsu  80 UACCAAUUUAUGCCUACAGGU 161
    AM05608-AS usAfscCfaAfuUfuAfuGfcCfuAfcAfgsusu  81 UACCAAUUUAUGCCUACAGUU 154
    AM05609-AS usAfscsCfaAfuUfuAfuGfcCfuAfcAfgcsc  82 UACCAAUUUAUGCCUACAGCC 162
    AM05610-AS usAfscsCfaAfuUfuAfuGfcCfuAfcAfgccusu  83 UACCAAUUUAUGCCUACAGCCUU 163
    AM05611-AS usAfscsCfaAfuUfuAfuGfcCfuAfcAfgccusc  84 UACCAAUUUAUGCCUACAGCCUC 164
    AM05612-AS usAfscscasuUfuAfuGfcCfuacagcsc  85 UACCAAUUUAUGCCUACAGGC 162
    AM05613-AS usAfscscaauUfuAfuGfcCfuacagccusu  86 UACCAAUUUAUGCCUACAGCCUU 163
    AM05614-AS usAfscscaauUfuAfuGfcCfuacagccusc  87 UACCAAUUUAUGCCUACAGCCUU 164
    AM05618-AS asUfsusgagaGfaAfgUfcCfaccacusu  88 AUUGAGAGAAGUCCACCACUU 156
    AM05621-AS usUfsusGfaGfaGfaAfgUfcCfaCfcAfcusu  89 UUUGAGAGAAGUCCACCACUU 165
    AM05623-AS asUfsusGfaGfaGfaAfgUfcCfaCfcAfcggusu  90 AUUGAGAGAAGUCCACCACGGUU 166
    AM05626-AS asUfsusgagaGfaAfgUfcCfaccacggusu  91 AUUGAGAGAAGUCCACCACGGUU 166
    AM05628-AS asUfsusGfaGfaGfaAfgUfcCfaCfcAfcgagsu  92 AUUGAGAGAAGUCCACCACGAGU 167
    AM05631-AS usAfsusUfgAfgAfgAfaGfuCfcAfcCfaCfsg  93 UAUUGAGAGAAGUCCACCACG 160
    AM05632-AS usAfsusugagAfgAfaGfuCfcaccacsg  94 UAUUGAGAGAAGUCCACCACG 160
    AM05633-AS usAfsusUfgAfgAfgAfaGfuCfcAfcCfaCfgusu  95 UAUUGAGAGAAGUCCACCACGUU 168
    AM05634-AS usAfsusugagAfgAfaGfuCfcaccacgasg  96 UAUUGAGAGAAGUCCACCACGAG 169
    AM05635-AS usAfsusUfgAfgAfgAfaGfuCfcAfcCfaCfgasg  97 UAUUGAGAGAAGUCCACCACGAG 169
    AM05637-AS usAfsusUfgAfgAfgAfaGfuCfcAfcCfaCfgsa  98 UAUUGAGAGAAGUCCACCACGA 170
    AM05638-AS usAfsusugagAfgAfaGfuCfcaccacgsa  99 UAUUGAGAGAAGUCCACCACGA 170
    AM05747-AS asGfsasAfaAfuugagAfgAfaGfuCfcAfsc 100 AGAAAAUUGAGAGAAGUCCAC 171
    AM05849-AS usAfscsCfaAfuuuauGfcCfuAfcAfgusu 101 UACCAAUUUAUGCCUACAGUU 154
    AM05850-AS usAfscsCfaAfuuuauGfcCfuAfcAfgcsc 102 UACCAAUUUAUGCCUACAGCC 162
    AM05851-AS usAfscsCfaAfuuuauGfcCfuAfcAfgcusu 103 UACCAAUUUAUGCCUACAGCUU 172
    AM05852-AS usAfscsCfaAfuuuauGfcCfuAfcAfgccsu 104 UACCAAUUUAUGCCUACAGCCU 173
    AM05853-AS usAfscsCfaAfuuuauGfcCfuAfcAfgccusu 105 UACCAAUUUAUGCCUACAGCCUU 163
    AM05854-AS usAfscsCfaAfuuuauGfcCfuAfcAfgccusc 106 UACCAAUUUAUGCCUACAGCCUC 164
    AM05855-AS cPrpusAfscsCfaAfuUfuAfuGfcCfuAfcAfgusu 107 UACCAAUUUAUGCCUACAGUU 154
    AM05860-AS cPrpusAfsusUfgAfgAfgAfaGfuCfcAfcCfaCfsg 108 UAUUGAGAGAAGCUUACCACG 160
    AM05862-AS usAfsusUfgAfgagaaGfuCfcAfcCfausu 109 UAUUGAGAGAAGUCCACCAUU 174
    AM05863-AS usAfsusUfgAfgagaaGfuCfcAfcCfacsg 110 UAUUGAGAGAAGUCCACCACG 160
    AM05864-AS usAfsusUfgAfgagaaGfuCfcAfcCfacsusu 111 UAUUGAGAGAAGUCCACCACUU 175
    AM05865-AS usAfsusUfgAfgagaaGfuCfcAfcCfacsgsa 112 UAUUGAGAGAAGUCCACCACGA 170
    AM05867-AS vpusAfsusUfgAfgagaaGfuCfcAfcCfaCfsg 113 UAUUGAGAGAAGUCCACCACG 160
    AM05873-AS usUfsusGfaGfagaagUfcCfaCfcAfcusu 114 UUUGAGAGAAGUCCACCACUU 165
    AM05874-AS usUfsusGfaGgagaagUfcCfaCfcAfcgsa 115 UUUGAGAGAAGUCCACCACGA 157
    AM05875-AS usUfsusGfaGfagaagUfcCfaCfcAfcgusu 116 UUUGAGAGAAGUCCACCACGUU 176
    AM05876-AS usUfsusGfaGfagaagUfcCfaCfcAfcgasg 117 UUUGAGAGAAGUCCACCACGAG 177
    AM05877-AS cPrpusUfsusGfaGfaGfaAfgUfcCfaCfcAfcusu 118 UUUGAGAGAAGUCCACCACUU 165
    AM06074-AS cPrpusAfsusUfgAfgagaaGfuCfcAfcCfacsusu 119 UAUUGAGAGAAGUCCACCACUU 175
    AM06142-AS usAfsusUfgAfgagaaGfuCfcAfcCfacusu 120 UAUUGAGAGAAGUCCACCACUU 175
    AM06143-AS usAfsusUfgAfgagaaGfuCfcAfcCfacgusu 121 UAUUGAGAGAAGUCCACCACGUU 168
    AM06144-AS usAfsusUfgAfgagaaGfuCfuAfcCfacuus(invAb) 122 UAUUGAGAGAAGUCCACCACUU 175
    AM06145-AS usAfsusUfgAfgagaaGfuCfcAfcCfacgasg 123 UAUUGAGAGAAGUCCACCACGAG 169
    AM06222-AS usAfsusUfgAfgAfgAfaGfuCfcAfcCfacusu 124 UAUUGAGAGAAGUCCACCACUU 175
    AM06281-AS asGfsasAfaAfuUfgAfgAfgAfaGfuCfcusu 125 AGAAAAUUGAGAGAAGUCCUU 178
    AM06282-AS asGfsasAfaAfuUfgAfgAfgAfaGfuCfcasc 126 AGAAAAUUGAGAGAAGUCCAC 171
    AM06283-AS asGfsasAfaAfuUfgAfgAfgAfaGfuCfcacusu 127 AGAAAAUUGAGAGAAGUCCACUU 179
    AM06284-AS asGfsasAfaAfuUfgAfgAfgAfaGfuCfcacsc 128 AGAAAAUUGAGAGAAGUCCACC 180
    AM06285-AS usGfsasAfaAfuUfgAfgAfgAfaGfuCfcusu 129 UGAAAAUUGAGAGAAGUCCUU 152
    AM06286-AS usGfsasAfaAfuUfgAfgAfgAfaGfuCfcasc 130 UGAAAAUUGAGAGAAGUCCAC 181
    AM06299-AS asCfscsAfaUfuUfaUfgCfcUfaCfaGfcusu 131 ACCAAUUUAUGCCUACAGCUU 182
    AM06300-AS asCfscsAfaUfuUfaUfgCfcUfaCfaGfccusu 132 ACCAAUUUAUGCCUACAGCCUU 183
    AM06301-AS asCfscsAfaUfuUfaUfgCfcUfaCfaGfccusc 133 ACCAAUUUAUGCCUACAGCCUC 184
    AM06302-AS usCfscsAfaUfuUfaUfgCfcUfaCfaGfcusu 134 UCCAAUUUAUGCCUACAGCUU 185
    AM06303-AS usCfscsAfaUfuUfaUfgCfcUfaCfaGfccusu 135 UCCAAUUUAUGCCUACAGCCUU 186
    AM06463-AS cPrpusAfscsCfaAfuUfuAfuGfcCfuAfcAfgcsc 136 UACCAAUUUAUGCCUACAGCC 162
    AM06464-AS usAfscsCfaAfuUfuAfuGfcCfuAfcAfgscsc 137 UACCAAUUUAUGCCUACAGCC 162
    AM06465-AS cPrpusAfscsCfaAfuUfuAfuGfcCfuAfcAfgscsc 138 UACCAAUUUAUGCCUACAGCC 162
    AM06604-AS usAfscsCfaAfuUfuAfuGfcCfuAfcAfgcsu 139 UACCAAUUUAUGCCUACAGCU 187
    AM06606-AS usAfscsCfaAfuUfuAfuGfcCfuAfcAfgcsg 140 UACCAAUUUAUGCCUACAGCG 188
    AM06608-AS asAfscsCfaAfuUfuAfuGfcCfuAfcAfgcsc 141 AACCAAUUUAUGCCUACAGCC 189
    AM06611-AS usAfscsCfaAfuUfUfAfuGfcCfuAfcAgfusu 142 UACCAAUUUAUGCCUACAGUU 154
    AM06612-AS usAfscsCfaAfuUfuAfuGfcCfuAfcAfgCfsc 143 UACCAAUUUAUGCCUACAGCC 152
    AM06614-AS asCfscAfaUfuUfaUfgCfcUfaCfaGfcCfsu 144 ACCAAUUUAUGCCUACAGCCU 190
    AM06616-AS usCfscAfaUfuUfaUfgCfcUfaCfaGfcCfsu 145 UCCAAUUUAUGCCUACAGCCU 191
    AM06618-AS asCfscAfaUfuUfaUfgCfvUfaCfaGfccsg 146 ACCAAUUUAUGCCUACAGCCG 192
    AM06620-AS usCfscAfaUfuUfaUfgCfcUfaCfaGfccsg 147 UCCAAUUUAUGCCUACAGCCG 193
    AM06751-AS usAfscsCfaAfuUfuAfuGfcCfuAfcAfggsg 148 UACCAAUUUAUGCCUACAGGG 194
  • TABLE 4
    HBV RNAi agent sense strand sequences.
    SEQ SEQ
    ID ID
    Strand ID Modified sequence (5′→3′) NO. Unmodified sequence (5′→3′) NO.
    AM04444-SS (NAG25)uusgsccuguagGfCfAfuaaauugguaus(invdT) 195 UUGCCUGUAGGCAUAAAUUGGUAUT 275
    AM04445-SS (NAG25)uauausgsccuguagGfCfAfuaaauuggu(invdA) 196 UAUAUGCCUGUAGGCAUAAAUUGGUA 276
    AM04767-SS (NAG25)gcggagsgcuguagGfCfAfuaaauuggTM(invdA) 197 GCGGAGGCUGUAGGCAUAAAUUGGTA 277
    AM05010-SS (NAG25)scsuguagGfCfAfuaaauugguauus(invAb) 198 CUGUAGGCAUAAAUUGGUAUU 278
    AM05015-SS (NAG25)sgsccuguagGfCfAfuaaauugguas(invAb) 199 GCCUGUAGGCAUAAAUUGGUA 279
    AM05016-SS (NAG25)sgsccuguagGfCfAfuaaauuggus(invdA) 200 GCCCUGUAGGCAUAAAUUGGUA 279
    AM05017-SS (NAG25)sgsccuguagGfCfAfuaaauugguAMs(invAb) 201 GCCUGUAGGCAUAAAUUGGUA 279
    AM05018-SS (NAG25)sgsccuguagGfCfAfuaaauuggTMAMs(invAb) 202 GCCUGUAGGCAUAAAUUGGTA 280
    AM05019-SS (NAG25)sasacuguagGfCfAfuaaauugguas(invAb) 203 AACUGUAGGCAUAAAUUGGUA 281
    AM05034-SS (NAG25)suscguggugGfAfCfuucucucaaus(invAb) 204 UCGUGGUGGACUUCUCUCAAU 282
    AM05046-SS (NAG25)sasaguggugGfAfCfuucucucaaus(invAb) 205 AAGUGGUGGACUUCUCUCAAU 283
    AM05047-SS (NAG25)suscguggugGfAfCfuucucucaAMTMs(invAb) 206 UCGUGGUGGACUUCUCUCAAT 284
    AM05048-SS (NAG25)scsgugguggAfCfUfucucucaauus(invAb) 207 CGUGGUGGACUUCUCUCAAUU 285
    AM05049-SS (NAG25)sasaugguggAfCfUffucucucaauus(invAb) 208 AAUGGUGGACUUCUCUCAAUU 286
    AM05050-SS (NAG25)scsgugguggAfCfUfucucucaaTMTMs(invAb) 209 CGUGGUGGACUUCUCUCAATT 287
    AM05051-SS (NAG25)sgsgacuucuCfUfCffaauuuucuaas(invAb) 210 GGACUUCUCUCAAUUUUCUAA 288
    AM05063-SS (NAG25)scsgugguggAfCfUfucucucaauas(invAb) 211 CGUGGUGGACUUCUCUCAAUA 289
    AM05064-SS (NAG25)suscguggugGfAfCffuucucucaaas(invAb) 212 UCGUGGUGGACUUCUCUCAAA 290
    AM05346-SS (NAG31)sasccuguagGfCfAfuaaauugguas(invAb) 213 ACCUGUAGGCAUAAAUUGGUA 291
    AM05347-SS (NAG31)s(invAb)scuguagGfCfAfuaaauugguas(invAb) 214 CUGUAGGCAUAAAUUGGUA 292
    AM05606-SS (NAG25)s(invAb)scuguagGfCfAfuaaauugguas(invAb) 215 CUGUAGGCAUAAAUUGGUA 292
    AM05607-SS (NAG37)s(invAb)scuguagGfCfAfuaaauugguas(invAb) 216 CUGUAGGCAUAAAUUGGUA 292
    AM05615-SS (NAG25)s(invAb)sacuguagGfCfAfuaaauugguas(invAb) 217 ACUGUAGGCAUAAAUUGGUA 293
    AM05616-SS (NAG25)sgsgcuguagGfCfAfuaaauugguas(invAb) 218 GGCUGUAGGCAUAAAUUGGUA 294
    AM05617-SS (NAG37)sasaguggugGfAfCffuucucucaaus(invAb) 219 AAGUGGUGGACUUCUCUCAAU 283
    AM05620-SS (NAG25)sasaguggugGfAfCfuucucucaas(invAb) 220 AAGUGGUGGACUUCUCUCAAA 295
    AM05622-SS (NAG25)scsguggugGfAfCfuucucucaaus(invAb) 221 CCGUGGUGGACUUCUCUCAAU 296
    AM05624-SS (NAG25)s(invAb)sccguggugGfAfCfuucucucaaus(invAb) 222 CCGUGGUGGACUUCUCUCAAU 296
    AM05627-SS (NAG25)scsucguggugGfAfCfuucucucaaus(invAb) 223 CUCGUGGUGGACUUCUCUCAAU 297
    AM05629-SS (NAG25)s(invAb)sguggugGfAfCfuucucucaaus(invAb) 224 GUGGUGGACUUCUCUCAAU 298
    AM05630-SS (NAG25)s(invAb)sguggugGfAfCfuucucucaauusu(invAb) 225 GUGGUGGACUUCUCUCAAUUU 299
    AM05636-SS (NAG25)suscgugguggAfCfUfucucucaauus(invAb) 226 UCGUGGUGGACUUCUCUCAAUU 300
    AM05639-SS (NAG25)s(invAb)sugguggAfCfUfucucucaauus(invAb) 227 UGGUGGACUUCUCUCAAUU 301
    AM05640-SS (NAG37)s(invAb)sugguggAfCfUfucucucaauus(invAb) 228 UGGUGGACUUCUCUCAAUU 301
    AM05746-SS (NAG25)sgsuggacuuCfUfCfucaauuuucus(invAb) 229 GUGGACUUCUCUCAAUUUUCU 302
    AM05856-SS (NAG25)s(invAb)scuguagGfCfAfuaaauugguausu(invAb) 230 CUGUAGGCAUAAAUUGGUAUU 278
    AM05857-SS (NAG25)s(invAb)sgcuguagGfCfAfuaaauugguausu(invAb) 231 GCUGUAGGCAUAAUUGGUAUU 303
    AM05858-SS (NAG25)s(invAb)sggcuguagGfCfAfuaaauugguausu(invAb) 232 GGCUGUAGGCAUAAAUUGGUAUU 304
    AM05859-SS (NAG25)s(invAb)saacuguagGfCfAfuaaauugguausu(invAb) 233 AACUGUAGGCAUAAAUUGGUAUU 305
    AM05868-SS (NAG25)s(invAb)ugguggAfCfUfucucucaauausu(invAb) 234 UGGUGGACUUCUCUCAAUAUU 306
    AM05869-SS (NAG25)s(invAb)sgugguggAfCfUfucucucaauausu(invAb) 235 GUGGUGGACUUCUCUCAAUAUU 307
    AM05870-SS (NAG25)sasaugguggAfCfUfucucucaauausu(invAb) 236 AAUGGUGGACUUCUCUCAAUAUU 308
    AM05871-SS (NAG25)scsgugguggAfCfUfucucucaauausu(invAb) 237 CGUGGUGGACUUCUCUCAAUAUU 309
    AM05872-SS (NAG31)scsgugguggAfCfUfucucucaauas(invAb) 238 CGUGGUGGACUUCUCUCAAUA 289
    AM05879-SS (NAG25)s(invAb)saaguggugGfAfCfuucucucaaus(invAb) 239 AAGUGGUGGACUUCUCUCAAU 283
    AM05880-SS (NAG25)s(invAb)sguggugGfAfCfuucucucaaausu(invAb) 240 GUGGUGGACUUCUCUCAAAUU 310
    AM05881-SS (NAG25)s(invAb)scguggugGfAfCfuucucucaausu(invAb) 241 CGUGGUGGACUUCUCUCAAAUU 311
    AM05882-SS (NAG25)sasaguggugGfAfCfuucucucaausu(invAb) 242 AAGUGGUGGACUUCUCUCAAAUU 312
    AM05883-SS (NAG25)sucuguggugGfAfCfuucucucaausu(invAb) 243 UCGUGGUGGACUUCUCUCAAAUU 313
    AM06146-SS (NAG37)s(invAb)sgugguggAfCfUfucucucaauausu(invAb) 244 GUGGUGGACUUCUCUCAAUAUU 307
    AM06147-SS (NAG37)s(invAb)scgugguggAfCfUfucucucaauausu(invAb) 245 CGUGGUGGACUUCUCUCAAUAUU 309
    AM06148-SS (NAG37)s(invAb)scucgugguggAfCfUfucucucaauas(invAb) 246 CUCGUGGUGACUUCUCUCAAUA 314
    AM06149-SS (NAG37)s(invAb)scucgugguggAfCfUfucucucaauausu(invAb) 247 CUCGUGGUGGACUUCUCUCAAUAUU 315
    AM06150-SS (NAG37)s(invAb)sggcuguagGfCfAfuaaauugguas(invAb) 248 GGCUGUAGGCAUAAAUUGGUA 294
    AM06151-SS (NAG37)s(invAb)sgaggcuguagGfCfAfuaaauugguas(invAb) 249 GAGGCUGUAGGCAUAAAUUGGUA 316
    AM06152-SS (NAG37)s(invAb)sgaggcuguagGfCfAfuaaauugguausu(invAb) 250 GAGGCUGUAGGCAUAAAUUGGUAUU 317
    AM06287-SS (NAG37)s(invAb)sggacuuCfUfCfucaauuuucuc(invAb) 251 GGACUUCUCUCAAUUUUCU 318
    AM06288-SS (NAG37)s(invAb)sguggacuuCfUfCfucaauuuucus(invAb) 252 GUGGACUUCUCUCAAUUUUCU 302
    AM06289-SS (NAG37)s(invAb)sgguggacuuCfUfCfucaauuuucus(invAb) 253 GGUGGACUUCUCUCAAUUUUCU 319
    AM06290-SS (NAG37)s(invAb)sggacuuCfUfCfucaauuuucas(invAb) 254 GGACUUCUCUCAAUUUUCA 320
    AM06291-SS (NAG37)s(invAb)sguggacuuCfUfCfucaauuuucas(invAb) 255 GUGGACUUCUCUCAAUUUUCA 321
    AM06304-SS (NAG37)s(invAb)sgcuguaGfGfCfauaaauuggus(invAb) 256 GCUGUAGGCAUAAAUUGGU 322
    AM06305-SS (NAG37)s(invAb)sggcuguaGfGfCfauaaauuggus(invAb) 257 GGCUGUAGGCAUAAAUUGGU 323
    AM06306-SS (NAG37)s(invAb)sgaggcuguaGfGfCfauaaauuggus(invAb) 258 GAGGCUGUAGGCAUAAAUUGGU 324
    AM06307-SS (NAG37)s(invAb)sgcuguaGfGfCfauaaauuggas(invAb) 259 GCUGUAGGCAUAAAUUGGA 325
    AM06308-SS (NAG37)s(invAb)sggcuguaGfGfCfauaaauuggas(invAb) 260 GGCUGUAGGCAUAAAUUGGA 326
    AM06603-SS (NAG37)s(invAb)sagcuguagGfCfAfuaaauugguas(invAb) 261 AGCUGUAGGCAUAAAUUGGUA 327
    AM06605-SS (NAG37)s(invAb)scgcuguagGfCfAfuaaauugguas(invAb) 262 CGCUGUAGGCAUAAAUUGGUA 328
    AM06607-SS (NAG37)s(invAb)sggcuguagGfCfAfuaaauugguus(invAb) 263 GGCUGUAGGCAUAAAUUGGUU 329
    AM06609-SS (NAG37)s(invAb)scuguagGfCfAfuaaauugguasuus(invAb) 264 CUGUAGGCAUAAAUUGGUAUU 278
    AM06610-SS (NAG37)s(invAb)scuGfuAfgGfCfAfuAfaAfuUfgGfuasuus 265 CUGUAGGCAUAAAUUGGUAUU 278
    (invAb)
    AM06613-SS (NAG37)s(invAb)saggcuguaGfGfCfauaaauuggus(invAb) 266 AGGCUGUAGGCAUAAAUUGGU 330
    AM06615-SS (NAG37)s(invAb)saggcuguaGfGfCfauaaauuggas(invAb) 267 AGGCUGUAGGCAUAAAUUGGA 331
    AM06617-SS (NAG37)s(invAb)scggcuguaGfGfCfauaaauuggus(invAb) 268 CGGCUGUAGGCAUAAAUUGGU 332
    AM06691-SS (NAG37)s(invAb)scggcuguaGfGfCfauaaauuggas(invAb) 269 CGGCUGUAGGCAUAAAUUGGA 333
    AM06750-SS (NAG37)s(invAb)scccuguagGfGfAfuaaauugguas(invAb) 270 CCCUGUAGGCAUAAAUUGGUA 334
    AM06752-SS (NAG37)csgcuguagGfCfAfuaaauugguas(invAb) 271 CGCUGUAGGCAUAAAUUGGUA 328
    AM06753-SS (NAG37)csccuguagGfCfAfuaaauugguas(invAb) 272 CCCUGUAGGCAUAAAUUGGUA 334
    AM06776-SS (NAG25)s(invAb)sguggacuuCfUfCfucaauuuucus(invAb) 273 GUGGACUUCUCUCAAUUUUCU 302
    AM06777-SS (NAG25)s(invAb)scgcuguagGfCfAfuaaauugguas(invAb) 274 CGCUGUAGGCAUAAAUUGGUA 328
  • The HBV RNAi agents described herein are formed by annealing an antisense strand with a sense strand. A sense strand containing a sequence listed in Table 4 can be hybridized to any antisense strand containing a sequence listed in Table 3, provided the two sequences have a region of at least about 85% complementarity over a contiguous 16, 17, 18, 19, 20, or 21 nucleotide sequence.
  • In some embodiments, the antisense strand of an HBV RNAi agent disclosed herein differs by 0, 1, 2, or 3 nucleotides from any of the antisense strand sequences in Table 3. In some embodiments, the sense strand of an HBV RNAi agent disclosed herein differs by 0, 1, 2, or 3 nucleotides from any of the sense strand sequences in Table 4.
  • In some embodiments, an HBV RNAi agent antisense strand comprises a nucleotide sequence of any of the sequences in Table 3. In some embodiments, an HBV RNAi agent antisense strand comprises the sequence of nucleotides (from 5′ end→3′ end) 1-17, 2-17, 1-18, 2-18, 1-19, 2-19, 1-20, 2-20, 1-21, 2-21, 1-22, 2-22, 1-23, 2-23, 1-24, 2-24, 1-25, 2-25, 1-26, or 2-26 of any of the sequences in Table 3.
  • In some embodiments, an HBV RNAi agent sense strand comprises the nucleotide sequence of any of the sequences in Table 4. In some embodiments, an HBV RNAi agent sense strand comprises the sequence of nucleotides (from 5′ end→3′ end) 1-17, 2-17, 3-17, 4-17, 1-18, 2-18, 3-18, 4-18, 1-19, 2-19, 3-19, 4-19, 1-20, 2-20, 3-20, 4-20, 1-21, 2-21, 3-21, 4-21, 1-22, 2-22, 3-22, 4-22, 1-23, 2-23, 3-23, 4-23, 1-24, 2-24, 3-24, 4-24, 1-25, 2-25, 3-25, 4-25, 1-26, 2-26, 3-26, or 4-26 of any of the sequences in Table 4.
  • For the HBV RNAi agents disclosed herein, the nucleotide at position 1 of the antisense strand (from 5′ end→3′ end) can be perfectly complementary to an HBV gene, or can be non-complementary to an HBV gene. In some embodiments, the nucleotide at position 1 of the antisense strand (from 5′ end→3′ end) is a U, A, or dT. In some embodiments, the nucleotide at position 1 of the antisense strand (from 5′ end→3′ end) forms an A:U or U:A base pair with the sense strand.
  • In some embodiments, an HBV RNAi agent antisense strand comprises the sequence of nucleotides (from 5′ end→3′ end) 2-18 or 2-19 of any of the antisense strand sequences in Table 3. In some embodiments, an HBV RNAi sense strand comprises the sequence of nucleotides (from 5′ end→3′ end) 1-17 or 1-18 of any of the sense strand sequences in Table 4.
  • In some embodiments, an HBV RNAi agent includes (i) an antisense strand comprising the sequence of nucleotides (from 5′ end→3′ end) 2-18 or 2-19 of any of the antisense strand sequences in Table 3, and (ii) a sense strand comprising the sequence of nucleotides (from 5′ end→3′ end) 1-17 or 1-18 of any of the sense strand sequences in Table 4.
  • A sense strand containing a sequence listed in Table 4 can be hybridized to any antisense strand containing a sequence listed in Table 3 provided the two sequences have a region of at least about 85% complementarity over a contiguous 16, 17, 18, 19, 20, or 21 nucleotide sequence. Representative sequence pairings are exemplified by the Duplex ID Nos. shown in Table 5.
  • In some embodiments, an HBV RNAi agent comprises of any of the Duplex ID Nos. presented herein. In some embodiments, an HBV RNAi agent consists of any of the Duplex ID Nos. presented herein. In some embodiments, an HBV RNAi agent comprises the sense strand and/or the antisense strand nucleotide sequences of any of the Duplex ID Nos. presented herein. In some embodiments, an HBV RNAi agent comprises the sense strand and antisense strand nucleotide sequences of any of the Duplex ID Nos. presented herein and a targeting group and/or linking group wherein the targeting group and/or linking group is covalently linked (i.e. conjugated) to the sense strand or the antisense strand. In some embodiments, an HBV RNAi agent comprises the sense strand and antisense strand modified nucleotide sequences of any of the Duplex ID Nos. presented herein. In some embodiments, an HBV RNAi agent comprises the sense strand and antisense strand modified nucleotide sequences of any of the Duplex ID Nos. presented herein and a targeting group and/or linking group wherein the targeting group and/or linking group is covalently linked to the sense strand or the antisense strand.
  • In some embodiments, an HBV RNAi agent comprises an antisense strand and a sense strand having the nucleotide sequences of any of the antisense strand/sense strand duplexes of Table 5, and further comprises an asialoglycoprotein receptor ligand targeting group.
  • In some embodiments, an HBV RNAi agent comprises an antisense strand and a sense strand having the nucleotide sequences of any of the antisense strand and/or sense strand nucleotide sequences of any of the duplexes of Table 5, and further comprises a targeting group selected from the group consisting of (PAZ), (NAG13), (NAG13)s, (NAG18), (NAG18)s, (NAG24), (NAG24)s, (NAG25), (NAG25)s, (NAG26), (NAG26)s, (NAG27), (NAG27)s, (NAG28), (NAG28)s, (NAG29), (NAG29)s, (NAG30), (NAG30)s, (NAG31), (NAG31)s, (NAG32), (NAG32)s, (NAG33), (NAG33)s, (NAG34), (NAG34)s, (NAG35), (NAG35)s, (NAG36), (NAG36)s, (NAG37), (NAG37)s.
  • In some embodiments, an HBV RNAi agent comprises an antisense strand and a sense strand having the modified nucleotide sequences of any of the antisense strand and/or sense strand nucleotide sequences of any of the duplexes of Table 5.
  • In some embodiments, an HBV RNAi agent comprises an antisense strand and a sense strand having the modified nucleotide sequences of any of the antisense strand and/or sense strand nucleotide sequences of any of the duplexes of Table 5, and further comprises an asialoglycoprotein receptor ligand targeting group.
  • In some embodiments, an HBV RNAi agent comprises any of the duplexes of Table 5.
  • In some embodiments, an HBV RNAi agent consists of any of the duplexes of Table 5.
  • TABLE 5
    Examples of HBV RNAi agent duplexes.
    Antisense Sense Strand
    Duplex ID Strand ID ID
    AD03498 AM03508-AS AM04445-SS
    AD03499 AM04441-AS AM04444-SS
    AD03500 AM04442-AS AM04444-SS
    AD03501 AM04443-AS AM04444-SS
    AD03738 AM04768-AS AM04767-SS
    AD03739 AM04769-AS AM04767-SS
    AD03967 AM04443-AS AM05010-SS
    AD03968 AM05011-AS AM05010-SS
    AD03969 AM04443-AS AM05015-SS
    AD03970 AM05011-AS AM05019-SS
    AD03971 AM05012-AS AM05015-SS
    AD03972 AM04443-AS AM05016-SS
    AD03973 AM04443-AS AM05017-SS
    AD03974 AM04443-AS AM05018-SS
    AD03975 AM05013-AS AM05015-SS
    AD03976 AM05014-AS AM05019-SS
    AD03977 AM05013-AS AM05017-SS
    AD03978 AM05013-AS AM04444-SS
    AD04001 AM05052-AS AM05034-SS
    AD04002 AM05053-AS AM05034-SS
    AD04003 AM05054-AS AM05046-SS
    AD04004 AM05052-AS AM05047-SS
    AD04005 AM05055-AS AM05064-SS
    AD04006 AM05056-AS AM05048-SS
    AD04007 AM05057-AS AM05048-SS
    AD04008 AM05058-AS AM05049-SS
    AD04009 AM05056-AS AM05050-SS
    AD04010 AM05060-AS AM05063-SS
    AD04176 AM05351-AS AM05346-SS
    AD04177 AM04443-AS AM05347-SS
    AD04178 AM05011-AS AM05347-SS
    AD04412 AM05011-AS AM05606-SS
    AD04413 AM05011-AS AM05607-SS
    AD04414 AM05608-AS AM05606-SS
    AD04415 AM05011-AS AM05615-SS
    AD04416 AM05609-AS AM05616-SS
    AD04417 AM05610-AS AM05616-SS
    AD04418 AM05611-AS AM05616-SS
    AD04419 AM05612-AS AM05616-SS
    AD04420 AM05613-AS AM05616-SS
    AD04421 AM05614-AS AM05616-SS
    AD04422 AM05054-AS AM05617-SS
    AD04423 AM05618-AS AM05046-SS
    AD04425 AM05621-AS AM05620-SS
    AD04426 AM05623-AS AM05622-SS
    AD04427 AM05623-AS AM05624-SS
    AD04428 AM05626-AS AM05622-SS
    AD04429 AM05626-AS AM05624-SS
    AD04430 AM05628-AS AM05627-SS
    AD04431 AM05054-AS AM05629-SS
    AD04432 AM05054-AS AM05630-SS
    AD04433 AM05631-AS AM05048-SS
    AD04434 AM05632-AS AM05048-SS
    AD04435 AM05633-AS AM05048-SS
    AD04436 AM05635-AS AM05048-SS
    AD04437 AM05634-AS AM05048-SS
    AD04438 AM05637-AS AM05636-SS
    AD04439 AM05638-AS AM05636-SS
    AD04440 AM05058-AS AM05639-SS
    AD04441 AM05057-AS AM05639-SS
    AD04442 AM05057-AS AM05640-SS
    AD04511 AM05747-AS AM05746-SS
    AD04570 AM05011-AS AM05856-SS
    AD04571 AM05849-AS AM05856-SS
    AD04572 AM05850-AS AM05856-SS
    AD04573 AM05851-AS AM05857-SS
    AD04574 AM05852-AS AM05857-SS
    AD04575 AM05853-AS AM05858-SS
    AD04576 AM05854-AS AM05858-SS
    AD04577 AM05011-AS AM05859-SS
    AD04578 AM05850-AS AM05858-SS
    AD04579 AM05014-AS AM05347-SS
    AD04580 AM05855-AS AM05347-SS
    AD04581 AM05860-AS AM05063-SS
    AD04583 AM05862-AS AM05868-SS
    AD04584 AM05863-AS AM05868-SS
    AD04585 AM05864-AS AM05869-SS
    AD04586 AM05865-AS AM05869-SS
    AD04587 AM05862-AS AM05870-SS
    AD04588 AM05863-AS AM05871-SS
    AD04590 AM05867-AS AM05063-SS
    AD04591 AM05860-AS AM05872-SS
    AD04592 AM05054-AS AM05879-SS
    AD04593 AM05873-AS AM05880-SS
    AD04594 AM05874-AS AM05880-SS
    AD04595 AM05875-AS AM05881-SS
    AD04596 AM05876-AS AM05881-SS
    AD04597 AM05873-AS AM05882-SS
    AD04598 AM05874-AS AM05883-SS
    AD04599 AM05877-AS AM05620-SS
    AD04734 AM06074-AS AM05869-SS
    AD04771 AM06142-AS AM06146-SS
    AD04772 AM06143-AS AM06147-SS
    AD04773 AM06144-AS AM06146-SS
    AD04774 AM06145-AS AM06148-SS
    AD04775 AM06145-AS AM06149-SS
    AD04776 AM05850-AS AM06150-SS
    AD04777 AM05854-AS AM06151-SS
    AD04778 AM05854-AS AM06152-SS
    AD04822 AM06222-AS AM06146-SS
    AD04823 AM05609-AS AM06150-SS
    AD04871 AM06281-AS AM06287-SS
    AD04872 AM06282-AS AM06288-SS
    AD04873 AM06283-AS AM06288-SS
    AD04874 AM06284-AS AM06289-SS
    AD04875 AM06285-AS AM06290-SS
    AD04876 AM06286-AS AM06291-SS
    AD04881 AM06299-AS AM06304-SS
    AD04882 AM06300-AS AM06305-SS
    AD04883 AM06301-AS AM06306-SS
    AD04884 AM06302-AS AM06307-SS
    AD04885 AM06303-AS AM06308-SS
    AD04962 AM05864-AS AM06146-SS
    AD04963 AM05855-AS AM05607-SS
    AD04981 AM06463-AS AM06150-SS
    AD04982 AM06464-AS AM06150-SS
    AD04983 AM06465-AS AM06150-SS
    AD05069 AM06604-AS AM06603-SS
    AD05070 AM06606-AS AM06605-SS
    AD05071 AM06608-AS AM06607-SS
    AD05072 AM05011-AS AM06609-SS
    AD05073 AM06611-AS AM06610-SS
    AD05074 AM06612-AS AM06150-SS
    AD05075 AM06614-AS AM06613-SS
    AD05076 AM06616-AS AM06615-SS
    AD05077 AM06618-AS AM06617-SS
    AD05078 AM06620-AS AM06619-SS
    AD05147 AM06751-AS AM06750-SS
    AD05148 AM06606-AS AM06752-SS
    AD05149 AM06751-AS AM06753-SS
    AD05164 AM06282-AS AM06776-SS
    AD05165 AM06606-AS AM06777-SS
  • In some embodiments, an HBV RNAi agent is prepared or provided as a salt, mixed salt, or a free-acid. The RNAi agents described herein, upon delivery to a cell expressing an HBV gene, inhibit or knockdown expression of one or more HBV genes in vivo.
    • Targeting Groups, Linking Groups, and Delivery Vehicles
  • In some embodiments, an HBV RNAi agent is conjugated to one or more non-nucleotide groups including, but not limited to a targeting group, linking group, delivery polymer, or a delivery vehicle. The non-nucleotide group can enhance targeting, delivery or attachment of the RNAi agent. Examples of targeting groups and linking groups are provided in Table 6. The non-nucleotide group can be covalently linked to the 3′ and/or 5′ end of either the sense strand and/or the antisense strand. In some embodiments, an HBV RNAi agent contains a non-nucleotide group linked to the 3′ and/or 5′ end of the sense strand. In some embodiments, a non-nucleotide group is linked to the 5′ end of an HBV RNAi agent sense strand. A non-nucleotide group may be linked directly or indirectly to the RNAi agent via a linker/linking group. In some embodiments, a non-nucleotide group is linked to the RNAi agent via a labile, cleavable, or reversible bond or linker.
  • In some embodiments, a non-nucleotide group enhances the pharmacokinetic or biodistribution properties of an RNAi agent or conjugate to which it is attached to improve cell- or tissue-specific distribution and cell-specific uptake of the conjugate. In some embodiments, a non-nucleotide group enhances endocytosis of the RNAi agent.
  • Targeting groups or targeting moieties enhance the pharmacokinetic or biodistribution properties of a conjugate to which they are attached to improve cell-specific distribution and cell-specific uptake of the conjugate. A targeting group can be monovalent, divalent, trivalent, tetravalent, or have higher valency. Representative targeting groups include, without limitation, compounds with affinity to cell surface molecule, cell receptor ligands, hapten, antibodies, monoclonal antibodies, antibody fragments, and antibody mimics with affinity to cell surface molecules. In some embodiments, a targeting group is linked to an RNAi agent using a linker, such as a PEG linker or one, two, or three abasic and/or ribitol (abasic ribose) groups. In some embodiments, a targeting group comprises a galactose derivative cluster.
  • The HBV RNAi agents described herein may be synthesized having a reactive group, such as an amine group, at the 5′-terminus. The reactive group may be used to subsequently attach a targeting moiety using methods typical in the art.
  • In some embodiments, a targeting group comprises an asialoglycoprotein receptor ligand. In some embodiments, an asialoglycoprotein receptor ligand includes or consists of one or more galactose derivatives. As used herein, the term galactose derivative includes both galactose and derivatives of galactose having affinity for the asialoglycoprotein receptor that is equal to or greater than that of galactose. Galactose derivatives include, but are not limited to: galactose, galactosamine, N-formylgalactosamine, N-acetyl-galactosamine, N-propionyl-galactosamine, N-n-butanoyl-galactosamine, and N-iso-butanoylgalactos-amine (see for example: Iobst. S. T. and Drickamer, K. J.B.C. 1996, 271, 6686). Galactose derivatives, and clusters of galactose derivatives, that are useful for in vivo targeting of oligonucleotides and other molecules to the liver are known in the art (see, for example, Baenziger and Fiete, 1980. Cell, 22, 611-620; Connolly et al., 1982, J. Biol. Chem., 257, 939-945). Galactose derivatives have been used to target molecules to hepatocytes in vivo through their binding to the asialoglycoprotein receptor (ASGPr) expressed on the surface of hepatocytes. Binding of ASGPr ligands to the ASGPr(s) facilitates cell-specific targeting to hepatocytes and endocytosis of the molecule into hepatocytes. ASGPr ligands can be monomeric (e.g., having a single galactose derivative) or multimeric (e.g., having multiple galactose derivatives). The galactose derivative or galactose derivative cluster may be attached to the 3′ or 5′ end of the RNAi polynucleotide using methods known in the art. The preparation of targeting groups, such as galactose derivative clusters, is described in, for example, U.S. patent application Ser. Nos. 15/452,324 and 15/452,423, the contents of both of which are incorporated herein in their entirety.
  • As used herein, a galactose derivative cluster comprises a molecule having two to four terminal galactose derivatives. A terminal galactose derivative is attached to a molecule through its C-1 carbon. In some embodiments, the galactose derivative cluster is a galactose derivative trimer (also referred to as tri-antennary galactose derivative or tri-valent galactose derivative). In some embodiments, the galactose derivative cluster comprises N-acetyl-galactosamines. In some embodiments, the galactose derivative cluster comprises three N-acetyl-galactosamines. In some embodiments, the galactose derivative cluster is a galactose derivative tetramer (also referred to as tetra-antennary galactose derivative or tetra-valent galactose derivative). In some embodiments, the galactose derivative cluster comprises four N-acetyl-galactosamines.
  • As used herein, a galactose derivative trimer contains three galactose derivatives, each linked to a central branch point. As used herein, a galactose derivative tetramer contains four galactose derivatives, each linked to a central branch point. The galactose derivatives can be attached to the central branch point through the C-1 carbons of the saccharides. In some embodiments, the galactose derivatives are linked to the branch point via linkers or spacers. In some embodiments, the linker or spacer is a flexible hydrophilic spacer, such as a PEG group (see, for example, U.S. Pat. No. 5,885,968; Biessen et al. J. Med. Chem. 1995 Vol. 39 p. 1538-1546). In some embodiments, the PEG spacer is a PEG3 spacer. The branch point can be any small molecule which permits attachment of three galactose derivatives and further permits attachment of the branch point to the RNAi agent. An example of branch point group is a di-lysine or di-glutamate. Attachment of the branch point to the RNAi agent can occur through a linker or spacer. In some embodiments, the linker or spacer comprises a flexible hydrophilic spacer, such as, but not limited to, a PEG spacer. In some embodiments, the linker comprises a rigid linker, such as a cyclic group. In some embodiments, a galactose derivative comprises or consists of N-acetyl-galactosamine. In some embodiments, the galactose derivative cluster is comprised of a galactose derivative tetramer, which can be, for example, an N-acetyl-galactosamine tetramer.
  • In some embodiments, pharmaceutical compositions for delivering an HBV RNAi agent to a liver cell in vivo are described. Such pharmaceutical compositions can include, for example, an HBV RNAi agent conjugated to a galactose derivative cluster. In some embodiments, the galactose derivative cluster is comprised of a galactose derivative trimer, which can be, for example, an N-acetyl-galactosamine trimer, or galactose derivative tetramer, which can be, for example, an N-acetyl-galactosamine tetramer.
  • Targeting groups include, but are not limited to, (PAZ), (NAG13), (NAG13)s, (NAG18), (NAG18)s, (NAG24), (NAG24)s, (NAG25), (NAG25)s, (NAG26), (NAG26)s, (NAG27), (NAG27)s, (NAG28), (NAG28)s, (NAG29), (NAG29)s, (NAG30), (NAG30)s, (NAG31), (NAG31)s, (NAG32), (NAG32)s, (NAG33), (NAG33)s, (NAG34), (NAG34)s, (NAG35), (NAG35)s, (NAG36), (NAG36)s, (NAG37), (NAG37)s, (NAG38), (NAG38)s, (NAG39), and (NAG39)s. Other targeting groups, including galactose cluster targeting ligands, are known in the art.
  • In some embodiments, a linking group is conjugated to the RNAi agent. The linking group facilitates covalent linkage of the agent to a targeting group or delivery polymer or delivery vehicle. The linking group can be linked to the 3′ or the 5′ end of the RNAi agent sense strand or antisense strand. In some embodiments, the linking group is linked to the RNAi agent sense strand. In some embodiments, the linking group is conjugated to the 5′ or 3′ end of an RNAi agent sense strand. In some embodiments, a linking group is conjugated to the 5′ end of an RNAi agent sense strand. Examples of linking groups, include, but are not limited to: reactive groups such a primary amines and alkynes, alkyl groups, abasic nucleosides, ribitol (abasic ribose), and/or PEG groups.
  • A linker or linking group is a connection between two atoms that links one chemical group (such as an RNAi agent) or segment of interest to another chemical group (such as a targeting group or delivery polymer) or segment of interest via one or more covalent bonds. A labile linkage contains a labile bond. A linkage may optionally include a spacer that increases the distance between the two joined atoms. A spacer may further add flexibility and/or length to the linkage. Spacers may include, but are not be limited to, alkyl groups, alkenyl groups, alkynyl groups, aryl groups, aralkyl groups, aralkenyl groups, and aralkynyl groups; each of which can contain one or more heteroatoms, heterocycles, amino acids, nucleotides, and saccharides. Spacer groups are well known in the art and the preceding list is not meant to limit the scope of the description.
  • Any of the HBV RNAi agent nucleotide sequences listed in Tables 3 and 4, whether modified or unmodified, may contain 3′ or 5′ targeting group and/or linking group. Any of the HBV RNAi agent sequences listed in Table 3 and 4 which contain a 3′ or 5′ targeting group and/or linking group, may alternatively contain no 3′ or 5′ targeting group and/or linking group, or may contain a different 3′ or 5′ targeting group and/or linking group including, but not limited to, those depicted in Table 3. Any of the HBV RNAi agent duplexes listed in Table 5, whether modified or unmodified, may further comprise a targeting group and/or linking group, including, but not limited to, those depicted in Table 3, and the targeting group or linking group may be attached to the 3′ or 5′ terminus of either the sense strand or the antisense strand of the HBV RNAi agent duplex.
  • Examples of targeting groups and linking groups are provided in Table 6. Table 4 provides several embodiments of HBV RNAi agent sense strands having a targeting group or linking group linked to the 5′ or 3′ end.
  • TABLE 6
    Structures representing various modified nucleotides, targeting groups, and linking groups.
    Figure US20190255091A1-20190822-C00001
    Figure US20190255091A1-20190822-C00002
    Figure US20190255091A1-20190822-C00003
    Figure US20190255091A1-20190822-C00004
    Figure US20190255091A1-20190822-C00005
    Figure US20190255091A1-20190822-C00006
    When positioned internally on oligonucleotide:
    Figure US20190255091A1-20190822-C00007
    When positioned internally on oligonucleotide:
    Figure US20190255091A1-20190822-C00008
    When positioned internally on oligonucleotide:
    Figure US20190255091A1-20190822-C00009
    Figure US20190255091A1-20190822-C00010
    Figure US20190255091A1-20190822-C00011
    Figure US20190255091A1-20190822-C00012
    Figure US20190255091A1-20190822-C00013
    Figure US20190255091A1-20190822-C00014
    Figure US20190255091A1-20190822-C00015
    Figure US20190255091A1-20190822-C00016
    Figure US20190255091A1-20190822-C00017
    Figure US20190255091A1-20190822-C00018
    Figure US20190255091A1-20190822-C00019
    Figure US20190255091A1-20190822-C00020
    Figure US20190255091A1-20190822-C00021
    Figure US20190255091A1-20190822-C00022
    Figure US20190255091A1-20190822-C00023
    Figure US20190255091A1-20190822-C00024
    Figure US20190255091A1-20190822-C00025
    Figure US20190255091A1-20190822-C00026
    Figure US20190255091A1-20190822-C00027
    Figure US20190255091A1-20190822-C00028
    Figure US20190255091A1-20190822-C00029
    Figure US20190255091A1-20190822-C00030
    Figure US20190255091A1-20190822-C00031
    Figure US20190255091A1-20190822-C00032
    Figure US20190255091A1-20190822-C00033
    Figure US20190255091A1-20190822-C00034
    Figure US20190255091A1-20190822-C00035
    Figure US20190255091A1-20190822-C00036
    Figure US20190255091A1-20190822-C00037
    Figure US20190255091A1-20190822-C00038
    Figure US20190255091A1-20190822-C00039
    Figure US20190255091A1-20190822-C00040
    Figure US20190255091A1-20190822-C00041
    Figure US20190255091A1-20190822-C00042
    Figure US20190255091A1-20190822-C00043
    Figure US20190255091A1-20190822-C00044
    Figure US20190255091A1-20190822-C00045
    Figure US20190255091A1-20190822-C00046
  • In each of the above structures in Table 6, NAG comprises an N-acetyl-galactosamine or another ASGPr ligand, as would be understood by a person of ordinary skill in the art to be attached in view of the structures above and description provided herein. For example, in some embodiments, NAG in the structures provided in Table 6 is represented by the following structure:
  • Figure US20190255091A1-20190822-C00047
  • Each (NAGx) may be attached to an HBV RNAi agent via a phosphate group (as in (NAG25), (NAG30), and (NAG31)), or a phosphorothioate group, (as is (NAG25)s, (NAG29)s, (NAG30)s, (NAG31)s, or (NAG37)s), or another linking group.
  • Figure US20190255091A1-20190822-C00048
  • Other linking groups known in the art may be used.
    • Delivery Vehicles
  • In some embodiments, a delivery vehicle may be used to deliver an RNAi agent to a cell or tissue. A delivery vehicle is a compound that improves delivery of the RNAi agent to a cell or tissue. A delivery vehicle can include, or consist of, but is not limited to: a polymer, such as an amphipathic polymer, a membrane active polymer, a peptide, a melittin peptide, a melittin-like peptide (MLP), a lipid, a reversibly modified polymer or peptide, or a reversibly modified membrane active polyamine.
  • In some embodiments, the RNAi agents can be combined with lipids, nanoparticles, polymers, liposomes, micelles, DPCs or other delivery systems available in the art. The RNAi agents can also be chemically conjugated to targeting groups, lipids (including, but not limited to cholesterol and cholesteryl derivatives), nanoparticles, polymers, liposomes, micelles, DPCs (see, for example WO 2000/053722, WO 2008/0022309, WO 2011/104169, and WO 2012/083185, WO 2013/032829, WO 2013/158141, each of which is incorporated herein by reference), or other delivery systems available in the art.
    • Pharmaceutical Compositions and Formulations
  • The HBV RNAi agents disclosed herein may be prepared as pharmaceutical compositions or formulations. In some embodiments, pharmaceutical compositions include at least one HBV RNAi agent. These pharmaceutical compositions are particularly useful in the inhibition of the expression of the target mRNA in a target cell, a group of cells, a tissue, or an organism. The pharmaceutical compositions can be used to treat a subject having a disease or disorder that would benefit from reduction in the level of the target mRNA, or inhibition in expression of the target gene. The pharmaceutical compositions can be used to treat a subject at risk of developing a disease or disorder that would benefit from reduction of the level of the target mRNA or an inhibition in expression the target gene. In one embodiment, the method includes administering an HBV RNAi agent linked to a targeting ligand as described herein, to a subject to be treated. In some embodiments, one or more pharmaceutically acceptable excipients (including vehicles, carriers, diluents, and/or delivery polymers) are added to the pharmaceutical compositions including an HBV RNAi agent, thereby forming a pharmaceutical formulation suitable for in vivo delivery to a human.
  • The pharmaceutical compositions that include an HBV RNAi agent and methods disclosed herein may decrease the level of the target mRNA in a cell, group of cells, group of cells, tissue, or subject, including: administering to the subject a therapeutically effective amount of a herein described HBV RNAi agent, thereby inhibiting the expression of a target mRNA in the subject.
  • In some embodiments, the described pharmaceutical compositions including an HBV RNAi agent are used for treating or managing clinical presentations associated with HBV infection. In some embodiments, a therapeutically or prophylactically effective amount of one or more of pharmaceutical compositions is administered to a subject in need of such treatment, prevention or management. In some embodiments, administration of any of the disclosed HBV RNAi agents can be used to decrease the number, severity, and/or frequency of symptoms of a disease in a subject.
  • The described pharmaceutical compositions including an HBV RNAi agent can be used to treat at least one symptom in a subject having a disease or disorder that would benefit from reduction or inhibition in expression of HBV mRNA. In some embodiments, the subject is administered a therapeutically effective amount of one or more pharmaceutical compositions including an HBV RNAi agent thereby treating the symptom. In other embodiments, the subject is administered a prophylactically effective amount of one or more HBV RNAi agents, thereby preventing the at least one symptom.
  • The route of administration is the path by which an HBV RNAi agent is brought into contact with the body. In general, methods of administering drugs and nucleic acids for treatment of a mammal are well known in the art and can be applied to administration of the compositions described herein. The HBV RNAi agents disclosed herein can be administered via any suitable route in a preparation appropriately tailored to the particular route. Thus, herein described pharmaceutical compositions can be administered by injection, for example, intravenously, intramuscularly, intracutaneously, subcutaneously, intraarticularly, or intraperitoneally. In some embodiments, there herein described pharmaceutical compositions via subcutaneous injection.
  • The pharmaceutical compositions including an HBV RNAi agent described herein can be delivered to a cell, group of cells, tumor, tissue, or subject using oligonucleotide delivery technologies known in the art. In general, any suitable method recognized in the art for delivering a nucleic acid molecule (in vitro or in vivo) can be adapted for use with a herein described compositions. For example, delivery can be by local administration, (e.g., direct injection, implantation, or topical administering), systemic administration, or subcutaneous, intravenous, intraperitoneal, or parenteral routes, including intracranial (e.g., intraventricular, intraparenchymal and intrathecal), intramuscular, transdermal, airway (aerosol), nasal, oral, rectal, or topical (including buccal and sublingual) administration. In certain embodiments, the compositions are administered by subcutaneous or intravenous infusion or injection.
  • Accordingly, in some embodiments, the herein described pharmaceutical compositions may comprise one or more pharmaceutically acceptable excipients. In some embodiments, the pharmaceutical compositions described herein can be formulated for administration to a subject.
  • As used herein, a pharmaceutical composition or medicament includes a pharmacologically effective amount of at least one of the described therapeutic compounds and one or more pharmaceutically acceptable excipients. Pharmaceutically acceptable excipients (excipients) are substances other than the Active Pharmaceutical ingredient (API, therapeutic product, e.g., HBV RNAi agent) that are intentionally included in the drug delivery system.
  • Excipients do not exert or are not intended to exert a therapeutic effect at the intended dosage. Excipients may act to a) aid in processing of the drug delivery system during manufacture, b) protect, support or enhance stability, bioavailability or patient acceptability of the API, c) assist in product identification, and/or d) enhance any other attribute of the overall safety, effectiveness, of delivery of the API during storage or use. A pharmaceutically acceptable excipient may or may not be an inert substance.
  • Excipients include, but are not limited to: absorption enhancers, anti-adherents, anti-foaming agents, anti-oxidants, binders, buffering agents, carriers, coating agents, colors, delivery enhancers, delivery polymers, dextran, dextrose, diluents, disintegrants, emulsifiers, extenders, fillers, flavors, glidants, humectants, lubricants, oils, polymers, preservatives, saline, salts, solvents, sugars, suspending agents, sustained release matrices, sweeteners, thickening agents, tonicity agents, vehicles, water-repelling agents, and wetting agents.
  • Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, N.J.) or phosphate buffered saline. It should be stable under the conditions of manufacture and storage and should be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, and sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
  • Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filter sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation include vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • Formulations suitable for intra-articular administration can be in the form of a sterile aqueous preparation of the drug that can be in microcrystalline form, for example, in the form of an aqueous microcrystalline suspension. Liposomal formulations or biodegradable polymer systems can also be used to present the drug for both intra-articular and ophthalmic administration.
  • The active compounds can be prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. Liposomal suspensions can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.
  • The HBV RNAi agents can be formulated in compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the disclosure are dictated by and directly dependent on the unique characteristics of the active compound and the therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.
  • A pharmaceutical composition can contain other additional components commonly found in pharmaceutical compositions. Such additional components include, but are not limited to: anti-pruritics, astringents, local anesthetics, or anti-inflammatory agents (e.g., antihistamine, diphenhydramine, etc.). It is also envisioned that cells, tissues or isolated organs that express or comprise the herein defined RNAi agents may be used as “pharmaceutical compositions.” As used herein, “pharmacologically effective amount,” “therapeutically effective amount,” or simply “effective amount” refers to that amount of an RNAi agent to produce a pharmacological, therapeutic or preventive result.
  • Generally, an effective amount of an active compound will be in the range of from about 0.1 to about 100 mg/kg of body weight/day, e.g., from about 1.0 to about 50 mg/kg of body weight/day. In some embodiments, an effective amount of an active compound will be in the range of from about 0.25 to about 5 mg/kg of body weight per dose. In some embodiments, an effective amount of an active ingredient will be in the range of from about 0.5 to about 3 mg/kg of body weight per dose. The amount administered will also likely depend on such variables as the overall health status of the patient, the relative biological efficacy of the compound delivered, the formulation of the drug, the presence and types of excipients in the formulation, and the route of administration. Also, it is to be understood that the initial dosage administered can be increased beyond the above upper level in order to rapidly achieve the desired blood-level or tissue level, or the initial dosage can be smaller than the optimum.
  • For treatment of disease or for formation of a medicament or composition for treatment of a disease, the pharmaceutical compositions described herein including an HBV RNAi agent can be combined with an excipient or with a second therapeutic agent or treatment including, but not limited to: a second or other RNAi agent, a small molecule drug, an antibody, an antibody fragment, and/or a vaccine.
  • The described HBV RNAi agents, when added to pharmaceutically acceptable excipients or adjuvants, can be packaged into kits, containers, packs, or dispensers. The pharmaceutical compositions described herein may be packaged in pre-filled syringes or vials.
    • Methods of Treatment and Inhibition of Expression
  • The HBV RNAi agents disclosed herein can be used to treat a subject (e.g., a human or mammal) having a disease or disorder that would benefit from administration of the compound. In some embodiments, the RNAi agents disclosed herein can be used to treat a subject (e.g., a human) having a disease or disorder that would benefit from reduction or inhibition in expression of HBV mRNA. The subject is administered a therapeutically effective amount of any one or more RNAi agents. The subject can be a human, patient, or human patient. The subject may be an adult, adolescent, child, or infant. The described pharmaceutical compositions including an HBV RNAi agent can be used to provide methods for the therapeutic treatment of diseases. Such methods include administration of a pharmaceutical composition described herein to a human being or animal.
  • In some embodiments, the HBV RNAi agents described herein are used to treat a subject infected with HBV. In some embodiments, the described HBV RNAi agents are used to treat at least one symptom in a subject having a HBV infection. The subject is administered a therapeutically effective amount of any one or more of the described RNAi agents.
  • In some embodiments, the subject has both a HBV infection and a HDV infection. In some embodiments, the HBV RNAi agents described herein are used to treat a subject infected with both HBV and HDV. In some embodiments, the described HBV RNAi agents are used to treat at least one symptom in a subject having a HBV or a HDV infection. The subject is administered a therapeutically effective amount of any one or more of the described RNAi agents.
  • In some embodiments, the HBV RNAi agents are used to treat or manage a clinical presentation wherein a subject infected with HBV. The subject is administered a therapeutically or effective amount of one or more of the HBV RNAi agents or HBV RNAi agent-containing compositions described herein. In some embodiments, the method comp rises administering a composition comprising an HBV RNAi agent described herein to a subject to be treated.
  • In some embodiments, the gene expression level and/or mRNA level of an HBV gene in a subject to whom a described HBV RNAi agent is administered is reduced by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or greater than 99% relative to the subject prior to being administered the HBV RNAi agent or to a subject not receiving the HBV RNAi agent. The gene expression level and/or mRNA level in the subject may be reduced in a cell, group of cells, and/or tissue of the subject. In some embodiments, the expressed protein level of an HBV gene in a subject to whom a described HBV RNAi agent has been administered is reduced by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or greater than 99% relative to the subject prior to being administered the HBV RNAi agent or to a subject not receiving the HBV RNAi agent. The protein level in the subject may be reduced in a cell, group of cells, tissue, blood, and/or other fluid of the subject. For example, in some embodiments, the amount or level of Hepatitis B surface antigen (HBsAg) in a subject to whom a described HBV RNAi agent has been administered is reduced by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or greater than 99% relative to the subject prior to being administered the HBV RNAi agent or to a subject not receiving the HBV RNAi agent. In some embodiments, the amount or level of Hepatitis B e-antigen (HBeAg) in a subject to whom a described HBV RNAi agent has been administered is reduced by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or greater than 99% relative to the subject prior to being administered the HBV RNAi agent or to a subject not receiving the HBV RNAi agent. In some embodiments, the amount or level of serum HBV DNA in a subject to whom a described HBV RNAi agent has been administered is reduced by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%/0, 90%, 95%, 96%, 97%, 98%, 99%, or greater than 99% relative to the subject prior to being administered the HBV RNAi agent or to a subject not receiving the HBV RNAi agent. A reduction in the presence of serum HBV DNA, HBV gene expression, HBV mRNA, or HBV protein amounts or levels may be assessed by methods known in the art. Reduction or decrease in HBV mRNA amount or level, expressed protein amount or level, and/or serum HBV DNA amount or level, are collectively referred to herein as a reduction or decrease in HBV or inhibiting or reducing the expression of HBV.
    • Cells and Tissues and Non-Human Organisms
  • Cells, tissues, and non-human organisms that include at least one of the HBV RNAi agents described herein is contemplated. The cell, tissue, or non-human organism is made by delivering the RNAi agent to the cell, tissue, or non-human organism.
  • The above provided embodiments and items are now illustrated with the following, non-limiting examples.
    • EXAMPLES Example 1. Synthesis of HBV RNAI Agents
  • HBV RNAi agent duplexes shown in Table 5 were synthesized in accordance with the following:
    • A. Synthesis.
  • The sense and antisense strands of the HBV RNAi agents were synthesized according to phosphoramidite technology on solid phase used in oligonucleotide synthesis. Depending on the scale, either a MerMade96E® (Bioautomation), a MerMade12® (Bioautomation), or an OP Pilot 100 (GE Healthcare) was used. Syntheses were performed on a solid support made of controlled pore glass (CPG, 500 Å or 600 Å, obtained from Prime Synthesis, Aston, Pa., USA). All RNA and 2′-modified phosphoramidites were purchased from Thermo Fisher Scientific (Milwaukee, Wis., USA). Specifically, the following 2′-O-methyl phosphoramidites were used: (5′-O-dimethoxytrityl-N6-(benzoyl)-2′-O-methyl-adenosine-3′-O-(2-cyanoethyl-N,N-diisopropylamino) phosphoramidite, 5′-O-dimethoxy-tritvl-N4-(acetyl)-2′-O-methyl-cytidine-3′-O-(2-cyanoethyl-N,N-diisopropyl-amino) phosphoramidite, (5′-O-dimethoxytrityl-N2-(isobutyryl)-2′-O-methyl-guanosine-3′-O-(2-cyanoethyl-N,N-diisopropylamino) phosphoramidite, and 5′-O-dimethoxytrityl-2′-O-methyl-uridine-3′-O-(2-cyanoethyl-N,N-diisopropylamino) phosphoramidite. The 2′-deoxy-2′-fluoro-phosphoramidites carried the same protecting groups as the 2′-O-methyl amidites. The abasic (3′-O-dimethoxytrityl-2′-deoxyribose-5′-O-(2-cyanoethyl-N,N-diisopropylanino) phosphoramidites were purchased from ChemGenes (Wilmington, Mass., USA). Targeting ligand containing phosphoramidites were dissolved in anhydrous dichloromethane or anhydrous acetonitrile (50 mM), while all other amidites were dissolved in anhydrous acetonitrile (50 mM) and molecular sieves (3 Å) were added. 5-Benzylthio-1H-tetrazole (BTT, 250 mM in acetonitrile) or 5-Ethylthio-1H-tetrazole (ETT, 250 mM in acetonitrile) was used as activator solution. Coupling times were 12 min (RNA), 15 min (targeting ligand), 90 sec (2′OMe), and 60 sec (2′F). In order to introduce phosphorothioate linkages, a 100 mM solution of 3-phenyl 1,2,4-dithiazoline-5-one (POS, obtained from PolyOrg, Inc., Leominster, Mass., USA) in anhydrous Acetonitrile was employed.
    • B. Cleavage and Deprotection of Support Bound Oligomer.
  • After finalization of the solid phase synthesis, the dried solid support was treated with a 1:1 volume solution of 40 wt. % methylamine in water and 28% ammonium hydroxide solution (Aldrich) for 1.5 hours at 30° C. The solution was evaporated and the solid residue was reconstituted in water (see below).
    • C. Purification.
  • Crude oligomers were purified by anionic exchange HPLC using a TSKgel SuperQ-5PW 13 μm column and Shimadzu LC-8 system. Buffer A was 20 mM Tris, 5 mM EDTA, pH 9.0 and contained 20%0/Acetonitrile and buffer B was the same as buffer A with the addition of 1.5 M sodium chloride. UV traces at 260 nm were recorded. Appropriate fractions were pooled then run on size exclusion HPLC using a GE Healthcare XK 26/40 column packed with Sephadex G-25 fine with a running buffer of filtered DI water or 100 mM ammonium bicarbonate, pH 6.7 and 20% Acetonitrile.
    • D. Annealing.
  • Complementary strands were mixed by combining equimolar RNA solutions (sense and antisense) in 1×Phosphate-Buffered Saline (Corning, Cellgro) to form the RNAi agents. Some RNAi agents were lyophilized and stored at −15 to −25° C. Duplex concentration was determined by measuring the solution absorbance on a UV-Vis spectrometer in 1× Phosphate-Buffered Saline. The solution absorbance at 260 nm was then multiplied by a conversion factor and the dilution factor to determine the duplex concentration. Unless otherwise stated, all conversion factor was 0.037 mg/(mL-cm). For some experiments, a conversion factor was calculated from an experimentally determined extinction coefficient.
    • Example 2 pHBV Model Mice
  • Six to eight-week-old female NOD.CB17-Prkdscid/NcrCrl (NOD-SCID) mice were transiently transfected in vivo with MC-HBV1.3 by hydrodynamic tail vein injection (Yang P L et al. “Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection,” PNAS USA 2002 Vol. 99: p. 13825-13830), administered 30 to 45 days prior to administration of an HBV RNAi agent or control. MC-HBV1.3 is a plasmid-derived minicircle that contains the same terminally redundant human hepatitis B virus sequence HBV1.3 as in plasmid pHBV1.3 and in the HBV1.3.32 transgenic mice (GenBank accession #V01460) (Guidotti L G et al., “High-level hepatitis B virus replication in transgenic mice,” J Virol 1995 Vol. 69, p 6158-6169.). 5 or 10 μg MC-HBV1.3 in Ringer's Solution in a total volume of 10% of the animal's body weight was injected into mice via tail vein to create pHBV model of chronic HBV infection. The solution was injected through a 27-gauge needle in 5-7 seconds as previously described (Zhang G et al., “High levels of foreign gene expression in hepatocytes after tail vein injection of naked plasmid DNA.” Human Gene Therapy 1999 Vol. 10, p 1735-1737.). At pre-dose (either day 1 pre-dose, day −1, or day −2), Hepatitis B surface antigen (HBsAg) HBsAg expression levels in serum were measured by ELISA and the mice were grouped according to average HBsAg expression levels.
    • Analyses:
  • At various times, before and after administration of HBV RNAi agents, serum HBsAg, serum HBeAg, serum HBV DNA, or liver HBV RNA may be measured. HBV expression levels were normalized to pre-administration expression levels and to control mice injected with phosphate buffered saline (“PBS”).
  • 1) Serum Collection:
  • Mice were anesthetized with 2-3% isoflurane and blood samples were collected from the submandibular area into serum separation tubes (Sarstedt AG & Co., Nümbrecht, Germany). Blood was allowed to coagulate at ambient temperature for 20 min. The tubes were centrifuged at 8,000×g for 3 min to separate the serum and stored at 4° C.
  • ii) Serum Hepatitis B Surface Antigen (HBsAg) Levels:
  • Serum was collected and diluted 10 to 8000-fold in PBS containing 5% nonfat dry milk. Secondary HBsAg standards diluted in the nonfat milk solution were prepared from serum of ICR mice (Harlan Sprague Dawley) that had been transfected with 10 μg HBsAg-expressing plasmid pRcCMV-HBs (Aldevron, Fargo, N. Dak.). HBsAg levels were determined with a GS HBsAg EIA 3.0 kit (Bio-Rad Laboratories, Inc., Redmond, Wash.) as described by the manufacturer. Recombinant HBsAg protein, ayw subtype, also diluted in nonfat milk in PBS, was used as a primary standard (Aldevron).
  • HBsAg expression for each animal was normalized to the control group of mice injected with PBS in order to account for the non-treatment related decline in expression of MC-HBV1.3. First, the HBsAg level for each animal at a time point was divided by the pre-treatment level of expression in that animal in order to determine the ratio of expression “normalized to pre-treatment”. Expression at a specific time point was then normalized to the control group by dividing the “normalized to pre-treatment” ratio for an individual animal by the average “normalized to pre-treatment” ratio of all mice in the normal PBS control group.
  • iii) Serum Hepatitis B e-Antigen (HBeAg) Levels:
  • HBeAg analysis was performed with the HBeAg enzyme linked immunosorbent assay (ELISA) as described by the manufacturer (DiaSorin) using serum diluted 4- to 20-fold in 5% nonfat dry milk. The amount of antigen was determined in the linear range of the assay and quantitated against HBeAg protein standards (Fitzgerald Industries International, catalog #30-AH18, Acton, Mass.).
  • HBeAg expression for each animal was normalized to the control group of mice injected with PBS in order to account for the non-treatment related decline in expression of MC-HBV1.3. For evaluation of HBeAg in serum, HBeAg is analyzed from pooled group or subgroup serum samples. First, the HBeAg level for each pooled group or subgroup was divided by the pre-treatment level of expression in the same group or subgroup in order to determine the ratio of expression “normalized to pre-treatment”. Expression at a specific time point was then normalized to the control group by dividing the “normalized to pre-treatment” ratio for a group or subgroup by the average “normalized to pre-treatment” ratio of all samples from the normal PBS control group.
  • iv) Serum HBV DNA Levels:
  • Equal volumes of serum from mice in a group or subgroup were pooled to a final volume of 100 μL. DNA was isolated from serum samples using the QIAamp MinElute Virus Spin Kit (Qiagen, Valencia, Calif.) following the manufacturer's instructions. Sterile 0.9% saline was added to each sample to a final volume of 200 μL. Serum samples were added to tubes containing buffer and protease. Carrier RNA was added to aid in the isolation of small amounts of DNA. 1 ng of pHCR/UbC-SEAP plasmid DNA (Wooddell C I, et al. “Long-term RNA interference from optimized siRNA expression constructs in adult mice.” Biochem Biophys Res Commun (2005) 334, 117-127) was added as a recovery control. After incubating 15 min at 56° C., nucleic acids were precipitated from the lysates with ethanol and the entire solution applied to a column. After washing, the samples were eluted into a volume of 50 μL Buffer AVE.
  • The number of copies of HBV genomes in DNA isolated from the pHBV mouse model serum was determined by qPCR. Plasmid pSEAP-HBV353-777, encoding a short segment of the HBV genome within the S gene (bases 353-777 of GenBank accession #V01460), was used to create a six log standard curve. Samples with recovery of DNA below 2 standard deviations from the average, based on detection of pHCR/UbC-SEAP were omitted. TaqMan chemistry-based primers and probes with fluor/ZEN/IBFQ are utilized.
  • qPCR assays were performed on a 7500 Fast or StepOne Plus Real-Time PCR system (Life Technologies). For evaluation of HBV DNA in serum, DNA was isolated from singlet or duplicate purification steps from pooled group serum samples. Quantitations of HBV DNA and recovery control plasmid were determined by qPCR reactions performed in triplicate. The probes to quantitate HBV and pHCR/UbC-SEAP were included in each reaction.
    • Example 3. HBV RNAi Agents in pHBV Model Mice
  • The pHBV mouse model described in Example 2, above, was used. At day 1, each mouse was administered a single subcutaneous injection of 200 μl containing 2 mg/kg (mpk) of an HBV RNAi agent formulated in phosphate buffered saline (“PBS”), or 200 μl of phosphate buffered saline without an HBV RNAi agent, to be used as a control. Each of the HBV RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5′-terminal end of the sense strand, as shown in Tables 4 and 5. The HBV RNAi agents tested included those having the duplex numbers shown in Table 7, below. The injections were performed between the skin and muscle (i.e. subcutaneous injections) into the loose skin over the neck and shoulder area. Three (3) mice in each group were tested (n=3).
  • Serum was collected on day 8, day 15, day 22, and day 29, and serum Hepatitis B surface antigen (HBsAg) levels were determined pursuant to the procedure set forth in Example 2, above. Data from the experiment is shown in the following Table:
  • TABLE 7
    Average HBsAg levels normalized to pre-treatment and PBS control in pHBV mice
    following administration of HBV RNAi agents from Example 3 (standard deviation
    reflected as (+/−)).
    Group Day 8 Day 15 Day 22 Day 29
    PBS 1.000 ± 0.185 1.000 ± 0.288 1.000 ± 0.540 1.000 ± 0.326
    AD04178 0.164 ± 0.043 0.206 ± 0.044 0.293 ± 0.050 0.348 ± 0.099
    AD04579 0.083 ± 0.028 0.099 ± 0.022 0.112 ± 0.022 0.138 ± 0.056
    AD04580 0.048 ± 0.007 0.073 ± 0.012 0.085 ± 0.012 0.126 ± 0.014
    AD04570 0.241 ± 0.076 0.294 ± 0.071 0.276 ± 0.068 0.474 ± 0.092
    AD04572 0.190 ± 0.040 0.279 ± 0.011 0.323 ± 0.049 0.441 ± 0.046
    AD04573 0.333 ± 0.143 0.505 ± 0.106 0.361 ± 0.060 0.444 ± 0.068
    AD04574 0.291 ± 0.032 0.650 ± 0.056 0.388 ± 0.048 0.485 ± 0.070
    AD04575 0.397 ± 0.189 0.514 ± 0.234 0.574 ± 0.204 0.689 ± 0.207
    AD04419 0.262 ± 0.038 0.174 ± 0.042 0.258 ± 0.064 0.311 ± 0.089
    AD04578  0.21 ± 0.056 0.235 ± 0.033 0.298 ± 0.035 0.336 ± 0.049
  • RNAi agents AD04178, AD04579, AD04580, AD04570, AD04572, AD04573, AD04574, AD04575, AD04419, and AD04578 were each designed to have antisense strand sequences at least partially complementary to the X open reading frame at positions 1781-1789 of the HBV genome shown in Tables 1 and 2, above. Each of the HBV RNAi agents showed substantial reduction in HBsAg as compared to the PBS control across all measured time points. For example, AD04580 showed greater than 95% reduction in s-antigen levels at day 8 (0.048±0.007 HBsAg level) when normalized to pre-treatment and PBS control.
  • Additionally, serum HBV DNA levels were determined for the PBS, AD04579, and AD04580 groups from serum samples collected on days 8, 15, 22, 29, 36, 43 and 50, pursuant to the procedure set forth in Example 2, above. Serum from each group was pooled and then DNA was isolated from the serum in duplicate isolations. Data are presented in the following Table:
  • TABLE 8
    Average Serum HBV DNA levels normalized to pre-treatment and PBS control in
    pHBV mice following administration of HBV RNAi agents from Example 3 (standard
    deviation reflected as (+/−)).
    Group Day 8 Day 15 Day 22 Day 29
    PBS 1.0000 ± 0.1185 1.0000 ± 0.0591 1.0000 ± 0.0322 1.0000 ± 0.0597
    AD04579 0.1541 ± 0.0070 0.1776 ± 0.0027 0.1810 ± 0.0450 0.3738 ± 0.0302
    AD04580 0.0921 ± 0.0253 0.0869 ± 0.0117 0.1444 ± 0.0755 0.0950 ± 0.0026
    Group Day 36 Day 43 Day 50
    PBS 1.0000 ± 0.1625 1.0000 ± 0.0055 1.0000 ± 0.1484
    AD04579 0.9670 ± 0.1247 0.7643 ± 0.1334 0.6299 ± 0.1319
    AD04580 0.4949 ± 0.0096 0.4350 ± 0.0344 0.6819 ± 0.0266
  • The data in Table 8 indicate that both RNAi agents examined provided a substantial reduction in HBV DNA levels compared to the PBS group, with AD04580 achieving slightly greater than 1 log knockdown at nadir (e.g., 0.0869±0.0117 average serum DNA level at day 15).
    • Example 4. HBV RNAi Agents in pHBV Model Mice
  • The pHBV mouse model described in Example 2, above, was used. At day 1, each mouse was given a single subcutaneous administration of 200 μl containing 2 mg/kg (mpk) of an HBV RNAi agent formulated in phosphate buffered saline, or 200 μl of phosphate buffered saline without an HBV RNAi agent to be used as a control. Each of the HBV RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5′-terminal end of the sense strand, as shown in Tables 4 and 5. The HBV RNAi agents administered included those listed in Table 9, below. The injections were performed between the skin and muscle (i.e. subcutaneous injections) into the loose skin over the neck and shoulder area. Three (3) mice in each group were tested (n=3).
  • Serum was collected on day 8, day 15, day 22, and day 29, and serum Hepatitis B surface antigen (HBsAg) levels were determined pursuant to the procedure set forth in Example 2, above. Data from the experiment is shown in the following Table:
  • TABLE 9
    Average HBsAg levels normalized to pre-treatment and PBS control in pHBV mice
    following administration of HBV RNAi agents from Example 4 (standard deviation
    reflected as (+/−)).
    Group Day 8 Day 15 Day 22 Day 29
    PBS 1.000 ± 0.085 1.000 ± 0.235 1.000 ± 0.171 1.000 ± 0.099
    AD04010 0.229 ± 0.141 0.165 ± 0.091 0.142 ± 0.085 0.116 ± 0.076
    AD04581 0.379 ± 0.042 0.221 ± 0.066 0.135 ± 0.040 0.112 ± 0.050
    AD04591 0.285 ± 0.101 0.145 ± 0.064 0.086 ± 0.024 0.081 ± 0.026
    AD04434 0.295 ± 0.041 0.191 ± 0.008 0.147 ± 0.016 0.187 ± 0.049
    AD04583 0.488 ± 0.018 0.545 ± 0.037 0.511 ± 0.086 0.663 ± 0.112
    AD04584 0.392 ± 0.136 0.337 ± 0.073 0.364 ± 0.075 0.515 ± 0.155
    AD04585 0.099 ± 0.016 0.042 ± 0.014 0.030 ± 0.009 0.044 ± 0.014
    AD04586 0.222 ± 0.056 0.107 ± 0.034 0.074 ± 0.016 0.106 ± 0.039
    AD04588 0.255 ± 0.065 0.205 ± 0.021 0.185 ± 0.021 0.207 ± 0.024
    AD04438 0.265 ± 0.106 0.113 ± 0.045 0.091 ± 0.031 0.130 ± 0.038
  • RNAi agents AD04010, AD04581, AD04591, AD04434, AD04583, AD04584, AD04585, AD04586, AD04588, and AD04438 were designed to have antisense strand sequences that are at least partially complementary to the S open reading frame at positions 257-275 of the HBV genome, as shown in Tables 1 and 2. The HBV RNAi agents shown in Table 9, directly above, each showed substantial reduction in HBsAg as compared to the PBS control across all measured time points. For example, AD04585 exhibited approximately a 900/o reduction of HBsAg at day 8, a 95% reduction at day 15, a 97% reduction at day 22, and a 95% reduction at day 29.
  • Additionally, serum HBV DNA levels were determined for the PBS, AD04585 groups from serum samples collected on days 8, 15, 22, 29, 36, 43 and 50, pursuant to the procedure set forth in Example 2, above. Serum from each group was pooled and then DNA was isolated from the serum in duplicate isolations. Data are presented in the following Table:
  • TABLE 10
    Average Serum HBV DNA levels normalized to pre-treatment and
    PBS control in pHBV mice following administration of HBV RNAi
    agents from Example 4 (standard deviation reflected as (+/−)).
    Group Day 8 Day 15 Day 22 Day 29
    PBS 1.000 ± 0.248 1.000 ± 0.089 1.000 ± 0.195 1.000 ±
    0.180
    AD04585 0.901 ± 0.183 0.225 ± 0.003 0.187 ± 0.023 0.191 ±
    0.004
    Group Day 36 Day 43 Day 50
    PBS 1.000 ± 0.018 1.000 ± 0.033 1.000 ± 0.778
    AD04585 0.209 ± 0.017 0.171 ± 0.019 0.305 ± 0.010
  • The data in Table 10 indicates that HBV RNAi agent AD04585 provided a reduction in HBV DNA levels compared to the PBS group.
    • Example 5. Dose Response and Combinations of HBV RNAI Agents in pHBV Model Mice
  • The pHBV mouse model described in Example 2, above, was used. The mice were divided into various groups including those set forth in Table 11, below, and the mice were given 200 μl subcutaneous injections pursuant to the dosing regimen set forth in Table 11:
  • TABLE 11
    Dosing groups of pHBV mice for Example 5.
    Group RNAi Agent and Dose Dosing Regimen
    A PBS (no RNAi agent) Single injection on day 1
    B 3.0 mg/kg AD04585 Single injection on day 1
    C 3.0 mg/kg AD04585 Injection on day 1, day 8, and day 15
    (i.e., three weekly injections)
    D 3.0 mg/kg AD04580 Single injection on day 1
    E 3.0 mg/kg AD04580 Injection on day 1, day 8, and day 15
    (i.e., three weekly injections)
    F 1.0 mg/kg AD4585 + Injection on day 1, and another injection
    1.0 mg/kg AD04580 on day 22
    G 1.0 mg/kg AD4585 + Injection on day 1, day 8, day 15,
    1.0 mg/kg AD04580 and day 43
    H 1.5 mg/kg AD4585 + Injection on day 1, day 22, and day 43
    1.5 mg/kg AD04580
    I 1.5 mg/kg AD4585 + Injection on day 1, day 8, day 15,
    1.5 mg/kg AD04580 and day 43
  • Each mouse was given a subcutaneous administration of 200 μl containing the amount of HBV RNAi agent(s) formulated in phosphate buffered saline, or 200 μl of phosphate buffered saline without an HBV RNAi agent, as set forth in Table 11. Each of the HBV RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5′-terminal end of the sense strand, as shown in Tables 4 and 5. The injections were performed between the skin and muscle (i.e. subcutaneous injections) into the loose skin over the neck and shoulder area. Three (3) mice in each group were tested (n=3).
  • Serum was collected on day 8, day 15, day 22, day 29, day 36, day 43, day 50, and day 57, and serum Hepatitis B surface antigen (HBsAg) levels were determined pursuant to the procedure set forth in Example 2, above. Data from the experiment is shown in the following Table:
  • TABLE 12
    Average HBsAg levels normalized to pre-treatment and PBS control in pHBV
    mice following administration of HBV RNAi agents from Example 5 (standard deviation
    reflected as (+/−)).
    Group Day 8 Day 15 Day 22 Day 29
    A 1.000 ± 0.162 1.000 ± 0.138 1.000 ± 0.083 1.000 ± 0.204
    B 0.060 ± 0.015 0.010 ± 0.003 0.006 ± 0.002 0.007 ± 0.002
    C 0.087 ± 0.014 0.004 ± 0.001  0.001 ± 0.0003 0.0002 ± 0.0001
    D 0.026 ± 0.009 0.035 ± 0.013 0.037 ± 0.014 0.046 ± 0.006
    E 0.023 ± 0.005 0.002 ± 0.001  0.001 ± 0.0003  0.001 ± 0.0004
    F 0.063 ± 0.046 0.083 ± 0.051 0.086 ± 0.016 0.027 ± 0.006
    G 0.062 ± 0.011 0.022 ± 0.008 0.009 ± 0.003 0.008 ± 0.002
    H 0.055 ± 0.015 0.062 ± 0.002 0.072 ± 0.013 0.011 ± 0.001
    I 0.031 ± 0.006 0.008 ± 0.001  0.003 ± 0.0004  0.003 ± 0.0003
    Group Day 36 Day 43 Day 50 Day 57
    A 1.000 ± 0.211 1.000 ± 0.189 1.000 ± 0.179 1.000 ± 0.062
    B 0.013 ± 0.005 0.027 ± 0.004 0.026 ± 0.004 0.057 ± 0.012
    C  0.001 ± 0.0002 0.002 ± 0.001 0.008 ± 0.004 0.020 ± 0.015
    D 0.116 ± 0.019 0.214 ± 0.056 0.263 ± 0.046 0.404 ± 0.030
    E  0.003 ± 0.0001 0.007 ± 0.001 0.012 ± 0.002 0.033 ± 0.011
    F 0.029 ± 0.003 0.065 ± 0.005 0.064 ± 0.004 0.161 ± 0.033
    G 0.014 ± 0.008 0.039 ± 0.011 0.018 ± 0.008 0.046 ± 0.008
    H 0.017 ± 0.005 0.039 ± 0.008 0.007 ± 0.001 0.013 ± 0.003
    I 0.007 ± 0.001 0.020 ± 0.002 0.005 ± 0.001 0.011 ± 0.002
  • HBV RNAi agents AD04580 and AD04585 each individually showed a reduction in HBsAg as compared to the PBS control across all measured time points. Furthermore, combination treatment of AD04585 and AD04580, which as noted in the Examples above target different regions of the HBV genome, also showed reduction in HBsAg as compared to the PBS control across all measured time points.
  • Additionally, serum HBV DNA levels were determined for each of the groups in Table 11 from serum samples collected on days 8, 15, 22, 29, and 36, pursuant to the procedure set forth in Example 2, above. Serum from each group was pooled and then DNA was isolated from the serum in duplicate reactions. Data are presented in the following Table:
  • TABLE 13
    Average Serum HBV DNA levels normalized to pre-treatment and PBS control in
    pHBV mice following administration of HBV RNAi agents from Example 5 (standard
    deviation reflected as (+/−))
    Group Day 8 Day 15 Day 22 Day 29 Day 36
    A 1.000 ± 0.063 1.000 ± 0.059 1.000 ± 0.372 1.000 ± 0.237 1.000 ± 0.024
    B 0.267 ± 0.003 0.043 ± 0.016 0.038 ± 0.008 0.044 ± 0.004 0.046 ± 0.007
    C 0.236 ± 0.016 0.023 ± 0.001 0.004 ± 0.001 0.002 ± 0.000 0.003 ± 0.000
    D 0.058 ± 0.016 0.085 ± 0.017 0.252 ± 0.071 0.217 ± 0.009 0.319 ± 0.034
    E 0.056 ± 0.002 0.0009 ± 0.0004 0.0005 ± 0.0002 0.003 ± 0.002 0.002 ± 0.000
    F 0.298 ± 0.013 0.351 ± 0.032 0.823 ± 0.127 0.217 ± 0.007 0.122 ± 0.004
    G 0.276 ± 0.035 0.112 ± 0.020 0.061 ± 0.002 0.073 ± 0.002 0.047 ± 0.006
    H 0.232 ± 0.012 0.213 ± 0.028 0.403 ± 0.047 0.079 ± 0.005 0.056 ± 0.003
    I 0.092 ± 0.026 0.055 ± 0.000 0.002 ± 0.003 0.010 ± 0.004 0.021 ± 0.007
  • The data in Table 13 indicate that the RNAi agents examined, both individually and in combination, provided a reduction in HBV DNA levels compared to the PBS group. Re-dosing or increasing the dose amount yielded additional HBV DNA reductions.
    • Example 6. HBV RNAI Agents in pHBV Mice: Dose Response and Combination Studies
  • The pHBV mouse model described in Example 2, above, was used. Mice were divided into various groups as set forth in Table 14, below, and each mouse was administered a single 200 μl subcutaneous injection pursuant to the dosing regimen set forth in Table 14:
  • TABLE 14
    Dosing groups of pHBV mice for Example 6.
    Group RNAi Agent and Dose Dosing Regimen
    A PBS (no RNAi agent) Single injection on day 1
    B 4.0 mg/kg AD04981 Single injection on day 1
    C 1.0 mg/kg AD04981 Single injection on day 1
    D 2.0 mg/kg AD04981 Single injection on day 1
    E 1.0 mg/kg AD04963 Single injection on day 1
    F 2.0 mg/kg AD04963 Single injection on day 1
    G 3.0 mg/kg AD04872 Single injection on day 1
    H 3.0 mg/kg AD04872 + Single injection on day 1
    1.0 mg/kg AD04981
    I 3.0 mg/kg AD04872 + Single injection on day 1
    1.0 mg/kg AD04963
    J 3.0 mg/kg AD04872 + Single injection on day 1
    2.0 mg/kg AD04981
  • Each mouse was given a subcutaneous administration of 200 μl containing the amount of HBV RNAi agent(s) formulated in phosphate buffered saline, or 200 μl of phosphate buffered saline without an HBV RNAi agent, as set forth in Table 14. Each of the HBV RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5′-terminal end of the sense strand, as shown in Tables 4 and 5. The injections were performed between the skin and muscle (i.e. subcutaneous injections) into the loose skin over the neck and shoulder area. Three (3) mice in each group were tested (n=3).
  • Serum was collected on day −1 prior to administration, and then on day 8, day 15, day 22, day 29, and day 36, and serum HBsAg levels were determined pursuant to the procedure set forth in Example 2, above. Data from the experiment is shown in the following Table 15, with Average HBsAg reflecting the normalized average value of HBsAg:
  • TABLE 15
    Average HBsAg levels normalized to pre-treatment and PBS control
    in pHBV mice following administration of HBV RNAi agents from
    Example 6 (standard deviation reflected as (+/−)).
    Group Day 8 Day 15 Day 22
    A 1.000 ± 0.068 1.000 ± 0.183 1.000 ± 0.181
    B 0.085 ± 0.020 0.068 ± 0.005 0.089 ± 0.014
    C 0.283 ± 0.039 0.343 ± 0.055 0.436 ± 0.004
    D 0.161 ± 0.052 0.137 ± 0.036 0.190 ± 0.068
    E 0.182 ± 0.040 0.233 ± 0.023 0.436 ± 0.029
    F 0.078 ± 0.024 0.093 ± 0.015 0.167 ± 0.028
    G 0.066 ± 0.030 0.013 ± 0.002 0.010 ± 0.002
    H 0.033 ± 0.012 0.016 ± 0.005 0.020 ± 0.005
    I 0.040 ± 0.011 0.028 ± 0.003 0.032 ± 0.007
    J 0.035 ± 0.010 0.019 ± 0.002 0.021 ± 0.001
    Group Day 29 Day 36
    A 1.000 ± 0.032 1.000 ± 0.141
    B 0.148 ± 0.016 0.194 ± 0.047
    C 0.622 ± 0.041 0.741 ± 0.132
    D 0.234 ± 0.055 0.280 ± 0.071
    E 0.623 ± 0.116 0.782 ± 0.114
    F 0.259 ± 0.014 0.368 ± 0.068
    G 0.010 ± 0.003 0.009 ± 0.004
    H 0.022 ± 0.005 0.024 ± 0.009
    I 0.065 ± 0.014 0.087 ± 0.015
    J  0.031 ± 0.0001 0.044 ± 0.002
  • The HBV RNAi agents tested showed a reduction in HBsAg as compared to the PBS control across all measured time points. Furthermore, combination treatment of AD04872 (which includes an antisense strand sequence that is at least partially complementary to the S ORF at positions 261-279 of the HBV genome, as shown in Tables 1 and 2) and either AD04981 or AD04963 (both of which include antisense strand sequences that are at least partially complementary to the X ORF at positions 1781-1799 of the HBV genome, as shown in Tables 1 and 2), which are shown in Groups H, I, and J of Example 6, illustrate that combination treatment of two RNAi agents targeting, one which targets in the S ORF, and the other which targets in the X ORF of the HBV genome, similarly showed reduction in HBsAg compared to the PBS control across all measured time points.
  • Additionally, Serum Hepatitis B e-antigen (HBeAg) levels were also assessed. Samples from the mice in each respective group were first pooled, and the resulting serum samples were assayed in singlet. Data from the experiment is shown in the following Table:
  • TABLE 16
    Average HBeAg levels normalized to pre-treatment and PBS control
    in pHBV mice following administration of HBV RNAi agents
    from Example 6.
    Group Day 8 Day 15 Day 22 Day 29 Day 36
    A 1.000 1.000 1.000 0.183 1.000
    B 0.138 0.180 0.274 0.005 0.089
    C 0.316 0.376 0.588 0.055 0.436
    D 0.167 0.250 0.262 0.036 0.190
    E 0.301 0.327 0.447 0.023 0.436
    F 0.167 0.172 0.305 0.015 0.167
    G 0.275 0.135 0.158 0.002 0.010
    H 0.080 0.053 0.094 0.005 0.020
    I 0.165 0.124 0.185 0.003 0.032
    J 0.120 0.057 0.101 0.002 0.021
  • As shown in Table 16, the combination AD04872 (which targets the S ORF of the HBV genome) with either AD04981 or AD04963 (both of which target the X ORF of the HBV genome), showed a further reduction in HBeAg levels relative to administering AD04872 alone.
    • Example 7. HBV RNAi Agents in pHBV Mice: Additional Dose Response and Combination Studies
  • The pHBV mouse model described in Example 2, above, was used. Mice were divided into various groups as set forth in Table 17, below, and each mouse was administered a single 200 μl subcutaneous injection pursuant to the dosing regimen set forth in Table 17:
  • TABLE 17
    Dosing groups of pHBV mice for Example 7.
    Group RNAi Agent and Dose Dosing Regimen
    A PBS (no RNAi agent) Single injection on day 1
    B 4.0 mg/kg AD04776 Single injection on day 1
    C 1.0 mg/kg AD04982 Single injection on day 1
    D 2.0 mg/kg AD04982 Single injection on day 1
    E 1.0 mg/kg AD04776 Single injection on day 1
    F 2.0 mg/kg AD04776 Single injection on day 1
    G 3.0 mg/kg AD04872 Single injection on day 1
    H 3.0 ma/kg AD04872 + Single injection on day 1
    1.0 mg/kg AD04982
    I 3.0 mg/kg AD04872 + Single injection on day 1
    2.0 mg/kg AD04982
  • Each mouse was given a subcutaneous administration of 200 μl containing the amount of HBV RNAi agent(s) formulated in phosphate buffered saline, or 200 μl of phosphate buffered saline without an HBV RNAi agent, as set forth in Table 17. Each of the HBV RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5′-terminal end of the sense strand, as shown in Tables 4 and 5. The injections were performed between the skin and muscle (i.e. subcutaneous injections) into the loose skin over the neck and shoulder area. Four (4) mice in each group were tested on day −1 and day 8 (n=4), and then one mouse per group was euthanized for histological evaluation. Three (3) mice in each group were tested at day 22 and day 29 (n=3).
  • Serum was collected on day −1 prior to administration, and then on day 8, day 15, day 22, and day 29, and serum Hepatitis B surface antigen (HBsAg) levels were determined pursuant to the procedure set forth in Example 2, above. Data from the experiment is shown in the following Table 18:
  • TABLE 18
    Average HBsAg levels normalized to pre-treatment (day −1) and
    PBS control in pHBV mice following administration of HBV RNAi
    agents from Example 7 (standard deviation reflected as (+/−)).
    Group Day 8 Day 15 Day 22 Day 29
    A 1.000 ± 0.347 1.000 ± 0.278 1.000 ± 0.194 1.000 ±
    0.318
    B 0.117 ± 0.069 0.085 ± 0.039 0.148 ± 0.045 0.198 ±
    0.049
    C 0.519 ± 0.058 0.375 ± 0.012 0.422 ± 0.046 0.525 ±
    0.037
    D 0.342 ± 0.062 0.255 ± 0.046 0.272 ± 0.122 0.314 ±
    0.068
    E 0.279 ± 0.057 0.245 ± 0.032 0.374 ± 0.121 0.304 ±
    0.035
    F 0.224 ± 0.018 0.161 ± 0.009 0.310 ± 0.016 0.482 ±
    0.053
    G 0.029 ± 0.010 0.005 ± 0.001 0.004 ± 0.001 0.006 ±
    0.001
    H 0.016 ± 0.005 0.004 ± 0.001 0.010 ± 0.006 0.015 ±
    0.008
    I 0.026 ± 0.012 0.008 ± 0.001 0.010 ± 0.002 0.015 ±
    0.005
  • The HBV RNAi agents tested showed a reduction in HBsAg as compared to the PBS control across all measured time points.
  • Additionally, Serum Hepatitis B e-antigen (HBeAg) levels were also assessed. Samples from the mice in each respective group were first pooled, and the resulting serum samples were assayed in singlet. Data from the experiment is shown in the following Table:
  • TABLE 19
    Average HBeAg levels normalized to pre-treatment and PBS
    control in pHBV mice following administration of HBV RNAi
    agents from Example 7.
    Group Day 8 Day 15 Day 22 Day 29 Day 36
    A 1.000 1.000 1.000 1.000 1.000
    B 0.193 0.213 0.260 0.307 0.464
    C 0.471 0.424 0.562 0.513 0.705
    D 0.335 0.310 0.411 0.442 0.500
    E 0.381 0.368 0.355 0.564 0.483
    F 0.275 0.255 0.370 0.495 0.449
    G 0.323 0.218 0.205 0.250 0.190
    H 0.124 0.102 0.099 0.156 0.156
    I 0.081 0.059 0.045 0.063 0.086
  • TABLE 19-1
    Average HBeAg fold knockdown normalized to pre-treatment and
    PBS control in pHBV mice following administration of HBV
    RNAi agents from Example 7.
    Day 8 Day 15 Day 22 Day 29 Day 36
    Group (Fold KD) (Fold KD) (Fold KD) (Fold KD) (Fold KD)
    A 1.0 1.0 1.0 1.0 1.0
    B 5.2 4.7 3.8 3.3 2.2
    C 2.1 2.4 1.8 2.0 1.4
    D 3.0 3.2 2.4 2.3 2.0
    E 2.6 2.7 2.8 1.8 2.1
    F 3.6 3.9 2.7 2.0 2.2
    G 3.1 4.6 4.9 4.0 5.3
    H 8.1 9.8 10.1 6.4 6.4
    I 12.3 17.0 22.3 15.7 11.6
  • Table 19-1 reflects the fold knockdown ratio of HBeAg compared to control, which is calculated as normalized HBeAg level of the control (PBS) group/normalized HBeAg level of the respected RNAi agent(s) group (i.e., 1.000/HBeAg level). The data in Table 19-1 indicate that the combination of AD04872 (which, as noted above, includes an antisense strand sequence that is at least partially complementary to the S ORF at positions 261-279 of the HBV genome) with AD04982 (which includes an antisense strand sequence that is at least partially complementary to the X ORF at positions 1781-1799 of the HBV genome), showed a further reduction in HBeAg levels relative to administering the individual RNAi agents alone (See. e.g., Tables 19 and 19-1 for Groups H and I). Further, the data from this Example also show that the combination of AD04872 with AD04982 resulted in fold decrease of HBeAg greater than the sum of the fold decrease of HBeAg in AD04872 and AD04982 administered individually. For example, Group I (which is the administration of 3.0 mg/kg AD04872+2.0 mg/kg AD04982) resulted in a fold decrease of HBeAg at day 15 of 17.0, which is greater than the sum of the fold decrease for Group G (3.0 mg/kg AD04872) of 4.6 plus the fold decrease for Group D (2.0 mg/kg AD04982) of 3.2.
  • Further, serum HBV DNA levels were determined for each of the groups in Table 17 from serum samples collected on days −1, 8, 15, 22, 29, and 36, pursuant to the procedure set forth in Example 2, above. Serum HBV DNA was isolated from each animal at each time point. Data are presented in the following Table:
  • TABLE 20
    Average Serum HBV DNA levels normalized to pre-treatment and PBS control in
    pHBV mice following administration of HBV RNAi agents from Example 7
    (standard deviation reflected as (+/−)).
    Group Day 8 Day 15 Day 22 Day 29 Day 36
    A 1.000 ± 0.493 1.000 ± 0.358 1.000 ± 0.424 1.000 ± 0.387 1.000 ± 0.326
    B 0.224 ± 0.150 0.263 ± 0.185 0.335 ± 0.204 0.449 ± 0.108 0.603 ± 0.068
    C 0.358 ± 0.207 0.428 ± 0.073 0.433 ± 0.220 0.474 ± 0.090 0.509 ± 0.163
    D 0.516 ± 0.163 0.523 ± 0.264 0.244 ± 0.123 0.241 ± 0.085 0.543 ± 0.079
    E 0.601 ± 0.388 0.319 ± 0.125 0.279 ± 0.138 0.506 ± 0.525 0.444 ± 0.407
    F 0.363 ± 0.128 0.374 ± 0.197 0.275 ± 0.146 0.385 ± 0.141 0.721 ± 0.043
    G 0.071 ± 0.032 0.022 ± 0.009 0.015 ± 0.015 0.025 ± 0.005 0.058 ± 0.030
    H 0.069 ± 0.070 0.018 ± 0.014 0.019 ± 0.020 0.022 ± 0.001 0.047 ± 0.021
    I 0.044 ± 0.024 0.033 ± 0.016 0.017 ± 0.012 0.022 ± 0.014 0.058 ± 0.051
  • The data in Table 20 indicate that the RNAi agents examined, both individually and in combination, provided a reduction in HBV DNA levels compared to the PBS group, and further show that the combination of AD04872 (which targets the S ORF) and AD04982 (which targets the X ORF) reduces serum HBV DNA to a similar degree as an equal amount of AD04872 alone.
    • Example 8. HBV RNAI Agents in pHBV Mice: Further Dose Response and Combination Studies
  • The pHBV mouse model described in Example 2, above, was used. Mice were divided into various groups as set forth in Table 21, below, and each mouse was administered a single 200 μl subcutaneous injection pursuant to the dosing regimen set forth in Table 21:
  • TABLE 21
    Dosing groups of pHBV mice for Example 8.
    Number of
    Group RNAi Agent and Dose Dosing Regimen Animals (n)
     1 PBS (no RNAi agent) Single injection on day 1 4
     2A 4.0 mg/kg AD04872 + Single injection on day 1 4
    1.0 mg/kg AD05070
     2B 4.0 mg/kg AD04872 + Single injection on day 1 4
    1.0 mg/kg AD05070
     3A 3.3 mg/kg AD04872 + Single injection on day 1 4
    1.7 mg/kg AD05070
     3B 3.3 mg/kg AD04872 + Single injection on day 1 4
    1.7 mg/kg AD05070
     4A 3.2 mg/kg AD04872 + Single injection on day 1 4
    0.8 mg/kg AD05070
     4B 3.2 mg/kg AD04872 + Single injection on day 1 4
    0.8 mg/kg AD05070
     5A 2.7 mg/kg AD04872 + Single injection on day 1 4
    1.3 mg/kg AD05070
     5B 2.7 mg/kg AD04872 + Single injection on day 1 4
    1.3 mg/kg AD05070
     6A 4.0 mg/kg AD05070 Single injection on day 1 4
     6B 4.0 mg/kg AD05070 Single injection on day 1 4
     7A 1.7 mg/kg AD05070 Single injection on day 1 4
     7B 1.7 mg/kg AD05070 Single injection on day 1 4
     8A 0.8 mg/kg AD05070 Single injection on day 1 4
     8B 0.8 mg/kg AD05070 Single injection on day 1 4
     9 1.7 mg/kg AD05148 Single injection on day 1 4
    10 2.7 mg/kg AD04872 Single injection on day 1 3
    11 1.7 mg/kg AD05147 Single injection on day 1 3
    12 4.0 mg/kg AD04872 Single injection on day 1 3
    13 1.7 mg/kg AD05149 Single injection on day 1 3
  • Additionally, the mice are scheduled to be euthanized pursuant to the following schedule:
      • Day 11: Euthanize 2 mice from groups 2A, 3A, 4A, 5A, 6A, 7A and 8A, and euthanize one mouse from group 9.
      • Day 14: Euthanize 2 mice from groups 2A, 3A, 4A, 5A, 6A, 7A, and 8A.
      • Day 21: Euthanize 2 mice from groups 2B, 3B, 4B, 5B, 6B, 7B, and 8B.
      • Day 28: Euthanize 2 mice from groups 1, 2B, 3B, 4B, 5B, 6B, 7B, and 8B, and all mice (4) from groups 10 and 12.
  • Each mouse was given a subcutaneous administration of 200 μl containing the amount of HBV RNAi agent(s) formulated in phosphate buffered saline, or 200 μl of phosphate buffered saline without an HBV RNAi agent, as set forth in Table 21. Each of the HBV RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5′-terminal end of the sense strand, as shown in Tables 4 and 5. The injections were performed between the skin and muscle (i.e. subcutaneous injections) into the loose skin over the neck and shoulder area. As shown in Table 14 above, four (4) mice in each group were tested (n=4), except for groups 10, 11, 12 and 13, in which three mice were tested (n=3).
  • Serum was collected on day −1 prior to administration, and on days 8, 14, 21 and 28, and serum Hepatitis B surface antigen (HBsAg) levels were determined pursuant to the procedure set forth in Example 2, above. Data from the experiment is shown in the following Table:
  • TABLE 22
    Average HBsAg levels normalized to pre-treatment and PBS control in pHBV
    mice following administration of HBV RNAi agents from Example 8
    (standard deviation reflected as (+/−)).
    Group
    Number Day 8 Day 14 Day 21 Day 28
     1 1.000 ± 0.089 1.000 ± 0.087 1.000 ± 0.132 1.000 ± 0.138
     2A 0.009 ± 0.003 0.005 ± 0.001
     2B 0.006 ± 0.003 0.002 ± 0.001 0.004 ± 0.001 0.005 ± 0.001
     3A 0.032 ± 0.021 0.009 ± 0.004
     3B 0.028 ± 0.027 0.008 ± 0.006 0.012 ± 0.005 0.015 ± 0.005
     4A 0.036 ± 0.020 0.012 ± 0.006
     4B 0.029 ± 0.025 0.010 ± 0.008 0.015 ± 0.005 0.022 ± 0.004
     5A 0.027 ± 0.014 0.008 ± 0.002
     5B 0.027 ± 0.013 0.007 ± 0.003 0.019 ± 0.004 0.031 ± 0.005
     6A 0.058 ± 0.035 0.069 ± 0.039
     6B 0.117 ± 0.058 0.079 ± 0.047 0.145 ± 0.082 0.135 ± 0.061
     7A 0.189 ± 0.100 0.084 ± 0.029
     7B 0.099 ± 0.010 0.147 ± 0.025 0.267 ± 0.048 0.345 ± 0.063
     8A 0.355 ± 0.099 0.366 ± 0.069
     8B 0.271 ± 0.058 0.334 ± 0.060 0.464 ± 0.055 0.624 ± 0.053
     9 0.239 ± 0.148 0.179 ± 0.127 0.309 ± 0.213 0.345 ± 0.225
    10 0.018 ± 0.009 0.005 ± 0.003 0.005 ± 0.002 0.007 ± 0.003
    11 0.129 ± 0.068 0.138 ± 0.060 0.239 ± 0.092 0.315 ± 0.119
    12 0.033 ± 0.022 0.002 ± 0.001 0.002 ± 0.001  0.002 ± 0.0004
    13 0.200 ± 0.093 0.239 ± 0.114 0.367 ± 0.123 0.477 ± 0.125
  • The HBV RNAi agents tested, both alone and in combination, showed a substantial reduction in HBsAg as compared to the PBS control across all measured time points.
    • Example 9. RNAi Agent Delivery
  • The pHBV mouse model described in Example 2, above, was used. At day 1, each mouse was administered a single subcutaneous injection of 200 μl containing 10 mg/kg (mpk) of an HBV RNAi agent formulated in phosphate buffered saline, or 200 μl of phosphate buffered saline without an HBV RNAi agent, to be used as a control. The HBV RNAi agents tested included those having the duplex numbers shown in Table 23, below, which each included N-acetyl-galactosamine targeting ligands conjugated to the 5′-terminal end of the sense strand, as shown in Tables 4 and 5. The injections were performed between the skin and muscle (i.e. subcutaneous injections) into the loose skin over the neck and shoulder area. Three (3) mice in each group were tested (n=3).
  • Serum was collected prior to administration, and then on day 8, day 15, day 22, and day 29, and serum Hepatitis B surface antigen (HBsAg) levels were determined pursuant to the procedure set forth in Example 2, above. Data from the experiment is shown in the following Table:
  • TABLE 23
    Average HBsAg levels normalized to pre-treatment and PBS
    control in pHBV mice following administration of HBV RNAi
    agents from Example 9 (standard deviation reflected as (+/−)).
    HBsAg in serum
    at nadir Day of
    RNAi agent (norm. fraction) % KD at nadir nadir
    PBS 1.000 N/A N/A
    AD03498 0.087 ± 0.016 91.3% 8
    AD03499 0.069 ± 0.011 93.1% 15
    AD03500 0.095 ± 0.031 90.5% 8
    AD03501 0.046 ± 0.020 95.4% 15
  • Each of the HBV RNAi agents shown in Table 23, above, included an antisense strand sequence that is at least partially complementary to the X ORF at positions 1781-1799 of the HBV genome. Each of the RNAi agents showed a significant knockdown compared to PBS control.
    • Example 10. HBV RNAI Agents in pHBV Mice: Further Combination Studies
  • The pHBV mouse model described in Example 2, above, was used. Mice were divided into various groups as set forth in Table 24, below, and each mouse was administered a single 200 μl subcutaneous injection pursuant to the dosing regimen set forth in Table 24:
  • TABLE 24
    Dosing groups of pHBV mice for Example 10.
    Group RNAi Agent and Dose Dosing Regimen
    A PBS Group I (no RNAi Single injection on day 1 and day 22
    agent)
    B PBS Group II (no RNAi Single injection on day 1 and day 22
    agent)
    C 3.0 mg/kg AD04585 Single injection on day 1, day 22,
    day 50, and day 64
    D 3.0 mg/kg AD04771 Single injection on day 1 and day 22
    E 3.0 mg/kg AD04580 Single injection on day 1, day 22,
    day 50, and day 64
    F 3.0 mg/kg AD04776 Single injection on day 1 and day 22
    G 1.5 mg/kg AD04585 + Single injection on day 1, day 22,
    1.5 mg/kg AD04580 day 50, and day 64
    H 1.5 mg/kg AD04771 + Single injection on day 1 and day 22
    1.5 mg/kg AD04776
    I 2.0 mg/kg AD04771 + Single injection on day 1 and day 22
    1.0 mg/kg AD04776
    J 2.25 mg/kg AD04771 + Single injection on day 1 and day 22
    0.75 mg/kg AD04776
  • Each mouse was given a subcutaneous administration of 200 μl containing the amount of HBV RNAi agent(s) formulated in phosphate buffered saline, or 200 μl of phosphate buffered saline without an HBV RNAi agent, as set forth in Table 24. Each of the HBV RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5′-terminal end of the sense strand, as shown in Tables 4 and 5. The injections were performed between the skin and muscle (i.e. subcutaneous injections) into the loose skin over the neck and shoulder area. Three (3) mice in each group were tested (n=3).
  • Serum was collected prior to administration, and then on day −1, day 8, day 15, day 22, day 29, day 36, day 43, day 50, day 57, and day 64. Serum Hepatitis B surface antigen (HBsAg) levels were determined pursuant to the procedure set forth in Example 2, above. Data from the experiment is shown in the following:
  • TABLE 25
    Average HBsAg levels normalized to pre-treatment and PBS
    control (Group A used as control) in pHBV mice following
    administration of HBV RNAi agents from Example 10
    (standard deviation reflected as (+/−)).
    Group Day 8 Day 15 Day 22
    A 1.000 ± 0.146 1.000 ± 0.095 1.000 ± 0.202
    B 0.931 ± 0.161 1.091 ± 0.156 1.132 ± 0.259
    C 0.071 ± 0.050 0.031 ± 0.022 0.024 ± 0.013
    D 0.134 ± 0.035 0.130 ± 0.024 0.119 ± 0.028
    E 0.015 ± 0.001 0.041 ± 0.012 0.087 ± 0.015
    F 0.197 ± 0.081 0.308 ± 0.138 0.476 ± 0.156
    G 0.029 ± 0.015 0.069 ± 0.029 0.094 ± 0.016
    H 0.191 ± 0.057 0.315 ± 0.094 0.420 ± 0.126
    I 0.153 ± 0.050 0.194 ± 0.076 0.233 ± 0.116
    J 0.155 ± 0.059 0.177 ± 0.067 0.316 ± 0.117
    Group Day 29 Day 36 Day 43
    A 1.000 ± 0.182 1.000 ± 0.287 1.000 ± 0.298
    B 1.417 ± 0.414 1.166 ± 0.248
    C 0.007 ± 0.005 0.004 ± 0.003 0.006 ± 0.001
    D 0.048 ± 0.023 0.036 ± 0.020 0.052 ± 0.027
    E 0.014 ± 0.006 0.021 ± 0.011 0.026 ± 0.011
    F 0.246 ± 0.081 0.244 ± 0.097 0.179 ± 0.061
    G 0.023 ± 0.009 0.027 ± 0.009 0.037 ± 0.013
    H 0.200 ± 0.080 0.185 ± 0.081 0.194 ± 0.055
    I 0.141 ± 0.082 0.133 ± 0.051 0.151 ± 0.082
    J 0.133 ± 0.064 0.102 ± 0.039 0.129 ± 0.050
    Group Day 50 Day 57 Day 64
    A 1.000 ± 0.296 1.000 ± 0.394 1.000 ± 0.395
    B
    C  0.015 ± 0.0001 0.002 ± 0.001 0.004 ± 0.001
    D
    E 0.052 ± 0.015 0.009 ± 0.002 0.018 ± 0.007
    F
    G 0.076 ± 0.020 0.012 ± 0.003 0.020 ± 0.007
    H
    I
    J
  • HBV RNAi agents AD04585 and AD04771 were designed to have antisense strand sequences that are at least partially complementary to the S open reading frame at positions 257-275 of the HBV genome, as shown in Tables 1 and 2. HBV RNAi agents AD04580 and AD04776 were designed to have antisense strand sequences that are at least partially complementary to the X open reading frame at positions 1781-1799 of the HBV genome, as shown in Tables 1 and 2 The HBV RNAi agents tested, both alone and in combination, showed a reduction in HBsAg as compared to the PBS control across all measured time points. Each subsequent dose further reduced the nadir of HBsAg reduction.
  • Additionally, serum HBV DNA levels were determined for Group C (3.0 mg/kg AD04585), Group E (3.0 mg/kg AD04580), and Group G (1.5 mg/kg AD04585+1.5 mg/kg AD04580) in Table 24, from serum samples collected on days −1, 8, 15, 22, 29, and 36, 43 and 50 pursuant to the procedure set forth in Example 2, above. Serum HBV DNA was isolated for each animal at each of these time points. Data are presented in the following Table:
  • TABLE 26
    Average Serum HBV DNA levels normalized to pre-treatment and
    PBS controls (both PBS groups A and B) in pHBV mice following
    administration of HBV RNAi agents from Example 10 (standard
    deviation reflected as (+/−)).
    Group Day 8 Day 15 Day 22 Day 29
    A/B 1.000 ± 0.316 1.000 ± 0.427 1.000 ± 0.428 1.000 ± 0.475
    (PBS)
    C 0.172 ± 0.151 0.142 ± 0.079 0.252 ± 0.132 0.072 ± 0.086
    E 0.024 ± 0.015 0.042 ± 0.037 0.449 ± 0.184 0.053 ± 0.048
    G 0.093 ± 0.053 0.083 ± 0.037 0.370 ± 0.153 0.211 ± 0.060
    Group Day 36 Day 43 Day 50
    A/B 1.000 ± 0.623 1.000 ± 0.532 1.000 ± 0.532
    (PBS)
    C 0.044 ± 0.020 0.104 ± 0.033 0.156 ± 0.016
    E 0.012 ± 0.004 0.061 ± 0.031 0.161 ± 0.019
    G 0.048 ± 0.022 0.147 ± 0.010 0.295 ± 0.041
  • The data in Table 26 indicate that the HBV RNAi agents examined, both individually and in combination, provided a reduction in HBV DNA levels compared to the PBS group.
    • Example 11. HBV RNAi Agents in pHBV Mice: Combination Studies
  • The pHBV mouse model described in Example 2, above, was used. Mice were divided into various groups as set forth in Table 27, below, and each mouse was administered a single 200 μl subcutaneous injection pursuant to the dosing regimen set forth in Table 27:
  • TABLE 27
    Dosing groups of pHBV mice for Example 11.
    Group RNAi Agent and Dose Dosing Regimen
    A PBS (no RNAi agent) Single injection on day 1
    B 3.0 mg/kg AD04962 Single injection on day 1
    C 3.0 mg/kg AD04963 Single injection on day 1
    D 1.5 mg/kg AD04962 + Single injection on day 1
    1.5 mg/kg AD04963
    E 2.0 mg/kg AD04962 + Single injection on day 1
    1.0 mg/kg AD04963
    F 2.25 mg/kg AD04962 + Single injection on day 1
    0.75 mg/kg AD04963
    G 1.5 mg/kg AD04962 + Single injection on day 1
    1.5 mg/kg AD04963
    H 3.0 mg/kg AD04962 + Single injection on day 1
    3.0 mg/kg AD04963
    I 1.5 mg/kg AD04962 + Single injection on day 1
    1.5 mg/kg AD04963
    J 4.5 mg/kg AD04962 + Single injection on day 1
    4.5 mg/kg AD04963
    K 3.0 mg/kg AD04872 Single injection on day 1
    L 3.0 mg/kg AD04882 Single injection on day 1
    M 3.0 mg/kg AD04885 Single injection on day 1
  • Each mouse was given a subcutaneous administration of 200 μl containing the amount of HBV RNAi agent(s) formulated in phosphate buffered saline, or 200 μl of phosphate buffered saline without an HBV RNAi agent, as set forth in Table 24. Each of the HBV RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5′-terminal end of the sense strand, as shown in Tables 4 and 5. The injections were performed between the skin and muscle (i.e. subcutaneous injections) into the loose skin over the neck and shoulder area. Three (3) mice in each group were tested (n=3).
  • Serum was collected on day −1 prior to administration, and then on day 8, day 15, day 22, day 29, and day 36 (except for Group L (AD04882) and Group M (AD04885), and serum Hepatitis B surface antigen (HBsAg) levels were determined pursuant to the procedure set forth in Example 2, above. Data from the experiment is shown in the following Table:
  • TABLE 28
    Average HBsAg normalized to pre-treatment and PBS control
    in pHBV mice following administration of HBV RNAi agents
    from Example 11 (standard deviation reflected as (+/−)).
    Group Day 8 Day 15 Day 22
    A 1.000 ± 0.048 1.000 ± 0.144 1.000 ± 0.083
    B 0.125 ± 0.025 0.083 ± 0.014 0.063 ± 0.016
    C 0.019 ± 0.005 0.035 ± 0.008 0.052 ± 0.009
    D 0.054 ± 0.013 0.079 ± 0.009 0.108 ± 0.021
    E 0.099 ± 0.025 0.098 ± 0.053 0.142 ± 0.050
    F 0.070 ± 0.015 1.103 ± 0.036 0.140 ± 0.020
    G 0.041 ± 0.021 0.012 ± 0.008 0.021 ± 0.013
    H 0.020 ± 0.006 0.044 ± 0.010 0.062 ± 0.019
    I 0.077 ± 0.017 0.019 ± 0.004 0.004 ± 0.001
    J 0.012 ± 0.002 0.021 ± 0.001 0.032 ± 0.002
    K 0.045 ± 0.014 0.013 ± 0.005 0.008 ± 0.005
    L 0.106 ± 0.020 0.176 ± 0.044 0.215 ± 0.082
    M 0.275 ± 0.029 0.378 ± 0.080 0.572 ± 0.043
    Group Day 29 Day 36
    A 1.000 ± 0.209 1.000 ± 0.270
    B 0.079 ± 0.020 0.096 ± 0.007
    C 0.087 ± 0.014 0.164 ± 0.026
    D 0.176 ± 0.014 0.292 ± 0.030
    E 0.223 ± 0.082 0.373 ± 0.150
    F 0.213 ± 0.020 0.328 ± 0.034
    G 0.031 ± 0.013 0.078 ± 0.064
    H  0.97 ± 0.028 0.160 ± 0.060
    I 0.008 ± 0.001  0.002 ± 0.0003
    J 0.044 ± 0.008 0.069 ± 0.009
    K 0.011 ± 0.007 0.011 ± 0.009
    L 0.299 ± 0.009
    M 0.792 ± 0.057
  • RNAi agent AD04962 was designed to have an antisense strand sequence that is at least partially complementary to the S open reading frame at positions 257-275 of the HBV genome, as shown in Tables 1 and 2. RNAi agent AD04872 was designed to have an antisense strand sequence that is at least partially complementary to the S open reading frame at positions 261-279 of the HBV genome, as shown in Tables 1 and 2. RNAi agent AD04963 was designed to have an antisense strand sequence that is at least partially complementary to the X open reading frame at positions 1781-1799 of the HBV genome, as shown in Tables 1 and 2. RNAi agents AD04882 and AD04885 were designed to have antisense strand sequences that are at least partially complementary to the X open reading frame at positions 1780-1798 of the HBV genome, as shown in Tables 1 and 2. The HBV RNAi agents shown in Table 9, directly above, each showed a reduction in HBsAg as compared to the PBS control across all measured timepoints, both individually and in combination. Re-dosing yielded additional HBsAg reduction.
  • Additionally, Serum Hepatitis B e-antigen (HBeAg) levels were also assessed for all groups except Groups L and M. Samples from the mice in each respective group were first pooled, and the resulting serum samples were assayed in singlet. Data from the experiment is shown in the following Table:
  • TABLE 29
    Average HBeAg levels normalized to pre-treatment and PBS
    control in pHBV mice following administration of HBV RNAi
    agents from Example 11.
    Group Day 8 Day 22 Day 29 Day 36
    A 1.000 1.000 1.000 1.000
    B 0.425 0.291 0.371 0.365
    C 0.152 0.170 0.328 0.356
    D 0.266 0.249 0.456 0.440
    E 0.278 0.295 0.589 0.561
    F 0.306 0.291 0.718 0.522
    G 0.183 0.138 0.291 0.249
    H 0.091 0.131 0.315 0.238
    I 0.183 0.052 0.069 0.036
    J 0.089 0.114 0.190 0.236
    K 0.458 0.172 0.322 0.207
  • Further, serum HBV DNA levels were determined for each of the groups in Table 27 from serum samples collected on days 8, 15, 22, and 29, pursuant to the procedure set forth in Example 2, above. Serum HBV DNA was isolated from each animal at each time point. Data are presented in the following Table:
  • TABLE 30
    Average Serum HBV DNA levels normalized to pre-treatment and PBS
    control in pHBV mice following administration of HBV RNAi agents
    from Example 7 (standard deviation reflected as (+/−)).
    Group Day 8 Day 15 Day 22 Day 29
    A 1.000 ± 0.232 1.000 ± 0.463 1.000 ± 0.272 1.000 ± 0.205
    B 0.577 ± 0.219 0.222 ± 0.064 0.196 ± 0.055 0.261 ± 0.117
    C 0.165 ± 0.051 0.070 ± 0.042 0.142 ± 0.105 0.228 ± 0.174
    D 0.343 ± 0.125 0.307 ± 0.091 0.300 ± 0.092 0.356 ± 0.032
    E 0.262 ± 0.033 0.216 ± 0.018 0.227 ± 0.028 0.279 ± 0.090
    F 0.320 ± 0.134 0.332 ± 0.208 0.344 ± 0.209 0.338 ± 0.211
    G 0.231 ± 0.036 0.034 ± 0.024 0.069 ± 0.039 0.077 ± 0.020
    H 0.229 ± 0.101 0.155 ± 0.121 0.148 ± 0.079 0.215 ± 0.035
    I 0.281 ± 0.129 0.109 ± 0.071 0.023 ± 0.019 0.011 ± 0.009
    J 0.078 ± 0.050 0.061 ± 0.020 0.074 ± 0.029 0.056 ± 0.030
    K 0.314 ± 0.064 0.119 ± 0.043 0.076 ± 0.067 0.078 ± 0.095
    L 0.295 ± 0.077 0.305 ± 0.101 0.213 ± 0.088 0.186 ± 0.084
    M 0.515 ± 0.247 0.505 ± 0.293 0.488 ± 0.318 0.478 ± 0.267
  • The data in Table 30 indicate that the RNAi agents examined, both individually and in combination, provided a reduction in HBV DNA levels compared to the PBS group. Re-dosing yielded addition reduction of HBV DNA.
    • Example 12. HBV RNAi Agents in pHBV Mice
  • The pHBV mouse model described in Example 2, above, was used. Mice were divided into various groups as set forth in Table 31, below, and each mouse was administered a single 200 μl subcutaneous injection pursuant to the dosing regimen set forth in Table 31:
  • TABLE 31
    Dosing groups of pHBV mice for Example 12.
    Group RNAi Agent and Dose Dosing Regimen
    A PBS (no RNAi agent) Single injection on day 1
    B 2.0 mg/kg AD04871 Single injection on day 1
    C 2.0 mg/kg AD04872 Single injection on day 1
    D 2.0 mg/kg AD04874 Single injection on day 1
    E 2.0 mg/kg AD04875 Single injection on day 1
    F 2.0 mg/kg AD04876 Single injection on day 1
    G 2.0 mg/kg AD04881 Single injection on day 1
    H 2.0 mg/kg AD04883 Single injection on day 1
    I 2.0 mg/kg AD04884 Single injection on day 1
  • Each mouse was given a subcutaneous administration of 200 μl containing the amount of HBV RNAi agent formulated in phosphate buffered saline, or 200 μl of phosphate buffered saline without an HBV RNAi agent, as set forth in Table 24. Each of the HBV RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5′-terminal end of the sense strand, as shown in Tables 4 and 5. The injections were performed between the skin and muscle (i.e. subcutaneous injections) into the loose skin over the neck and shoulder area. Three (3) mice in each group were tested (n=3).
  • Serum was collected prior to administration, and then on day 8, day 15, and day 22. Group A (PBS), Group B (2.0 mg/kg AD04871), Group C (2.0 mg/kg AD04872), Group D (2.0 mg/kg AD04874), Group E (2.0 mg/kg AD04875), and Group F (2.0 mg/kg AD04876) also had serum collected on day 29, day 36, day 43, and day 50. Serum Hepatitis B surface antigen (HBsAg) levels were determined pursuant to the procedure set forth in Example 2, above. Data from the experiment is shown in the following Table:
  • TABLE 32
    Average HBsAg normalized to pre-treatment and PBS control in pHBV mice
    following administration of HBV RNAi agents from Example 12
    (standard deviation reflected as (+/−)).
    Group Day 8 Day 15 Day 22 Day 29
    A 1.000 ± 0.132 1.000 ± 0.089 1.000 ± 0.080 1.000 ± 0.098
    B 0.102 ± 0.034 0.041 ± 0.021 0.049 ± 0.033 0.048 ± 0.031
    C 0.153 ± 0.064 0.064 ± 0.032 0.063 ± 0.034 0.042 ± 0.017
    D 0.123 ± 0.022 0.049 ± 0.017 0.039 ± 0.010 0.023 ± 0.001
    E 0.190 ± 0.075 0.094 ± 0.038 0.107 ± 0.061 0.081 ± 0.051
    F 0.190 ± 0.031 0.076 ± 0.035 0.084 ± 0.038 0.049 ± 0.024
    G 0.159 ± 0.047 0.216 ± 0.057 0.235 ± 0.151
    H 0.508 ± 0.078 0.666 ± 0.131 0.543 ± 0.048
    I 0.279 ± 0.087 0.357 ± 0.078 0.614 ± 0.156
    Group Day 36 Day 43 Day 50
    A 1.000 ± 0.065 1.000 ± 0.242 1.000 ± 0.224
    B 0.054 ± 0.038 0.064 ± 0.030 0.092 ± 0.025
    C 0.049 ± 0.017 0.054 ± 0.015 0.085 ± 0.010
    D 0.037 ± 0.004 0.037 ± 0.010 0.065 ± 0.012
    E 0.126 ± 0.077 0.125 ± 0.063 0.170 ± 0.079
    F 0.089 ± 0.044 0.082 ± 0.034 0.115 ± 0.028
    G
    H
    I
  • HBV RNAi agents AD04871, AD04872, AD04874, AD04875, and AD04876 were each designed to have antisense strand sequences that are at least partially complementary to the S open reading frame at positions 261-279 of the HBV genome, as shown in Tables 1 and 2. Each of these HBV RNAi agents should a substantial reduction in HBsAg compared to PBS control. For example, a single 2 mg/kg dose of each of AD04871 (Group B), AD04872 (Group C) and AD04874 (Group D), and AD04876 (Group F), exhibited a greater than 90% reduction in HBsAg for each of the timepoints measured from day 15 through day 43 compared to control. HBV RNAi agents AD04881, AD04883, AD04884 were each designed to have antisense strand sequences that are at least partially complementary to the X open reading frame at positions 1780-1798 of the HBV genome, as shown in Tables 1 and 2.
    • Example 13. Dose Response and Combinations of HBV RNAI Agents in X Region Knockout Model Mice
  • As an alternative means in assessing the effects of the combination of an RNAi agent that includes an antisense strand sequence that is at least partially complementary to a region located in the S ORF of an HBV mRNA, and a second RNAi agent that includes an antisense strand sequence that is at least partially complementary to a region located in the X ORF of an HBV mRNA, a plasmid was generated that included the HBV genome with a knockout of the binding site for HBV RNAi agents that target positions 1780 and 1781, as shown in Tables 1 and 2 (hereinafter referred to as X Region Knockout mice). This model was generated by mutating ten (10) bases in the pHBV1.3 plasmid within the binding site of these RNAi agents. The remainder of the HBV mRNA, including the S-region, remained functional. Thus, in this HBV mouse model, inclusion of an HBV RNAi agent having an antisense strand that targets positions 1780 and 1781 of the HBV genome disclosed herein is expected to be ineffective in silencing expression.
  • The mice were divided into various groups including those set forth in Table 33, below, and the mice were given 200 μl subcutaneous injections pursuant to the dosing regimen set forth in the following Table:
  • TABLE 33
    Dosing groups of X Region Knockout mice for Example 13.
    Number of
    Group RNAi Agent and Dose Dosing Regimen Animals (n)
    1 PBS (no RNAi agent) Single injection 4
    on day 1
    2 2.0 mg/kg AD04585 + Single injection 4
    1.0 mg/kg AD04963 on day 1
    3 2.0 mg/kg AD04872 + Single injection 4
    1.0 mg/kg AD04963 on day 1
    4 2.5 mg/kg AD04585 + Single injection 4
    0.5 mg/kg AD04963 on day 1
    5 2.5 mg/kg AD04872 + Single injection 4
    0.5 mg/kg AD04963 on day 1
    6 3.0 mg/kg AD04963 Single injection 1
    on day 15
  • Each mouse was given a subcutaneous administration of 200 μl containing the amount of HBV RNAi agent(s) formulated in phosphate buffered saline, or 200 μl of phosphate buffered saline without an HBV RNAi agent, as set forth in Table 33. Each of the HBV RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5′-terminal end of the sense strand, as shown in Tables 4 and 5. The injections were performed between the skin and muscle (i.e. subcutaneous injections) into the loose skin over the neck and shoulder area. Three (3) mice in each group were tested (n=3).
  • Serum was collected on day 5, day 8, day 15, day 22, and day 29 and serum Hepatitis B surface antigen (HBsAg) levels were determined pursuant to the procedure set forth in Example 2, above. Serum was also collected for Groups 1 through 5 on days 36 and 43. Data from the experiment is shown in the following Table 34:
  • TABLE 34
    Average HBsAg normalized to pre-treatment and PBS control in
    X Region Knockout mice following administration of HBV RNAi agents
    from Example 13 (standard deviation reflected as (+/−)).
    Group Day 8 Day 15 Day 22
    1 1.000 ± 0.186 1.000 ± 0.165 1.000 ± 0.132
    2 0.061 ± 0.034 0.041 ± 0.035 0.030 ± 0.015
    3 0.020 ± 0.011 0.007 ± 0.003 0.003 ± 0.002
    4 0.063 ± 0.039 0.022 ± 0.011 0.029 ± 0.013
    5 0.027 ± 0.014 0.003 ± 0.003 0.001 ± 0.001
    6 0.948 1.360 1.652
    Day 29 Day 36 Day 43
    1 1.000 ± 0.059 1.000 ± 0.044 1.000 ± 0.045
    2 0.051 ± 0.029 0.062 ± 0.029
    3 0.004 ± 0.003 0.008 ± 0.003 0.018 ± 0.007
    4 0.040 ± 0.022 0.061 ± 0.030
    5 0.002 ± 0.001 0.003 ± 0.002 0.014 ± 0.006
    6 1.831
  • As expected, Group 6, which was a single dose of 3.0 mg/kg of HBV RNAi agent AD04963 and includes an antisense strand that is at least partially complementary to the X open reading frame at positions 1781-1799 of the HBV genome, was unable to provide knockdown of HBsAg. Additionally, each of Groups 2 through 5 provided substantial knockdown of HBsAg compared to PBS control, with both Group 3 and Group 5 exhibiting a greater than 2 log reduction in HBsAg at nadir (day 22).
    • Example 14. Dose Response and Combinations of HBV RNAI Agents in X Region Knockout Model Mice
  • The X Region Knockout mouse model described in Example 13, above, was used. Mice were divided into various groups including those set forth in Table 31, below, and each mouse was administered a single 200 μl subcutaneous injection pursuant to the dosing regimen set forth in Table 35:
  • TABLE 35
    Dosing groups of X Region Knockout mice for Example 14.
    Group RNAi Agent and Dose Dosing Regimen
    1 PBS (no RNAi agent) Single injection on day 1
    2 2.0 mg kg AD04872 Single injection on day 1
    3 2.0 mg/kg AD04872 + Single injection on day 1
    0.7 mg/kg AD05070
    4 2.0 mg/kg AD04872 + Single injection on day 1
    1.0 mg/kg AD05070
    5 2.0 mg/kg AD04872 + Single injection on day 1
    2.0 mg/kg AD05070
  • Each mouse was given a subcutaneous administration of 200 μl containing the amount of HBV RNAi agent(s) formulated in phosphate buffered saline, or 200 μl of phosphate buffered saline without an HBV RNAi agent, as set forth in Table 35. Each of the HBV RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5′-terminal end of the sense strand, as shown in Tables 4 and 5. The injections were performed between the skin and muscle (i.e. subcutaneous injections) into the loose skin over the neck and shoulder area. Three (3) mice in each group shown in Table 35 were tested (n=3).
  • Serum was collected on day 1 (pre-dose), day 8, day 15, day 22, and day 29, and serum Hepatitis B surface antigen (HBsAg) levels were determined pursuant to the procedure set forth in Example 2, above. Data from the experiment is shown in the following Table:
  • TABLE 36
    Average HBsAg levels normalized to pre-treatment and PBS
    control in X Region Knockout mice from Example 14.
    Group Day 8 Day 15 Day 22 Day 29
    1 1.000 ± 0.120 1.000 ± 0.255 1.000 ± 0.224 1.000 ± 0.143
    2 0.104 ± 0.104 0.009 ± 0.009 0.005 ± 0.004 0.005 ± 0.003
    3 0.076 ± 0.041 0.010 ± 0.009 0.006 ± 0.005 0.005 ± 0.005
    4 0.036 ± 0.008 0.002 ± 0.001 0.001 ± 0.001 0.002 ± 0.001
    5 0.019 ± 0.017 0.003 ± 0.002 0.003 ± 0.001 0.004 ± 0.000
  • Table 36 shows that HBV RNAi agent AD04872 administered alone, and the combination of AD04872 (which includes an antisense strand that is at least partially complementary to the S open reading from at positions 261-279 of the HBV genome) and AD05070 (which includes an antisense strand that is at least partially complementary to the X open reading frame at positions 1781-1799 of the HBV genome), provided significant knockdown of HBsAg compared to PBS control across each of the time points measured. Addition of 0.7 mg/kg to 2 mg/kg HBV RNAi agent AD05070 for which there was a mutated target site in this X Region Knockout model did not diminish the activity of the 2 mg/kg HBV RNAi agent AD04872.
  • Additionally, serum HBV DNA levels were determined from serum samples collected on days 8, 15, and 22 pursuant to the procedure set forth in Example 2, above. Serum from each group was pooled and then DNA was isolated from the serum in singlet. Data are presented in the following Table:
  • TABLE 37
    Average Seram HBV DNA levels normalized to pre-treatment
    and PBS controls in X Region Knockout mice following
    administration of HBV RNAi agents from Example 14
    (standard deviation reflected as (+/−)).
    Group Day 8 Day 15 Day 22
    1 1.000 ± 0.007 1.000 ± 0.011 1.000 ± 0.066
    2 0.225 ± 0.019 0.022 ± 0.001 0.036 ± 0.001
    3 0.151 ± 0.002 0.029 ± 0.001 0.042 ± 0.003
    4 0.140 ± 0.006 0.016 ± 0.000 0.018 ± 0.000
    5 0.069 ± 0.002 0.018 ± 0.003 0.043 ± 0.002
  • Addition of 0.7 mg/kg to 2 mg/kg HBV RNAi agent AD05070 for which there was a mutated target site in this X Region Knockout model did not diminish the activity of the 2 mg/kg HBV RNAi agent AD04872.
    • Example 15. HBV RNAI Agents in pHBV Mice
  • The pHBV mouse model described in Example 2, above, was used. Mice were divided into various groups including those set forth in Table 38, below, and each mouse was administered a single 200 d subcutaneous injection pursuant to the dosing regimen set forth in Table 38:
  • TABLE 38
    Dosing groups of pHBV mice for Example 1.5.
    Group RNAi Agent and Dose Dosing Regimen
    1 PBS (no RNAi agent) Single injection on day 1
    2 2.0 mg/kg AD04776 Single injection on day 1
    3 2.0 mg/kg AD05069 Single injection on day 1
    4 2.0 mg/kg AD05070 Single injection on day 1
    5 2.0 mg/kg AD05071 Single injection on day 1
    6 2.0 mg/kg AD05073 Single injection on day 1
    7 2.0 mg/kg AD05074 Single injection on day 1
    8 2.0 mg/kg AD05075 Single injection on day 1
    9 2.0 mg/kg AD05076 Single injection on day 1
    10 2.0 mg/kg AD05077 Single injection on day 1
    11 2.0 mg/kg AD05078 Single injection on day 1
    12 3.0 mg/kg AD04872 + Single injection on day 1
    1.0 mg/kg AD04776
    13 3.0 mg/kg AD04872 + Single injection on day 1
    1.0 mg/kg AD05069
    14 3.0 mg/kg AD04872 + Single injection on day 1
    1.0 mg/kg AD05070
    15 3.0 mg/kg AD04872 + Single injection on day 1
    1.0 mg/kg AD05071
    16 3.0 mg/kg AD04872 + Single injection on day 1
    1.0 mg/kg AD05073
    17 3.0 mg/kg AD04872 + Single injection on day 1
    1.0 mg/kg AD05074
    18 3.0 mg/kg AD04872 + Single injection on day 1
    1.0 mg/kg AD05075
    19 3.0 mg/kg AD04872 + Single injection on day 1
    1.0 mg/kg AD05076
    20 3.0 mg/kg AD04872 + Single injection on day 1
    1.0 mg/kg AD05077
    21 3.0 mg/kg AD04872 + Single injection on day 1
    1.0 mg/kg AD05078
  • Each mouse was given a subcutaneous administration of 200 μl containing the amount of HBV RNAi agent(s) formulated in phosphate buffered saline, or 200 μl of phosphate buffered saline without an HBV RNAi agent, as set forth in Table 38. Each of the HBV RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5′-terminal end of the sense strand, as shown in Tables 4 and 5. The injections were performed between the skin and muscle (i.e. subcutaneous injections) into the loose skin over the neck and shoulder area. Three (3) mice in each group were tested (n=3).
  • Serum was collected on day −1 prior to administration, and then on day 8, day 15, day 22, day 29, day 36, day 43, and day 50. Serum Hepatitis B surface antigen (HBsAg) levels were determined pursuant to the procedure set forth in Example 2, above. Data from the experiment is shown in the following Table 39, with Average HBsAg reflecting the normalized average value of HBsAg:
  • TABLE 39
    Average HBsAg normalized to pre-treatment and PBS control in pHBV
    mice following administration of HBV RNAi agents from Example 15.
    Group Day 8 Day 15 Day 22 Day 29
    1 1.000 ± 0.119 1.000 ± 0.047 1.000 ± 0.080 1.000 ± 0.027
    2 0.339 ± 0.076 0.414 ± 0.126 0.385 ± 0.067 0.450 ± 0.075
    3 0.240 ± 0.096 0.361 ± 0.078 0.446 ± 0.073 0.508 ± 0.114
    4 0.081 ± 0.026 0.127 ± 0.031 0.223 ± 0.057 0.330 ± 0.112
    5 0.452 ± 0.020 0.431 ± 0.126 0.373 ± 0.079 0.383 ± 0.080
    6 0.375 ± 0.181 0.632 ± 0.192 0.463 ± 0.117 0.567 ± 0.159
    7 0.325 ± 0.032 0.438 ± 0.125 0.393 ± 0.056 0.443 ± 0.096
    8 0.155 ± 0.031 0.322 ± 0.019 0.333 ± 0.077 0.463 ± 0.043
    9 0.245 ± 0.063 0.467 ± 0.090 0.477 ± 0.045 0.562 ± 0.049
    10 0.120 ± 0.062 0.173 ± 0.029 0.289 ± 0.019 0.331 ± 0.042
    11 0.128 ± 0.042 0.172 ± 0.046 0.179 ± 0.015 0.215 ± 0.049
    12 0.040 ± 0.015 0.014 ± 0.004 0.014 ± 0.006 0.015 ± 0.004
    13 0.050 ± 0.020 0.015 ± 0.011 0.017 ± 0.008 0.022 ± 0.009
    14 0.020 ± 0.011 0.011 ± 0.006 0.015 ± 0.006 0.023 ± 0.004
    15 0.043 ± 0.005 0.013 ± 0.005 0.010 ± 0.002 0.011 ± 0.004
    16 0.021 ± 0.017 0.008 ± 0.004 0.012 ± 0.003 0.011 ± 0.001
    17 0.032 ± 0.011 0.009 ± 0.003 0.007 ± 0.002  0.008 ± 0.0003
    18 0.023 ± 0.014 0.010 ± 0.006 0.009 ± 0.006 0.009 ± 0.004
    19 0.025 ± 0.006 0.010 ± 0.004 0.009 ± 0.002 0.010 ± 0.003
    20 0.061 ± 0.013 0.027 ± 0.006 0.020 ± 0.003 0.029 ± 0.006
    21 0.061 ± 0.050 0.013 ± 0.010 0.012 ± 0.005 0.018 ± 0.006
    Group Day 36 Day 43 Day 50
    1 1.000 ± 0.031 1.000 ± 0.114 1.000 ± 0.112
    2 0.617 ± 0.116 0.643 ± 0.154 0.665 ± 0.199
    3 0.638 ± 0.067 0.743 ± 0.015 0.792 ± 0.115
    4 0.472 ± 0.121 0.515 ± 0.126 0.689 ± 0.167
    5 0.591 ± 0.159 0.604 ± 0.086 0.709 ± 0.115
    6 0.717 ± 0.136 0.686 ± 0.194 0.781 ± 0.301
    7 0.586 ± 0.069 0.775 ± 0.143 0.747 ± 0.095
    8 0.666 ± 0.066 0.803 ± 0.096 0.856 ± 0.180
    9 0.801 ± 0.047 0.667 ± 0.055 0.765 ± 0.208
    10 0.640 ± 0.059 0.667 ± 0.034 0.742 ± 0.133
    11 0.429 ± 0.063 0.383 ± 0.005 0.497 ± 0.060
    12 0.037 ± 0.013 0.044 ± 0.012 0.056 ± 0.014
    13 0.046 ± 0.011 0.055 ± 0.010 0.070 ± 0.010
    14 0.054 ± 0.016 0.070 ± 0.018 0.096 ± 0.012
    15 0.029 ± 0.011 0.032 ± 0.015 0.051 ± 0.020
    16 0.033 ± 0.005 0.038 ± 0.007 0.062 ± 0.004
    17 0.021 ± 0.002 0.031 ± 0.004 0.061 ± 0.005
    18 0.034 ± 0.014 0.047 ± 0.016 0.079 ± 0.017
    19 0.028 ± 0.005 0.037 ± 0.006 0.060 ± 0.011
    20 0.070 ± 0.009 0.063 ± 0.018 0.097 ± 0.018
    21 0.040 ± 0.012 0.066 ± 0.007 0.120 ± 0.036
  • RNAi agents AD04776, AD05069, AD05070, AD05071, AD05073, and AD05074 were each designed to have an antisense strand sequence that is at least partially complementary to the X open reading frame at positions 1781-1799 of the HBV genome, as shown in Tables 1 and 2. RNAi agents AD05075, AD05076. AD05077, and AD05078 were each designed to have antisense strand sequences that are at least partially complementary to the X open reading frame at positions 1780-1798 of the HBV genome, as shown in Tables 1 and 2.
  • Table 39 shows that HBV RNAi agents AD04776, AD05069, AD05070, AD05071, AD05073, and AD05074 administered alone or their combination with AD04872 (which includes an antisense strand that is at least partially complementary to the S open reading from at positions 261-279 of the HBV genome) provided significant knockdown of HBsAg compared to PBS control across each of the time points measured.
    • Example 16. HBV RNAI Agents in pHBV Mice: Dose Response and Combination Studies
  • The pHBV mouse model described in Example 2, above, was used. Mice were divided into various groups as set forth in Table 40, below, and each mouse was administered a single 200 μl subcutaneous injection pursuant to the dosing regimen set forth in Table 40:
  • TABLE 40
    Dosing groups of pHBV mice for Example 16.
    Group RNAi Agent and Dose Dosing Regimen
    1 PBS (no RNAi agent) Single injection on day 1
    2 3.2 mg/kg AD04872 Single injection on day 1
    3 3.2 mg/kg AD04872 Single injection on day 1 and day 22
    4 3.0 mg/kg AD04872 + Single injection on day 1
    0.8 mg/kg AD05070
    5 3.0 mg/kg AD04872 + Single injection on day 1 and day 22
    0.8 mg/kg AD05070
    6 3.0 mg/kg AD04872 + Single injection on day 1
    1.0 mg/kg AD05070
    7 3.0 mg/kg AD04872 + Single injection on day 1 and day 22
    1.0 mg/kg AD05070
    8 2.7 mg/kg AD04872 + Single injection on day 1
    1.3 mg/kg AD05070
    9 2.7 mg/kg AD04872 + Single injection on day 1 and day 22
    1.3 mg/kg AD05070
    10 2.0 mg/kg AD04872 + Single injection on day 1 and day 22
    2.0 mg/kg AD04776
    11 0.8 mg/kg AD05070 Single injection on day 1 and day 22
    12 1.3 mg/kg AD05070 Single injection on day 1 and day 22
  • Each mouse was given a subcutaneous administration of 200 μl containing the amount of HBV RNAi agent(s) formulated in phosphate buffered saline, or 200 μl of phosphate buffered saline without an HBV RNAi agent, as set forth in Table 40. Each of the HBV RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5′-terminal end of the sense strand, as shown in Tables 4 and 5. The injections were performed between the skin and muscle (i.e. subcutaneous injections) into the loose skin over the neck and shoulder area. Six (6) mice in each group were tested (n=6).
  • Serum was collected prior to administration, and then on day 8, day 15, day 22, and day 29, and serum Hepatitis B surface antigen (HBsAg) levels were determined pursuant to the procedure set forth in Example 2, above. Data from the experiment is shown in the following Table 41:
  • TABLE 41
    Average HBsAg levels normalized to pre-treatment and PBS control
    in pHBV mice following administration of HBV RNAi agents from
    Example 16 (standard deviation reflected as (+/−)).
    Group Day 8 Day 15 Day 22 Day 29
    1 1.000 ± 0.117 1.000 ± 0.213 1.000 ± 0.169 1.000 ± 0.130
    2 0.050 ± 0.018 0.015 ± 0.007 0.011 ± 0.005 0.009 ± 0.006
    3 0.051 ± 0.037 0.014 ± 0.011 0.010 ± 0.006 0.002 ± 0.001
    4 0.029 ± 0.018 0.010 ± 0.006 0.011 ± 0.006 0.010 ± 0.005
    5 0.022 ± 0.003 0.007 ± 0.001 0.009 ± 0.003 0.001 ± 0.001
    6 0.027 ± 0.012 0.007 ± 0.004 0.008 ± 0.005 0.011 ± 0.005
    7 0.028 ± 0.012 0.010 ± 0.005 0.009 ± 0.005 0.001 ± 0.000
    8 0.033 ± 0.016 0.016 ± 0.008 0.020 ± 0.009 0.021 ± 0.011
    9 0.034 ± 0.025 0.015 ± 0.011 0.018 ± 0.013 0.003 ± 0.002
    10 0.038 ± 0.021 0.015 ± 0.005 0.019 ± 0.004 0.003 ± 0.001
    11 0.446 ± 0.143 0.376 ± 0.120 0.474 ± 0.149 0.338 ± 0.123
    12 0.307 ± 0.111 0.257 ± 0.122 0.236 ± 0.057 0.138 ± 0.031

    The HBV RNAi agents tested, both individually and in combination, showed a reduction in HBsAg as compared to the PBS control across all measured time points. HBsAg expression was further reduced in all groups that were re-dosed on day 22.
  • Additionally, Serum Hepatitis B e-antigen (HBeAg) levels were also assessed. For the day 8 measurement, the serum samples for all six mice in each group were pooled, and the resulting samples were assayed in singlet. For the day −1, day 15, day 22, and day 29 measurements, the six mice from each group were paired within each group and their respective serum samples were pooled, forming three subgroups for each group. The serum samples for each of the three subgroups for each group were then assayed. Data from the experiment is shown in the following Table 42:
  • TABLE 42
    Average HBeAg levels normalized to pre-treatment and
    PBS control in pHBV mice following administration
    of HBV RNAi agents from Example 16 (standard deviation
    for days 15, 22, and 29 reflected as (+/−)).
    Group Day 8 Day 15 Day 22 Day 29
    1 1.000 1.000 ± 0.011 1.000 ± 0.170 1.000 ± 0.173
    2 0.510 0.308 ± 0.031 0.217 ± 0.021 0.226 ± 0.035
    3 0.488 0.301 ± 0.065 0.283 ± 0.081 0.147 ± 0.030
    4 0.213 0.216 ± 0.067 0.192 ± 0.029 0.141 ± 0.048
    5 0.192 0.211 ± 0.053 0.216 ± 0.088 0.047 ± 0.016
    6 0.176 0.163 ± 0.022 0.238 ± 0.069 0.117 ± 0.011
    7 0.165 0.175 ± 0.046 0.215 ± 0.061 0.028 ± 0.012
    8 0.128 0.166 ± 0.065 0.386 ± 0.284 0.167 ± 0.118
    9 0.172 0.171 ± 0.037 0.244 ± 0.052 0.032 ± 0.010
    10 0.180 0.211 ± 0.012 0.283 ± 0.034 0.034 ± 0.001
    11 0.634 0.594 ± 0.082 0.840 ± 0.152 0.271 ± 0.029
    12 0.486 0.441 ± 0.066 0.804 ± 0.096 0.214 ± 0.039
  • The HBV RNAi agents tested, both individually and in combination, showed a reduction in HBeAg as compared to the saline control across all measured time points. HBeAg expression was further reduced in all groups that were re-dosed on day 22.
  • Further, serum HBV DNA levels were determined for each of the groups in Table 40 from serum samples collected on days −1, 8, 15, and 22, pursuant to the procedure set forth in Example 2, above. Serum from each pair of mice was pooled and then DNA was isolated from each serum pool in a single isolation. Data are presented in the following Table:
  • TABLE 43
    Average Serum HBV DNA levels normalized to pre-treatment and PBS
    control in pHBV mice following administration of HBV RNAi agents
    from Example 16 (standard deviation reflected as (+/−)).
    Group Day 8 Day 15 Day 22
    1 1.000 ± 0.122 1.000 ± 0.299 1.000 ± 0.241
    2 0.312 ± 0.016 0.126 ± 0.008 0.087 ± 0.018
    3 0.264 ± 0.065 0.081 ± 0.023 0.073 ± 0.028
    4 0.321 ± 0.254 0.120 ± 0.066 0.134 ± 0.101
    5 0.319 ± 0.081 0.108 ± 0.038 0.098 ± 0.051
    6 0.260 ± 0.095 0.068 ± 0.010 0.076 ± 0.031
    7 0.170 ± 0.028 0.082 ± 0.013 0.062 ± 0.018
    8 0.188 ± 0.020 0.192 ± 0.160 0.307 ± 0.309
    9 0.242 ± 0.003 0.100 ± 0.042 0.075 ± 0.028
    10 0.322 ± 0.028 0.159 ± 0.025 0.086 ± 0.016
    11 1.124 ± 0.142 0.742 ± 0.127 0.807 ± 0.192
    12 1.004 ± 0.144 0.541 ± 0.340 0.569 ± 0.060
  • The HBV RNAi agents tested, both individually and in combination, showed a reduction in serum HBV DNA as compared to the saline control across all measured time points except in groups 11 and 12 that had no reduction in serum HBV DNA at Day 8.
    • Example 17. HBV RNAi Agents in in pHBV Mice
  • The pHBV mouse model described in Example 2, above, was used. Mice were divided into various groups as set forth in Table 44, below, and each mouse was administered a single 200 td subcutaneous injection pursuant to the dosing regimen set forth in Table 44:
  • TABLE 44
    Dosing groups of pHBV mice for Example 17.
    Group RNAi Agent and Dose Dosing Regimen
    1 PBS (no RNAi agent) Single injection on day 1
    2 5 mg/kg AD04585 + Single injection on day 1
    1 mg/kg AD04963
    3 5 mg/kg AD04872 + Single injection on day 1
    1 mg/kg AD04963
    4 5 mg/kg AD04585 + Single injection on day 1
    1 mg/kg AD04963 and day 8
    5 5 mg/kg AD04872 + Single injection on day 1
    1 mg/kg AD04963 and day 8
    6 2.5 mg/kg AD04585 + Single injection on day 1
    0.5 mg/kg AD04963
    7 2.0 mg/kg AD04585 + Single injection on day 1
    1.0 mg/kg AD04963
    8 2.5 mg/kg AD04872 + Single injection on day 1
    0.5 mg/kg AD04963
    9 2.0 mg/kg AD04872 + Single injection on day 1
    1.0 mg/kg AD04963
    10 5 mg/kg AD04872 + Single injection on day 1
    1 mg/kg AD04981
    11 2.5 mg/kg AD04872 + Single injection on day 1
    0.5 mg/kg AD04981 and day 8
    12 2.5 mg/kg AD04872 + Single injection on day 1
    0.5 mg/kg AD04981
    13 2 mg/kg AD04872 + Single injection on day 1
    1 mg/kg AD04981
    14 2.5 mg/kg AD04585 + Single injection on day 1
    0.5 mg/kg AD04981
    15 2 mg/kg AD04585 + Single injection on day 1
    1 mg/kg AD04981
    16 0.5 mg/kg AD04981 Single injection on day 1
  • Each mouse was given a subcutaneous administration of 200 μl containing the amount of HBV RNAi agent(s) formulated in phosphate buffered saline, or 200 μl of phosphate buffered saline without an HBV RNAi agent, as set forth in Table 44. Each of the HBV RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5′-terminal end of the sense strand, as shown in Tables 4 and 5. The injections were performed between the skin and muscle (i.e. subcutaneous injections) into the loose skin over the neck and shoulder area. Three (3) mice in each group were tested (n=3).
  • Serum was collected prior to administration, and then on day 8, day 14, day 21, and day 29 and day 36, and serum Hepatitis B surface antigen (HBsAg) levels were determined pursuant to the procedure set forth in Example 2, above. Data from the experiment is shown in the following Table 45:
  • TABLE 45
    Average HBsAg levels normalized to pre-treatment and PBS control
    in pHBV mice following administration of HBV RNAi agents from
    Example 17 (standard deviation reflected as (+/−)).
    Group Day 8 Day 14 Day 21 Day 29
    1 1.000 ± 0.068 1.000 ± 0.125 1.000 ± 0.152 1.000 ± 0.110
    2 0.058 ± 0.033 0.059 ± 0.022 0.085 ± 0.023 0.158 ± 0.021
    3 0.025 ± 0.009 0.014 ± 0.006 0.015 ± 0.008 0.026 ± 0.015
    4 0.032 ± 0.007 0.005 ± 0.001 0.006 ± 0.002 0.014 ± 0.002
    5 0.024 ± 0.009 0.003 ± 0.001  0.001 ± 0.0004  0.001 ± 0.0005
    6 0.063 ± 0.020 0.077 ± 0.013 0.131 ± 0.011 0.214 ± 0.026
    7 0.041 ± 0.018 0.059 ± 0.017 0.091 ± 0.016 0.140 ± 0.045
    8 0.070 ± 0.008 0.046 ± 0.016 0.043 ± 0.009 0.055 ± 0.012
    9 0.043 ± 0.006 0.027 ± 0.003 0.064 ± 0.017 0.064 ± 0.014
    10 0.015 ± 0.008 0.005 ± 0.003 0.005 ± 0.003 0.005 ± 0.003
    11 0.047 ± 0.014 0.005 ± 0.003 0.003 ± 0.002 0.003 ± 0.003
    12 0.062 ± 0.006 0.025 ± 0.007 0.027 ± 0.005 0.033 ± 0.005
    13 0.092 ± 0.029 0.050 ± 0.021 0.050 ± 0.022  0.054 ± 0.0019
    14 0.310 ± 0.180 0.056 ± 0.010 0.081 ± 0.010  0.112 ± 0.0018
    15 0.304 ± 0.044 0.083 ± 0.021 0.115 ± 0.013 0.165 ± 0.025
    16 1.667 ± 0.217 0.416 ± 0.163 0.341 ± 0.179  0.511 ± 0.0011
    Group Day 36
    1 1.000 ± 0.225
    2
    3 0.049 ± 0.019
    4
    5  0.004 ± 0.0004
    6
    7
    8 0.081 ± 0.010
    9 0.108 ± 0.026
    10 0.009 ± 0.004
    11 0.005 ± 0.003
    12 0.060 ± 0.014
    13 0.094 ± 0.027
    14
    15
    16 0.634 ± 0.005
  • The HBV RNAi agent combinations tested showed a reduction in HBsAg as compared to the saline control across all measured time points. Combinations containing AD04872 showed greater reductions than the equivalent combinations with AD04585 in place of AD04872.
  • Additionally, serum HBV DNA levels were determined for serum samples collected on days 8, 14, 21, and 29 pursuant to the procedure set forth in Example 2, above. Serum HBV DNA was isolated from each animal at each time point. Data are presented in the following Table 46:
  • TABLE 46
    Average Serum HBV DNA levels normalized to pre-treatment and PBS
    control in pHBV mice following administration of HBV RNAi agents
    from Example 17 (standard deviation reflected as (+/−)).
    Group Day 8 Day 14 Day 21 Day 29
    1 1.000 ± 0.280 1.000 ± 0.269 1.000 ± 0.418 1.000 ± 0.383
    2 0.136 ± 0.068 0.192 ± 0.071 0.173 ± 0.032 0.292 ± 0.039
    3 0.097 ± 0.034 0.068 ± 0.016 0.076 ± 0.034 0.131 ± 0.061
    4 0.061 ± 0.039 0.002 ± 0.001 0.003 ± 0.001 0.019 ± 0.013
    5 0.068 ± 0.025 0.003 ± 0.002 0.0009 ± 0.0003 0.0009 ± 0.0003
    6 0.354 ± 0.299 0.345 ± 0.187 0.522 ± 0.234 0.509 ± 0.106
    7 0.103 ± 0.064 0.291 ± 0.025 0.203 ± 0.043 0.203 ± 0.015
    8 0.336 ± 0.142 0.185 ± 0.071 0.183 ± 0.065 0.162 ± 0.064
    9 0.198 ± 0.055 0.093 ± 0.023 0.118 ± 0.054 0.143 ± 0.032
    10 0.122 ± 0.071 0.024 ± 0.026 0.023 ± 0.020 0.014 ± 0.017
    11 0.160 ± 0.069 0.016 ± 0.023 0.003 ± 0.001 0.005 ± 0.004
    12 0.158 ± 0.039 0.120 ± 0.044 0.100 ± 0.049 0.091 ± 0.034
    13 0.190 ± 0.038 0.169 ± 0.025 0.066 ± 0.015 0.081 ± 0.015
    14 0.434 ± 0.136 0.318 ± 0.104 0.144 ± 0.094 0.240 ± 0.029
    15 0.358 ± 0.185 0.287 ± 0.108 0.279 ± 0.080 0.303 ± 0.038
    16 0.713 ± 0.085 0.674 ± 0.140 0.496 ± 0.128 0.590 ± 0.093
  • The HBV RNAi agent combinations tested showed a reduction in serum HBV DNA as compared to the saline control across all measured time points. Combinations containing AD04872 showed greater reductions than the equivalent combinations with AD04585 in place of AD04872. These greater reductions were observed at Day 22 and Day 29.
    • Example 18. HBV RNAi Agents in a HBV-Infected Humanized Mouse Model
  • For this study, Male FRG® (genotype Fah−/−/Rag2−/−/Il2rg−/− triple knockout mice on a C57BL/6 background (Yecuris) were transplanted with human hepatocytes when they were 1-2 months old. The human hepatocytes were allowed to repopulate the liver for approximately 6 months with periodic NTBC treatment to discourage growth of mouse hepatocytes. At 9 months of age the mice were given an intravenous inoculation of 4×108 genomes/kg HBV genotype C, which infected the human hepatocytes. After 2-3 months, serum HBV DNA levels reached a plateau indicating the human hepatocytes were maximally infected (mouse hepatocytes cannot be infected by HBV). Mice were one year old at the start of treatment with HBV RNAi agents, thus nearing the end of their life span.
  • Pre-treatment serum samples were taken on day −10 and day −3. Beginning on day 1, each mouse was administered an oral daily gavage with 0.01 mg/kg Entecavir dissolved in water to inhibit HBV replication. Daily dosing of Entecavir continued until the day mice were euthanized. Entecavir administration was expected to reduce serum HBV DNA in chronically infected human patients, but not reduce HBsAg.
  • Mice were divided into various groups including those set forth in Table 47, below:
  • TABLE 47
    Dosing groups of HBV-infected FRG humanized
    model mice for Example 18.
    RNAi Agent and Terminal
    Group Dose Dosing Regimen Day
    A- mouse PBS (no RNAi Single injection Euthanized
    1 agent) on day 1 day 21
    (unhealthy
    animal)
    A- mouse PBS (no RNAi Single injection Euthanized
    2 agent) on day 1 and day day 36
    29
    B- mouse 4.0 mg/kg AD04872 + Single injection Euthanized
    1 2.0 mg/kg AD05070 on day 1 and day day 36
    29
    B- mouse 4.0 mg/kg AD04872 + Single injection Euthanized
    2 2.0 mg/kg AD05070 on day 1 and day day 40
    29
    C- mouse 4.5 mg/kg AD04872 + Single injection Euthanized
    1 1.5 mg/kg AD05070 on day 1 day 15
    C- mouse 4.5 mg/kg AD04872 + Single injection Euthanized
    2 1.5 mg/kg AD05070 on day 1 and day day 36
    29
    C- mouse 4.5 mg/kg AD04872 + Single injection Euthanized
    3 1.5 mg/kg AD05070 on day 1 and day 40
    day 29
  • Each mouse was also given a subcutaneous administration of 100 μl per 20 grams body weight containing the amount of HBV RNAi agent(s) formulated in phosphate buffered saline, or an equal volume of phosphate buffered saline without an HBV RNAi agent, on day 1 and on day 29 (if still alive on day 29), pursuant to the schedule as set forth in Table 47, directly above. Each of the HBV RNAi agents included N-acetyl-galactosamine targeting ligands conjugated to the 5′-terminal end of the sense strand, as shown in Tables 4 and 5. The injections were performed between the skin and muscle (i.e. subcutaneous injections) into the loose skin over the neck and shoulder area.
  • Serum was collected on day 8, day 15, day 22, day 29, day 36, and day 40 and serum Hepatitis B surface antigen (HBsAg) levels were determined pursuant to the procedure set forth in Example 2, above. Data from the experiment is shown in the following Table:
  • TABLE 48
    Average HBsAg levels normalized to pre-treatment (day −3) for each
    individual HBV-infected humanized FRG model mouse from Example 18.
    Group Day 8 Day 15 Day 22 Day 29 Day 36 Day 40
    A-1 0.830 0.828 0.932 0.858 1.107
    A-2 1.303 1.328
    B-1 0.548 0.314 0.272 0.207 0.138
    B-2 0.592 0.337 0.243 0.215 0.160 0.175
    C-1 0.643 0.460 0.415 0.251 0.164
    C-2 0.353 0.228 0.182 0.172 0.224 0.216
    C-3 0.814 0.674
  • Additionally, serum HBV DNA levels were determined from serum samples collected on days −10, −3, 8, 15, 22, 29, 36, and 40, pursuant to the procedure set forth in Example 2, above. Data are presented in the following Table 49:
  • TABLE 49
    Serum HBV DNA levels normalized to the average of pre-treatment day −10 and
    day −3 for each HBV-infected FRG humanized mouse following administration of HBV
    RNAi agents from Example 14.
    Group Day −10 Day −3 Day 8 Day 15 Day 22 Day 29 Day 36 Day 40
    A-1 0.883 1.117 0.072 0.038 0.015 0.027 0.060
    A-2 1.070 0.930 0.130 0.075
    B-1 1.538 0.462 0.032 0.017 0.011 0.006 0.010
    B-2 1.350 0.650 0.042 0.018 0.012 0.007 0.008 0.007
    C-1 1.348 0.652 0.041 0.020 0.016 0.005 0.004
    C-2 1.030 0.970 0.031 0.015 0.006 0.011 0.008 0.008
  • As expected, administration of Entecavir reduced viral replication in both the absence and presence of HBV RNAi agents.
    • OTHER EMBODIMENTS
  • It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

Claims (64)

1-66. (canceled)
67. A composition comprising one or more RNAi agents, wherein the one or more RNAi agents comprise:
(a) an antisense strand comprising a nucleotide sequence of any one of the following:
SEQ ID NO:100, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:171, SEQ ID NO:179 and SEQ ID NO:180; and
(b) a sense strand comprising a nucleotide sequence of any one of the following: SEQ ID NO:229, SEQ ID NO:252, SEQ ID NO:253, SEQ ID NO:273, SEQ ID NO:302 and SEQ ID NO:319.
68. The composition of claim 67, wherein the one or more RNAi agents comprise at least one modified nucleotide or at least one modified inter-nucleoside linkage.
69. The composition of claim 68, wherein substantially all of the nucleotides in the one or more RNAi agents are modified nucleotides.
70. The composition of claim 67, wherein the one or more RNAi agents further comprise a targeting ligand that is conjugated to the one or more RNAi agents.
71. The composition of claim 70, wherein the targeting ligand comprises N-acetyl-galactosamine.
72. The composition of claim 71, wherein the targeting ligand comprises an N-acetyl-galactosamine trimer or an N-acetyl-galactosamine tetramer.
73. The composition of claim 72, wherein the targeting ligand is selected form the group consisting of (NAG13), (NAG13)s, (NAG18), (NAG18)s, (NAG24), (NAG24)s, (NAG25), (NAG25)s, (NAG26), (NAG26)s, (NAG27), (NAG27)s, (NAG28), (NAG28)s, (NAG29), (NAG29)s, (NAG30), (NAG30)s, (NAG31), (NAG31)s, (NAG32), (NAG32)s, (NAG33), (NAG33)s, (NAG34), (NAG34)s, (NAG35), (NAG35)s, (NAG36), (NAG36)s, (NAG37), (NAG37)s, (NAG38), (NAG38)s, (NAG39), and (NAG39)s.
74. The composition of claim 73, wherein the targeting ligand is (NAG25), (NAG25)s, (NAG31), (NAG31)s, (NAG37), or (NAG37)s.
75. The composition of claim 70, wherein the targeting ligand is conjugated to the sense strand of the one or more RNAi agents.
76. The composition of claim 70, wherein the targeting ligand is conjugated to the antisense strand of the one or more RNAi agents.
77. The composition of claim 75, wherein the targeting ligand is conjugated to the 5′ terminus of the sense strand of the one or more RNAi agents.
78. The composition of claim 76, wherein the targeting ligand is conjugated to the 3′ terminus of the antisense strand of the one or more RNAi agents.
79. The composition of claim 67, wherein the sense strand further comprises one or more inverted abasic nucleosides.
80. The composition of claim 67 further comprising a pharmaceutically acceptable excipient, carrier, or diluent.
81. The composition of claim 67 further comprising an additional RNAi agent, wherein the additional RNAi agent comprises: an antisense strand comprising a nucleotide sequence of any one of the following: SEQ ID NO:140, SEQ ID NO:137, SEQ ID NO:102, SEQ ID NO:162 and SEQ ID NO:188, and a sense strand comprising a nucleotide sequence of any one of the following: SEQ ID NO:248, SEQ ID NO:294, SEQ ID NO:262, SEQ ID NO:271, SEQ ID NO:274, and SEQ ID NO:328.
82. The composition of claim 81, wherein the composition comprises two or more RNAi agents independently selected from the group consisting of: AD04571 (SEQ ID NO: 100 and SEQ ID NO:229), AD04776 (SEQ ID NO: 102 and SEQ ID NO:248), AD04872 (SEQ ID NO: 126 and SEQ ID NO:252), AD04873 (SEQ ID NO: 127 and SEQ ID NO:252), AD04874 (SEQ ID NO: 128 and SEQ ID NO:253), AD04982 (SEQ ID NO: 137 and SEQ ID NO:248), AD05070 (SEQ ID NO:140 and SEQ ID NO:262), AD05148 (SEQ ID NO:140 and SEQ ID NO:271), AD05164 (SEQ ID NO:126 and SEQ ID NO:273) and AD05165 (SEQ ID NO:140 and SEQ ID NO:274).
83. The composition of claim 82, wherein the ratio of the one or more RNAi agents to the additional RNAi agent by weight is in the range of about 1:2 to about 5:1.
84. The composition of claim 83, wherein the ratio of the one or more RNAi agents to the additional RNAi agent by weight is about 2:1 or about 3:1.
85. The composition of claim 84, wherein the one or more RNAi agents comprise an antisense strand comprising SEQ ID NO: 126 and a sense strand comprising SEQ ID NO: 252, the additional RNAi agent comprises an antisense strand comprising SEQ ID NO: 140 and a sense strand comprising SEQ ID NO: 262.
86. The composition of claim 84, wherein the one or more RNAi agents comprise an antisense strand comprising SEQ ID NO: 126 and a sense strand comprising SEQ ID NO: 252, the additional RNAi agent comprises an antisense strand comprising SEQ ID NO:102 and a sense strand comprising SEQ ID NO: 248.
87. The composition of claim 84, wherein the one or more RNAi agents comprise an antisense strand comprising SEQ ID NO: 126 and a sense strand comprising SEQ ID NO: 252, the additional RNAi agent comprises an antisense strand comprising SEQ ID NO:137 and a sense strand comprising SEQ ID NO: 248.
88. The composition of claim 82, wherein the two or more RNAi agents are each independently conjugated to a targeting ligands comprising N-acetyl-galactosamine.
89. The composition of claim 85, wherein the sense strand of the one or more RNAi agents or the additional RNAi agent further comprises one or more inverted abasic nucleosides.
90. A pharmaceutical composition comprising the composition of claim 67 and a pharmaceutically acceptable excipient, carrier, or diluent.
91. A kit comprising the pharmaceutical composition of claim 90.
92. The kit of claim 91 further comprising a syringe or a vial.
93. A composition comprising one or more RNAi agents, wherein the one or more RNAi agents comprise:
(a) an antisense strand comprising a nucleotide sequence of any one of the following: SEQ ID NO:140, SEQ ID NO:102, SEQ ID NO:137, SEQ ID NO:162 and SEQ ID NO:188; and
(b) a sense strand comprising a nucleotide sequence of any one of the following: SEQ ID NO:248, SEQ ID NO:294, SEQ ID NO:262, SEQ ID NO:271, SEQ ID NO:274, and SEQ ID NO:328.
94. The composition of claim 93, wherein the one or more RNAi agents comprise at least one modified nucleotide or at least one modified inter-nucleoside linkage.
95. The composition of claim 94, wherein substantially all of the nucleotides in the one or more RNAi agents are modified nucleotides.
96. The composition of claim 93, wherein the one or more RNAi agents further comprise a targeting ligand that is conjugated to the one or more RNAi agents.
97. The composition of claim 96, wherein the targeting ligand is selected form the group consisting of (NAG13), (NAG13)s, (NAG18), (NAG18)s, (NAG24), (NAG24)s, (NAG25), (NAG25)s, (NAG26), (NAG26)s, (NAG27), (NAG27)s, (NAG28), (NAG28)s, (NAG29), (NAG29)s, (NAG30), (NAG30)s, (NAG31), (NAG31)s, (NAG32), (NAG32)s, (NAG33), (NAG33)s, (NAG34), (NAG34)s, (NAG35), (NAG35)s, (NAG36), (NAG36)s, (NAG37), (NAG37)s, (NAG38), (NAG38)s, (NAG39), and (NAG39)s.
98. The composition of claim 96, wherein the targeting ligand is conjugated to the sense strand of the one or more RNAi agents.
99. The composition of claim 96, wherein the targeting ligand is conjugated to the antisense strand of the one or more RNAi agents.
100. The composition of claim 93, wherein the sense strand further comprises one or more inverted abasic nucleosides.
101. A pharmaceutical composition comprising the composition of claim 93 and a pharmaceutically acceptable excipient, carrier, or diluent.
102. A kit comprising the pharmaceutical composition of claim 101.
103. A method of reducing or inhibiting the expression of at least one Hepatitis B Virus gene in a subject in need thereof, comprising administering to the subject an effective amount of one or more RNAi agents according to claim 67.
104. The method of claim 103, wherein the one or more RNAi agents are administered in the amount of about 0.25-5 mg/kg.
105. The method of claim 104, wherein the one or more RNAi agents are formulated for subcutaneous or intravenous injection.
106. The method of claim 103 further comprising administering to the subject one or more additional therapeutics.
107. The method of claim 106, wherein the additional therapeutic is lamivudine, tenofovir, tenofovir alafenamide, tenofovir disoproxil, or entecavir.
108. A method of treating a disease or disorder associated with Hepatitis B Virus infection in a subject in need thereof, comprising administering to the subject an effective amount of one or more RNAi agents according to claim 67.
109. The method of claim 108, wherein the one or more RNAi agents are administered in the amount of about 0.25-5 mg/kg.
110. The method of claim 109, wherein the one or more RNAi agents are formulated for subcutaneous or intravenous injection.
111. The method of claim 110, wherein the subject has an infection caused by the Hepatitis B Virus.
112. The method of claim 108 further comprising administering to the subject one or more additional therapeutics.
113. The method of claim 112, wherein the additional therapeutic is lamivudine, tenofovir, tenofovir alafenamide, tenofovir disoproxil, or entecavir.
114. A combination of at least two RNAi agents comprising a first RNAi agent and a second RNAi agent, wherein:
(a) the first RNAi agent comprising: an antisense strand comprising a nucleotide sequence of any one of the following: SEQ ID NO:100, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:171, SEQ ID NO:179, and SEQ ID NO:180, and a sense strand comprising a nucleotide sequence of any one of the following: SEQ ID NO:229, SEQ ID NO:252, SEQ ID NO:253, SEQ ID NO:273, SEQ ID NO:302, and SEQ ID NO:319; and
(b) the second RNAi agent comprising: an antisense strand comprising a nucleotide sequence of any one of the following: SEQ ID NO:140, SEQ ID NO:102, SEQ ID NO:137, SEQ ID NO:162 and SEQ ID NO:188, and a sense strand comprising a nucleotide sequence of any one of the following: SEQ ID NO:248, SEQ ID NO:294, SEQ ID NO:262, SEQ ID NO:271, SEQ ID NO:274, and SEQ ID NO:328.
115. The combination of claim 114, wherein the first or the second RNAi agent comprises at least one modified nucleotide or at least one modified inter-nucleoside linkage.
116. The combination of claim 114, wherein the first or the second RNAi agent further comprises a targeting ligand that is conjugated to the first or the second RNAi agent.
117. The combination of claim 116, wherein the targeting ligand is selected form the group consisting of (NAG13), (NAG13)s, (NAG18), (NAG18)s, (NAG24), (NAG24)s, (NAG25), (NAG25)s, (NAG26), (NAG26)s, (NAG27), (NAG27)s, (NAG28), (NAG28)s, (NAG29), (NAG29)s, (NAG30), (NAG30)s, (NAG31), (NAG31)s, (NAG32), (NAG32)s, (NAG33), (NAG33)s, (NAG34), (NAG34)s, (NAG35), (NAG35)s, (NAG36), (NAG36)s, (NAG37), (NAG37)s, (NAG38), (NAG38)s, (NAG39), and (NAG39)s.
118. The combination of claim 117, wherein the targeting ligand is conjugated to the 5′ terminus of the sense strand of the one or more RNAi agents.
119. The combination of claim 114, wherein the sense strand in the first or the second RNAi agents further comprises one or more inverted abasic nucleosides.
120. The combination of claim 114 further comprising a pharmaceutically acceptable excipient, carrier, or diluent.
121. The combination of claim 114, wherein the ratio of the first RNAi agent to the second RNAi agent by weight is in the range of about 1:2 to about 5:1.
122. The combination of claim 114, wherein the first and the second RNA agents are formulated in a single pharmaceutical composition.
123. The combination of claim 114, wherein the first and the second RNA agents are formulated in separate pharmaceutical compositions.
124. The combination of claim 114, wherein the first and the second RNA agents are formulated for subcutaneous or intravenous injection.
125. A cell, tissue or non-human organism comprising one or more RNAi agents according to claim 67.
126. A method of preparing an RNAi agent comprising conjugating a targeting group to a reactive group at the 5′- or 3′-terminus of the RNAi agent, wherein:
the RNAi agent comprises: (a) an antisense strand comprising a nucleotide sequence of any one of the following: SEQ ID NO:100, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:171, SEQ ID NO:179 and SEQ ID NO:180; and (b) a sense strand comprising a nucleotide sequence of any one of the following: SEQ ID NO:229, SEQ ID NO:252, SEQ ID NO:253, SEQ ID NO:273, SEQ ID NO:302 and SEQ ID NO:319;
the reactive group at the 5′- or 3′-terminus of the RNAi agent is selected from the group consisting of amine, alkyne, alkyl, abasic nucleoside, ribitol and PEG; and
the targeting group comprises N-acetyl-galactosamine.
127. The method of claim 126, wherein the reactive group is an amine.
128. The method of claim 126, wherein the targeting group is selected from the group consisting of (NAG13), (NAG13)s, (NAG18), (NAG18)s, (NAG24), (NAG24)s, (NAG25), (NAG25)s, (NAG26), (NAG26)s, (NAG27), (NAG27)s, (NAG28), (NAG28)s, (NAG29), (NAG29)s, (NAG30), (NAG30)s, (NAG31), (NAG31)s, (NAG32), (NAG32)s, (NAG33), (NAG33)s, (NAG34), (NAG34)s, (NAG35), (NAG35)s, (NAG36), (NAG36)s, (NAG37), (NAG37)s, (NAG38), (NAG38)s, (NAG39), and (NAG39)s.
129. The method of claim 126, wherein the sense strand further comprises one or more inverted abasic nucleosides.
US16/267,194 2016-08-04 2019-02-04 RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION Abandoned US20190255091A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/267,194 US20190255091A1 (en) 2016-08-04 2019-02-04 RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662370754P 2016-08-04 2016-08-04
US201762534733P 2017-07-20 2017-07-20
US201762540639P 2017-08-03 2017-08-03
PCT/US2017/045446 WO2018027106A2 (en) 2016-08-04 2017-08-04 RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION
US16/267,194 US20190255091A1 (en) 2016-08-04 2019-02-04 RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/045446 Continuation WO2018027106A2 (en) 2016-08-04 2017-08-04 RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION

Publications (1)

Publication Number Publication Date
US20190255091A1 true US20190255091A1 (en) 2019-08-22

Family

ID=61073185

Family Applications (5)

Application Number Title Priority Date Filing Date
US15/766,036 Active US10780108B2 (en) 2016-08-04 2017-08-04 RNAi agents for Hepatitis B virus infection
US16/267,194 Abandoned US20190255091A1 (en) 2016-08-04 2019-02-04 RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION
US16/990,916 Active US11590156B2 (en) 2016-08-04 2020-08-11 RNAi agents for hepatitis B virus infection
US17/529,107 Active US11517584B2 (en) 2016-08-04 2021-11-17 RNAi agents for Hepatitis B virus infection
US18/074,268 Pending US20230355651A1 (en) 2016-08-04 2022-12-02 Rnai agents for hepatitis b virus infection

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US15/766,036 Active US10780108B2 (en) 2016-08-04 2017-08-04 RNAi agents for Hepatitis B virus infection

Family Applications After (3)

Application Number Title Priority Date Filing Date
US16/990,916 Active US11590156B2 (en) 2016-08-04 2020-08-11 RNAi agents for hepatitis B virus infection
US17/529,107 Active US11517584B2 (en) 2016-08-04 2021-11-17 RNAi agents for Hepatitis B virus infection
US18/074,268 Pending US20230355651A1 (en) 2016-08-04 2022-12-02 Rnai agents for hepatitis b virus infection

Country Status (23)

Country Link
US (5) US10780108B2 (en)
EP (1) EP3494123A4 (en)
JP (3) JP7237816B2 (en)
KR (4) KR102540359B1 (en)
CN (2) CN116514890A (en)
AU (2) AU2017306692B2 (en)
BR (1) BR112019002117A2 (en)
CA (2) CA3032945A1 (en)
CL (4) CL2019000278A1 (en)
CO (1) CO2019002017A2 (en)
CR (3) CR20190056A (en)
EC (1) ECSP19015395A (en)
IL (2) IL264575B2 (en)
JO (2) JOP20170161A1 (en)
MA (1) MA45863A (en)
MX (3) MX2019001493A (en)
NZ (1) NZ750390A (en)
PE (1) PE20190567A1 (en)
PH (1) PH12019500245A1 (en)
SG (2) SG11201900910TA (en)
TW (1) TW202334420A (en)
UY (1) UY37353A (en)
WO (1) WO2018027106A2 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10780108B2 (en) 2016-08-04 2020-09-22 Arrowhead Pharmaceuticals, Inc. RNAi agents for Hepatitis B virus infection
US10806750B2 (en) 2015-08-07 2020-10-20 Arrowhead Pharmaceuticals, Inc. RNAi therapy for hepatitis B virus infection
USRE48345E1 (en) 2011-06-30 2020-12-08 Arrowhead Pharmaceuticals Inc. Compositions and methods for inhibiting gene expression of hepatitis B virus
WO2021249484A1 (en) * 2020-06-10 2021-12-16 南京明德新药研发有限公司 Conjugate group and conjugate
US11414665B2 (en) 2017-12-01 2022-08-16 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
US11414661B2 (en) 2017-12-01 2022-08-16 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
US11492620B2 (en) 2017-12-01 2022-11-08 Suzhou Ribo Life Science Co., Ltd. Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof
US11633482B2 (en) 2017-12-29 2023-04-25 Suzhou Ribo Life Science Co., Ltd. Conjugates and preparation and use thereof
US11660347B2 (en) 2017-12-01 2023-05-30 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing same, preparation method, and use thereof
US11896674B2 (en) 2018-09-30 2024-02-13 Suzhou Ribo Life Science Co., Ltd. SiRNA conjugate, preparation method therefor and use thereof
US11918600B2 (en) 2018-08-21 2024-03-05 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190084B1 (en) 2016-11-01 2023-09-17 Arrowhead Pharmaceuticals Inc Alpha-v beta-6 integrin ligands and uses thereof
FI3607069T3 (en) 2017-04-05 2023-01-13 Products and compositions
US11324820B2 (en) 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
RS64001B1 (en) 2017-10-20 2023-03-31 Dicerna Pharmaceuticals Inc Methods for treating hepatitis b infection
CR20200178A (en) 2017-11-01 2020-06-28 Arrowhead Pharmaceuticals Inc Integrin ligands and uses thereof
EA202091513A1 (en) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани VACCINES AGAINST HEPATITIS B VIRUS (HBV) AND THEIR APPLICATION
SG11202100715WA (en) 2018-08-13 2021-02-25 Alnylam Pharmaceuticals Inc HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
TW202039000A (en) * 2018-12-20 2020-11-01 瑞士商休曼斯生物醫藥公司 Combination hbv therapy
JOP20210208A1 (en) * 2019-02-07 2023-01-30 Arrowhead Pharmaceuticals Inc Rnai agents for hepatitis b virus infection
AU2020259482A1 (en) * 2019-04-18 2021-10-14 Janssen Pharmaceuticals, Inc. Combination therapy for treating Hepatitis B Virus infection
US20200332297A1 (en) * 2019-04-18 2020-10-22 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
US20220305117A1 (en) 2019-06-18 2022-09-29 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai
CN114340663A (en) * 2019-06-18 2022-04-12 爱尔兰詹森科学公司 Combination of Hepatitis B Virus (HBV) vaccine and HBV-targeted RNAi
CN110218728A (en) * 2019-06-28 2019-09-10 厦门甘宝利生物医药有限公司 A kind of noval chemical compound and its application
CN116096383A (en) * 2020-06-22 2023-05-09 杨森制药公司 Compositions and methods for treating hepatitis delta virus infection
EP4210759A1 (en) 2020-09-11 2023-07-19 Arrowhead Pharmaceuticals, Inc. Lipid conjugates for the delivery of therapeutic agents
TW202227102A (en) 2020-09-22 2022-07-16 瑞典商阿斯特捷利康公司 Method of treating fatty liver disease
WO2022078479A1 (en) * 2020-10-16 2022-04-21 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
TW202245809A (en) * 2020-12-18 2022-12-01 美商詹森藥物公司 Combination therapy for treating hepatitis b virus infection
US20240124879A1 (en) * 2020-12-18 2024-04-18 Olix Pharmaceuticals, Inc. Rnai agent for inhibiting hbv expression and use thereof
WO2022152869A1 (en) * 2021-01-15 2022-07-21 Janssen Sciences Ireland Unlimited Company Use of oligonucleotides for individuals with hepatic impairment
BR112023024615A2 (en) * 2021-05-28 2024-02-20 Arrowhead Pharmaceuticals Inc RNAI AGENTS FOR INHIBITING MUCIN 5AC (MUC5AC) EXPRESSION, COMPOSITIONS THEREOF, AND METHODS OF USE
WO2023233290A1 (en) 2022-05-31 2023-12-07 Janssen Sciences Ireland Unlimited Company Rnai agents targeting pd-l1
WO2023246750A1 (en) * 2022-06-21 2023-12-28 正大天晴药业集团股份有限公司 Double-stranded ribonucleic acid for inhibiting hepatitis b virus
WO2024015796A1 (en) * 2022-07-11 2024-01-18 Sanegene Bio Usa Inc. Optimized 2'- modified ribose derivatives and methods of use

Family Cites Families (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
DE3851889T2 (en) 1987-06-24 1995-04-13 Florey Howard Inst NUCLEOSIDE DERIVATIVES.
US4924624A (en) 1987-10-22 1990-05-15 Temple University-Of The Commonwealth System Of Higher Education 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
EP0942000B1 (en) 1989-10-24 2004-06-23 Isis Pharmaceuticals, Inc. 2'-Modified oligonucleotides
US5264562A (en) 1989-10-24 1993-11-23 Gilead Sciences, Inc. Oligonucleotide analogs with novel linkages
DE69031305T2 (en) 1989-11-03 1998-03-26 Univ Vanderbilt METHOD FOR GENERATING FUNCTIONAL FOREIGN GENES IN VIVO
US5177198A (en) 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5212295A (en) 1990-01-11 1993-05-18 Isis Pharmaceuticals Monomers for preparation of oligonucleotides having chiral phosphorus linkages
US5506351A (en) 1992-07-23 1996-04-09 Isis Pharmaceuticals Process for the preparation of 2'-O-alkyl guanosine and related compounds
US5587470A (en) 1990-01-11 1996-12-24 Isis Pharmaceuticals, Inc. 3-deazapurines
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5578718A (en) 1990-01-11 1996-11-26 Isis Pharmaceuticals, Inc. Thiol-derivatized nucleosides
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5321131A (en) 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5470967A (en) 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5541307A (en) 1990-07-27 1996-07-30 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5218105A (en) 1990-07-27 1993-06-08 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US6262241B1 (en) 1990-08-13 2001-07-17 Isis Pharmaceuticals, Inc. Compound for detecting and modulating RNA activity and gene expression
US5214134A (en) 1990-09-12 1993-05-25 Sterling Winthrop Inc. Process of linking nucleosides with a siloxane bridge
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
ATE239484T1 (en) 1991-10-24 2003-05-15 Isis Pharmaceuticals Inc DERIVATIZED OLIGONUCLEOTIDES WITH IMPROVED ABSORPTION CAPACITY
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
US20030206887A1 (en) 1992-05-14 2003-11-06 David Morrissey RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
WO2002081494A1 (en) 2001-03-26 2002-10-17 Sirna Therapeutics, Inc. Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
EP0577558A2 (en) 1992-07-01 1994-01-05 Ciba-Geigy Ag Carbocyclic nucleosides having bicyclic rings, oligonucleotides therefrom, process for their preparation, their use and intermediates
NL9201440A (en) 1992-08-11 1994-03-01 Univ Leiden Triantennary cluster glycosides, their preparation and application.
GB9304618D0 (en) 1993-03-06 1993-04-21 Ciba Geigy Ag Chemical compounds
EP0691977B1 (en) 1993-03-31 1997-11-26 Sanofi Oligonucleotides with amide linkages replacing phosphodiester linkages
US5571902A (en) 1993-07-29 1996-11-05 Isis Pharmaceuticals, Inc. Synthesis of oligonucleotides
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5554746A (en) 1994-05-16 1996-09-10 Isis Pharmaceuticals, Inc. Lactam nucleic acids
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
US5856459A (en) 1995-06-06 1999-01-05 Hybridon, Inc. Oligonucleotides specific for hepatitis B virus
US5985662A (en) 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
US6127533A (en) 1997-02-14 2000-10-03 Isis Pharmaceuticals, Inc. 2'-O-aminooxy-modified oligonucleotides
US6172209B1 (en) 1997-02-14 2001-01-09 Isis Pharmaceuticals Inc. Aminooxy-modified oligonucleotides and methods for making same
US6271358B1 (en) 1998-07-27 2001-08-07 Isis Pharmaceuticals, Inc. RNA targeted 2′-modified oligonucleotides that are conformationally preorganized
AU6430599A (en) 1998-10-09 2000-05-01 Cytogenix, Inc. Enzymatic synthesis of ssdna
US5977341A (en) 1998-11-20 1999-11-02 Isis Pharmaceuticals Inc. Antisense modulation of inhibitor-kappa B kinase-beta expression
CA2365625A1 (en) 1999-03-10 2000-09-14 Phogen Limited Delivery of substances to cells
US7019113B2 (en) 1999-06-07 2006-03-28 Mirus Bio Corporation Reversible modification of membrane interaction
WO2000075164A1 (en) 1999-06-07 2000-12-14 Mirus Corporation COMPOSITIONS AND METHODS FOR DRUG DELIVERY USING pH SENSITIVE MOLECULES
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
US20050032733A1 (en) 2001-05-18 2005-02-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US8273866B2 (en) 2002-02-20 2012-09-25 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
CA2526831C (en) 2001-05-18 2012-07-31 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina)
WO2007022369A2 (en) 2005-08-17 2007-02-22 Sirna Therapeutics, Inc. Chemically modified short interfering nucleic acid molecules that mediate rna interference
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US20060217331A1 (en) * 2001-05-18 2006-09-28 Sirna Therapeutics, Inc. Chemically modified double stranded nucleic acid molecules that mediate RNA interference
US10590418B2 (en) 2001-07-23 2020-03-17 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for RNAi mediated inhibition of gene expression in mammals
US20030198627A1 (en) 2001-09-01 2003-10-23 Gert-Jan Arts siRNA knockout assay method and constructs
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
US6635428B2 (en) 2001-12-04 2003-10-21 Quest Diagnostics Investments Incorporated Oligonucleotides and methods for detecting hepatitis B viral nucleic acids
JP2005515780A (en) 2002-02-01 2005-06-02 セクイター インコーポレイテッド Double stranded oligonucleotide
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
US8232383B2 (en) 2002-02-20 2012-07-31 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
DE60310944T3 (en) 2002-08-05 2017-08-03 Silence Therapeutics Gmbh OTHER NEW FORMS OF INTERFERING RNS MOLECULES
US7956176B2 (en) 2002-09-05 2011-06-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
EP1578765A4 (en) 2002-11-05 2008-04-23 Isis Pharmaceuticals Inc Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US7816337B2 (en) 2003-02-18 2010-10-19 Roche Madison Inc. Reversible attachment of a membrane active polymer to a polynucleotide
US20040162235A1 (en) 2003-02-18 2004-08-19 Trubetskoy Vladimir S. Delivery of siRNA to cells using polyampholytes
CN1257284C (en) * 2003-03-05 2006-05-24 北京博奥生物芯片有限责任公司 Method of blocking expression of hepatitis B virus
US7750144B2 (en) 2003-06-02 2010-07-06 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of RNA silencing
WO2005009346A2 (en) 2003-06-24 2005-02-03 Mirus Corporation Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo
US20080207539A1 (en) 2003-09-01 2008-08-28 Patrick Arbuthnot Self-Processing Rna Expression Cassette
EP1709178A4 (en) 2003-12-16 2008-01-09 Agency Science Tech & Res Methods and compounds for altering the load of hepatitis virus
CA2553211A1 (en) 2004-01-12 2005-07-21 Genesense Technologies Inc. Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in combination therapies for the treatment of cancer
EP2514758B2 (en) 2004-03-15 2021-06-23 City of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
CA2566286A1 (en) 2004-05-11 2005-12-08 Rnai Co., Ltd. Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
EP1786905B1 (en) 2004-08-18 2011-08-03 Lorus Therapeutics Inc. Small interfering rna molecules against ribonucleotide reductase and uses thereof
WO2006096018A1 (en) 2005-03-09 2006-09-14 Mogam Biotechnology Research Institute Small interfering rna and pharmaceutical composition for treatment of hepatitis b comprising the same
PL1866414T3 (en) 2005-03-31 2012-10-31 Calando Pharmaceuticals Inc Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
CN101426912A (en) 2005-08-17 2009-05-06 瑟纳治疗公司 Chemically modified short interfering nucleic acid molecules that mediate RNA interference
RU2418068C2 (en) 2005-08-17 2011-05-10 Сирна Терапьютикс, Инк. Chemically modified short interfering nucleic acid molecules that mediate rna interference
BRPI0618214A2 (en) 2005-11-01 2011-08-23 Alnylam Pharmaceuticals Inc inhibition of replication of influenza virus replication
CN100447243C (en) 2005-11-15 2008-12-31 中国人民解放军第四军医大学 HBV specificity interference target point gene and its siRNA and application in anti HBV infecting thereof
CN101024088A (en) 2006-02-20 2007-08-29 桂林医学院 B-type hepatitis virus micro ribonucleic-acid interference moleculars and its designing method
AU2007285782B2 (en) 2006-08-18 2010-06-24 Arrowhead Research Corporation Polyconjugates for in vivo delivery of polynucleotides
WO2008119000A1 (en) 2007-03-27 2008-10-02 University Of Iowa Research Foundation Zinc-finger nuclease and rna interference mediated inactivation of viral genomes
US8877917B2 (en) 2007-04-23 2014-11-04 Alnylam Pharmaceuticals, Inc. Glycoconjugates of RNA interference agents
CN101755049B (en) 2007-05-29 2014-03-12 约翰内斯堡威特沃特斯兰德大学 Primary micro RNA expression cassette
US20100209491A1 (en) 2007-09-17 2010-08-19 Mogam Biotechnology Research Institute Method for enhancing serum stability and lowering immune response of sirna down-regulating gene expression of hbv or hcv
CA2702028A1 (en) 2007-10-02 2009-04-09 Rxi Pharmaceuticals Corp. Tripartite rnai constructs
CA2910760C (en) 2007-12-04 2019-07-09 Muthiah Manoharan Targeting lipids
CA2721183C (en) 2008-04-11 2019-07-16 Alnylam Pharmaceuticals, Inc. Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
CN101603042B (en) 2008-06-13 2013-05-01 厦门大学 RNA interference target for treating hepatitis B virus infection
CN101322847A (en) 2008-06-23 2008-12-17 淮安市第四人民医院 Anti-hepatitis b virus gene medicament based on siRNA pool interference and mediated by complex carrier
US20100249214A1 (en) 2009-02-11 2010-09-30 Dicerna Pharmaceuticals Multiplex dicer substrate rna interference molecules having joining sequences
CN105907756A (en) 2008-12-18 2016-08-31 戴瑟纳制药公司 Extended Dicer Substrate Agents And Methods For The Specific Inhibition Of Gene Expression
US9221886B2 (en) 2009-04-28 2015-12-29 President And Fellows Of Harvard College Supercharged proteins for cell penetration
JP5883381B2 (en) 2009-05-05 2016-03-15 ミラゲン セラピューティクス，インコーポレイテッド Lipophilic polynucleotide conjugate
US8207138B2 (en) 2009-05-19 2012-06-26 Medtronic, Inc. Methods and devices for improved efficiency of RNA delivery to cells
CA2766608C (en) 2009-07-06 2018-06-19 F. Hoffmann-La Roche Ag Bi-specific digoxigenin binding antibodies
US20110152349A1 (en) 2009-12-18 2011-06-23 Anke Geick Compositions and methods for inhibiting expression of il-18 genes
US9198972B2 (en) 2010-01-28 2015-12-01 Alnylam Pharmaceuticals, Inc. Monomers and oligonucleotides comprising cycloaddition adduct(s)
EA024534B1 (en) 2010-02-24 2016-09-30 Эрроухэд Рисерч Корпорейшн CONJUGATE DELIVERY SYSTEM AND COMPOSITION FOR TARGETED DELIVERY OF SMALL INTERFERING RNA (siRNA) AND PROCESS FOR PREPARING THE COMPOSITION
EP2390327A1 (en) 2010-05-27 2011-11-30 Sylentis S.A. siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
RU2624045C2 (en) * 2010-08-17 2017-06-30 Сирна Терапьютикс,Инк RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2616543A1 (en) 2010-09-15 2013-07-24 Alnylam Pharmaceuticals, Inc. MODIFIED iRNA AGENTS
CN101948834B (en) 2010-09-16 2012-07-04 山东大学 siRNA for treating HBV
LT3124610T (en) 2010-10-28 2019-08-12 Benitec Biopharma Limited Hbv treatment
EP2632472B1 (en) 2010-10-29 2017-12-13 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
US8501930B2 (en) * 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
WO2012089352A1 (en) 2010-12-29 2012-07-05 F. Hoffmann-La Roche Ag Small molecule conjugates for intracellular delivery of nucleic acids
EP2699583A4 (en) 2011-04-21 2015-04-15 Isis Pharmaceuticals Inc Modulation of hepatitis b virus (hbv) expression
JP6050329B2 (en) 2011-05-18 2016-12-21 ヤンセン・サイエンシズ・アイルランド・ユーシー Quinazoline derivatives for treating viral infections and other diseases
TW202244278A (en) * 2011-06-30 2022-11-16 美商艾羅海德製藥公司 Compositions and methods for inhibiting gene expression of hepatitis b virus
TWI623618B (en) 2011-07-12 2018-05-11 傳斯堅公司 Hbv polymerase mutants
KR20140051357A (en) 2011-08-26 2014-04-30 애로우헤드 리서치 코오포레이션 Poly(vinyl ester) polymers for in vivo nucleic acid delivery
KR102385013B1 (en) 2011-11-18 2022-04-12 알닐람 파마슈티칼스 인코포레이티드 RNAi AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING TRANSTHYRETIN (TTR) ASSOCIATED DISEASES
KR20150001710A (en) 2012-04-18 2015-01-06 애로우헤드 리서치 코오포레이션 Poly(acrylate) Polymers for In Vivo Nucleic Acid Delivery
WO2013159109A1 (en) 2012-04-20 2013-10-24 Isis Pharmaceuticals, Inc. Modulation of hepatitis b virus (hbv) expression
US9212363B2 (en) 2012-05-11 2015-12-15 City Of Hope RNAI molecules with non-watson crick pairing based on artificial mutation consensus sequences to counter escape mutations
JP6343605B2 (en) 2012-05-25 2018-06-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Methods and compositions for RNA-dependent target DNA modification and RNA-dependent transcriptional regulation
GB201215857D0 (en) 2012-09-05 2012-10-24 Sylentis Sau siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
CN103333890B (en) * 2012-12-21 2015-04-15 厦门成坤生物技术有限公司 RNA interference preparation used for treating viral hepatitis B
US9943604B2 (en) 2013-09-20 2018-04-17 Ionis Pharmaceuticals, Inc. Targeted therapeutic nucleosides and their use
EP3052107B1 (en) * 2013-10-04 2018-05-02 Novartis AG Organic compounds to treat hepatitis b virus
EP3811977A1 (en) 2014-05-01 2021-04-28 Ionis Pharmaceuticals, Inc. Method for synthesis of reactive conjugate clusters
CN104059916A (en) 2014-06-17 2014-09-24 湖北医药学院附属太和医院 Sequence of hepatitis B virus (HBV) specific microRNA like siRNA (msiRNA) and application thereof
JOP20200115A1 (en) 2014-10-10 2017-06-16 Alnylam Pharmaceuticals Inc Compositions And Methods For Inhibition Of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression
JOP20200092A1 (en) * 2014-11-10 2017-06-16 Alnylam Pharmaceuticals Inc HEPATITIS B VIRUS (HBV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
US20170137821A1 (en) 2015-07-17 2017-05-18 Arcturus Therapeutics, Inc. Molecules and agents for treating hepatitis b virus
US20170016000A1 (en) 2015-07-17 2017-01-19 Arcturus Therapeutics, Inc. Compositions and agents against hepatitis b virus and uses thereof
WO2017019891A2 (en) 2015-07-29 2017-02-02 Protiva Biotherapeutics, Inc. Compositions and methods for silencing hepatitis b virus gene expression
KR20180038465A (en) 2015-08-07 2018-04-16 애로우헤드 파마슈티컬스 인코포레이티드 RNAi therapy for hepatitis B virus infection
JP6983797B2 (en) 2016-03-07 2021-12-17 アローヘッド ファーマシューティカルズ インコーポレイテッド Targeted ligand for therapeutic compounds
MA45478A (en) 2016-04-11 2019-02-20 Arbutus Biopharma Corp TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS
JOP20170161A1 (en) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc RNAi Agents for Hepatitis B Virus Infection
CN116942841A (en) 2016-09-02 2023-10-27 箭头药业股份有限公司 Targeting ligands
US11020476B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV)
EA202091513A1 (en) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани VACCINES AGAINST HEPATITIS B VIRUS (HBV) AND THEIR APPLICATION
US11389531B2 (en) 2017-12-19 2022-07-19 Janssen Sciences Ireland Unlimited Company Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines
TW201945003A (en) 2018-03-01 2019-12-01 愛爾蘭商健生科學愛爾蘭無限公司 2,4-diaminoquinazoline derivatives and medical uses thereof
JOP20210208A1 (en) 2019-02-07 2023-01-30 Arrowhead Pharmaceuticals Inc Rnai agents for hepatitis b virus infection
US20200332297A1 (en) 2019-04-18 2020-10-22 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
CN114126628A (en) 2019-05-13 2022-03-01 维尔生物科技有限公司 Compositions and methods for treating Hepatitis B Virus (HBV) infection
US20220305117A1 (en) 2019-06-18 2022-09-29 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai
JP2023533528A (en) 2020-07-08 2023-08-03 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー RNA replicon vaccine against HBV
TW202245809A (en) 2020-12-18 2022-12-01 美商詹森藥物公司 Combination therapy for treating hepatitis b virus infection

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE48345E1 (en) 2011-06-30 2020-12-08 Arrowhead Pharmaceuticals Inc. Compositions and methods for inhibiting gene expression of hepatitis B virus
US10806750B2 (en) 2015-08-07 2020-10-20 Arrowhead Pharmaceuticals, Inc. RNAi therapy for hepatitis B virus infection
US11534453B2 (en) 2015-08-07 2022-12-27 Arrowhead Pharmaceuticals, Inc. RNAi therapy for hepatitis B virus infection
US10780108B2 (en) 2016-08-04 2020-09-22 Arrowhead Pharmaceuticals, Inc. RNAi agents for Hepatitis B virus infection
US11590156B2 (en) 2016-08-04 2023-02-28 Arrowhead Pharmaceuticals, Inc. RNAi agents for hepatitis B virus infection
US11517584B2 (en) 2016-08-04 2022-12-06 Arrowhead Pharmaceuticals, Inc. RNAi agents for Hepatitis B virus infection
US11492620B2 (en) 2017-12-01 2022-11-08 Suzhou Ribo Life Science Co., Ltd. Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof
US11414661B2 (en) 2017-12-01 2022-08-16 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
US11414665B2 (en) 2017-12-01 2022-08-16 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
US11660347B2 (en) 2017-12-01 2023-05-30 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing same, preparation method, and use thereof
US11633482B2 (en) 2017-12-29 2023-04-25 Suzhou Ribo Life Science Co., Ltd. Conjugates and preparation and use thereof
US11918600B2 (en) 2018-08-21 2024-03-05 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof
US11896674B2 (en) 2018-09-30 2024-02-13 Suzhou Ribo Life Science Co., Ltd. SiRNA conjugate, preparation method therefor and use thereof
WO2021249484A1 (en) * 2020-06-10 2021-12-16 南京明德新药研发有限公司 Conjugate group and conjugate

Also Published As

Publication number Publication date
KR20230025949A (en) 2023-02-23
BR112019002117A2 (en) 2019-07-09
SG10201913585SA (en) 2020-02-27
MA45863A (en) 2019-06-12
US11590156B2 (en) 2023-02-28
JOP20170161A1 (en) 2019-01-30
JP7237816B2 (en) 2023-03-13
CL2019000278A1 (en) 2020-03-20
KR20240039232A (en) 2024-03-26
US20230355651A1 (en) 2023-11-09
CA3032945A1 (en) 2018-02-08
PE20190567A1 (en) 2019-04-22
KR20230084607A (en) 2023-06-13
KR20190038606A (en) 2019-04-08
US20220079973A1 (en) 2022-03-17
US11517584B2 (en) 2022-12-06
IL264575A (en) 2019-02-28
JP2019527694A (en) 2019-10-03
CR20190056A (en) 2019-05-20
CL2021001195A1 (en) 2021-10-22
WO2018027106A2 (en) 2018-02-08
NZ750390A (en) 2023-11-24
IL264575B1 (en) 2023-10-01
CN109843902A (en) 2019-06-04
AU2017306692A1 (en) 2019-02-21
US20190292547A1 (en) 2019-09-26
CO2019002017A2 (en) 2019-05-31
WO2018027106A3 (en) 2018-03-15
CA3229270A1 (en) 2018-02-08
SG11201900910TA (en) 2019-02-27
CN116514890A (en) 2023-08-01
KR102650107B1 (en) 2024-03-20
CL2022001478A1 (en) 2023-01-13
TW202018081A (en) 2020-05-16
EP3494123A4 (en) 2020-07-22
IL305507A (en) 2023-10-01
JP2022068222A (en) 2022-05-09
AU2022205929A1 (en) 2022-10-06
TW202334420A (en) 2023-09-01
KR102500675B1 (en) 2023-02-15
JP2023123469A (en) 2023-09-05
CR20220468A (en) 2023-05-12
US20210100829A1 (en) 2021-04-08
PH12019500245A1 (en) 2019-10-14
JOP20190015A1 (en) 2019-02-04
MX2020011805A (en) 2020-12-07
MX2019001493A (en) 2019-07-12
US10780108B2 (en) 2020-09-22
IL264575B2 (en) 2024-02-01
CR20220469A (en) 2022-10-26
UY37353A (en) 2018-02-28
MX2020011806A (en) 2020-12-07
CL2020002156A1 (en) 2020-12-18
CN109843902B (en) 2023-05-30
AU2017306692B2 (en) 2022-08-04
KR102540359B1 (en) 2023-06-02
ECSP19015395A (en) 2019-06-30
EP3494123A2 (en) 2019-06-12

Similar Documents

Publication Publication Date Title
US11517584B2 (en) RNAi agents for Hepatitis B virus infection
US20210395745A1 (en) Rnai agents for hepatitis b virus infection
US20210238602A1 (en) RNAi Agents And Compositions for Inhibiting Expression of Angiopoietin-Like 3 (ANGPTL3), And Methods Of Use
US20200283777A1 (en) RNAi Agents And Compositions for Inhibiting Expression of Asiaglycoprotein Receptor 1
OA19828A (en) RNAi agents for hepatitis B virus infection
EA044937B1 (en) RNAi AGENTS AGAINST HEPATITIS B VIRUS INFECTION
US20240141351A1 (en) Alpha-1 antitrypsin (aat) rnai agents, compositions including aat rnai agents, and methods of use
NZ790939A (en) RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION
OA19470A (en) RNAi agents for hepatitis B virus infection.
NZ790940A (en) RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

AS Assignment

Owner name: ARROWHEAD PHARMACEUTICALS, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LI, ZHEN;ZHU, RUI;WOODDELL, CHRISTINE I.;AND OTHERS;SIGNING DATES FROM 20190718 TO 20191113;REEL/FRAME:051080/0579

STCB Information on status: application discontinuation

Free format text: EXPRESSLY ABANDONED -- DURING EXAMINATION